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Glycoform Structure and Function
Glycoproteins generally consist of populations of glycosylated variants of a single protein 
(glycoforms). While the potential oligosaccharide processing pathways available to a protein 
are dictated by the cell in which it is expressed, the final glycosylation pattern reflects 
constraints imposed by the three dimensional structure of the individual protein. This thesis 
explores the extent to which a protein controls its own glycosylation by comparing the 
glycosylation patterns of soluble forms of leucocyte surface antigens (CD2, CD5d1, CD59, 
CD5/CD4d3,4 and CD48) expressed in Chinese Hamster Ovary cells (ch.2). In chapter 3 the N- 
and 0-linked and anchor glycans of human erythrocyte CD59 were characterised; the data 
suggested that the individual protein may influence the processing of glycosylphosphatidyl 
inositol anchor glycans. In chapter 4-7 consequences of variable glycosylation were explored 
by preparing defined sets of glycoforms for testing in functional assays. Individual glycoforms 
of RNase B reduced the susceptibility of the protein to proteases and modulated the activity of 
the enzyme (ch.4). IgG rheumatoid factor, from patients with rheumatoid arthritis, contained a 
specific subset of IgG glycoforms with Fc oligosaccharides terminating in GlcNAc (IgGO) and 
an extra-glycosylated heavy chain. Exposed GlcNAc residues on multiply presented IgGO 
bound serum mannose binding protein, suggesting a role for Fc sugars in recognition (ch.6). In 
chapter 7 a subset of highly active tissue plasminogen activator (tPA) glycoforms, type II 
dimers, was identified. In the fibrin stimulated activation of plasminogen, glycosylation of tPA 
site 184 (type I glycoforms) decreased kcat, while the Km was decreased by glycosylation at 
the variably occupied plasminogen site, Asn289. Chapter 8, which deals with technology, 
explores applications of HPLC and mass spectrometry to the analysis of oligosaccharides and 
in chapter 5 capillary electrophoresis was used to resolve transferrin glycoforms, suggesting a 
rapid diagnostic for carbohydrate deficient glycoprotein syndrome.
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Figure 1 : A summary of the glycosylation processing pathway.
Glycosylation is initiated in the rough ER where the membrane bound oligosaccharide 
transferase mediates the transfer of the oligosaccharide precursor, G/CgMa/ig G/c/V/ICg, to the 
nitrogen in the side chain of some asparagine residues. Processing of the glycans begins in the 
ER by the enzymatic trimming of the three glucose residues and one of the mannose residues. 
The glycoproteins are then transported by transporter proteins in membranous vesicles to the 
Golgi apparatus for further processing. In the trans Golgi the completed glycoproteins are 
sorted for their final destinations such as the lysosomes, the plasma membrane or extemal 
secretion. Some of the enzymes involved and representative examples of the three classes of 
N-linked glycans and are shown: microheterogeneity within each structural class yields many 
more structures than are shown here. (Taken from Natuska, S. and Lowe, J.B. 1994). For key 
see previous page.
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Figure 2: Monosaccharide residues commonly found in N- and O-linked
oligosaccharides attached to proteins in mammalian systems.
Chapter 1
Introduction to the structure and function of glycoforms
1.1 The N-linked glycosylation biosynthetic pathway
The N-linked glycosylation pathway is initiated co-translationally for polypeptides which contain 
the potential glycosylation sequon AsnXaaSer, where Xaa is any other amino acid except 
proline. Oligosaccharyl transferases catalyse the covalent attachment of the oligosaccharide 
precursor, GICgMangGlcNACg, to some potential glycosylation sites on the protein. The 
glycoproteins are transported through the lumen of the endoplasmic reticulum (ER) into the cis, 
medial and trans Golgi stacks. Each of these compartments contains a different combination of 
highly specific glycosylating enzymes (Fig.1) which are anchored in the subcellular membranes 
'With their active sites facing the lumen. An oligosaccharide chain is modified when a 
glycosidase or glycosyltransferase enzyme interacts with a specific glycoform of the developing 
glycoprotein, mediating the transfer or removal of a monosaccharide (Fig. 2) at the non­
reducing end of the glycan chain. Three major classes of N-linked glycans have been identified: 
oligomannose, complex and hybrid (Fig.1). The efficient binding and processing of a 
glycoprotein by an enzyme requires the correct oligosaccharide to be presented in the context 
of a protein with a suitable local three dimensional structure. When processing involves the 
addition of a monosaccharide by a glycosyl transferase the event also involves a donor sugar- 
nucleotide (Fig. 3). The glycoproteins which emerge from the trans-Golgi are the end products 
of a series of enzyme reactions in which the immature glycoprotein generated by one reaction 
becomes the substrate for the next. The reactions may not necessarily go to completion, 
therefore glycoproteins generally consist of mixtures of glycosylated variants or glycoforms.
1.2 O-glycans
All Ser(Thr) O-linked glycosylation is initiated by the incorporation of a single N- 
acetylgalactosamine residue from UDP-GalNAc into the polypeptide chain, and elongation 
requires the sequential addition of monosaccharide residues. At least six core structures have 
been identified (Fig. 4; Schaefer and Brockhausen 1992). In general no consensus sequence is 
required for O-glycosylation, however it has been noted that proline residues are often close to 
an O-glycosylated Ser(Thr) residue, and that regions of peptides which contain a high 
proportion of serine, threonine and proline residues are frequently O-glycosylated. Also tPA 
(ch.7) contains an O-linked fucose residue attached to Thr61 in the growth factor domain 
(Harris et al 1991). Threonine 61 is part of a consensus sequence for 0-fucosylation, Gly Gly 
Ser/Thr, which has been noted in other epidermal growth factor regions in other molecules 
associated with the blood coagulation cascade such as human factor VII,IX,XII and bovine 
Factor VII (Nishimura et al 1992). In this thesis O-linked glycans containing type 1 cores were 
identified on human CDS domain (d) 1 and a chimera of CDS and CD4dS,4 expressed in CHO 
cells, and also on human erythrocyte CDS9 and neutrophil gelatinase B.
QH
CH,OH
P-P-O-P-0-ÇH
HO OH
p-D-galactose
OH OH
Base
Sugar Nucleotide
Figure 3: Galactose uridine diphosphate.
Each monosaccharide is linked to a sugar nucleotide from which it is transferred to the glycan 
chain by a glycosyl tranferase. The sugar nucleotides and some of their corresponding 
monosaccharides are as follows: UDP: GlcNAc, GalNAc, Gal, Glc, Xyl; GDP: Fuc, Man; CMP: 
N-acetyl neuraminic acid (sialic acid).
Core 1 : Gaipi-3 GalNAc-R
Core 2 : GlcNAc^1-6 (Gaipi-3) GalNAc-R
Core 3 : GlcNAcpi-3 GalNAc-R
Core 4 : GlcNAcpi-6 GlcNAcpi-3 GalNAc-R
Core 5 : GalNAca1-3 GalNAc-R
Core 6 : GlcNAcpi-6 GalNAc-R (R is a  Ser/Thr)
Figure 4: The O-glycan core structures
1.3 Glycosylphosphatidyl inositol membrane anchors
Glycosylphosphatidyl inositol (GPI) anchors are complex glycolipids found covalently attached 
to a wide variety of cell surface plasma membrane proteins (Ferguson 1991, McConville and 
Ferguson 1993). A protein destined to receive a GPI anchor must contain an N-terminal signal 
sequence for entry into the lumen of the endoplasmic reticulum where the pre-assembled 
anchor precursor is attached. The C-terminus of the protein must contain a GPI signal 
sequence, the most common feature of which is a series of 12-20 hydrophobic residues at the 
C-terminus of the primary translation product preceded by a polar region of amino acids. This 
signal sequence is cleaved and replaced by a pre-assembled GPI precursor. The C-terminal 
cleavage amino acid (restricted to either Cys, Asp, Asn, Gly, Arg or Ser) is linked via 
ethanolamine phosphate to a glycan with a conserved backbone sequence (Mana1-2Mana1- 
6Mana1-4GlcNH2) which may be further processed. The backbone is linked to the 6-position of 
the myo-inositol ring of phosphatidyl inositol (PI). GPI anchors contain two lipids, normally one 
acyl and one alkyl, attached through the phosphate on the inositol ring. In addition, a subset of 
anchors are palmitoylated at 03/4 on the inositol ring. In this thesis the glycosylation of the GPI 
anchor attached to human erythrocyte CD59 (Fig. 5) has been determined (ch.3).
1.4 Variable sequon occupancy
Although the same glycosylation machinery is available to all the proteins which are 
translated in a particular cell and use the secretory pathway, it has been estimated that 
between 10% and 30% of potential glycosylation sites are not occupied (Gavel and Heijne, 
1990, Mononen and Karjalainen 1984). At the cellular level two factors which control the 
proportion of occupied glycosylation sites are the availability of the oligosaccharyl 
transferase and the dolichol pyrophosphate linked IVIangGlcNACgGICg precursor 
oligosaccharide. The lipid component of the precursor is dolichol, a long chain isoprenol of 
14-20 isoprene units (Fig. 6) which anchors the growing oligosaccharide in the lipid bi-layer 
of the endoplasmic reticulum (ER). Initially the sugar chain is processed in the cytoplasm 
(Fig. 7a) by sequential additions of mannose. When it contains a Man 5 glycan the molecule 
flips' so that the remainder of the processing of the Man 5 glycan to the MangGlcNACgGICg 
precursor takes place within the lumen of the ER. The precursor is transferred to the 
asparagine residue in the glycosylation sequon of the nascent glycoprotein by an 
oligosaccharyl transferase which is situated 30-40A above the membrane of the ER and 
oriented roughly parallel to the membrane surface (Nillson et al 1993). If the normal levels 
of either the transferase or the precursor are significantly altered the proportion of occupied 
glycosylation sites may change. For example, in oviduct tissue the level of oligosaccharyl 
transferase activity may control the extent of protein glycosylation (Singh et al 1981) and the 
addition of dolichol phosphate to tissue slices has been shown to increase the percentage of 
ribonuclease (RNase) B in bovine pancreatic RNase from 12-90% (Carson et al 1981). 
Under occupancy of N-linked sites on many glycoproteins is characteristic of Carbohydrate 
Deficient Glycoprotein Syndrome (CDGS) (Jaeken at al 1984) and this may reflect 
abnormalities in the glycosylation pathway. Human transferrin is a clinical marker for CDGS
N-linked glycan
O-linked
glycan
Peptode
tN EtN
Mu1 -2Ma1 -6Ma1 -4GlcN
Figure 5: The human erythrocyte complement regulatory protein, CD59, contains a GPI 
anchor
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CH, O
C H o -C H -C H j-C H z-O -P - Q -P
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carbohydrate
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Figure 6: The lipid component of the dolichol phosphate precursor oligosaccharide
and has two glycosylation sites, both of which are normally occupied. Some of these sites 
are not occupied in transferrin from CDGS patients, and the resulting abnormal glycoforms 
have been resolved and quantified in this thesis (ch.5). Site occupancy may also be 
controlled at the protein level. The three dimensional structure of the individual protein has 
a role in determining the extent of its glycosylation (Goochee et al 1992). A number of 
mechanisms may be involved, including the position of the glycosylation site in the protein. 
N-linked sites at the exposed turns of p-pleated sheets, which may be close to proline 
residues, are normally occupied while those close to the amino- or carboxy termini are 
generally less efficiently glycosylated. For example, the cytokine interleukin-1 p, which has a 
potential glycosylation site at Asn 7 Cys Thr, is 50% glycosylated when expressed in 
Saccharomyces cerevisiae. Increasing the distance between the Asn 7 residue and the 
signal processing site to at least nine amino acids resulted in almost 100% glycosylation of 
the sequon (Livi et al 1991). Another influential factor may be the local environment of 
amino acids which surround the sequon. In particular, folding or packaging of the protein 
which involves disulphide bridges may hinder glycosylation as is the case with IL-6. It has 
been shown that eliminating the disulphide bond between Cys 45 and Cys 51 increases the 
efficiency with which the sequon at Asn 46 is glycosylated (Hasegawa et al 1992). The 
polypeptide sequence may determine the speed with which protein folding renders the 
sequon inaccessible, and this may result in a 'competition' between the rate of folding and 
the addition of the dolichol linked precursor (Savvidou et al 1984). In general, glycosylation 
at one site does not determine the sequon occupancy of another. For example, the rabies 
virus glycoprotein has a sequon at Asn 37 Leu Ser which is not normally glycosylated; the 
glycosylation efficiency at this site is not significantly increased when the normally 
glycosylated sequons at Asn 247GluThr and Asn 319LysThr are deleted (Shakin-Eshleman 
et al 1992). In this thesis three enzymes all of which contain one variably occupied N- 
glycosylation site have been studied. The possibility that variable site occupancy may 
modulate functional activity has been examined in the natural glycosylation variants of 
ribonuclease (RNase A and B), tissue plasminogen activator (tPA type I and II) (Fig. 8) and 
plasminogen (type 1 and 2).
1.5 Cell specific glycosylation
Glycosylation allows the cell a means of modifying many different proteins without recourse to 
the genome, and to respond flexibly to both transitory changes which occur during the cell 
cycle, and developmental changes in the organism. For cells in stasis a steady state is 
assumed to prevail in each of the subcellular compartments and the final populations of 
glycoforms are reproducible and not random. This may change, as for example when cell 
culture conditions cause both enzyme and substrate levels to vary. The cells respond to the 
changing conditions by modulating the expression of glycoproteins, glycosylating enzymes and 
sugar nucleotides. Different cell lines contain different repertoires of glycosylating enzymes and 
may process the glycans attached to the same protein in a highly specific manner. For 
example, Thy-1 expressed in rat brain has no glycoforms in common with the same protein
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Figure 7: The synthesis of the dolichol phosphate precursor. This takes place first on the 
cytoplasmic face and secondly on the lumen face of the ER.
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Figure 7b; Human CD2 shows site specific glycosylation
Asn 65 in domain 1 (upper domain) contains exclusively oligomannose sugars (Recney et a l l  992) 
while the two remaining sites in domain 2 (lower domain) contain complex and oligomannose 
glycans (ch 2c).
expressed in rat thymus (Parekh et al 1987). In this thesis differences in cell specific 
glycosylation machinery were explored by mapping the glycoform patterns of one protein, 
tissue plasminogen activator, expressed in ten different cell cultures using five different cell 
lines (ch.7). In mammalian systems polyclonal glycoproteins are secreted by mixtures of clones 
of cells which have many different sets and ratios of glycosyl transferases, and changes in the 
observed glycosylation patterns of such proteins may result from expansions in particular 
populations of cells. For example, the presence of increased levels of the agalactosyl 
glycoform population of polyclonal serum IgG in rheumatoid arthritis (RA) is well established 
(Parekh et al 1985) and has been noted in this thesis (ch.6). It has been proposed (Furukawa et 
al 1989) that agalactosyl IgG glycoforms in RA are secreted by a specific set of B-cell clones in 
which the IgG specific galactosyl transferase has decreased activity and affinity for UDP- 
galactose compared with that in normal B-cells.
1.6 Site specific glycosylation
A single multiply glycosylated glycoprotein starting in the endoplasmic reticulum with identical 
glycans may contain non-identical structures at each site after processing. For example, in rat 
brain Thy-1 site 23 (Asn-Asn-Thr) contains only oligomannose sugars while site 74 (Asn-Phe- 
Thr) contains both complex and hybrid structures and site 98 (Asn-Lys-Ser) is associated with 
complex, hybrid and oligomannose glycans (Parekh et al 1987). This indicates that, at each 
site, the combination of the local protein structure and the attached glycan constitutes a 
different structure as substrate for the processing enzymes. Another example of a 
glycoprotein which shows site specific glycosylation is CD2 (Fig7b). CD2 has three N- 
glycosylation sites, one of which (Asn 65), contains exclusively oligomannose structures 
(Recny et al 1992) while the remaining two sites (Asn 116 and Asn 126) contain a mixture of 
oligomannose and complex glycans (ch.2). A possible reason for the conservation of 
glycosylation at Asn 65 has been explored in this thesis. IgG shows site specific glycosylation: 
for example Fab contains more sialic acid than Fc and in RA the Fc contains higher levels of 
glycans terminating in N-acetyl glucosamine than those attached to Fab (ch.6).
1.7 The generation of glycoforms
An oligosaccharide chain attached to a protein is modified when a glycosidase or glycosyl 
transferase enzyme interacts with a specific glycoform of a glycoprotein. The structure of the 
developing glycoprotein is an important factor which modulates the efficiency of each reaction, 
and the reaction rates for a single enzyme interacting with a range of different glycoproteins 
and glycoforms varies according to the affinity of the enzyme for the substrate. At any time 
many different glycoproteins may be in the glycosylating pathway, simultaneously competing 
for the active sites of the enzymes. Reaction rates also depend on the relative concentrations 
of enzyme to substrate. If these are not optimal some glycoprotein substrates in the pathway 
may be not processed, allowing variations to arise in the glycosylation of different proteins and 
microheterogeneity to develop in the glycoform population of a single glycoprotein. Another 
factor which increases the potential for heterogeneity is suggested by the finding that some
MFigure 8: Schematic model of tissue plasminogen activator type I (above) and II (below).
Tissue plasminogen activator is composed of five domains of domains: the fibronectin type 1 
'finger' module, the epidermal growth factor-type (EGF) domain, kringles 1 and 2 and the catalytic 
serine protease domain. This model was constructed using the co-ordinates of the finger and 
growth factor pair (Smith et al 1995), and kringle 2 (de Vos et al 1992) from human tPA. Kringle 1 
has been modelled by homology. The figure illustrates the relative sizes of the sugars with respect 
to the protein and the site specific glycosylation. The oligomannose sugars at site Asn 117 and 
complex structures at Asn184 and Asn 448 are shown in green. The lysine binding site and the 
catalytic triad are highlighted in red and yellow respectively. Type II t-PA lacks glycosylation at Asn 
184. Comparison of the glycosylation of types 1 and 2 tPA suggests that glycosylation at site 184 
may sterically interfere with lysine binding. (Rudd et al 1995)
glycosyltransferases are localised throughout the Golgi stacks (Paulson and Colley 1989). One 
of these is (3-galactosyl a2,6-sialyltransferase which, by competing with p-N-acetyl 
glucosaminyl transferase for terminal galactose residues, initiates a competition between chain 
elongation and chain termination. As a result of many factors glycoproteins with a range of 
glycans at different stages of processing may be transported into the next subcellular 
compartment to encounter a different set of enzymes. Since a glycoprotein which fails to be 
processed by one enzyme cannot become the substrate for the next, modification of the glycan 
chains will terminate whenever the developing glycoform is unable to interact further with the 
specific glycosylation machinery available in the cell. The glycoproteins which emerge from the 
trans-Golgi are the end products of a series of enzyme reactions in which the immature 
glycoprotein generated by one reaction becomes the substrate for the next. Glycoproteins, 
therefore, may be differently glycosylated from each other even when expressed in the same 
cell (ch.2) and moreover single glycoproteins generally consist of mixtures of glycosylated 
variants or glycoforms.
1.8 Key steps in the glycosylation pathway determine the class of glycan
Several key steps are involved in the biosynthesis of N-linked oligosaccharides; together these 
determine which of the potential glycosylation sites in the protein will be occupied, the class of 
the oligosaccharides (oligomannose, complex or hybrid) located at each site, and the terminal 
residues on the sugars. The efficiency of these key enzyme reactions and those which refine 
the basic structures in intermediate glycosylation processing, determine the final structures of 
the glycans. Initiation of glycosylation in the ER is mediated by an oligosaccharyl transferase 
which transfers the oligomannose precursor to the potential glycosylation site in the peptide. 
The pattern of cleavage of the mannose residues in the oligomannose precursor, 
GICgMangGlcNACg. by a-mannosidase I controls the proportions of Man 6-Man9 oligomannose 
glycoforms which will be in the final mixture of glycosylated variants. Processing of the 
oligomannose Man 5 glycans to hybrid structures in the Golgi follows the trimming of Man 8 
oligomannose structures by a-mannosidase I to Man5. When presented in the context of an 
appropriate protein structure this glycan is a substrate for N-acetyl glucosaminyl transferase I 
which may substitute N-acetyl glucosamine on the a1,3 arm of the glycan. Branching to 
multiantennary structures requires the action of a series of N-acetyl glucosaminyl transferase 
enzymes (Schacter 1986), one for each antenna (Fig. 9). The number of antennae in mammals 
ranges from 2-4 but hen oviduct, which contains GlcNAc transferase VI, can make a penta- 
antennary structure. Processing to complex sugars depends on the removal of the two 
remaining terminal mannose residues on the a l ,6 arm of the glycan by a-mannosidase II. The 
product of this reaction is a potential substrate for (3-N-acetyl glucosaminyl transferase II which 
may add N-acetyl glucosamine to the 1,6 arm of the glycan, committing the glycoprotein to the 
complex sugar processing pathway. This pathway may terminate after the addition of galactose 
to one or both arms of the glycan or continue to extend the complex glycan by the addition of 
polylactosamine units (Gaipi,4GalNAc). Termination steps may be regulated by enzyme : 
substrate ratios, and oligomannose structures may be terminated at any stage of the trimming
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Figure 9: The GlcNAc transferases required for branching. Five antennae can be initiated 
on ttie Mana1,6(Mana1,3) Man/31-4GlcNAcfi1-4GlcNAcfi-Asn core of N-glycans by the GlcNAc 
transferases I, II, IV, and V. A bisecting GlcNAc can be added by GlcNAc tranferase III. (Figure 
taken from Oxford GlycoSystems catalogue 1994)
process which reduces Man 9 structures to Man 5. Complex or hybrid structures contain 
processed arms which terminate in galactose, N-acetyl glucosamine or sialic acid.
1.9 Many enzymes are required to process the oligosaccharides on a glycoprotein
Each of the key steps requires the interaction of the glycoprotein with one or more highly 
specific enzymes (Reviews; Natsuka and Lowe 1994, Schacter 1991). For example, 11 
different enzymes are required to attach and process one of the most common N-glycans in 
mammalian systems, the sialylated core fucosylated biantennary complex N-linked glycan 
(Fig.1) demonstrating how many aspects of cellular structure and metabolism are committed to 
glycoprotein synthesis. It has been calculated (Natsuka and Lowe 1994) that there must be in 
the order of a few hundred distinct glycosyltransferases, and the corresponding genes, to 
synthesise the many different oligosaccharides identified in mammalian species. Some 
glycosyltransferases are themselves glycosylated, and many are processed into soluble forms 
by the action of proteases which release them from the Golgi membrane. While each glycosyl 
tranferase with its corresponding sugar nucleotide can catalyse the synthesis of only a single 
glycosidic linkage, multiple distinct enzymes can catalyse the synthesis of identical sugar 
linkages, for example five a l ,3 fucosyl tranferase genes have been cloned and characterised. 
To date some 30 glycosyltransferases have been characterised. Despite the finding that there 
is very little, if any, primary sequence homology between enzymatically distinct 
glycosyltransferase families, the enzymes which have been cloned suggest that there is a 
common topology. In general, the enzymes consist of a short (<25 residues) amino-terminal 
cytoplasmic domain, a single transmembrane segment and a larger carboxyl- terminal catalytic 
domain (generally more than 325 residues) in the lumen of the Golgi apparatus. Superimposed 
on the direct enzyme regulated mechanisms is the modulation of substrate availability 
controlled by the 3-dimensional structure of the protein, and it is the combination of these 
factors which directs the glycosylation of each protein.
2. The role of oligosaccharides In modifying structure and functional activity and In 
recognition
Some general principles relating to the role of oligosaccharides which are relevant to this thesis 
are discussed in the following three sections. First, oligosaccharides modify the local structure 
and overall dynamics of the protein to which they are attached. Second, oligosaccharides may 
modify the functional activity of a protein and third, oligosaccharides may be involved in 
molecular recognition events (review: Rademacher et al 1988).
2.1 Oligosaccharides modify the local structure and overall dynamics of proteins
X-ray crystallography has shown that each region of homology in the IgG molecule corresponds 
to a compact, independently folded unit, and that these are linked together by short sections of 
polypeptide chain. Each domain consists of two p-pleated sheets with anti-parallel strands 
connected by loop regions. This general pattern has been termed the immunoglobulin fold 
(Amzel and Poljak 1979). Crystallographic studies on immunoglobulin Fc fragments
Figure 10: The Fc fragment of IgG
The model is based on the crystal structure of Diesenhofer (1981). The region between the two 
CH2 domains accommodates the oligosaccharides which are attached to Asn 297 on each heavy 
chain. The a1,3 arms of the glycans form a bridge across the domains while the a1,6 arms interact 
with the protein surface (ch6). The a l,  6 arm of the complex biantennary oligosaccharide attached 
to the heavy chain on the left contains galactose (red) and terminates in sialic acid (red) while the 
glycan on the right terminates in galactose (red). In rheumatoid arthritis there are increased level of 
glycoforms in which both sialic acid and galactose are absent and which therefore terminate in N- 
acetyl glucosamine. In contrast to the C lq and Protein A binding sites, which are at the carboxy 
terminal side of Asn 297 (Phe 319 and He 332), the monocyte binding site involving residues 234- 
237 on the lower hinge region is markedly affected by the removal of carbohydrate.
(Diesenhofer 1981; Sutton et al 1983) have shown that, unlike other immunoglobulin domains, 
the two CH2 domains do not form extensive lateral associations. The resulting interstitial region 
accommodates the oligosaccharides, which are attached to Asn 297 on each heavy chain, such 
that the 1,3 arms of the complex carbohydrates form a bridge across the domains and the 1,6 
arms interact with the protein surface (Fig. 10). The effects of glycosylation may be highly 
specific. Both the C lq and protein A binding sites on IgG are located in the CH2 domain 
between Phe 319 and lie 332 (distal or at the carboxy terminal side from the N-linked 
glycosylation site). Neither of these functions is markedly affected by the absence of 
carbohydrate (Leatherbarrow and Dwek 1983; Leatherbarrow et al 1985). However the binding 
of monocytes, which involves residues 234-237 (proximal to the amino terminus) on the lower 
hinge region, is eliminated in aglycosylated monoclonal murine IgG. This may be because the 
absence of sugars results in a lateral movement of domains in the hinge region relative to the 
normally glycosylated antibody. Moreover, in aglycosylated IgG a protein structural change has 
been detected by IN NMR at His 268, which is also in the vicinity of the lower hinge. These 
data suggest that the oligosaccharides may stabilise a particular hinge conformation essential 
for monocyte binding. The spatial relationship between the CH2 and CH3 domains, on the other 
hand, does not seem to depend on the presence of the oligosaccharides since, in their 
absence, protein A and C lq binding are unaffected.
Bovine pancreatic RNase contains one N-linked glycosylation sequon (Asn 34 Lys Thr). It 
occurs naturally as both the non-glycosylated form, (RNase A) and a mixture of glycosylated 
variants collectively known as RNase B. NMR structural studies (Joao et al 1992) have 
compared the hydrogen-deuterium solvent exchange rates for the NH protons of RNase A and 
B. The presence of the sugar decreases the exchange rate in 30 of the 124 amino acid 
residues suggesting that the overall dynamic stability of the molecule is enhanced such that it 
becomes more rigid. Some of the affected residues are close to the oligosaccharide attachment 
site, others are as far away as 30A, while three (Glyl 1, Asn 44, and His 12) are involved in the 
active site, which catalyses the cleavage of the phosphodiester linkages of RNA. The sugars 
attached to proteins are large compared to the domains to which they are attached. For 
example the glycans on tPA (Fig. 8) are approximately the same size as a kringie region (3nm), 
and a single monosaccharide unit (O.Snm) is approximately the same size as a tryptophan ring. 
The dynamics of the sugar and the flexibility of the Asn side chain allow oligosaccharides to 
shield large areas of the protein surface (Fig. 11, Woods et al 1994). Thus sugars may modify 
the dynamics, stability and functional activities of the proteins to which they are attached.
2.2 Oligosaccharides may modify the functional activity of a protein
Oligosaccharides may modify the functional activity of an enzyme by steric hindrance of a 
functionally important site. Tissue plasminogen activator (t-PA) (Fig.8) is a serine protease 
glycoprotein consisting of five domains: a fibronectin linger' domain, an epidermal-growth 
factor domain, two kringles and the catalytic serine protease domain (Ny et al 1984, Patthy 
1985). Binding sites for fibrin are present within the 'finger' and kringle domains. There are two 
main classes of glycosylated variants of the molecule. Type I and Type II; Type I has three N-
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Figure 11: The Man 9 oligomannose oligosaccharides attached to RNase B
The dynamics of the sugar and die flexibility of the Asn side chain allow the oligosaccharides to 
shield large areas of the protein surface (Woods et al 1994). The model shows the effect of 
flexibility of the Asn-34 side chain on the orientation of the oligosaccharides attached to RNase B. 
The Man9 glycoform is shown based on the crystal structure (yellow CPK spheres) (Williams et al 
1987) with an overlay of-10 oligosaccharide conformations. The total van der Waals surfaces of the 
oligosaccharides are illustrated by white dots.
linked sugars, at Asn 117, Asn 184 and Asn 448, while Type II has only two, at Asn 117 and 
Asn 448. In addition to structural differences in t-PAs derived from various cell lines, functional 
differences have been established by comparing the activity of Type I and Type II in assays 
which involve the kringle 2 domain in which the variably occupied sequon at site 184 is situated 
(Parekh et al 1989a, Parekh et al 1989b, Wittwer et al 1989). A two - fold reduction in the rate 
of t-PA mediated fibrin-dependent plasminogen activation has been observed. This may be the 
result of steric hindrance by the sugar of the kringle 2 lysine binding site which binds exposed 
lysine sites on partially degraded fibrin.
2.3 Oligosaccharides may be involved in molecular recognition events
Oligosaccharides may confer an orthogonal property on the protein, such as a mechanism for 
clearance, without affecting the other functions of the molecule. There are a number of 
clearance mechanisms, some of which are sugar mediated. For example, the hepatic asialo 
receptor recognises glycoproteins with terminal galactose residues which have become 
exposed as a result of de-sialylation by neuraminidase. Such a general mechanism allows the 
cell to attach the same oligosaccharide recognition units to many different proteins without the 
need to 'code' this in the DNA for the protein. Many of the biological functions of 
carbohydrates are mediated through recognition by a receptor. One of the most important 
classes of receptor is the calcium-dependent animal lectins (C-type lectins) (Drickamer 1988; 
Hoppe and Reid 1994; Weiss and Drickamer 1994). The prototype of this family is the 
asialoglycoprotein receptor, found on mammalian hepatocytes, which mediates clearance of 
glycoproteins. The receptor protein contains a single carboxy-terminal carbohydrate 
recognition domain (CRD). C-type CRDs have been found in a large number of proteins in 
association with a variety of effector domains. They are approximately 120 amino acids long 
and are characterised by 31 invariant or highly conserved amino acids. C-type lectins may 
therefore mediate carbohydrate-recognition in many different processes. X-ray data on the 
CRD from the mannose binding protein illustrates the type of recognition involved in the 
binding of oligosaccharides. The CRD shows specificity for terminal residues including 
GlcNAc, mannose, glucose and fucose and the interaction involves chelation of the sugar to 
the Ca2+ ion via cis hydroxyl groups (Fig. 12). There are also interactions between the CRD 
and the monosaccharide residues in the oligosaccharide which are mediated by water 
molecules - effectively increasing the surface area of the oligosaccharide in contact with the 
CRD. C-type lectins and their constituent CRDs display weak affinity for monosaccharides. 
The specificity for multi-branched oligosaccharides results from clustering of several CRDs, 
usually by the formation of oligomers of polypeptide chains each of which contains a single 
CRD.
Another important system which can involve oligosaccharide recognition is defence. Both the 
antibody molecule and the mannose binding protein recognise and bind oligosaccharides 
attached to pathogens, a step which may lead to their elimination. Some details of the antibody 
recognition of carbohydrate antigens have been worked out in a study of the binding of the 
antibody molecule to a cell surface oligosaccharide of pathogenic Salmonella typhimurium of
%Figure 12: The mannose binding protein
A single carboxy-terminal carbohydrate recognition domain of the calcium dependent lectin 
mannose binding protein binding an oligosaccharide terminating in N-acetyl glucosamine 
(Wormald, M. - unpublished data based on Weiss et al 1992). The sugar chelates to the ion 
(red) via the 3- and 4- hydroxyl groups. The structure is stabilised by interactions between the CRD 
and the monosaccharide residues in the oligosaccharide which are mediated by water molecules.
serogroup B involves all these types of interactions (Cygler et al 1991). These indicate that the 
antibody binding site contains specific sub-sites for individual monosaccharide units. Binding to 
these sub-sites involves four distinct types of interaction all of which may contribute to the 
thermodynamics of association of a neutral oligosaccharide with an antibody combining site. 
First, the precision with which the oligosaccharide fits the binding site determines the residues 
in the complementarity determining region (CDR) that will contribute significant van der Waals 
forces to the binding. Second, amino acids with polar side chains, such as His and Glu, may 
interact with hydroxyl groups on the sugars. Third, monosaccharides in particular conformations 
can present a planar hydrophobic face which can interact with the planar rings of aromatic 
amino acids such as Phe, Tyr and Trp. Often these are in a position to be stacked against 
aromatic regions of monosaccharides, in a sandwich-like arrangement. Finally, water 
molecules, sometimes bound to amino acid residues buried deep in the structure, can form 
hydrogen bonds linking protein to sugar. The sugar hydroxyls themselves can stabilise 
particular conformations of the oligosaccharide by forming hydrogen bonds between adjacent 
monosaccharide units. Oligosaccharide binding to the antibody molecule is therefore a result of 
a combination of events which allow individual monosaccharide subunits to bind in specific 
sites on the protein. Although the affinity of each interaction may be low, high affinity as well as 
high specificity are achieved from the presence and relative orientation of several subsites and 
their relative presentations.
In contrast, serum mannose-binding protein is a C-type lectin which mediates antibody- 
independent recognition of pathogens which contain a high concentration of mannose or N- 
acetylglucosamine on their surface. This recognition is followed either by complement fixation 
or by opsonization. The clustering of CRDs together in the mannose binding protein allows 
recognition in high affinity of multi branched oligosaccharide ligands such as occur in yeast 
mannans which contain a main a-(1,6) linked chain with short branches of 1-3 mannose units 
linked either a-(1 ,2) or a-(1,3).
Oligosaccharides are frequently located on cell surface proteins where they are exposed and 
available to act as recognition markers. Some recent studies of lectin-carbohydrate interactions 
have suggested a number of reasons to suggest that oligosaccharides may be well adapted to 
mediate cell-cell or protein-protein interactions. The crystal structure of wheat germ agglutinin- 
glycophorin sialoglycopeptide receptor complex (Wright et al 1992) indicates that a single 
multivalent tetrasaccharide can bind several protein ligands. In addition, the tetrasaccharide 
was found to adopt different conformations in different lattice environments demonstrating that 
oligosaccharides can respond to accommodate the spatial requirements of lectin-protein 
ligands. Oligosaccharide flexibility is also important in the binding of the lectin LOL-1, isolated 
from the seeds of Lochrus (Bourne et al 1992). The sugar adopts an extended S-shape 
conformation when bound to the lectin. Two residues (Man4 and GlcNAcS) interact on either 
side of a phenyl ring, gripping it as a clamp while two more glycan residues fit into a partly 
hydrophobic cleft and participate in numerous interactions with the lectin. The X-ray data also 
shows that the lectin adapts to the sugar; the protein backbone was observed to move towards 
mannose in the formation of the complex, which was stabilised by hydrogen bonds. It has also
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been proposed from a study of the presentation of the N-linked complex sugar on human 
leucocyte elastase (Walter et al 1992), that one role of core fucosylation may be to order the 
presentation of the oligosaccharide by interacting with the protein and restricting the movement 
of the oligosaccharide in the region of the protein - carbohydrate linkage.
3. Introduction to the chapters in this thesis
The glycans associated with a range of leucocyte cell surface antigens (CDS domain 1, CD2, 
soluble CD59, CD48 and a chimera of CDS domain 1 and CD4 domains 3,4) have been 
analysed (ch.2). There were several reasons for this study. In the first place, the glycoproteins 
were all expressed in CHO cells and this allowed a study to be made of the extent to which the 
individual proteins direct their own glycosylation within a common biosynthetic pathway. 
Second, the glycans from CD2 and soluble CDS9 were analysed to provide additional 
information for the X-ray and NMR studies which have been carried out on this material. Third, 
this sequencing project provided an opportunity to explore some new technology and develop 
some alternative strategies to those used in conventional approaches to oligosaccharide 
analysis (ch.8). The glycosylation of CD59 from human erythrocytes was also examined and 
the glycans within the GPI anchor compared with those N-linked to the protein (ch.3). 
Examination of a molecular model explored a role for the N-linked sugar in orienting the active 
site towards the binding site in C8 and or C9 which has been proposed by Ninomiya et al 
(1992). In general, many functions for sugars have been established both in recognition and in 
modifying functional activity, however the consequences of the arrays of glycoforms which are 
associated with individual glycoproteins have seldom been addressed. In the second part of 
this thesis the technical difficulties (ch. 8) involved in isolating and analysing single glycoform 
populations have been addressed in a number of systems (Ch.4-7). Individual sets of 
glycoforms were obtained either by modification of the natural population (RNaseB, transferrin, 
IgG) or by isolating natural glycosylation variants (RNase A and B, tPA types I and II, and 
rheumatoid factor IgG). Individual pure glycoforms or specific subsets of glycoforms were 
analysed, isolated and examined in a variety of assays. Single, pure glycoforms of RNase were 
prepared and examined for their ability to confer stability on the protein and to shield areas of 
the protein surface (ch.4). The glycoforms of transferrin were modified using exoglycosidase 
enzymes and variations in the glycoform populations with disease were monitored by capillary 
electrophoresis (ch.5). Pure glycoforms of IgG, Fab and Fc were prepared to examine a role for 
specific sugars in recognition (ch.6). The activity of cell type specific sets of glycoforms of tPA 
was tested, revealing a subset with increased fibrin dependent and independent activity. 
Finally, the role of variable sequon occupancy in the modulating the kinetics of the interaction 
of tPA with plasminogen types 1 and 2 was explored (ch.7). The results suggested a possible 
role for glycosylation in modulating the protease cascade associated with remodelling of the 
extracellular matrix. As a preliminary step to probing this possibility the glycosylation of 
gelatinase B, an enzyme involved in this cascade, was determined (ch.8).
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Figure 13: The largest natural glycoform of bovine pancreatic ribonuclease B, RNase Man9 
(Woods et al 1994). The natural glycoform population, containing a mixture of glycoforms with from 
5-9 mannose residues attached through the chitobiose core to Asn34, was enzymatically modified 
to give the single, electrophoretically pure glycoforms of RNase f\/lan5, Mani and fJlanO (ch.4).
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Abstract: The glycosylation of proteins is a complex event which is controlled by the 
interactions of the specific glycosylation machinery within the cell with each developing 
glycoform. In this chapter the extent to which the individual protein can control Its final 
glycosylation pattern has been explored by analysing the glycosylation of the extracellular 
regions of the soluble recombinant forms of five leucocyte antigens all expressed in CHO cells. 
The antigens, which are members of different superfamilies, were human CD59 (Ly6), human 
CD2 (IgSF), human CDS domain! (ScR), human CDS/rat CD4d3,4 (IgSF) chimera and rat 
CD48 (IgSF). Sialylation varied from 100% in the chimera to 10% in CD2, oligomannose 
structures ranged from 46% in CD2 to 0% in CDSdl and the chimera. CDS9 contained the 
highest proportion of multiantennary and polylactosamine glycans (4S%); at the other extreme 
CDS contained none. Interestingly, CDS contained only one glycoform and addition of the IgSF 
protein, CD4d3,4 to CDSdl did not alter the processing significantly. Only CDS and the 
chimera, which contain stretches of Pro/Ser/Thr contained O-glycans. These results indicate 
that both the developing glycan and the local protein structure around the glycosylation site are 
involved in the addition of monosaccharide residues by the tranferase enzymes. Although all 
glycoproteins begin in the endoplasmic reticulum with the identical oligosaccharide precursor, 
GIC3 MangGlcNAc2 , they emerge from the Golgi with a set of unique glycoforms whose 
processing is controlled by the protein to which they are attached.
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Figure 1; The glycoproteins which were analysed in this study.
Soluble human CD59, human CD5 domain 1, human CD5/rat CD4d3,4 chimera, human CD2 
and human CD4 were all expressed in CHO cells.
Protein specific glycosylation patterns of five leucocyte cell surface 
antigens expressed in Chinese Hamster Ovary cells. 
Introduction
1. Background:
1.1 T- cell surface antigens
It has been estimated that 20% of the T-cell surface is covered by characterised proteins many 
of which are heavily glycosylated (Williams et al 1987). These leucocyte antigens have been 
systematically named with a cluster differentiation (CD) number. The CD antigens can be 
grouped into approximately 10 different superfamilies according to sequence similarities in their 
extracellular domains. Three of these structurally distinct groups are the Ly-6, the scavenger 
receptor (ScR) families and the immunoglobulin (IgSF) superfamilies. In this chapter the 
glycosylation of a soluble form of a leucocyte antigen from each of these structural groups has 
been analysed (Fig.1). The extracellular regions of CD59 (Ly6), CDS (ScR) domain 1, a 
chimera consisting of CDS and CD4 (IgSF) domains 3 and 4, and CD2 (IgSF), were all 
expressed in the CHO-K1 cell line, allowing a study to be made of the extent to which individual 
proteins exposed to the same biochemical pathway can control their own glycosylation.
The Ly-6 family contains molecules with a structural unit consisting of 70-80 amino acids 
containing 10 cysteine residues. The protein was first identified in the mouse and subsequently 
homologues of the Ly-6 antigens have been found in rats but not in humans. Human CD59 has 
been identified as a member of the Ly-6 super family, however there are too many differences 
in the sequence for it to be a Ly-6 homologue. Interestingly, all the members of the Ly-6 family 
so far identified are attached to cell surfaces by a GPI anchor; in addition to the analysis of the 
glycans of soluble CD59 in this chapter, the glycans associated with the GPI anchor of human 
erythrocyte CD59 have been analysed in this thesis (ch3).
CDS, of which domain 1 was analysed in this study, was the first member of the ScR family to 
be identified. It contains three scavenger receptor domains in the extracellular region and these 
were later identified in other molecules including the macrophage ScR type I. The function of 
the C-terminal 110-amino acid cysteine rich domain is not known and no tertiary structural data 
is available. Interestingly, the class II macrophage scavenger receptor, which is identical to the 
class I type in every way except that the C-terminal domain is replaced by a 6-amino acid C- 
terminus, mediates the endocytosis of acetylated low density lipoproteins with essentially the 
same broad specificity and affinity as the type I molecules (Freeman et al 1990).
The IgSF is a large group of structurally related proteins that function in the immune system 
mainly in cell - cell recognition (Williams 1987; Williams and Barclay 1988). The various 
members of the superfamily are built of domains of approximately 100 residues each having a 
structure formed by two p-pleated sheets packed face to face. Individual members can differ in 
the number and size of strands in the two p-sheets, and in the size and conformation of the
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The basic structural component of the immunoglobulin superfamily is the immunoglobulin fold. 
The two p-sheets of the fold consist of anti-parallel p-strands containing 5-10 amino acids. 
Between the sheets a hydrophobic interior is formed from in-pointing hydrophobic amino acids 
that alternate in the p-strands with hydrophilic residues that point to the outside of the fold. The 
interaction between the sheets is stabilised by the conserved disulphide bond. The core of the 
fold consists of p-strands A, B and E in one sheet and G, F, and C in the other. These strands 
come from the first and last parts of the domain sequence, while in the middle there is 
considerable variation in sequence length. V and V-related domains have about 65-75 amino 
acid residues between the conserved disulphide bond, and there are 4 p-strands in each p- 
sheet plus a short p-strand segment across the top of the domain. In C domains the sequence 
between the disulphide bond is shorter (55-60 residues), giving rise to sheets with 4 and 3 p- 
strands.
(Taken from Williams and Barclay 1988.)
links between the strands. Nevertheless, similarities in sequences and structure allow the 
molecules to be grouped into sets based on three structurally distinct domains: variable (V), 
constant (C)1 and C2. The basic structural component of the immunoglobulin superfamily is the 
immunoglobulin fold (Fig.2). The Ig-related domains of non-lg molecules are described as 
belonging to V- or C-sets depending on whether they have a pattern of strands approximating 
to a V or C domain. The C1 set are distinguished from C2 set in some conserved sequence 
patterns. The glycosylation of three members of the IgSF, which all contain V and C2 domains, 
have been studied in this chapter: human CD2, rat CD48 and rat CD4 domains 3 and 4 which 
were expressed as a chimera with human CDS domain!.
1.2 The glycosylation of the leucocyte antigens in this study
Most of the leucocyte antigens are glycoproteins. The number of glycosylation sites varies 
from one molecule to another. For example, CD2 (M.Wt.37kD) has 3 Asn-linked sugars, 
CDSdl (11 kD) has 1, the CDS/CD4,d3,4 chimera (76kD) has three, CD48 (26kD) has 4 and 
CDS9 (19kD) has 1 (Fig.1). In most cases O-linked glycans have not been identified, although 
most molecules contain potential O glycosylation sites (Ser/Thr residues). Some, such as CDS, 
contain a peptide region rich in Ser, Thr and Pro residues and this is a common feature of O- 
glycosylated peptides (see ch.8 section 3 discussion). The approximate sizes of a V-domain 
and the glycans which are attached to it can be compared. The molecular weight of an N-linked 
sugar is of the order of 2kD, the length of a complex biantennary glycan is about 3nm, each 
sugar is about 0.6nm in length. A V domain is about 3nm long and has a molecular weight of 
about 12.SkD. On a weight for weight basis the sugars occupy a higher molecular volume than 
the proteins which are more densely packed, therefore in many instances the length of the 
sugar and the diameter of the antigen domain to which it is attached are of the same order of 
magnitude. The glycosylation of leucocyte antigens has not been analysed in detail, with the 
exception of rat and human soluble CD4 (Ashford et al 1993), rat CD2 (Davis et al 1993) and of 
one of the sites on CD2 (Recny et al 1992). The functions of the sugars are not generally 
known. The ligand (CD58 in human and CD48 in rat) and antibody binding properties of CD2 
were reported to be dependent on glycosylation (Recny et al 192; Withka et al 1993), although 
this has not been confirmed (Davis et al 1995). However de-N-glycosylation of human 
erythrocyte CD59 with N-glycanase resulted in an 88% reduction of the C5b-9 complement 
inhibitory activity of the protein, and it has been proposed that the glycans attached to CD59 
may orient the binding site towards its ligand, the C5b-9 complex (Ninomiya et al 1992).
1.3 The role of the protein In oligosaccharide processing
Some of the general principles which control glycosylation were discussed in chapter 1. In the 
following section some of ways in which the protein structure regulates the fine details of glycan 
processing are addressed.
The protein structure controls the specific glycosylation at individual sites
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Within a specific cell type the protein structure may influence the class of glycan, the extent of 
elongation, and the termination steps in a site specific manner. A single, multiply glycosylated 
glycoprotein starting in the endoplasmic reticulum with identical glycans at each site may 
contain non-identical structures after processing. Although different glycan structures in 
different proteins from the same cell could be explained on the basis of different compartments 
and enzyme exposures, this is not the case for a single molecule, and this indicates that each 
of the initially identical oligosaccharide precursors in a protein represents a different structure 
as substrate for the processing enzymes. For example, in rat brain Thy-1 site 23 (Asn-Asn-Thr) 
contains only oligomannose structures while site 98 (Asn-Lys-Ser) is associated with complex, 
hybrid and oligomannose structures and site 74 (Asn-Phe-Thr) contains both complex and 
hybrid structures (Parekh et al 1987). The local three dimensional structure of the protein 
determines the proximity of the protein surface to the glycans and this may be an important 
factor which determines the glycosylation pattern at individual glycosylation sites on proteins 
expressed in a single cell by controlling the affinity of different enzymes for the developing 
glycoforms. In multidomain proteins the quaternary structure may also influence site specific 
glycosylation and this is demonstrated by a study of the MAC 1 integrin which contains the 
subunit and LFA1 integrin which contains the subunit. These glycoproteins have a common
subunit (p) and the ap-dimers form before processing making it possible to compare the 
glycosylation of the p subunit sites and to determine the influence of different a-subunits on 
processing (Dahms and Hart 1986).
The protein influences the class of glycans
In the early stages of processing the protein may shield the oligosaccharide from the 
mannosidase enzymes, so that in bovine pancreatic RNase B, 6% of the structures are not 
processed beyond Man 9, 17% remain as Man 8 glycoforms, 11% terminate at Man 7, 20% of 
the glycans reach the Man 6 stage and only 48% are processed fully by the mannosidase 
enzymes to Man 5. In other molecules such as IgG, no oligomannose structures are detected in 
the final population of glycoforms. Interestingly, the protein structure may also affect some of 
the later steps in glycan processing, when the terminal sugars are further from the protein, as 
well as the earlier steps when the smaller oligosaccharides are close to the protein surface. In a 
model system the relative rates of reaction were determined for individual glycosyl transferases 
presented with a single substrate which was either free or exposed at different distances from 
avidin protein (Yet et al 1988). Substrates were prepared in which glycans derivatised with 
asparaginyl biotin were immobilised to avidin with and without the insertion of a hexanoyl 
hydrocarbon spacer arm. The rates of reactions of the free biotinylated sugars were compared 
with those for the same sugars closely bound to the avidin surface or held at a distance by the 
hexanoyl spacer arm in assays in which each substrate was exposed sequentially to the same 
set of complex sugar processing enzymes. The major effect of the protein in the avidin 
derivatives was in promoting the early stages of glycosylation, especially the addition of 
GlcNAc to the Man 5 glycan. This step, which ensures that the sugars will be processed to 
complex and hybrid oligosaccharides, was essentially eliminated in the molecule which
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complex and hybrid oligosaccharides, was essentially eliminated in the molecule which 
contained the spacer arm. Compared with the free biotinylated glycans the final termination 
steps were retarded in protein bound complex sugar populations which contained a greater 
proportion of the intermediate glycans, Galt and SAGal2. These data suggest that the distance 
of the protein surface from the oligosaccharides influences both the affinity of the GlcNAc 
tranferase and the extent of sialylation. In this thesis the rate of digestion of the a1,2 linked 
oligomannose sugars attached to RNase B with A. Saitoi a1,2 mannosidase indicated that this 
reaction was 150 times slower than the rate of digestion of the free sugars, and that the Man6 
glycoform was more resistant than the Man7,8 or 9 (ch.4 section 4.1). This suggests that there 
may be a similar role for the protein in biosynthesis. The individual protein structure may also 
control the class of glycan by blocking key enzyme reactions and interestingly, in the study by 
Yet et al (1988) described above it was not possible to produce hybrid structures with the 
biotinylated substrates either when free or when avidin bound. Nor could tri- and tetra- 
antennary structures be developed, even on the free biotinylated glycans. Enzyme specificity 
stipulates a rigorous order of processing and these data suggest that if branching requires 
blockage of an alternative processing reaction, such as the addition of GlcNAc residues to the
1,3 arm, the protein structure is required to provide this. Alternatively, proteins with 
multiantennary glycoforms may contain positive effectors responsible for the additional 
branching suggesting that the protein may regulate the extent of branching not only by steric 
hindrance, but also through the stimulation of particular steps. Binding studies showed that the 
rate differences between the activities of the transferases with respect to the avidin bound and 
free substrates resulted from an altered turn over rate (Vmax) (typically 25x decrease in Vmax, 
2-3x increase in Km going from free to bound substrate). Thus the processing GlcNAc 
transferases can recognise and bind either form of the substrate equally well but only 4% of the 
interactions are productive when the glycans are bound to avidin. It has been proposed that 
these non-productive enzyme-substrate complexes involve distortion of the conformation of 
either the enzyme or the substrate.
The conformation of the glycan may also influence the affinity of transferases for a particular 
glycoform and if, for example, the protein structure crowds the reducing end of the sugar the 
conformation of some glycoforms may be disturbed altering the affinity of the processing 
enzymes. In particular, the outer sugars on the 1,6 arm of oligomannose, hybrid or bisected 
complex sugars are flexible and can adopt a conformation in which the outer arm sugars are in 
close proximity to the reducing end (Brisson and Carver 1983). In some glycoproteins a 
particular conformation such as this may be inhibited by the proximity of the protein surface. In 
some instances the structure of the developing glycan may determine the structure of the final 
glycoform, for example, in the synthesis of sialyl Lewis X (sialyla2,3Gal(31,4(Fuca1-3)GlcNAc) 
a2,3 sialylation precedes outer arm a1,3 fucosylation, and the sialyl transferase is unable to 
process a fucosylated structure (Kitagawa and Paulson 1994; Lowe et al 1991). Both the glycan 
structure and the substrate specificity of individual enzymes may therefore impose rigid 
sequential order on the processing steps of branched oligosaccharides.
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The protein influences the elongation and termination steps
The addition of sialic acid is a chain termination step. Consequently, in contrast to other 
monosaccharide residues, sialic acid is normally found only at the non-reducing termini of 
glycan chains, where it is linked a2- 3, -6 or, rarely, -8 to terminal galactose. Cells exert control 
over their glycosylation machinery to produce terminal glycosylation sequences in a cell type 
specific and developmentally regulated manner. CHO cells produce N-linked sugar chains with 
the terminal NeuNAca2,3Gaipi,4GlcNAc-R sequence and are therefore believed to lack the 
Gala2,6-sialyl transferase which synthesises the 2,6 linkage. Consistent with this conclusion an 
a2,6 sialyl transferase transfected into CHO cells competed with wild type a2,3 sialyl 
transferase and glycans containing both 2,3 and 2,6 sialic acid were synthesised (Lee et al 
1989). Interestingly, the subcellular location of the 2,6-sialyl transferase was similar to that of 
the wild type enzyme and extended from the cis to the trans Golgi indicating that termination 
can take place at many locations in the Golgi or ER, and as early as in the cis Golgi cisternae. 
In vitro studies with purified sialyltransferases have also demonstrated that Gala2,6-sialyl 
transferase competes with Gala2,3-sialyl transferase (Weinstein et al 1982). The role of the 
oligosaccharide in the addition of sialic acid to complex glycans has been explored in studies of 
several glycoproteins. The relationship between chain length, charge and sialic acid linkage has 
been investigated in glycoproteins from a mouse lymphoma cell line (Merkle and Cummings 
1987), thyroid glycoprotein (Edge and Spiro 1985), and fetal lactosaminoglycan (Fukuda et al 
1984). In general, these studies show that sialylation is more likely to occur in the early stages 
of processing and the incidence falls off as the chains become more elongated. Moreover, the 
sialic acid present on shorter oligosaccharides (less than 3 linear units of the repeating 
disaccharide 3Galf31,4GlcNAcp1) is more often a2,6 while the a2,3 linkage is more common in 
the relatively less sialylated longer polylactosamine extensions (Merkle and Cummings 1987). 
This suggests that the length of the glycan chain, and therefore the proximity of the protein 
matrix, are factors which regulate the addition of an a-2,3 or an a-2,6 linked sialic acid residue. 
However, a developing glycan containing terminal galactose need not necessarily be sialylated, 
but may terminate with galactose or be further elongated by the addition of terminal GlcNAc or 
polylactosamines. This suggests that in a homogeneous population of glycoforms the 
proportion taking each of the alternative processing pathways is a competitive event, controlled 
by the location and concentration of the various enzymes, the affinity of the developing 
glycoform for each and the transit time of each glycoform through the ER and Golgi.
1.4 Poly-N-acetyllactosamine extensions
Complex glycans which have not been terminated by sialic acid can be further extended by the 
addition of GlcNAc and Gal to the terminal galactose residues. The level of p-1,3 N-acetyl 
glucosaminyl transferase is the limiting factor for lactosamine (Galpl ,4GlcNAcp1,3) extensions 
rather than p-1,4-galactosyl transferase and the terminal sugar for complex glycans carrying 
lactosamine extensions is normally galactose. Polylactosamine extensions were first identified 
on human erythrocytes which may express glycoproteins with 5-15 repeats in one side chain.
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Tetrantennary N-glycan with polylactosamine 
extensions
+/. SAo2-3(Gaini -4GlcNAcpl -3)^ Galpi •4GlcNAcp1
Mana1
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* 1- SAo2-3(Gal(Sl-4GlcNAcp1-3)^ Galpi-iGlcNAcpl  4 ^
e~ Manal
+/- SAa2-6Galpl -4 GlcNAcpi
X>Y>Z
Figure 3: Complex tetrantennary structure with polyN-acetyllactosamlne extensions on
three branches. The lactosamine extensions (x,y,z) are preferentially added to the a  1,6 arm of 
the Manal, 6 branch of the primary mannose (x) which is>y>z. Sialic acid is more commonly 
linked in the a2,3 position to the Manal, 6 arm of the primary mannose, while the a1,2 branch 
of the a1,3 arm is more often associated with a2,6 linked sialic acid.
Both linear and branched polylactosamines may be modified to carry the ABO blood group 
antigens, and they also constitute the developmentally regulated I/i antigens. In infants under 
one year the I/i antigens are mainly linear polylactosamines (I), after which the structures 
become predominantly branched (i). Poly-N-acetyllactosaminyl repeats are more often found in 
the side chains attached to the a-mannose residue attached to the 1-6 arm of the C6p- 
mannose (fig. 3). Many of the glycoproteins which carry lactosamine extensions are membrane 
proteins. These include the type III membrane proteins, human erythrocyte band III (Fukuda et 
al 1984) and the lysosomal glycoprotein CD63 (Fukuda 1991). Based on these findings it has 
been suggested (Fukuda 1994) that the transmembrane section of the protein must cross the 
membrane more than once for lactosamine structures to be added to the glycans. However, 
thymocyte Thy-1, which has a glycosylphosphatidylinositol anchor contains 20% of 
polylactosamine structures (Parekh et al 1987) and in this thesis polylactosamines were 
identified on human erythrocyte CD59, which also contains a GPI anchor (ch3) rather than a 
transmembrane section. During processing proteins containing membrane anchors are located 
in the Golgi membrane and as a result may have extended transit times during which long 
polylactosamine extensions may be synthesised. Increased transit times have been shown to 
increase the polylactosamine content of the glycans attached to lamp proteins-1 and -2 (Wang 
et al 1991). In addition, the close proximity of anchored glycoproteins to the glycosylating 
enzymes, which are also anchored in the Golgi membranes, may increase the efficiency of the 
enzymes. The role of the protein in controlling the extension of the glycan chain has been 
investigated. In this respect the amino acid sequences of proteins carrying polylactosamines 
have been compared, but no consensus sequence has emerged that could provide a signal. 
However, it has been noted that the glycosyl transferases require access to the protein surface 
to process complex glycans. In the same way the three dimensional structure of the protein, 
including modifications such as O-glycosylation, may be important for the activity of p-1,3 N- 
acetyl glucosaminyl and p-1,4-galactosyl transferase enzymes in the processing of lactosamine 
extensions.
Thus the processing steps leading to complex or hybrid structures, extent of branching, and 
specific structures at the non-reducing terminals are determined by the interaction of individual 
oligosaccharides in the context of the local protein structure with the exquisitely specific 
processing apparatus available in each cell. In this chapter the possibility that differences in the 
structures of individual proteins may lead to oligosaccharide diversity has been explored in five 
leucocyte antigens expressed in the same CHO cell line.
2. The importance of controlling the glycosylation of recombinant leucocyte antigens
Many of the known functions of the glycosylated T-cell surface antigens involve protein-protein 
recognition and, for the most part, the roles of the oligosaccharides are not known. To probe 
aspects of recognition and function a number of cell lines have been established in which both 
intact proteins and constructs can conveniently be expressed, since the abundance of the
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intact proteins and constructs can conveniently be expressed, since the abundance of the 
natural proteins is generally low in biological samples. It is well established that glycosylation is 
cell type specific (Parekh et al 1989) and that the activity of recombinant glycoproteins may, as 
has been demonstrated with tPA (Parekh et al 1989), be significantly modified by glycosylation. 
Cell specific glycosylation is therefore a factor to be taken into account when selecting cell lines 
in which to express recombinant glycoproteins. In the absence of information concerning the 
role of the sugars, it is important to maintain the integrity of the oligosaccharides and to avoid 
problems with events such as folding, transport or secretion which may depend on specific 
glycan structures. This may be achieved by expressing the recombinant proteins in cell lines 
where the biosynthetic pathways are similar to those of the cell in which the natural protein is 
expressed. The Chinese Hamster Ovary cell line produces stable cells which are readily grown 
and transplanted; this cell line also has glycosylation machinery competent to modify proteins 
with a wide range oligosaccharides including those commonly associated with human 
glycoproteins.
Functional studies may include an examination of the role of glycosylation, and one common 
approach is to establish whether the N-linked oligosaccharides are essential for a particular 
function by comparing the activity of the natural material with aglycosylated or deglycosylated 
protein. There are several methods by which non-glycosylated protein can be prepared. First, it 
may be possible to de-N-glycosylate the native protein with PNGase F, and as has been shown 
in this thesis (ch.3 and 4); this depends on the extent to which the local protein structure can 
shield the sugar-amide linkage. An alternative method is to grow cells in the presence of 
tunicamycin, which inhibits the addition of the oligosaccharide precursor, GlcNACgMangGIc^, so 
that aglycosylated proteins are expressed. Cells grown in the presence of N-butyl 
deoxynijiromycin (DNJ), which inhibits the removal of glucose from the precursor, are secreted 
only as MangGICg glycoforms from which sugars can be removed by endo H (Davis et al 1995) 
which cleaves within the chitobiose core. There is also the possibility of making significant 
mutations such as replacing the asparagine residue required for the addition of the precursor to 
the protein although this involves a change in the primary sequence of the protein which may 
have important implications for the structure. A powerful approach which has been developed 
recently is to develop strains of animals or cells in which the genes for selected glycosylating 
enzymes have been deleted (Stanley et al 1994, Metzler et al 1994).
Analysis of the glycans is an important complement to the structural analysis of glycoproteins, 
since this is normally based on techniques such as X-ray crystallography and nuclear magnetic 
resonance (NMR), which do not define the glycosylation in detail.
3. Introduction to the studies in chapter 2
In this chapter the glycans attached to CD2 and soluble CD59 were characterised to give 
further information to the NMR and X-ray crystallography studies of these samples. Non- 
glycosylated human erythrocyte CD59 showed an 88% reduction in complement inhibitory
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In addition to determining glycosylation to complement structural and functional analysis this 
study also explores the extent to which an individual glycoprotein can control the biosynthetic 
processes which determine its own glycosylation, subject to the biosynthetic pathways available 
in a cell. The first stage in the N-linked glycosylation process involves the transfer of a 
GIC3 MangGlcNAc2  oligosaccharide precursor to some asparagine residues in the protein. 
During transport of the glycoprotein through the ER and Golgi this common precursor may be 
processed in different ways by the glycosidase and glycosyl transferase enzymes which are 
located in the ER and the Golgi stacks. A single glycosylated variant (glycoform) of a protein is 
the product of the particular series of enzyme reactions which have processed the 
GIC3 MangGlcNAc2  structures which were initially attached to it, and in general glycoproteins 
consist of collections of glycoforms. Within the same cell the glycosylation profiles of the 
oligosaccharides attached both to different proteins and to different sites on the same protein 
may be distinct from each other, although all the glycoproteins have been exposed to the same 
glycosylation machinery. This suggests that the local protein structure close to the glycosylation 
sites has some control over the sequence of enzyme reactions which determine its 
glycosylation. In this study the sugars attached to five cell surface antigens expressed in the 
same Chinese Hamster Ovary (CHO) cell line were analysed to investigate the extent to which 
individual glycoproteins influence the biosynthetic processes which determine the structure of 
their own glycans. The antigens are discussed in three sections: (A) soluble human CD59, (B) 
human CDS domain 1 and a chimera consisting of human CDS and rat CD4 domains 3 and 4 
(C) human CD2 and human CD48. In a complementary study (ch3) the glycosylation of human 
erythrocyte CD59 was analysed.
4. Methods
The general strategy shown below was developed for the analysis of the glycans attached to 
leucocyte antigens and some approaches to oligosaccharide sequencing involving newly 
developed anion exchange chromatography and mass spectrometric techniques were explored. 
(Details of these are in ch.8, which also includes the oligosaccharide sequencing methods used 
throughout this thesis.)
1. Release of glycans by hydrazine at 95°C
2. 2AB and tritium labelling
3. Determination of relative amounts of N, NA1 and NA2 glycans by WAX chromatography
4. Determination of nature of charged species: digestion with Arthrobacter Ureafaciens/ 
Newcastle disease virus neuraminidase
5. Separation of asialo glycans by P4 GPC
6. Analysis of oligomannose series by exoglycosidase digestions analysed by P4 GPC and MS
7. Analysis of asialo N-linked glycan pool by exoglycosidase digestions analysed by MALDI MS
8. Analysis of purified individual asialo N-linked glycans by RAAM analysed by P4
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Figurela: A schematic representation of CD59. The glycosylation of soluble (s) CD59 
expressed in CHO cells is discussed analysed in this chapter. The glycosylation of the native 
form of the molecule, which contains a GPI anchor, is discussed in chapter 3.
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Figure 1b: Preparation of recombinant sCD59 expressed in CHO cells. (A) sCD59 purified by 
affinity chromatography was applied to a Superdex S-75 gel filtration column and eluted in 
three fractions (1,11 and III). The arrow indicates the elution position of CD2 used as a molecular 
weight marker. (B) 5mg of fraction II used for oligosaccharide analysis was subjected to SDS 
PAGE analysis under reducing conditions in a 20% gel and stained with Coomassie blue 
(Kieffer et al 1994).
Ch. 2A The glycosylation of soluble human CD59 expressed in 
OHO cells
1. Background
The extracellular region of CD59 (Fig. 1a) consists of a single Ly-6 superfamily domain 
containing two N-linked glycosylation sequons (AsnSProThr and AsnlSCysSer), one of which 
(AsnS) is not occupied. CD59 is attached by a glycosylphosphatidyl inositol (GPI) membrane 
anchor to the cell surfaces of a wide variety of cell types including leucocytes, endothelial and 
epithelial cells, erythrocytes and placenta where it restricts the cytolytic activity of homologous 
complement by binding to C8 and C9 (Walsh et al 1992, Lachman 1991). sCD59 is a relatively 
flat, disc shaped molecule consisting of a two stranded p-sheet finger loosely packed against a 
protein core formed by a three stranded p-sheet and a short helix (Kieffer et al 1994). The 
structure and function of human erythroctyte CD59 is discussed in detail in the background to 
chapter 3.
Significant quantities (up to 2mg/l) of the extracellular region of CD59 required for NMR 
structural analysis (Kieffer et al 1994) were produced (Dr. Simon Davis, William Dunn School) 
by heterologous expression of the truncated cDNA in CHO cells. CD59 cDNA was modified by 
the insertion of a stop codon after the codon for Asn-70 of the mature protein sequence. This 
eliminated the region coding for carboxy-terminal segment which contains a cluster of 18 
mainly hydrophobic amino acids (residues 87-105) preceded by 8 polar amino acids, which, 
together define a typical signal peptide for GPI anchored proteins. The cleavage site for the 
anchor attachment, which is between Asn 77 and Gly78, (Tomita et al 1991) was also deleted. 
This soluble form of CD59 was purified from the supernatant of cell cultures of CHO cells by 
affinity chromatography using YTH53.1 monoclonal antibody (Davis et al 1989) and gel 
filtration. SDS PAGE analysis indicated that fractions II and III from the gel filtration column 
contained sCD59. Fraction III contains unglycosylated CD59, suggesting that glycosylation is 
not required for folding or secretion. The molecular weight of the glycosylated fraction II was 
approximately 14kD (Fig. 1b). NMR studies of this material identified resonances of the N- 
acetyl groups from at least three N-acetyl glucosamine residues, including two forming part of 
the pentasaccharide core common to N-linked glycans. The absence of a network of glycan- 
protein interactions suggested that the oligosaccharides behave as a flexible appendage to the 
protein. The analysis of the glycosylation, which is the subject of this chapter, was undertaken 
to provide additional structural information to complement the NMR analysis and also to 
compare the glycosylation of sCD59 with that of other proteins expressed in CHO cells to 
explore the effect of the 3-dimensional structure of the protein on glycosylation patterns. The 
oligosaccharide sequencing methods used here are described in chapter 8 of this thesis, and 
some details of the function of CD59 in controlling homologous lysis are discussed in chapter 3.
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2. Strategy
Glycans were released from sCD59 using the OGS GlycoPrep 1000. Fractions of the glycan 
pool were radiolabelled with tritium, fluorescently labelled with 2-aminobenzamide (2AB) or 
retained unlabelled for MS analysis. The relative amounts of neutral glycans (N), N-linked 
glycans containing a single charged group (NA1) and N-linked glycans with 2 charged groups 
(NA2) were determined by weak anion exchange (WAX) chromatography. The linkages and 
type of the charged species were characterised by determining the susceptibility to Arthrobacter 
Ureafaciens and Newcastle Disease Virus sialidases. Hydrodynamic volumes in glucose units 
(gu) were determined using P4 GPC. The molecular weights of the components of the glycan 
pool were determined by MALDI MS, and the products of exoglycosidase sequencing were 
monitored by MALDI MS. The pool was separated by charge and analysed by simultaneous 
exoglycosidase sequencing and mass spectrometry. A second fraction of the pool was 
desialylated and the components analysed by P4 GPC and exoglycosidase digestions involving 
the Reagent Array Analysis Method (described in chapter 8 secton 1.8).
3. Results
Glycans (130nmoles) were released from sCD59 (1.9ng) using the OGS GlycoPrep 1000 (The 
manufacturers estimate the recovery is >85%). 80% was radiolabelled with tritium (total counts 
7.2E8). 2% was labelled with 2AB; the remainder was retained for MS analysis.
3.1 Charge analysis of glycans released from sCD59
A fraction of the released glycans (2%, 2.6nmoles, 3.6E6) was analysed by WAX 
chromatography (Fig.2a) and the peaks assigned by reference to a set of fetuin standards 
resolved under the same conditions (Fig.2b). The glycans were again analysed by WAX 
chromatography after digestion with Arthrobacter ureafaciens sialidase (Fig.2c) and with 
Newcastle Disease Virus sialidase (Fig.2d). All structures are reduced to neutral with both 
sialidases, indicating that the charge is due to 2,3-linked sialic acid.
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Figure 2a: WAX chromatography profile of CD59 2AB labelled glycan pool.
N (neutral): 35%; NA1 (monosialylated): 35%; NA2b (dislalylated, biantennary) 12%; NA2t 
(dislalylated, tri-antennary or polylactosamlne) 18%.
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Figure 2b: Standard fetuin N-linked glycans analysed by WAX chromatography
CD 59 post AB neuraminidase
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Figure 2c: WAX chromatography profile of tritium labelled CD59 glycans post 
Arthrobacter ureafaciens neuraminidase digestion.
All charged species have become neutral; all charge is due to a2,3 or a2,6-linked sialic acid.
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Figure 2d: WAX chromatography profile of 2AB labelled CD59 glycans post Newcastle
Disease virus neuraminidase digestion.
All charged species have become neutral therefore all charge is due to 2,3 linked sialic acid.
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Conclusion:
Charge profile of glycan pool released from sCDS9:
N: 35% NA1 ; 35% NA2: 30%
3.2 Analysis of asialo glycans from sCD2 by hydrodynamic volume using P4 GPC 
A fraction of the tritium labelled glycan pool (53%; 70nmoles; 4E4cpm) was de-sialylated with 
Arthrobacter ureafaciens sialidase and analysed by P4 GPC (Fig. 3, Table 1) and MALDI MS 
(Fig. 4, Table 2). Schematic representations of the structures are shown in figure 7.
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Figure 3: P4 GPC profile of asialo glycans from soluble human CD59
Peaks 1-8 contain complex glycans, peaks l-lll contain oligomannose structures (Table 1 and 
figure 7).
3.3 Structural analysis of asialo glycan pool by sequential exoglycosidase digestions analysed 
by n/IALDI MS
The asialo glycan pool was sequentially digested with the following enzymes:
1. Bovine Testes (3-galactosidase
2. Jack Bean p-hexoseaminidase
3. Bovine Testes p-galactosidase
4. Jack Bean p-hexoseaminidase
5. Choronia Lampas a-fucosidase
After purification on mixed bed resins the products were analysed by MALDI MS (Fig. 5b-f ).
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Figure 4: MALDI MS analysis of asialo glycans from sCD59. The data in this figure are
analysed in Table 2 columns 2 and 3 and in figure 5.
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Peak no. G.U. %
M5 i 9.1 2.8
H3N3F 1 10 1.1
M6 ii 10.2 1.4
M7 iii 11.4 1.7
H4N3F 2 11 5s
H3N4F 3 12.5 1.8
H4N4F 4 13.5s
H5N4F 5 14 7 46
H6N5F 6 18 28
H7N6F (t) 7 '21.2 (t) 9.2
H7N6F (p) 7 2 1 ^ ( 0
H8N7F? 8 2& 6 4.8
9 i 26.4 3.2
Table 1 : Analysis of data from figure 3, the P4 GPC of sCD59
M: mannose; H; hexose; N: hexosaminidase; F: fucose
M5 '
iCh. mass MS : m/z BT Gal JB Hex BT Gal(2) JB Hex(2) 'CL Fuc
 ^ 1258.1 1257.9" 1257.9 1257 4 1257.8 1257.8' 1259.2
H3N3F 1 1283.13 1280.8 1282.5 1079.4 1080.2 1079.41 934.5
M6 1 1420.24  ^ 1418.9 1419.5 1419.8 1419.9 '  -  i ^1419.8M7 : 1582.38 1 1581.6 1485.6 —t-
H4N3F" j 1445.27 1444.6 1282.5 1079.4 1080.2 1079.4: "93^5
H3N4F 1 1486.32 1486.6 1485.6 1079.4 1080 2 1079.41 934.5
H4N4F i 1648.46 1647.7 1485.6 1079.4 1080.2 ^  1079.4! “' 934.5
H5N4F i  1810.6 1809.7 1485.6 1079.4 1080.2 1079.41 934.5
H6N5F 1 2175.93 2174.9 1850.6 1444.8 1283.5 1079 4' 934.5
H7N6F(p) 1 2541 26' 2540.9 2215.8 1809.9 1486.8 1079.4 934.5
H7N6F (t) 1 2541.26 2540.9 2053.8 1444.8 1283.5 1079.41 934.5
Table 2: Analysis of data from figure 4, the MALDI MS of sCD59 (columns 1-3) and of the 
sequential exoglycosidase digestions of the sCD59 asialo glycans (columns 3-7).
Ch. mass : chemical mass; MS;m/z ; experimental molecular weights from the m/z values;
BT Gal: bovine testes galactosidase; JB Hex: Jack Bean p-hexosaminidase; CL Fuc : Choronia 
Lampas fucosidase.
For diagrams of structures see figure 7.
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Figure 5a-f: MALDI MS analyses of sequential enzyme digestions of sCD59 asialo
glycans. (a) pool of asialo glycans from CD59 (b) after digestion with Bovine Testes p- 
gaiactosidase (c) after Jack Bean p-hexoseaminidase (d) after Bovine Testes p-gaiactosidase 
(e) after Jack Bean p-hexoseaminidase (f) after Choronia Lampas a-fucosidase. The results of 
this analysis are summarised in Table 2, and the information is incorporated into figure 7.
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Figure 7: Asialo glycans from sCD59 analysed by a combination of exoglycosidase 
sequencing, P4 GPC and MALDI MS showing termination of glycosylation at many points in the 
biosynthetic pathway. MS does not give linkage or arm specificities. Although some of this 
information was obtained by the use of specific exoglycosidase enzymes, the arm specificity 
assigned to the triantennary glycans is based on the probability that the GlcNAcal,6Mana1,6 
arm is the most likely to be extended (Fukuda et al 1984).
3.4 Confirmation of the structures of the two major asialo glycans using RAAf\/l 
The 14.4 and 17.5gu peaks from figure 3 were identified as H5N4F and H6N5F as shown in 
figure 6 . Peak 7 (21.2gu) was also subjected to RAAM analysis. No matching signatures were 
found, possibly because there are both tri- antennary and biantennary glycans with the same 
structural formula within this peak.
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Figure 6: RAAM analysis of peaks 5 and 6 from figure 3
3.5 Analysis of peak A (3gu). Attempts were made to identify this by MALDI MS. No signals 
were obtained at m/z ratios which correlated with known glycans and may be an artefact arising 
from an environmental contaminant. The peak was resistant to Bovine Testes (3-galactosidase.
A combination of sequential and RAAM exoglycosidase sequencing, P4 GPC and MALDI MS 
analysis allowed the structures in figure 7 to be assigned to the asialo glycans of sCD59.
3.6 Analysis of CD59 glycans after fractionation by charge
The 2AB labelled fractions from each of the peaks N, NA1, NA2b and NA2tp (Fig.2a) were 
desialylated with Arthrobacter ureafaciens neuraminidase and analysed by MALDI MS (Fig.8 a- 
d). The structural formulae consistent with the molecular masses, including the 2AB label 
(120D), are summarised in Table 3. All the glycans previously detected were present as neutral 
structures. All the complex glycans from H5N4 and above were also present both as mono- and 
di- sialylated species. In addition a small percentage of H5N5F was detected in the NA1 
fraction. This had not been identified in the earlier analyses.
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Figure 8: The MALDI MS analysis of asialo 2AB labelled glycans from peaks N, NA1, NA2b and 
NA2tp (figure 2a). The data are analysed in table 3.
N(0) N(C) NA1
MS 1378.3
M6 1540.4
M7 1702.4
H3N3F 1280.2
H4N3 1565.2
H3N4F 1606.3
H4N4F 1647.6
H5N4F 1929.2 1929.3
H5N5F 2132.0
H6N5F 2294.7 2294.7
H7N6F 2658.6 2658.7
NA2(b) NA2(tp)
1929.1
2294.6
Table 3: MS analysis of 2AB labelled sCD59 asialo oligosaccharides separated 
according to charge (see figs 2a and 8). Numbers are m/z values from figure 8. N(0) /  N(C): 
neutral oligomannose or complex glycans, NA1: N-linked glycans with one charged residue, 
NA2: N-linked glycans with 2 charged residues. NA2b - contained a biantennary structure, 
NA2t- contained a triantennary glycan or polylactosamlne structure. Additional peaks may 
represent the underivitised glycans (e.g. peak 1808.9 in 8b is underivitised H5N4F)
3.7 Molecular modelling of soluble CD59
The relative sizes of the sugars and the protein were explored by molecular modelling (Fig.9). 
The glycan attached to Asn 18 is the disialylated biantennary complex glycan SA2H5N4F. The 
length of the glycan is of the same order as the diameter of the protein (approximately 4.2nM)
4. Conclusions
sCD59 contains at least eleven different oligosaccharides of which approximately 94% are 
complex bi- or triantennary structures with or without polylactosamine extensions and only 6 % 
of unprocessed oligomannose sugars were detected. This suggests that the CHO cell line has 
efficient glycosylation machinery and that the local protein conformation allows the interaction 
of GlcNAc transferases 1,11 and III with the developing glycan chain. The addition of terminal 
sialic acid prevents the development of lactosamine extensions in approximately 1 0 % of 
disialylated biantennary structures (Fig.2a). However 12% of the glycans are elongated 
suggesting that in some cases GlcNAc transferase competes effectively with sialyl transferase. 
All the complex sugars were present as both neutral (35%) and sialylated (35%:A1; 30% A2) 
structures although not every galactose residue was sialylated and tri-antennary glycans were
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Human sCD59 with modelled glycosylation
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Figure 9: A molecular model of soluble CD59
The protein structure (red) is based on the NMR solution structure (Kieffer 1994). The 
oligosaccharide (yellow) attached at Asn 18 is the di-sialylated form of the biantennary 
complex glycan H5N4F which constitutes 41% of the glycans associated with the molecule.
only mono or di-sialylated. Di-sialylated biantennary structures accounted for 12% of the A2 
structures while 18% of the A2 glycans were di-sialylated triantennary glycans. The CHO cell 
line does not express an a-2 , 6  sialyl transferase, and, consistent with this all the terminal sialic 
acid linkages associated with soluble CD59 were of the a2,3 type. The incomplete sialylation of 
polylactosamine structures suggests that elongation of the oligosaccharide as well as the 
protein structure has a role in controlling the addition of sialic acid to complex glycans. This is 
consistent with a study of sialylation in a mouse lymphoma cell line, thyroid glycoprotein G PI, 
and fetal lactosaminoglycan (Merkle and Cummings 1987) which indicates that sialylation is 
more likely to occur in the early stages of processing and the incidence falls off as the chains 
become more elongated.
These data indicate that the developing oligosaccharide chain at Asn 18 on sCD59, the smallest 
of the domains of the proteins analysed in this chapter, is accessible to all the glycosylating 
enzymes. A comparison of the glycosylation of sCD59 with that of other leucocyte antigens is 
made in the discussion at the end of chapter 2 .
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Figure 1: A schematic representation of the molecules and constructs involved in this 
study.
Ch. 2B The glycosylation of domain 1 of human CD5 and of a chimera of 
human CD5/rat CD4d3&4, both expressed in Chinese Hamster Ovary cells
1. Background
CDS (T1, Leu-1, Ly-1) (Fig. 1) (67kD, 471 amino acids) is expressed on all mature T-cells, most 
thymocytes and on a subset of mature B-cells. The extra-cellular region consists of three 
scavenger receptor domains (amino acids 1-112, 147- 243, 244-347). The function of 
scavenger receptor domains is unclear, but they may have a role in macrophage associated 
immune responses and inflammation (Freeman et al 1990). In general they provide a stable 
core structure which can withstand the extracellular environment. In CDS domain 1 is separated 
from domain 2 by a connecting peptide, or link region, (113-146) which contains 17 threonine 
and proline residues within a stretch of 20 amino acids (114-133). There are S potential N- 
glycosylation sites of which only the two N-terminal sites, Asn92CysSer and Asn217SerSer in 
domains 1 and 2 respectively, are occupied. The role of CDS in immune interactions is still 
unknown, but it may function as a receptor delivering co-stimulatory signals to T-cells in a 
manner similar to CD2. Anti-CDS antibodies stimulate T-cell proliferation (Review: Beyers et al 
1989), the secretion of interleukin- 2  and its receptor and also induce a rise in intracellular Ca^+ 
concentration. CDS and CD2 bind to the T cell receptor complex (Beyers et al 1992) to form a 
loosely associated complex which also involves CD4 or CDS. It has been proposed (Van de 
Velde et al 1991) that B and T cells communicate through the interaction of CDS with CD72 
(Fig.1), a cell surface glycoprotein found only on B-cells, however this has not been confirmed 
(Brown, M. and Barclay, N. personal communication). CDS+ B lymphocytes secrete 
monoreactive IgMRF, and also polyreactive IgM antibodies with broad specificities. In contrast 
CDS" cells secrete mainly IgG monoreactive antibodies. Interestingly, CDS+ B cells are 
upregulated in Rheumatoid Arthritis (RA) when the cells produce increased levels of IgMRF and 
IgGRF (see ch. 6  for glycosylation analysis of IgGRF). Also in RA CDS’*" T-cells express a cell 
surface lectin which binds the O-linked Gal|31-3GalNAc glycans in the hinge regions of IgG and 
IgD (Rudd et al 1994).
The glycosylated molecules analysed in this chapter are shown schematically in figurel. The 
glycosylation of CDS domain 1 (1 N-linked glycosylation site) was compared with that of 
another single domain protein, sCD59 (ch 2A) and with CD2 (ch 2B) to investigate the influence 
of the 3 -dimensional structure of the protein on glycosylation. In particular, this study explored 
the glycosylation machinery in CHO cells operating on a single N-linked site (Asn 92) in domain 
1 of CDS (CDSdl) (M.Wt. 17kD) which included the first 8  amino acids of the link region. The 
link region, which is rich in proline and threonine residues, was examined for the presence of 
O-linked glycans. Secondly, the glycosylation of a chimera (7SkD) consisting of CDS, a link 
region of 23 amino acids and CD4 domains 3 and 4 (CD4d3/4) (1 N-linked glycosylation site) 
was analysed. This explored the consequences for the glycosylation of adding four further 
domains to CDSdl. Finally, to explore the possibility that the insertion of link regions into
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recombinant proteins may be a means of creating O-linked domains in the CHO cell expression 
system, the extent of 0 -glycosylation of an 8 -amino acid C-terminal region attached to CD5d1 
was compared with the 0-glycosylation of intact CDS attached to domains 3 and 4 of CD4 
which contains a 23 amino acid link region between CD5d1 and 2.
2. Strategy:
Glycans were released by hydrazinolysis and fluorescently labelled with 2 -aminobenzamide 
(2AB) or sodium amino napthalene trisulphonic acid (ANTS) or radiolabelled with tritium. The 
relative amounts of neutral glycans (N), N-linked glycans containing a single charged group 
(NA1) and N-linked glycans with 2 charged groups (NA2) were determined by weak anion 
exchange (WAX) chromatography and fluorophore assisted carbohydrate electrophoresis 
(FACE).
The linkages and type of the charged species were characterised by determining the 
susceptibility to Arthrobacter Ureafaciens and Newcastle Disease Virus sialidases. Asialo 
glycans were resolved by P4 GPC and FACE (FACE data in ch . 8  2.4). N-linked glycans 
isolated from P4 GPC were characterised by RAAM analysed by P4 GPC (data in ch . 8  1.8 ) and 
by MALDI MS (data in ch . 8  2.1.Ü). Asialo N-linked glycans were analysed by MALDI MS and 
structures were determined by exoglycosidase sequencing followed by MALDI MS. Structural 
analysis of the O-linked glycans was by exoglycosidase sequencing followed by P4 GPC and 
the end group analysis of the O-linked glycan was carried out by radioactive Gas 
Chromatography (GC).
The oligosaccharide sequencing methods used here are described in chapter 8  of this thesis.
3. Results
The CD5d1 and CD5/CD4d3,4 constructs were prepared by in vitro mutagenesis. The proteins 
were purified by affinity chromatography and gel filtration (Dr. M. McAllister and Dr. M. Brown).
Analysis of oligosaccharides attached to CD5d1
3.1 Reiease and iabeliing of glycans from CD5d1
Sugars (85 nmoles assuming 85% release and recovery from the GlycoPrep machine) were 
released from CD5d1 (1mg) by hydrazinolysis using the GlycoPrep 1000 (OGS) under 
conditions optimised for maximum recovery of N- and O-links. The glycans were evaporated to 
dryness and re-dissolved in 200pl water. 75 nmoles of CD5d1 sugar was labelled at the 
reducing terminus with tritium (total counts 4.4E7) according to standard procedures. Inmole 
was labelled with sodium amino napthalene trisulphonic acid (ANTS) and analysed by 
Fluorophore Assisted Carbohydrate Electrophoresis (FACE). 10n moles were labelled with 2- 
aminobenzamide (2AB); the remainder was unlabelled and used for the Matrix Assisted Laser 
Desorption Mass Spectrometry (MALDI MS) analyses. 80% of the glycans from the chimera 
were radiolabelled (total counts 1.7E8), 2% was used for the FACE analysis and 5% was 
labelled with 2AB. The remainder was unlabelled and used for the mass spectrometric analysis.
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3.2 Charge analysis of the glycans released from CD5
3.2.1 WAX chromatography
Figure 2a shows the resolution of five populations of CDS glycans on a WAX chromatography 
column separated according to charge (see table 1). On digestion with Arthrobacter ureafaciens 
neuraminidase all of the glycans were reduced to neutral structures (Fig 2b) indicating that all 
the charge was due to either a1,3 or a1,6 linked sialic acid. The small peak eluting at fraction 
35 is an artefact of the radiolabelling procedure which does not elute with any standard glycan. 
It is not present in figure 2c where the glycans have been fluorescently labelled with 2- 
aminobenzidine (2AB).
Complete digestion of the charged glycans to neutral structures by Newcastle Disease Virus 
(NDV) neuraminidase (Figure 2c) specific for a 2,3 (or a 2,8) linkages confirmed that all the 
charge was due to a1 ,3 linked sialic acid and indicated that 85% of the sugars recovered in this 
pool were N-linked. This is in close agreement with the data from figure 2a. Comparison of the 
data in figures 2a and 2c shows that there are no naturally neutral O-linked sugars associated 
with CD5.
w
M inutes
Figure 2a: Analysis of the hydrazine released pool of 2AB labelled CDS glycans by weak 
anion exchange chromatography.
Assignment of peaks was by comparison with standard fetuin sugars. N, NA1, NA2 neutral, 
mono- and di-sialylated N-linked glycans respectively. OA1,OA2: mono- and di-sialylated O- 
linked glycans, respectively.
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Figure 2b: Weak anion exchange chromatography analysis of tritium labelled CDS 
glycans after digestion with Arthrobacter ureafaciens neuraminidase
5
t
I
141210ft4 620
M inutes
Figure 2c: Weak anion exchange chromatography analysis of 2AB labelled CDS glycans 
after digestion with Newcastle Disease Virus neuraminidase
The analysis of the tritium labelled sample in figure 2b shows a radiolabelled contaminant which 
is not present in the 2AB labelled sample analysed in figure 2o. This contaminant may account 
for the discrepancy in the percentages of N: O-links calculated from P4 (radiolabelled) and WAX 
(2AB labelled) data in Table 2.
The charged sugars were also analysed by Fluorophore Assisted Carbohydrate Electrophoresis 
(FACE) to compare the results of a gel electrophoresis separation with the separation by HPLC. 
The data (ch 8  section 2.4) confirm that two populations of charged sugars can be reduced to a 
single species by incubating with Arthrobacter ureafaciens neuraminidase.
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N N-links N O-links NA1 NA2 OA1 OA2
(i) WAX (2a)
(ii) WAX (2c)
(iii) P4(3)
------- 15%-------
85% 15% 
6 6 % 33%
32% 36% 1 2 % 5%
Table 1: A comparison of the charge profiles of CDS obtained by different methods, (i)
The percentages of the charged (NA1, NA2, OA1, 0A2) and neutral (N N or N O) populations 
were calculated from figure 2a. The percentages of neutral N- and O- links cannot be 
separated, (ii) The ratio of total N : O-links taken from the WAX analysis (fig. 2b). Percentages 
were obtained by integration of the WAX data, (iii) Ratio of N: O-links calculated from integration 
of the P4 data in figure 3.
3.3 Size analysis of asialo glycans from CD5
3.3.1 Analysis of CD5 asialo glycans by P4 GPC
The asialo glycans from figure 2b were resolved by P4 GPC (Fig.3). Two peaks were obtained, 
at 14.8 and 3.5 glucose units in the ratio 66:33 respectively.
P4; CD 5 Asialo glycans
14.8gu
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I 3.5gu
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Figure 3: P4 GPC of asialo CDSdl glycans
3.3.2 Analysis of the CD5 neutral glycan at 14.5gu by RAAf\A.
The pool of glycans eluting at 14.8gu (Fig.3) was analysed using the standard RAAM N-glycan 
enzyme array. The products of the digestion were analysed by P4 GPC and by MALDI MS (see 
ch. 8  section 1.8 and ch. 8  section 2.1 (ii) respectively for the data). The glycan was identified as 
the core fucosylated biantennary complex glycan, with the structural formula H5N4F, shown in 
figure 4.
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Figure 4: The N-linked 14.8gu glycan attached to CDS Identified by RAAM.
The arrows show the cleavage positions of the enzymes used in the sequential exoglycosidase 
digestions. The products were analysed by MALDI MS (see figure 5a-d) to confirm the 
structure.
3.3.3 Structure of the CDS asialo N-linked glycans confirmed by MALDI MS and sequential 
exoglycosidase digestions
Figure 5a shows the MALDI MS analysis of the asialo glycan pool from figure 1b over the range 
900-3500 mass units. The peak at 1809.7 mass units is consistent with the H5N4F structure 
identified by RAAM and shown in figure 4. Figures 5b,c and d are the analyses of the products 
of digestions A,B, and 0 3 respectively. The peaks are at 1485.6, 1079.1 and 933.1 mass units, 
consistent with the structures H3N4F, H3N2F and H3N2.
3.4.1 Analysis of the O-linked glycan eluting at 3.5gu in figure 2 by exoglycosidase digestion 
The 3.5gu (figure 3) structure was digested with Bovine Testes p-galactosidase and the product 
was analysed by P4 GPC (Fig.6 ). The glycan was reduced by Igu to a structure eluting at 2.5gu 
consistent with the presence of an O-linked glycan Gaipi-3/4-GalNAc.
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Figure 6. P4 GPC profile of the product of the digestion of the CDS O-linked glycan 
Galp1-3/4GalNAc with Bovine Testes galactosidase
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Figure 5a-d: 5a is the MALDI MS analysis of the glycan pool (H5N4F). 5b,c and d are the
analyses of the products of digestions A.B and C respectively (see figure 4). The peaks at 
1485, 1079 and 933 mass units are consistent with the structures H3N4F, H3N2F and H3N2 
respectively.
3.4.2 Analysis of the sugar at the reducing terminus.
The reducing terminal glycan was identified by gas chromatography (GC) equipped with a 
radioactive detection system. The 2.5 gu peak from figure 6  was co-injected into the GC 
column with radiolabelled inositol, used as an intemal marker (Fig. 7). In this technique 
structures are assigned by comparing the difference in the elution times between the unknown 
sample and inositol with the differences between standard sugars and inositol. The 2.5 gu peak 
eluted at the same position as N-acetyl galactosamine (GalNAc), consistent with the presence 
of an O-linked glycan terminating in GalNAc.
C P S GalNAc
Inositol
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Minutes
Figure 7: The radioactive GC analysis of the terminal glycan on the CDS S.Sgu glycan
4. Results of analysis of glycans attached to the CDS/CD4d3,4 chimera:
Glycans were released by hydrazine at 95°C and labelled with 2AB or tritium. The relative 
amounts of N, NA1 and NA2 were determined by WAX chromatography and the charged 
species characterised by digestion with Arthrobacter Ureafaciens sialidase. Asialo glycans were 
resolved by P4 GPC and MALDI MS and analysed by RAAM followed by P4 GPC and MALDI 
MS. O-linked glycans were analysed by exoglycosidase sequencing and P4 GPC and end 
group analysis of O-linked glycan used radioactive GC.
4.1 Release and labelling of glycans
The glycans (10.2nmoles, estimated 85% yield) were released from 300)j.g of the CD5/CD4d3,4 
chimera (M.Wt. 75kD). 18% was used for MS studies, 2% was labelled with 2AB and the 
remainder (9.6nmoles) was radiolabelled with tritium (1.7E8 cpm in total).
4.2 Analysis of CD5/CD4d3/4 by charge
The WAX chromatography analysis of 2AB labelled glycans (Figure 8 a) shows that none of the 
glycans are neutral, 25% are monosialylated N-linked glycans, 46% are disialylated N-links and
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29% are monosialylated O-links and 0% are disialylated O-links (compared with 15%, 32%, 
36%, 12% and 5% for CDSdl alone). The ratio of N : O-links was 71.4% ; 28.5% (compared 
with 85% ; 15% in CDSdl). All structures were reduced to neutral with Arthrobacter ureafaciens 
sialidase (Fig. 8 b) indicating that all the charge is due to sialic acid.
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Figure 8a: WAX chromatography analysis of 2AB labelled glycans released from
CD5/CD4d3/4
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Figure 8b: WAX chromatography analysis of asialo tritium labelled glycans from
CD5/CD4d3/4
4.3 Analysis of CD5/CD4d3/4 asialo N- and O- glycans by P4 GPC and radio GC 
Figure 9 shows the P4 profile of the asialo glycans released from CD5/CD4d3/4. 92% of the N- 
linked glycans eluted at 14.6gu and were identified by RAAM and MALDI MS as the core 
fucosylated biantennary complex sugar, H5N4F, found on CD5. The 3.6gu O-linked sugar was 
also identical to the glycan on CD5d1. It was cleaved with p-galactosidase to a 2.5gu structure 
which was shown by radioactive GC to be N-acetyl galactosamine. The material eluting at 0.5 
gu was not analysed and may be an environmental contaminant since the molecular volume is 
less than that of a monosaccharide. There was a small amount of material eluting at more than 
14.6gu, but insufficient to be analysed.
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Figure 9: P4 GPC of the asialo glycans attached to CD5/CD4d3/4. The peaks are at 14.6,
3.6 and 2.5gu
5. Conclusions
A comparison of the P4 profiles for the two molecules released under the same conditions 
shows that CD5/CD4d3/4 has a higher proportion of O-linked sugars than CD5d1 (Figs. 3 and 
9). This may reflect the increased length of the link region and the higher proportion of Thr and 
Pro residues in the chimera. Interestingly, there have been no previous reports of O-linked 
sugars attached to CD5. In neither case is there evidence of significant quantities of N-glycans 
other than the core fucosylated bi-antennary complex glycan, H3N4F, commonly found on 
serum glycoproteins. This homogeneity of glycosylation is extremely unusual and in direct 
contrast to the diversity of structures found on sCD59, which is also a single domain protein. 
This suggests that there is a difference in the control exerted over the glycosylation pathway by 
the scavenger domain in CD5d1 and the Ly6  domain in CD59. The fact that the same single 
glycan is also present on all three sites of the chimera, (which is fully glycosylated - Brown, M. 
and Barclay, N. - personal communication) is also remarkable. It implies that all sites are 
equally accessible to the enzymes, and that there has been no site specific processing although 
both scavenger and Ig-like domains are involved. The data suggest that the additional domains 
do not shield the glycans in CD5d1 from the processing enzymes and this is consistent with the 
suggestion that the five domains are linear (Dr. N. Barclay - personal communication), A 
comparison of CD5d1 with the chimera shows an increase in sialic acid content in the chimera. 
The CD5/CD4d3,4 chimera contains no neutral structures while 17% of the glycans in CD5d1 
are neutral bi-antennary complex sugars. Interestingly, a study of the glycosylation of the intact 
rat CD4 protein (Ashford et al 1993) identified neutral glycans. Moreover, in contrast to the CD4 
chimera, no core fucosylation of rat CD4 was observed. This is consistent with the well 
established finding that glycosylation is cell type specific and that the protein may control its 
own glycosylation. The quaternary structure of the protein may also be important, but this has 
not been established. In the following section the glycosylation of CD2 was analysed. This 
protein consist of two domains, both of the IgSF class.
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Figure la: CD2, Its ligand CD58 and possible ligand CD59.
Ch. 20 The glycosylation of human CD2 and rat CD48
1. Background
CD2 (T11, LFA-2) is expressed on most T-lymphocytes, NK cells and thymocytes. It is a 
membrane bound protein with a transmembrane anchor (Fig. 1a) and plays a role in 
mediating adhesion between T-cells and target cells (Qin et al 1994). In humans proposed 
ligands include the cell surface antigens CD58, CD48 and CD59 while in rat CD2 binds 
CD48 (van der Merwe et al 1995). CD2 interacts with the T-cell receptor complex 
(TcR/CD3). The structures of both rat and human soluble CD2 have been determined by X- 
ray crystallography (Jones et al 1992, Bodian et al 1994), when the molecules formed 
dimers through head to head interactions between the amino-terminal domains. CD2 and its 
proposed ligands CD58 and CD48 are part of a subgroup within the immunoglobulin 
superfamily (IgSF) and their genes are linked in the genome indicating that they may have 
evolved by gene duplication. The extracellular domain of CD2 (M.Wt. 36.8KD) (Fig.1b) is 
made up of two IgSF domains each of which contains one N-glycosylation sequon at N65GT 
and N126GT. The two domains are joined by a linker region which also has a single N- 
glycosylation site at N117TT. The amino acid sequence contains many serine and threonine 
residues, however no O-linked sugar has been reported.
(i) Interaction of CD2 with CD58 (LFA3)
CD2 interacts through its amino terminal domain with CD58 to form an adhesion pair, for 
example between T-cells and cytotoxic targets or antigen presenting cells (Selvaraj et al 
1987). Such recognition events have a role in the process of cell-mediated cytotoxicity, 
antigen and mitogen-induced T-cell proliferation and lymphokine production. Through a 
series of mutations it has been shown that the binding site for CD58 lies on one face of the 
first domain of CD2 (Somoza et al 1992). This active site is on the opposite side of the 
molecule to the glycans at Asn 65.
(ii) The roie of giycosyiation at Asn 65 in the CD2/CD58 interaction.
In studies of CD2 deglycosylated with PNGase F, N-glycosylation was shown to be required 
for human CD2 immunoadhesion functions (Recny et al 1992). Neither deglycosylated CD2, 
nor the mutant CD2 molecule containing a single Asn65 to Gln65 substitution, bound CD58 
or monoclonal antibodies directed at native CD2 adhesion domain epitopes. However, rat 
CD2 containing only a single GlcNAc residue at each of the glycosylation sites showed no 
decrease in activity or antigen binding (van der Merwe et al 1993).
(Hi) Interaction of CD2 with CD48
CD48 is reported to be a ligand for CD2 in murine and rat cell systems (Sandrin et al 1993, 
van der Merwe et al 1993). CD48 (M  ^48kD) is present on leucocytes and, like CD58, has a 
GPI anchor. In many other respects it is similar to CD58: for example, it has 6 8 % similarity 
at the amino acid sequence level, and similar polypeptide length, hydrophobicity and 
predicted secondary structure. It has a low affinity for CD2 (IC5 0  : lO ^M determined by
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Figure 1b: Soluble CD2 and CD48 analysed in this study.
The molecules were expressed without the transmembrane section with the result that 
they were secreted into the tissue culture medium.
inhibiting the binding of peripheral blood lymphocytes to CD48 transfectants by either CD48 
mAb pre-treatment of COS cells or CD2 mAb pre-treatment of preipheral blood 
lymphocytes) (Sandrin et al 1993) compared with CD58 (10 50:<10'^ M) (Parish et al 1993). 
CD58 and CD48 interact with the T il^  epitope of CD2 suggesting that CD48 and CD58 are 
alternative ligands for the same region of CD2.
(iv) Interaction of CD2 with CD59.
OHO cells stably transfected with human CD59 form rosettes with human T-cells and these 
can be inhibited by a CD59 monoclonal antibody (Deckert et al 1992). However, the 
interpretation of this result is unclear, and binding studies using plasmon surface resonance 
have been unable to demonstrate this interaction at the molecular level (van der Merwe et al 
1994).
(v) Interaction of CD2 with the T-cell receptor complex.
Normal T-cells express a multimolecular complex consisting of CD4 or CD8 , TcR/CD3, CD2 
and CDS in association with internal tyrosine kinases. It has been proposed that the 
interaction of CD2 with CD58 (LFA3) may regulate transmembrane signalling by interacting 
with this multimolecular complex (Beyers et al 1992).
2. Strategy
In this chapter the glycans attached to human soluble CD2 (Fig. 1b) were released by 
hydrazinolysis, labelled with 2AB or tritium and analysed on the basis of charge by WAX 
chromatography. Asialo glycans were analysed by a combination of P4 GPC, MALDI MS 
and exoglycosidase sequencing. Glycans released by hydrazinolysis from rat CD48 were 
desialylated and analysed by MALDI MS. Molecular models of CD2 and CD48 were 
constructed.
3. Results
3.1 Preparation of CD2 and release of glycans
The CD2 which was used in this study was expressed without the transmembrane and polar 
regions of the peptide and was secreted into the medium as a soluble protein.
2mg of human CD2 expressed in CHO cells and purified by affinity chromatography and gel 
filtration (Dr. Simon Davis, William Dunn School) was dialysed into 0.1%TFA. Glycans 
(6 8 nmoles - assuming 85% release and recovery as determined by OGS) were released by 
hydrazinolysis at 95°C under conditions designed to cleave N- and O- glycosidic bonds and 
re-N-acetylated using the GlycoPrep 1000 (OGS). 80% of the released sugars were labelled 
with tritium, 5% was used for mass spectrometric analysis, 1% for FACE analysis and for 
5% for preliminary studies involving the analysis of fluorescently derivitised sugars. 9% was 
retained unlabelled.
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3.2 Analysis of CD2 glycans by charge using WAX chromatography 
Fig. 2a is the charge profile of the tritium labelled glycans released from CD2 and analysed 
by weak anion exchange (WAX) chromatography. On treatment with Arthrobacter 
ureafaciens neuraminidase all the structures become neutral (Fig. 2b) indicating that all the 
charge is due to sialic acid. Figure 2c is the analysis of the same pool of released glycans 
labelled with 2-aminobenzamide (2AB) and with on line fluorescence detection. A 
comparison of figures 2a and 2c shows that the 2AB labelling procedure is highly specific for 
sugars compared with sodium borotritide reduction. This procedure may result in the 
radiolabelling of peptide fragments remaining after hydrazinolysis and it is common for 
artefacts to be detected as in figure 2a. The glycan peaks were assigned by reference to
standard fetuin sugars.
Charge analysis of CD2 glycans
CD2 Asialo glycans
“  8000
Figure 2a*c: Analysis of the radiolabelled CD2 glycan pool before (a) and after (b,c) 
digestion with Arthrobacter ureafaciens neuraminidase to remove sialic acid. The
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sugars were resolved by WAX chromatography (Vydac 301VHP575) and the peaks 
assigned by comparison with fetuin sugars resolved on the same column. 90% of the CD2 
glycans are neutral and all the charge is due to sialic acid. Fig. 2c shows the separation of 
the same charged glycan pool under the same conditions as in fig.2a. In 2c the 
oligosaccharides were labelled with 2AB.
Analysis of CD2 glycans by charge
N:90% NA1:10%
3.3 Analysis of asialo CD2 glycans using a combination of P4 Gel Permeation 
Chromatography (GPC) and exoglycosidase sequencing.
3.3.1 Resolution of asialo CD2 glycans by P4 Gel Permeation Chromatography 
Figure 3a is the P4 profile of the asialo CD2 glycan library derived from the released 
glycans after treatment with neuraminidase (Fig. 2b). Eleven peaks were resolved between 
25 and 8  glucose units. No glycans in the size range which is exclusive for O-linked 
structures (between 2.5 and 8.9 gu) were detected. The data are summarised in Table 1.
CD2 N-glycans
14 5
23.3
2 0 11600
10.1
1400- 9.76
6.913.51 2 0 0 -
16.8
'12.21000
400-
200 -
Figure 3a: P4 GPC separation of the neutral glycans in fig. 2b
The sizes of the peaks are labelled in glucose units and the peaks are numbered along the 
x-axis from 1-11.
3.3.2 Exoglycosidase analysis of CD2 oligomannose structures
Fractions of the pool of desialylated N-linked glycans were incubated with (i) A. Saitoi 
a -1,2 mannosidase and (ii) Jack Bean a-mannosidase which cleaves terminal, non­
substituted, a-D-1,2,6>3 mannose residues. The digests were analysed by P4 gel filtration 
and the profiles compared with the original analysis of the glycan pool (Fig. 3a).
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Glycan Ch. mass G.U. %
M5 1257.9 8.85 1 0
M6 1418.9 9.79 1 2
M7 1581.6 10.82 18
M8 1743.74 12.16 3
M9 1905.88 13.84 3
H5N4F 1809.7 14.48 2 2
H5N5F 2012.89 16.86 8
H6N5F t 2174.9 17 4
H6N5F p 2174.9 17
H7N6F 2540.9 20.05 1 0
H8N7D 2906.23 23.3 7
Table 1: Results of P4 GPC MALDI MS analysis of CD2 glycans
The products of the digestion of a fraction of the asialo glycan pool with A.Saitoi a-1,2 
mannosidase is shown in Fig.3b. A series of peaks (7-11) have been reduced to a single 
peak with a hydrodynamic volume of 8.85gu. This result indicates that CD2 contains an 
oligomannose series (Man9-Man5) which has been digested to a single population of ManS 
glycans. Digestion of a second fraction of the asialo sugars with Jack Bean a-mannosidase 
reduced the same series of glycans to sugars eluting at 6 .8 , 6.3 and 5.6gu, elution positions 
which are consistent with those of Man3, 2 and 1 (Fig. 3c). The data suggest that small 
oligomannose sugars are relatively resistant to the enzyme. The sugars from the 6 .8 , 6.3 
and 5.6 gu peaks were therefore pooled and digested further with Jack Bean a-1 ,2,6>3 
mannosidase to yield mainly Mani (Fig. 3d).
CD 2 glycans + A. Saitoi mannosidase
4500 1
4000 --
14 5
3500 --
3000 --
g 2500 -- 
"  2000 - -
16.7
1500 --
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500 --
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3b
CD2 glycans +Jack Bean a-mannosidase
1400
23.3
1200
1000
800
I
600
400
200 -
R
ml
3c
Figure 3b,c: The P4 GPC separation of the CD2 neutral glycans following digestion with 
(b) A. Saitoi a1-2 mannosidase (c) Jack Bean a-mannosidase. The hydrodynamic volume of 
the peak fractions are marked in GU.
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Q. Matching signatures -  N-Glycons
Database Ref Degeneracy Match Quality
comp-7457 1 81
Experimental signature
Theoretical signature 
81
16 14 12 10 8 6 2 GU
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▲  1 4 0 l  - 2 # L
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b. Matching signatures-N-Glycans
Database Ref Degeneracy Match Quality 
comp-7453 2 85
,ri ,n ,n JLji
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j  Matching signatures-N-Glycans including polyloctosamines 
Database Ref. Degeneracy Match Quality 
poly-131069 6 70
p o ly -125521 9 67
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Theoretical signature 
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.6,#1.
\ 6  \ 6  
•  1 - - 4 0 1 -  - 4 Û  
/ 3
Al - -4 OI— 2 ® 1 ^
22 20 18 16 14 12 10 6 4 2 GU
Figure 4 a -d  RAAM analysis o f asialo g lycans from CD2. Peaks 3 ,4 ,5  and 6 (F ig .3a) were 
identified as H7N6F (I9.9gu), H6N5F (17.3gu), H6N5F (I6.8gu) and H5N4F (I4 .4gu) 
respectively.
CD2 oligomannose glycans + Jack Bean a-Mannosidase
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Figure 3d: P4 analysis of the products of the extensive digestion of the glycans at 
6.8, 6.3 and 5.6gu (Fig. 3b) with Jack Bean a-mannosidase
The data in figure 3a-d indicate that CD2 contains an oligomannose series consisting of 
Man9: 3%, ManS: 3%, Man?: 18%, Man6 : 12%, ManS: 10% (Tables 1 and 2a, below). 
Oligomannose glycans account for 46% of the total oligosaccharides associated with CD2.
3.3.3 CD2 does not contain hybrid type structures
A comparison of figures 3a and b indicates that all the glycans from the asialo glycan pool 
which were digested by A. Saitoi mannosidase were reduced to Man 5 suggesting that CD2 
does not contain hybrid type sugars carrying a mannose arm susceptible only to Jack Bean 
a-mannosidase.
3.4 Analysis of individual glycans by Reagent Array Analysis Method (RAAM)
The peak fractions from each of the peaks numbered from 2-6 (along the x-axis) in figure 3a 
were analysed using the standard RAAM N-glycan array (see ch. 8  section 1.8).
(i) Peaks 3, 4, 5 and 6  were identified as H7N6F (19.9gu), H6N5F (17.3gu), H6N5F (16.8gu) 
and H5N4F (14.4gu) respectively (see figure 4a-d).
(ii) The tri-antennary glycan, H6N5F, was present in at least two isoforms. These were 
identified by RAAM analysis (4b and 4c) although they were indistinguishable by MS. There 
is no difference in the molecular weight of these isoforms nor in the number of branches 
they contain, however differences in arm specificity between the degenerate structures in 4b 
and 4c gives rise to different molecular volumes, and in the original P4 separation of the 
asialo CD2 glycans they elute at 16.8 and 17.3 gu respectively, in peaks 4 and 5 (Fig.3a).
(iii) RAAM analysis failed to identify the glycans in peak 2; this may be because the 
molecular volume of the original glycan exceeded that of the internal standard dextran 
marker. However the MS data (Fig. 5) suggests the peak (Fig. 3a) contains H8N7F (23.3gu). 
This result highlights the need to develop an automated sequencing strategy for large 
polylactosamine structures. A number of glycans all with the structural formula H6N5F were 
identified within the envelope of peaks 4 and 5 by a combination of RAAM and MS (section
3.6 below). These consist of two sets (Fig. 6 ), the bi- and tri- antennary isoforms.
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H6N5F 
(a) 17.3gu
H6NSF 
(b) 17.3gu
Peak 5
Peak 4
H6N5F 
(c) 16.8gu
Three CD2 glycans with the structural formula H6N5F
(b) and (c) were identified by RAAM 
They differ in arm specificity and have different molecular volumes.
(a) was distinguished from (b) and (c) by mass spectrometry
Figure 6
3.5 Analysis of asialo glycans of CD2 by MALDI MS
The desialylated, purified, unlabelled glycans released from CD2 were analysed by MALDI 
MS (Fig.5, Table 2a). To confirm the finding that CD2 contains an oligomannose series, but 
not hybrid structures, another fraction of the desialylated CD2 glycan pool (Fig.7a) was 
extensively digested with Jack Bean a-mannosidase and analysed by MALDI MS (Fig. 7b). 
The results (Table 2a) are consistent with the P4 data.
1 5 8 1 . 5100 !
90.
80
7 0. 
60 
50. 
40
1 4 1 9 . 5
1 2 5 7 . 6
2 1 7 4 . 6
2012.6
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60.
50.
40.
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9 3 3  . 7
1 0 . 2 1 7 5 . 05 6 . 2
m / z2 5 0 02 00 01 5 0 010005Ô0
Fig 7a,b The MALDI MS analysis o f the asialo CD2 glycan pool purified from protein and 
salts on a mixed bed resin. The oligomannose series is M4GlcNAc2 - M9GlcNAc2 (7a) with
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Figure 9a-f: Simultaneous exoglycosidase sequencing of CD2 asialo glycans using
MALDI MS. The arrows show the different sequential digestions of two glycans both with the 
structural formula H6N5F. The digestions are shown diagramatically in figure 8.
m/z values of 1095.6, 1257.6, 1419.5, 1581.5, 1743.5 and 1905.4 respectively. After 
extensive digestion with Jack Bean a-mannosidase the mannose series is reduced to a 
single population of ManiGlcNAc2 (Fig. 7b) m/z: 609.4.
3.6 Determination of CD2 asialo glycans by simultaneous exoglycosidase digestions and 
analysis by MALDI MS.
A fraction of the asialo glycan pool (MS fig.9a) was digested sequentially with Bovine 
Testes p-galactosidase, Jack Bean (3-hexoseaminidase, Bovine Testes p-galactosidase, 
Jack Bean (3-hexoseaminidase, and Choronia lampas a-fucosidase. Two typical 
examples of the digestion sequence are shown diagramatically in Figure 8. After each 
incubation the sample was purified on a mixed bed resin and analysed by MALDI MS 
(figure 9b-f).
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Figure 8: Typical examples of the effects of the exoglycosidase sequencing 
digestions.
The glycans have been chosen to illustrate the way in which the combination of enzyme 
digestions and MALDI MS has been used to distinguish between two isoforms of 
H6N5F, which have the same molecular weight, but which react differently with the 
sequencing enzymes in this analysis.
The structural formulae of the glycans determined by mass spectrometry were 
consistent with the P4 analysis and are summarised in Table 2b and figure 10.
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Glycan Mol. Wt. G.U. % JBManGU JBManMS
M5 1257 8.85 10 5.62 609
M6 1419 9.79 12 5.62 609
M7 1581 10.82 18 5.62 609
M8 1743 12.16 3 5.62 609
M9 1905 13.84 3 5.62 609
H5N4F 1810 14.48 22 14.48 1810
H5N5F 2013 16.86 8 16.86 2013
H6N5F t 2175 17 4 17 2175
H6N5F p 2175 17 17 2175
H7N6F 2540 20.05 10 20.05 2540
H8N7D 2907 23.3 7 23.3 2907
Table 2a
ICh.mass a. MS:m/z b. B TG al c. JB Hex d. B TG al e. JB Hex f. CL Fug
M5 1257.9 1257.9 1258 1256 1256 1257 1257
M6 j 1418.9 1419.9 1419.5 1419.4 1419.5 1418.9 1419
M7 1581.6 1582 1582 1581 1581 1581 1581
M8 1743.74 1744.1 1745.4
M9 1905.88 1905.8
H5N4F 1809.7 1810.1 1486 1079.2 1079.3 1079 933.4
H5N5F 2012.89 2014.3 1689.2 1079.2 1079.3 1079 933.4
H6N5F t 2174.9 2175.4 1689.2 1079.2 1079.3 1079 933.4
H6N5F p 2174.9 2175.4 1851.3 1445.4 1283 1079 933.4
H7N6F 2540.9 2541.6 2055.3 1445.4 1283 1079 933.4
H8N7F 2906.23 2907 - . 2421 1809.4 1488 1079 933.4
Table 2b
Table 2a: Analysis of data in figure 3a, the P4 analysis of the 
asialo glycans of CD2.
Table 2b: Analysis of data in figure 5, the MALDI MS analysis of the 
asialo glycans of CD2 and figure 9, the sequential digestions of the glycans.
The following conclusions can be drawn from the MALDI MS analysis of CD2 asialo 
glycans:
(i) CD2 contains an oligomannose series (Man5-Man9) and a series of five complex 
sugars (Fig. 6) which have the general formulae H5N4F, H5N6F, H6N5F, H7N6F and 
H8N7F. These two series are shown diagramatically in figure 10.
(ii) All the branches of all the complex glycans terminate in galactose. Following 
digestion with BT galactosidase MS shows that all structures have been reduced in size 
by the same number of galactose residues as the branches they contain (Fig. 9a,b).
(iii) FI6N5F (Fig. 3a: 16.8-17.3gu, Fig. 7a: 2175 mass units) is a mixture of glycans i.e. 
a triantennary complex structure and a bi-antennary polylactosamine glycan with the 
same molecular weight. Following digestion with galactosidase, the 2175 mass units 
peak (fig. 9a) has been reduced to two peaks in Fig. 9b (1689 mass units and 1851 
mass units). The digestions of these two species (shown schematically in figure 8) can 
be followed independently through the remaining profiles (9c-f).
(iv) All the glycans are core fucosylated; this is confirmed by the final digestion with 
fucosidase (Fig. 9d to 9e) in which all of the structures accumulated at 1079.3 mass 
units were reduced by approximately 145.9 to 933.4 mass units.
(v) The oligomannose series is unaffected by all of these enzymes. The relative 
amounts of these structures appears to decrease and there have been some losses of 
material; in addition, since the complex sugars accumulate into a smaller number of 
peaks following each digestion, the mannose glycans appear less by comparison.
Percentages of glycan structures associated with soluble CD2 (CHO)
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Figure 10: Proposed structures of N-linked glycans associated with soluble CD2
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Human sCD2 crystal structure 
with modelled glycosylation
Membrane
Figure 11 : The leucocyte antigen CD2 dimer modelled with the Man6 glycan at site 65, 
the disialylated biantennary core fucosylated complex sugar at site 126 (H5N4F), and a 
triantennary structure with a lactosamine extension at site 117 (H7N6F). The binding site for 
CD58 (LFA3) on monomeric CD2 is close to the N-terrninus on the opposite face of the 
molecule to the glycans at site 65.
3.7 A molecular model of glycosylated CD2 has been proposed.
A molecular model was constructed based on the X-ray crystal structure of human CD2 
(Bodian et al 1994) and the glycan analysis from this study. The site specificity of the 
glycans has yet to be established, however glycan analysis of domain 1 (Recny et al 1990) 
has allowed us to propose a model of one of the possible glycoforms of CD2 (Fig. 11). The 
glycans at each site were selected on the following basis:
(i) Site Asn65GlyThr
46% of the glycans attached to CD2 were found to be of the oligomannose type. MS 
analysis (Recny et al 1992) of the glycans attached to domain 1 at Asn 65 found only the 
oligomannose type. Taken together these data suggest that site 65 should contain only 
oligomannose glycans of which the greatest proportion in the analysis were of the Man? 
type (39%). Site 65 has been modelled with a Man6 sugar (12% of total glycans) attached to 
the Asn. The N-glycans at Asn 65 are attached to a tight loop connecting p-strands D and E 
of a classical Ig p-sandwich domain (Jones et al 1992). It has been proposed that, 
depending on the length and flexibility of the D/E loop and the orientation of the asparaginyl 
side chain within this loop, the oligomannose glycans at Asn65 may be positioned alongside 
p-strands B, D and E in the face of the p-sheet opposite to the proposed binding site for 
CD58. From the molecular model (Fig.11) it appears that the sugars can fit into a cleft in 
the p-strands of the protein. However NMR spectroscopy studies by Wyss et al (1995) found 
no interactions between the protein and the sugar, suggesting that the glycans are not 
situated in the cleft.
(ii) Site Asn126ThrThr
The two domains of CD2 are linked by 6 amino acids which are relatively close to this 
glycosylation site. 50% of all the structures at sites 117 and 126 consist of the biantennary 
core fucosylated complex sugar, H5N4F (Fig. 10). This predominant structure was modelled 
at site 126.
(iii) Site Asn117GlyThr
Asn 117 is close to the membrane surface. By analogy with the interaction of CD59 with 
C5b-8 (see ch.3) the N-glycans at this site may orient the binding site towards the receptor 
ligands in CD58 and CD48. Over 50% of the glycoforms of CD59 (one glycosylation site) 
are large polylactosamine structures, therefore the tri-antennary glycan which contains a 
lactosamine extension, H7N6F (Figure 10; 23% of structures at sites 117 and 126), has 
been modelled at site 117.
3.8 Analysis of the asialo N-linked glycans associated with rat CD48, a low affinity ligand of 
rat CD2, by MALDI MS
The glycans from the six N-linked glycosylation sites on rat CD48, expressed in CHO cells, 
were released by hydrazinolysis, desialylated with Arthrobacter ureafaciens neuraminidase 
(fig.2a-c), purified on mixed bed resins and analysed by MALDI MS. At least 26 different 
glycans were detected, without accounting for isomers (Fig 12, Table 3). Figure 12 has been
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M5 H3N3F
1257 1282.42
H4N3F
1444.4
H3N4F H3N5F
1485.5 1688.58
H4N4F H4N5F
1650.1 1852.8
H5N4F H5N5F H5N6F H5N7F
1810.7 2012.5 2219.4 2422.5
H6N5F H6N6F H6N7F
2177.5 2378.6 2585.5
H7N6F H8N7F
2543.7 2908.7
Table 3a: Composition of fucosylated glycans identified by MALDI MS in the pool of
oligosaccharides released from CD48.
H3N3 H3N4
1136.36 1339.44
H4N3 H4N4 H4N5
1298.41 1501.5 1704.6
H5N4 H5N5 H5N6
1663.5 1866.6 2069.7
H6N6
2231.73
H7N6
2393.8
Table 3b: Composition of non-fucosylated glycans identified by MALDI MS in the pool of 
oligosaccharides released from CD48.
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Figure 12; The MALDI MS analysis of CD48
The data are analysed in Tables 2a and 2b.
Rat SCD48 
(based on CD2 Xtal 
structure) with modelled 
glycosylation
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Figure 13: Rat soluble CD48 with modelled glycosylation.
The crystal structure of CD48 is not available, therefore the protein structure (blue ribtx)n) has 
been based on the CD2 crystal structure (Bodian et al 1994). Sequence alignment has been 
used to obtain equivalent residues in CD2 for the oligosaccharide substitutions in CD48. CD48 
is glycosylated at sites at Asn 16, 75, 164 and 181. The equivalent positions In CD2 are 13, 67, 
150 and 167. The site distribution of the oligosaccharides is not known. The oligosaccharides 
which are modelled at each of the sites (yellow ball and stick) are selected from the most 
prevalent structures Identified in this analysis. Sites 150 and 167 contain the biantennary 
structure H5N4F, site 13 contains SAH6N5F (a monosialylated biantennary sugar with one 
polylactosamine repeat) and site 67 contains the tetra antennary sugar, H7N6F.
annotated with some possible alternative structures which are consistent with the MS 
composition analysis. The major structure (1808 mass units) had the same mass/ charge 
ratio as that predicted for the fucosylated bi-antennary glycan H5N4F. The largest structure 
detected was 3038 mass units, consistent with the general formula H8N7F. The smallest 
was a glycan of 933 mass units (Man 3). There were two series of oligosaccharides. The 
major series was fucosylated while the minor one contained most of the same structures 
without fucosylation. The origin of the oligomannose glycans smaller than Man 5 is unclear 
since these are not normal biosynthetic products.
The approximate proportions of the different populations of glycan classes was determined 
by measuring peak height. A major advantage of the magnetic sector instrument used in this 
MALDI MS analysis is that the individual peak heights are directly proportional to the ion 
concentration of each component. It has also been demonstrated that oligosaccharides are 
non-selectively ionised (Dr. D. Harvey - unpublished data). However, to obtain quantitative 
data it is necessary to take many scans (typically 20-30) over a wide area of the sample 
spot, since accurate quantitation depends on an even distribution of the individual sugars 
across the target area. MS also gives only the m/z ratios of the oligosaccharides and no 
linkage information is available from these data.
The relative proportions of the different classes of glycans in CD48 based on peak height 
measurements were approximately as follows: oligomannose 10%, hybrid 10%, complex 
biantennary 40%, and polylactosamine complex glycans 20%. The remaining structures 
have not been identified and may be fragment ions.
4. Conclusions
The MALDI MS analysis of the four glycans attached to rat sCD48 suggests that processing 
by the CHO cell glycosylation machinery has terminated at almost every possible stage. At 
least 47 different glycans are N-linked to CD48. Interestingly the molecular model indicates 
that all four sites are on the same face of the molecule and this may suggest that there may 
be limited access to some of the processing enzymes, in particular the sialyl transferase, 
and that consequently glycosylation processing at one site affects another. This is in 
contrast to CD4 where glycosylation at one site did not affect the processing at others 
(Ashford et al 1993). 90% of the glycans attached to CD2 were neutral, and 10% were 
monosialylated. All the charge was due to 1,3-linked sialic acid. An oligomannose series 
(Man 9-Man 5) and five different core fucosylated, fully galactosylated, complex glycans 
ranging in size from H5N4F to H8N7F were identified. The heterogeneity of the sugars 
attached to this protein appears to be very extensive. The identification of three distinct 
glycans all with a general formula H6N5F (two isoforms of a tri-antennary structure and an 
extended polylactosamine bi-antennary glycan) beneath the envelope of peaks 4 and 5 in 
the P4 separation (figure 3a) indicates the need for second dimensional methods for 
separating structures co-eluting on GPC. This study also demonstrates the use of a 
combination of P4 GPC and MS for the analysis of glycan mixtures. 46% of the total glycan
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Figure 14: The Interaction of rat CD2 and rat C048 with modelled glycosylation.
The protein structure of CD48 is based on the CD2 crystal structure (Bodian et al 1994; 
see figures 11 and 13). The glycosylation of CD48 is based on data from this thesis and 
the glycosylation of rat CD2 on data taken from Davis et al 1993). The topology of the 
CD2/CD48 interaction is based on the study by van der Merwe et al (1995).
pool consists of an oligomannose series, Man 5-9. Assuming that all the glycosylation sites 
on CD4 are fully glycosylated and that site 65 contains only oligomannose sugars (Recny ot 
al 1992) this Implies that 13% of the glycans at sites 117 and 128 are also of the 
oligomannose type.
The sugars shield a large area of the protein surface and may give protection from 
proteases as has been demonstrated for ritwnuclease (ch.4). A possible structural role for 
each of the oligosaccharides was explored using a molecular model of glycosylated CD2 
(Fig.11).
(I) Site Asn65GlyThr (domain 1)
From the molecular model (Flg.11) It appears that the sugars can fit Into a cleft In the p- 
strands of the protein and stabilise a particular conformation of the molecule. However NMR 
spectroscopy studies by Wyss et al (1995) found no Interactions between the protein and the 
sugar, suggesting that the glycans do not He within this cleft. However the local protein 
conformation at the cleft may shield the developing glycan chain from the biosynthetic 
enzymes which process oligomannose structures to hybrid and complex glycans, ensuring 
that the glycan processing terminates at the oligomannose stage. Interestingly, while the 
sugars are not In a position to serve as a ligand for the receptor, both de-N-glycosylated 
(PNGase F) sCD2 as well as sCD2 In which the site at Asn 65 has t>een deleted fall to bind 
CD58. (Recny et al 1992). Activity Is retained when the oligomannose N-glycans are 
trimmed back to Man^GlcNACg by digestion with a-mannosldase Indicating that a minimum 
N-glycan core tri-saccharide Is required to give conformational stability within the CD2 
adhesion domain and maintain a functional CD58 receptor binding site. (Knoppers et al 
1992). Functional activity was also retained when the protein was expressed In the presence 
of a glycoskJase Inhibitor, BuDNJ, which leaves unprocessed MangGlcNAc2 GIC3  residues at 
each glycosylation site (Davis et al 1995).
(H )Site Asn126GiyThr (Domain 2)
The two domains of CD2 are joined by a link region of 6 amino adds (99-104). The 
molecular volume of the glycans at site 126 Is large compared with the protein and this 
raises the possltxilty that the sugars at this site may Interfere with the orientation or rotation 
of the two domains. In general membrane anchors restrict the rotation and translation of cell 
adhesion molecules; In CD2 the linker region Is a key factor which allows additional freedom 
to domain 1, which carries the binding site. Interestingly, the major difference between rat 
(which does not have a sugar at this site) and human CD2 Is a 13-20° difference In the 
orientation of the two domains observed In the crystal structure (Bodian et al 1994).
(iii) Site Asn117ThrThr (lOomain 2)
Asn 117 Is dose to the membrane surface and is the only site oonserved between rat and 
human CD2. The glycosylation sites In rat CD2 are at Asn 67, 77, 84 and 112. By analogy 
with the Interaction of CD59 with C5b-8 (see ch.3) the N-glycans at this site may Interact 
with the membrane protecting the protein from Interactions with the llpid bl-layer. The large
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size may be a means of influencing the spacing of cell surface molecules. In addition It may 
orient the binding site towards the receptor ligands In CD58 and CD48 by reducing the 
space available to domain 2 of the protein.
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Discussion
1. The structural diversity of the leucocyte antigens in this study
The recombinant glycoproteins studied in this chapter have different structural features and 
levels of complexity (Table 1a). CD59 is a member of the Ly-6 family, CDS contains a 
scavenger receptor domain while CD48. CD4 and CD2 are members of the immunoglobulin 
superfamily. sCD59 has only one domain while the CD5/CD4d3,4 chimera has five. The 
number of glycosylation sites associated with each protein ranges from one on sCD59 to four 
on CD48. Two of the glycans in CD2 are attached to the IgSF domains, in CD48 two are 
attached to the IgSF domains and two are located close to the junctions of the domains and the 
flexible loops, and in CD4 one is attached to the IgSF domain (see introduction to ch. 2 fig.1).
Antigen Domains N-gtycosylation
sites
Ugands Stmctural
studies
Hu sCD2 2D Asn65,117,126 CD58, CD48 Xtal; (Bodian, 1994)
(T11,LFA2)
Xtal: (Jones, 1992) 
NMR:(Driscoll, 1991)
Rat sCD2 2D Asn67,77,84,112 CD48
RatsCD48 2D Asn13,67,150,167 CD2 mutagenesis; rat 
sCD48/rat sCD2 
van der. Menve, 1995
HUECD59 ID Asn18 CD5b-8/C9 NMR (Kieffer, 1994)
Hu CDSdl ID Asn92 CD5:CD72 No details available
HuCDS/ 5D Asn92
ratCD3,4 Asnl 59,270 d3,4 X-ray 
(Brady, 1993)
Table la: Some structural details of the molecules Involved in this study
Molecular modelling has been used to explore possit>le roles for the oligosaccharides. In 
particular the relative sizes and location of the glycans has been examined (ch.2A section 3.7 
and Ch.2C section 3.7). The protein structures were taken from X-ray crystallographic or NMR 
structural data which is available for sCD59 and sCD2. The length of the sugars attached to 
sCD59 is of the same order of magnitude as the diameter of the globular protein (4.2nm) and 
are located on the opposite side of the molecule to the binding site for C5I>8/C9. The sugars 
associated with CD2 are also of the same order of magnitude as the protein domains and none 
of the sugars appears to be in a position to shield the binding site for CD58. CD2 shows site 
specific glycosylation and only oligomannose glycans are located at Asn65 (Recny et al 1992) 
which is located at a cleft in the protein which may restrict access to GlcNAc transferase I. The 
sugar attached at the flexible link region (Asn117) in CD2 may be In a position to affect the 
orientation of the two domains. In addition the glycan at Asn126 is close to the membrane, and
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Figure 1: The P4 GPC elution profiles of the asialo glycans released from the soluble 
forms of the leucocyte antigens studied in this chapter.
(a) CD59 (b) CDS domain 1 (c) CD5/CD4 domains 3,4 chimera (d) 002
may, by restricting the space available to the protein and limiting its interactions with the 
membrane, orient the CD2 binding site towards its ligand CD58. Interestingly, on CD48 the 
sugars are all located on one face of the molecule, and, as with CD2 and CD59, are not close 
to the binding site. No structural information is available for the scavenger domains oh CDS, 
which therefore could not be modelled.
2. Processing of complex glycans by CHO cells
The P4 profiles of the asialo glycans associated with the leucocyte antigens studied in this 
thesis are shown in figure 1 and the data are summarised in table 1b. The main findings were 
as follows: (i) the percentage of charged structures (all o2,^l[nked sialic acid) ranged from 10% 
in CD2 to 100% In CD5/CD4d3,4 (ii) the percentage of ' ^ lylactosamine/multiantennary 
structures ranged from 45% on sCD59 to 0% on CDSdl (iii) CDS, very remarkably, contained 
only one glyeoform, the biontennary, core fucosylated complex glycan H4N5F, while at the 
other extreme CD48 was associated with at least 47 different sugars (iv) only CD2 contained 
significant levels of oligomannose sugars (v) only CDSdl and the chimera contained O l^inked 
glycans (v) shorter oligosaccharides were more often sialylated than those containing more 
than one unit of lactosamine.
Glyco­
protein Doms
No. N- 
glycans
Charge status Types of N- glycan
%N Ai A2 A3 %OI H P/M OB
SCD59 1 1 3S 3S 12(b) 
18 (t)
0 6 0 4S 49
CDSdl 1 1 17 38 4S 0 0 0 0 100
CDS/
CD4d3,4
3 2 0 3S 6S 0 0 0 S 9S
CD2 2 3 90 10 0 0 46 0 32 22
CD48 2 4 Not determined 10* 10* 20* 40*
Table 1b Summary of glycosylation analyses in chapter 2
N-neutral glycans; A1 - glycans containing one sialic acid residue; À2 - gfycano containing two 
siaTic acid residues; A3 - ^yoans containing throe sialic acid residues  ^ 0-oligomannose; H- 
hybrid; CD-compiex biantennary; PM- polyiactosamine 'and/or multiantonnary type giyoans; b 
biantentvy,tiriantennary structures. *  The data for soluble CD59, CDS domain t  the chimera
A?
and ÇD2, was derived from integration of the peaks obtained by fractionation of the released 
ol^saccharides on P4 GPC or WAX chromatography. In contrast the values for CD48 were 
obtained from the MALDf MS analysis by measuring the peak heights of the various 
components o f the glycan pod. The numt>ers for CD48 should therefore t>e regarded only as 
approximate estimations (see ch. 8 section 2.1).
The majority of the glycans associated with these proteins were of the complex biantennary 
core fucosylated type; the only hybrid structures were Identified on rat sCD48, which was found 
to contain at least 47 possible glycan structures. CD5d1, CD5/CD4d3,4 and sCD59 contain very 
low levels of oligomannose sugars (6%). Although CD2 contains 46% of oligomannose 
structures, 33% are at one glycosylation site (Recny et al 1992). These data indicate that, with 
the exception of CD2 site 65, CHO cells are able to process complex oligosaccharides 
indicating that the local protein structure allows GlcNAc transferases I and II to transfer N- 
acetylglucosamine efficiently to the MangGlcNACg and MaryGlcNACg glycoforms respectively. 
These are the key enzyme steps in the processing of complex sugars. In CD2, the presence of 
oligomannose sugars at Asn 65 suggests that g ic n a c  transferase I and UDP-GlcNAc may not 
form an effective temary complex at this site. Asn 65 is located at a cleft in the protein and this 
may interfere with complex formation, suggesting that the protein is able to control its own 
glycosylation in a site specific manner by means of the local protein structure. Interestingly the 
range of glycosylation In human sCD2 is not reflected in rat sCD2 (4 glycosylation sites) also 
expressed in CHO cells: the asialo glycans associated with rat CD2 contained 80% of the core 
fucosylated biantennary complex glycan H5N4F (Davis et al 1993).
21 The protein may restrict the number of glycoforms
Domain 1 of CD5 contains one N-llnked glycosylation site. The glycans associated with the site 
were found to be highly restricted, both in size and type. Only a single glycan, the biantennary 
core fucosylated structure, H5N4F, (83% sialylated), was identified. The absence of 
microheterogeneity is extremely unusual, therefore to Investigate whether the presence of 
additional domains would increase the range of sugars the glycosylation of a chimera 
consisting of human CD5/rat CD4d3&4 (5 domains, 3 sites) was analysed. Interestingly, 95% of 
the glycans were the same complex sugar structure as CDSdl and 100% were sialylated. The 
addition of four domains to CD5d1 in CD5/CD4d3/4 therefore roculted in very little extra (5%) 
processing of the bi-antennary complex glycan which occupied the 100% of the glycosylation 
sites in CDSdl, suggesting that in this case the quatemary structure does not significantly affect 
the asialo glycosylation pattern. The glycans associated with rat sCD4 (expressed in CHO cells) 
Is more typically heterogeneous, and include 42% of hybrid and 22% of oligomannose 
structures and only 14% of H5N4F (Ashford et al 1993). This suggests that the structure of the 
CDS scavenger domain may influence the glycosylation processing of both CDSdl and the 
chimera. In the construct the scavenger domains of CDS replace the immunoglobulin domains 
1 and 2 which are normally attached to CD4; the glycans are not elongated and this may result
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Figure 2: Charge profiles of CHO cell derived CD antigens
from a decrease in the Golyi transit time of the chimera compared to intact €04 . An increased 
transit time has been shown to increase the percentage of elongated complex glycans (Wang 
et al 1995). Fuithennore, the addition of terminal sialic acid prcdudOG elongation; the high 
degree of sialylation and the lack of elongation suggests that, compared with outer arm GlcNAc 
tranferase, sialyl transferase has a high affinity for the complex H5N4F glycans attached to 
both CDSdl and the chimera.
2.2 Elonga^n and branching of oligosaccharides
SCD59 contains a higher proportion of polyiactosamine and multiantennary structures (36%) 
than 002, COSdl and C05/C04d3,4. This indicates that the protein structure allows access to 
the GlcNAc transferases IV, V and VI. Additions of N-acetyl glucosamine by these enzymes is 
required for a high degree of branching. The presence of a high proportion of polyiactosamine 
and multiantennary structures also suggests that GlcNAc transferase competes effectively with 
sialyl transferase for outer arm galactose and also that the transit time of .the protein through 
the Golgi is sufficient to allow extension of the* bi-antennary complex glycans. Sialylation 
prevents the addition of lactosamine extensions in approximately 10% of dislalylated 
biantennary structures. Interestingly, only 12% of sCO 59 glycans are elongated, while 24% are 
of the triantennary type, indicating that the protein structure does not preclude either possibility, 
interestingly, in human erythrocyte C059 approximately 40% of the glycans are of the 
polyiactosamine type (ch.3) of which 30% are greater than 23gu. This suggests that an 
important factor in determining the percentage of polyiactosamine structures may t)e the 
attachment of a GPI anchor which increases the transit time of the glycoprotein through the 
Golgi. In contrast to the native 0059, human sC059 expressed in CHO cells does not contain 
significant amounts of polyiactosamine or multiantennary structures larger than 23 gu. 
Interestingly both glycosylated and unglcosylated sC059 is expressed and secreted (ch. 2A, 
Fig. 1b). In contrast, human erythrocyte 0059 is expressed on the cell surface only in the 
glycosylated form (ch.3. Fig.7) suggesting that the GPI anchor may play a role in controlling 
sequon occupancy.
2.3 Sialylation of oligosacchandes
The weak anion exchange chromatography profiles of the glycans associated with the 
leucocyte antigens studied in this thesis are shown in figure 2. The percentage of neutral 
structures on the four proteins, all expressed in CHO-K1 cells, ranged from 0-90%; the chimera 
C05/C04d3,4 contained only charged glycans, while at the other extreme 90% of the glycans 
on 002 were neutral. The charge associated with complex sugars was invariably due to sialic 
acid. The CHO cell line does not express a-2,6 sialyi transferase, and, consistent with this, all 
the terminal sialic acid linkages associated with soluble 0059 were of the o2,3 type. In 
contrast, erythrocytes express both o2,3 and o2.6 sialyl transferases, and the erythrocyte 0059 
N-linked oligosaccharides contained t>oth sialic acid linkages (ch.3). Ali the complex sugars 
were present as neutral and sialylated structures although not every galactose residue was
A4
sialylated and tri-ahtennary glycans were only mono or di-sialylated. The subcellular location of 
sialyl transferase extends from the cisto the trans Golgi (Weinstein et al 1982), suggesting that 
addition of sialic acid to terminal galactose may occur at any stage in the elongation process. 
The relationship t>etween chain length and sialylation is summarised in table 2. Sialylation is 
more likely to occur in the early stages of processing (Merkle and Cummings 1987, Edge and 
Spiro 1985, Fukuda et al 1984) and the incidence falls off as the chains become more 
elongated; shorter oligosaccharides (less than 3 linear units of the repeating disaccharide 
Galp1,4GlcNAcpi) more often contain o2,6-linked sialic acid, whiie the o2,3 linkage is more 
common in the relatively less sialylated longer polyiactosamine extensions (Merkle and 
Cummings 1987).
Glycoprotein/ 
cell line
% complex N-links 
with 1 unit of 
Gaipi,4GlcNAcpi
% charged 
N-links
%2,3SA % 2.6SA
CD5d1 (CHO) 100% 83% 100% 0%
CD5/CD4d3,4 (CHO) 95% 100% 100% 0%
CD2 (CHO) 79% 10% 100% 0%
SCD59 (CHO) 64% 65% 100% 0%
Hu erythrocyte CD59 50% 66% 85% 15%
Table 2
These data, which indicate that the sugar chains attached to the recombinant proteins in this 
study contain only <x2,3-linked sialic acid, are consistent with previous studies (Ashford 1993) 
indicating that CHO-K1 cells lack Galo2,6-sialyl transferase. The trend in these data suggests 
that glycoproteins with a higher percentage of short structures (defined as 1 linear unit of the 
repeating disaccharide Galpl ,4GlcNAcp1/arm) are more extensively sialylated. CD5d1 is 
glycosylated exclusively with glycans of this type and 83% are sialylated. The CD5/CD4d3,4 
chimera which contains 95% of such glycans is 100% sialylated. However, sCD59, which 
contains 64% is only 65% sialylated; this result may partly be explained by the analysis of the 
glycans separated by chatige into NA1 and NA2 pools. This indicates that only one or two 
branches of the triantennary glycans (approximately 10% of the structures) are sialylated, 
although the branches may each contain a single disaccharide unit. Clearly there are other 
factors involved in modulating sialylation apart from the length of the glycan chain and the
65
proximity of the protein matrix, for example in the case of CD2, which on this basis is 
anomalous. Asn 65 in CD2 may be protected from the processing enzymes by the protein 
structure (ch.2C, 3.7). Interestingly, it has been suggested that an additional factor may be the 
requirement for a recognition sequence for sialyi transferase in the protein. In support of this, 
sequence analysis of cloned transferases has identified a conserved peptide motif (the sialyl 
motif) embedded within othenwise dissimilar sequences (Kitagawa et al 1993). However 
recently this motif has been shown to bind the donor substrate, CMP-NeuNAc, (Datta and 
Paulson 1995) rather than the glycoprotein substrate.
The study of the human erythrocyte (HE) glycoprotein, CD59, (ch3) showed that approximately 
50% of the biantennary N-glycans contained one Gaipi ,4GlcNAcpi unit/arm. The remaining 
sugars were larger structures. 66% of the total population of N-linked sugars were sialylated; 
85% of the sialylated glycans contained o2,3 linked sialic acid, while 15% (which may be all 
monosialylated glycans) were o2,6 linked. From the generalisations discussed above it appears 
probable that the large polyiactosamine structures on HECD59 are more likely to contain sialic 
acid in the o2,3 linkage than the smaiier glycans. Interestingly, a comparison of the 
glycosylation of recombinant erythropoietin (CHO cells) with native erythropoietin isolated from 
human urine has showed that the former contains oniy SA o2,3 Gal linkages whiie the native 
material contains 40% of SA o2,6 linkages (Takeuchi et al 1988). These data support the 
finding that the CHO cell line does not contain o2,6 siaiyi transferase and, in addition, indicate 
that the partially processed glycoforms of both CD59 and erythropoetin contain the necessary 
information to be recognised by both enzymes.
3 .0-glycans associated with the leucocyte antigens in this study
Gaipi.3/4GaiNAc O-linked glycans were identified on CD5d1 (8 amino acid 'link' region) and 
CD5/CD4d3,4 (23 amino acid link region). The chimera has a higher proportion of O-linked 
sugars than CD5d1 suggesting that the inclusion of a region rich in threonine and proline 
residues may be a means of introducing O-linked glycans into a recombinant protein. In 
contrast sCD2 and sHuCD59 expressed in CHO cells are not O-glycosylated. Interestingly, 
human erythrocyte (HuE) CD59 does contain O-linked glycans (ch. 3) although the 
glycosylation site on HuECD59 has not been determined; these data suggest that there may be 
a conformational change in the truncated sCD59 protein which precludes O-glycosylation, or 
that, in this case, O-glycosylation requires the presence of the GPI anchor.
4. Conclusion
The glycosylation of proteins is a complex event which is in part controlled by the interactions 
of the specific glycosylation machinery within a cell with each partialiy processed glyeoform, 
and 130th glycan and protein are involved. The unique structure of each glyeoform is defined 
both by the oligosaccharide and the local protein structure at the site to which it is attached. 
Initiation of glycosylation is controlled by the protein structure in as much as the processing of 
oligomannose structures requires the mannosidase enzymes to access the MangGlcNAc2
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precursor within the local protein conformation Thé blocking of the a t,3 N-acetylglucosaminyl 
transferase It, which gives rise to hybrid glycans, is also primarily a function of the protein. 
Interestingly, mutant mice in which the gene which onoodes GlcNAo transferase I was deleted 
died at mid-gestation, mainly from abnormalities in neuronal development. This means of 
interfering with processing has indicated an essential role for complex and/or hybrid N-linked 
cartwhydrates (Ioffe and Stanley 1994). The proportion of polyiactosamine type structures and 
the percentage of charged structures depends on the outcome of a competition for outer arm 
GlcNAc by galactosyl tranferase and sialyl transferase; the less processed the glycan chain the 
more likely it is to terminate with sialic acid suggesting that the affinity of the sialyl tranferase is 
enhanced by the proximity of the protein and shorter glycans. The type of sialic acid linkage is 
also related to glycan chain length and o2,6 linked sialic acid is more often associated with 
shorter chains than the o2,3 type.
As a result of these multiple interactions most glycoproteins consist of mixtures of glycoforms, 
and in the following chapters the composition and some possible functions for glyeoform 
populations have been explored in a number of systems including human erythrocyte GD59, 
RNase, transferrin, IgG and tPA.
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Abstract
Lysis of invading micro-organisms by tlie membrane attack complex (MAC) of the 
complement system is an integral part of the innate immune response. Complement 
activation involves powerful effector mechanisms against which hoot cells are protected by 
homologous restriction. One of the molecules involved in this process is CD59, a cell surface 
glycoprotein with a giycosylphosphatidyl inositol (GPI) anchor. CD59 is believed to bind to 
the complement proteins C8 and/or C9 in the activated macrophage attack compiex (MAC), 
preventing the formation of the fully developed complex. In this study the glycosylation of the 
human erythrocyte CD59 glcoprotein and Its glycan anchor have been examined. The 
principle conclusions are as follows: (a) 32% of the glycans attached to the protein were 
neutral; 68% contained from 1 to 3 sialic acid residues, (b) Over 50% of the N-linked glycans 
attached at Asn 18 were polyiactosamine tri- and tetra- antennary structures larger than 17 
glucose units, (c) An O-linked disaccharide, GaiGalNAc, was recovered in approximately the 
same molar proportions as the N-linked glycans. (d) 95% of the glycans associated with the 
GPI anchor were Manal -2Manal-6 Manal -4GlcNH. (e) The ratio of lipid to inositol was 3:1 
suggesting palmitoylation of the inositol ring. Some of the implications of this study are: (a) 
In common with another GPI anchored erythrocte membrane protein, acetyi cholinesterase, 
the consen/ed MangGlcNH core has not been further processed. This first comparison of 
two GPi anchored proteins from the same cell suggests that modifications to the core 
glycans may be cell-type specific, (b) Palmitoylation of the inositol ring reduces the 
possibility that CD59 wiii be cleaved frorri the erythrocyte cell surface by naturally occurring 
phospholipases. It also suggests that CD59 will not readily migrate from the erythrocyte 
surface and compromise homologous restriction by solubilisirig in membranes of non-host 
cells, (c) Enzyme digestions and examination of molecular models indicated that the 
asparagine-sugar amide linkage of CD59 is not protected from the proposed active sites of 
PNGase F by the local protein conformation, (d) The N-linked oligosaccharides (size range 
3-6nM) attached to CD59 (diarrieter approximately 12nM) at Asn18CysSer are close to the 
membrane surface. The glycans may orient the N-terminal active site of CD59 towards the 
binding site on the C5b-9 complex by restricting the conformationai space availabie to the 
protein and iimiting its interaction with the lipid bilayer.
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CD 59 inhibits complement mediated cell lysis
C6bS CSbS
pnnn:: n:rr\i:
(a)4=C :C9 loodey bound (b) 37%: C9 tightly bound (c) Poly^  C9
(d)lnthapres«iceofCDS9 (e)lnswtlon of active C9I» blocked
Figure 1; Schematic representation of the proposed mechanism of CD59 function
(Taken from Mari at a! (1990) Immunology 71,1-9)
Two hypothetical binding sites (1 and 2) on C5b-8 are envisaged, (a) At 4®C C9 is looseiy 
bound at site 1. (b) At 37®C C9 unfolds ano interacts with site 2. (c) Membrane damage 
follows exposure of hydrophobic interaction sites with the lipid bilayer and by formation of 
transmembrane channels. In the presence of CD59 the initial binding of 09 to C5b-0 occurs 
(q), but the oubsoquont insertion of GO and intoraotion with site 2 on CSb^ is prevented. 
Inhibition of the interaction between C5b-8 and 09 may be due to blocking of site 2 on 05b- 
8 by 0059. The association of the first 09 molecuie with 05b-8-0D59 compiex could be 
achieved by the interaction of OD59 with 09 preventing the recruitment of additional 09 
rnolecules into the complex.
The glycosylation of the human erythrocyte complement regulatory
protein, CD59
1. Background
1.1 The need to control homologous lysis in erythrocytes
The earliest committed eiythroid precursor cells differentiate into nucieated erythrobiasts 
that begin to synthesise hemoglobin. Further ceil differentiation and division brings about the 
formation of the normoblasts which, having extruded their nuclei, are released as 
erythrocytes through the capiiiaries of the bone marrow into the bkxxJ stream. For their first 
two days in the bloodstream the anuclear erythrocytes (reticulocytes) contain remnants of 
RNA and other intraceiluiar organelles and continue to synthesise hemoglobin. Erythrocytes 
have a life span of 120 days after which they are engulfed by the macrophages of the 
reticuloendothelial system, particularly in the liver or spleen. Some 20% of erythrocytes are 
prematurely destroyed in the serum, therefore protection of host ceiis from further loss by 
homoigous lysis is an important process.
1.2 Functions and locatbn of CD59 (also known as protectin, MIRL, HRF20, MACIF, P I8, 
HI 9)
CD59 is a cell surface glycoprotein that binds to the complement proteins 08 and/or 09 in 
the activated MAC, protecting host cells from non-specific lysis by homologous restriction 
(Fig. 1). Bound CD59 is believed to prevent the unfolding of the first molecule of 09 which 
binds to the MAC, a step that is necessary for membrane insertion (Meri et ai 1990, 
Lachman 1991). There is then no further binding of 09 or polymerisation to form a ring 
(Sugita et al 1988). In addition, and controversially, it has been proposed that CD59 has a 
second function in mediating T-ceii adhesive interactions by synergising with CD58 via CD2. 
Whiie CD58 interacts with region 1 of CD2, OD59 has been reported to interact with region II 
(Hahn et al 1992), however this has not been confirmed at the molecular level (van der 
Menve et al 1994).
CD59 is present on a wide variety of cell types, including leucocytes, erythrocytes, platelets, 
epithelial and endothelial cells and placental cells, and is attached to the cell surfaces via a 
glycophosphatidyl inositol (GPI) anchor. (Review: Waish et al 1992, Cross, 1990, Ferguson
1991) A number of soluble forms of CD59 have been found, for example in saliva, amnlotic 
fluid, milk and urine. These may be secreted from surrounding cells or result from GPI 
cleavages of membrane bound molecules by endogenous phospholipases. The wide tissue 
distribution of CD59 appears to reflect a general need for host cell protection where the 
complement system is active, increased vulnerability to complement attack has been noted 
where membrane bound CD59 is absent as, for example, on the erythrocytes of patients 
with paroxysmal nocturnal hemoglobinuria (Taguchi et al 1989). Conversely, CD59 is absent 
on cells which have less access to complement, such as liver parenchyma.
78
l î i r i i i i
Human érythrocyte CD59
Figure 2: Human erythrocyte CD59 (M.Wt. 19kD) is a giyooprotein with one N-iinked sugar at 
AsnfSCysSer, a çfiyoosyiphosphatidytinositol anchor and O linked glycan(G) at sites which have 
rwtbeen defined.
CD59 normally protects only host cells from homologous complement activity (Hughes et al 
1992); however, since the GPI anchor is readily soluble in most lipid bilayers, purified CD59 
can be readily inserted into the membranes of many cells. For example, protection can be 
conferred on human PNH erythrocytes by passively incorporating HuCD59 into the cell 
membranes (Holguin et al 1989) while the stable transfection of human CD59 protects both 
CHO cells (Zhao et al 1991, Takizawa et al 1993) and rat T-cells (Walsh et al 1991) from 
human complement. It has been proposed that CD59 is a ligand for CD2 (Dockort ot al
1992) but this has not been confirmed at the molecular level (van der Merwe et al 1994).
The number of molecules of CD59 / erythrocyte is between 2.5x10* and 5x10*. On 
endothelial cells base levels are around 2x10^ - 3x10^ (Brooimans et al 1992) reflecting the 
fact that the endothelial lining of blood vessels is under constant complement attack. During 
inflammation the levels are upregulated 3-fold by activators of cellular second messenger. A 
number of cytokines (including ILIa, TNFa or IFNy ) have been shown to have no effect on 
the regulation of CD59, which appears to be controlled at the transcriptional level.
1.3 StiiK t^ure ofHuCDSQ
(i) CD59 (Fig 2) is a monomeric protein (18-20kD) containing 77 amino acids in a single 
domain. The precursor (Table 1) contains 128 amino acids; these include 25 amino acids of 
signal peptide. The carboxy-terminal segment contains a cluster of 18 mainly hydrophobic 
amino acids preceded by 8 polar amino acids, a sequence typical of a signal peptide for 
GPI anchored proteins, (ii) The cleavage site for the anchor attachment is between Asn 77 
and Gly78 (Tomita et ai 1991). (iii) There are two potential N-iinked glycosylation sites 
(Asn8PPoThr and Asn18CysSer), one of which (Asn 8) contains a proline residue in the 
sequon and has never been shown to be occupied, (iv) No O-linked sugars have been 
reported on any CD59 molecule analysed to date. Asialo human erythrocyte CD59 failed to 
bind peanut agglutinin, a lectin which is specific for one of the core sequences for O-linked 
sugars Gaipi.3GalNAc (Ninomiya et al 1992).
Amino acid sequence of human CD59
signal sequenea 
MGIQGGSVLF GLLLVLAVFC H8GHS 1-2S
LQCYNCPN*PT ADCKTAVN**CS SDFDACUTK 1-30
AGLQVYNKCWKFEHCNFNDV TTRLRENELT 3140
YYCCKKDLCN FNEQLEN#GOT SL8EKTVLLL 61-00
VTPFLAAAWS LHP 91-103
N*PT Unoccupied glycosylation sequon (NBPT)
N**CS Glycosylation site (N180S)
# Cleavage and anchor attachment site (Asn 77)
GGT SL8EKT - Polar region 
VLLL VTPFLftAA W3 LHP - hydrophobic region
Table 1. Amino acid sequence of the CD 59 precursor
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Residues 1-25 are the signal sequence for entry into the endoplasmic reticulum. Residues 
1-77 are the amino acids which comprise the protein, Residues 78-86 are a polar region of 
amino acids. Residues 87-103 constitute a hydrophobic region of amino acids which, 
together with the polar region, define a structure typical of a GPi anchor signal sequence.
1.4 Giycosylphosphatidyl inositol membrane anchors
GPI membrane anchors are used by a wide variety of cell surface glycoproteins (McConville 
et al 1993). They constitute an alternative to the hydrophobic transmembrane polypeptide 
domain for the anchorage of membrane bound proteins. A protein destined to receive a GPI 
anchor must contain an N-tenninal signal sequence for entry into the lumen of the 
endoplasmic reticulum (Table 1) where the anchor is attached. The C-terminus of the protein 
must contain a GPI signal sequence, the most common feature of which is a series of 12-20 
hydrophobic residues at the C-terminus of the primary translation product. This signal 
sequence is cleaved and replaced by a pre-assembled GPI precursor, in the case of CD59 
this occurs at Asn77/Gly78 (Table 1). The C-termiriai amino acid (restricted to either Cys, 
Asp, Asn, Gly, Arg or Ser) is linked via ethanolamine phosphate to a glycan with a 
conserved backbone sequence (Manal-2Mana1-6Mana1-4GlcNH2) which is in turn linked 
to the 6-position of the myo-inositol ring of phosphatidyl inositol (PI) (Fig.4a). GPI anchors 
contain two lipids, normally one acyl and one alkyl, attached through the phosphate on the 
inositol ring (Fig. 4a). In addition, a subset of anchors are palmitoylated at C3/4 on the 
inositol ring making them resistant to PIPLC since the action of this enzyme involves the 
formation of a cyclic phosphate at inositol C3 and C4 (Fig. 15). The tetrasaccharide 
backbone of GPI anchors may be substituted with other sugars; in common with other 
oligosaccharide processing events which take place in the cell, the type and extent of these 
modifications may be species and tissue specific and depend on the structure of the 
individual protein to which the anchor is attached. In contrast to the GPI anchored proteins, 
the more common transmembrane anchors contain a polar sequence of amino acids at the 
C terminus of the peptide preceded by a hydrophobic region. The polar region remains in the 
lumen of the Golgi, and later in the cytosol of the cell, and fixes the protein in the membrane. 
If the polar sequence is missing the protein may still be anchored, but with the hydrophobic 
region replaced with a lipid anchor. It has been suggested that GPI anchors allow greater 
lateral mobility of proteins through the membrane compared to those with a transmembrane 
domain. (Low et al 1989) In the case of CD59 this may allow rapid movement towards sites 
of complement attack, before lytic plugs can form.
2. Introduction to chapter 3
The N- and O-linked glycans covalently attached to human erythrocyte CD59 were released 
with hydrazine and partially characterised. The structures were compared with those 
associated with human soluble CD59, expressed in CHO cells without a glycan anchor, 
which were analysed in ch.2. The accessibility of the sugar-asparagine linkage was probed
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with PNGase F. The glycan component of the GPI anchor was also isolated and 
characterised, and compared with the structures present in the glycan anchor attached to 
another human erythrocyte GPI anchored glycoprotein, acetyl cholinesterase. The 
oligosaccharides were analysed using a combination of P4 gel filtration and exoglycosidase 
digestions and GCMS composition analysis. Molecular modelling was used to explore a 
possible role for the glycans attached to CD59 in the function of the molecule in protecting 
erythrocytes from homologous lysis.
3. Methods
3.1 De-N-glyœsylation of CD59 with PNGase F.
CD59 was incubated for 16h at 37°C with Flavobacterium meningoseptum peptide-N- 
glycosidase F (analytical grade) in 20mM sodium phosphate buffer pH 7.5 containing 50mM 
EDTA and 0.02% azide buffer to deglycosylate the protein prior to ESMS.
3.2 Analysis of glycan moiety of the GPI anchor
3.2.1 Nitrous acid deamination and sodium borohydride reduction
The sample was dried in an Eppendorf tube in the Speed-Vac, and redissolved in 10pl (1 
volume) pH 4.0 buffer (0.1 M sodium acetate adjusted to pH 4 with acetic acid). 10pl (1 
volume) freshly prepared 0.5M NaN02 were added and incubated for 2.5h at room 
temperature. 5pl (0.5 volume) 0.8M boric acid were added. The amount of NaOH required to 
adjust the pH to about 10.5 was determined using buffer controls (typically equivalent to 8- 
lOpI i.e. 0.8 -1  volume per sample digest). This amount Was added to the reaction mixture 
and mixed. 5pl of 36mM NaB^H  ^ (10-15 Ci/mmol) dissolved in 0.1M NaOH were added 
immediately (hot reduction), followed by freshly prepared 1M NaBD^ in water to give a final 
concentration of 0.2 M NaBD^ (cold reduction). The reduction mixture was acidified with 1M 
acetic acid. The reaction was carried out in the fume hood as tritium gas was evolved. The 
sample was dialysed against water using a Spectropore membrane with a 2000 dattons cut 
off, freeze dried and 20% dissolved in 50pl water.
3.2.2 Aqueous HF dephosphoryiatbn
The sample was placed in a screw top Eppendorf tube, dried in a Speed-Vac, and placed on 
an ice/water mixture in a Dewar flask. 50pl 48% aqueous HF (BDH Aristar) at -20°C were 
accurately measured into the tube containing the sample and into 5 blank tubes. All the 
tubes were incubated for 48-60 hours at 0°C. The blank tubes were spun briefly in the 
microfuge. 250pl of saturated LiOH (prepared by shaking 10g of LiOH with 30ml of water in 
plastic tube) were added to one blank. After centrifuging (Microfuge 20sec) 1ml aliquots 
checked for pH. If pH was <3 10pl saturated LiOH were added, vortexed and the pH re­
checked. The previous step was repeated until pH >3; the volume of LiOH required to give 
final pH of 3-5 was estimated and the reproducibility checked against other blanks. This
81
volume of LlOH was frozen in a labelled Eppendorf tube on dry Ice. Tfie HF digest was 
transferred to the frozen LIOH, vortexed, spun and transferred to original tube using the 
same pipette tip. The pellet was washed twice with SOpI water and supernatants transferred 
to original tube.
3.2.3 Re-N-acetylatbn
Re-N-acetylation was carried out by adding 10mg NaHCOg to saturation (approx. 100mg/ml; 
1M) to the combined supernatants from 3.1.2, followed by lOpI acetic anhydride. The 
mixture was Incubated for 10 minutes at 4°C, twice. lOpJ acetic anhydride were added and 
the mixture Incubated at room temperature for 30 minutes, desalted by passing through 
0.2ml AG50X12(H+), eluted with 1ml water. The eluate contained the glycan core (Gc), 
starting from the deamlnated and reduced glycopeptlde (dAR-gp). The sample was dried by 
rotary evaporation, and flash evaporated with toluene to remove residual acetic add. The 
sample was d l^ lved  In 25pl water and applied to a 3x40cm paper strip (Whatman 3MM) 10 
cm from the end. Descending paper chromatography for 60h In 1-butanol:ethanol:water 
(4:1:0.6) was used to remove radiolabelled contaminants (labelled GPI glycans remain at the 
origin If phosphorylated and within 3 cm of origin If neutral). The paper was dried and 
scanned and the relevant region cut from the chromatogram and eluted with water 
(SOpl/cm )^ by Incubating for 5 mlns and centrifuging through a syringe hung Inside a rotary 
evaporator tube (Smin at 2-3000rpm). This elution procedure was repeated 3 times using 
25pl/cm^ water and the combined eluates evaporated to dryness. The eluted glycans were 
passed through a mixed-bed column of 0.1ml of Chelex 1000 (Na+), over AG50X12 (H+), 
over AG3X4 (OH"), over QAE-Sephadex A25 (OH ), and filtered through a 0.2mm syringe 
microfllter.
3.2.4 DbnexHPLC
This technique allows glycans to be separated on the basis of net charge at high pH.
The system was fitted with a Dionex Cartx)Pac column which Is a strong anion exchange 
column designed to separate carbohydrates at high pH. At high pH sugar hydroxyl groups 
are ionised and glycans can be separated by bn exchange using an acetate gradient. 
(Townsend et al Y.C. (1989). In Methods in Enzymobgy Vol. 179 (ed. V. Ginsburg), p 779. 
Academb Press, New York.) A callbratbn standard consisting of a glucose oligomer 
standard mixture (5mi of 50 mg/ml standard mix) was resolved and detected by high 
sensitivity pulsed amperometric detection (PAD). The elutbn posltbns of the neutral glycans 
are defined in Dbnex Units (Du) by linear Interpolatbn of their elutbn posltbns between two 
adjacent Internal standards. These Du have no speclfb meaning but are a reliable 
chromatographb property whbh correlate with partbular glycan structures. The sample was 
detected on line by a Raytest Romana radioactive monitor, and by hand counting using a 
Beckman Scintillation counter, and correlated with the standards.
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3.2.5 Dionex HPLC conditbns:
Buffer 1, 0.15M NaOH; buffer 2, 0.15M NaOH containing 0.25M sodium acetate. Row rate
0.6ml/mln.
Time % buffer 1 % buffer 2
0 95 5
50 80 20
51 0 100 (wash cycle)
60 0 100 (wash cycle)
61 95 5 (re-equlllbratlon for > 10 mln)
3.2.6 Bbgei P-4 gel flltratbn
This technique allows the separation of neutral glycans on the basis of hydrodynamic 
volume, giving a direct measurement of size. It can be used preparatively, without Internal 
standards, or analytically by co-chromatographIng a set of glucose oligomer Internal 
standards with radlolabelled neutral glycans. The detection of the oligomer standards by 
refractive Index (Rl) and the neutral glycans by an on-line radioactive monitor allows 
accurate determination of the size of the glycans In terms of effective glucose units' (gu). A 
combination of specific exoglycosldase digestions and re-chromatography of the digests 
allows an analysis of the glycan structures.
The analyses described were performed using the Oxford GlycoSystems Glycomap 
Instrument which Is based on the P4 chromatography system.
3.2.7 Exoglycosldase sequencing
1. Aspergillus phoenbus al-2mannosldase (APAM) (also known as ASaltol a1-2 
mannosldase.)
This enzyme Is specific for a-D-Man1-2D-Man glycosldic bonds. Digestions were perfonned 
In lOpI 0.1 M sodium acetate pH 5.0 containing 0.01 mU (0.04mg) of APAM (Oxford 
GlycoSystems Ltd! X-5009) for 16-24 hours at 37°C under a toluene atmosphere at a 
substrate concentration of betwen 15mM and 2mM. The products were de-salted by passing 
through 0.2ml AG50X12 (H+) and elution with 1ml water. The samples were evaporated to 
dryness and residual acetic add removed by flash drying.
2. Jack bean a-mannosldase (JBAM)
This enzyme has a broad specificity for any terminal, non-substltuted, a-D-Man residue. 
Digestions were performed In 30ml enzyme (25U/ml in 0.1 M sodium acetate pH5). Substrate 
concentration was between lOmM and 5mM, Incubation was for 2-4 hours at room 
temperature followed by 16-24 hours at 37°C. The products were desalted with 
AG50X12(H+) (0.2ml), filtered through a 0.2mm membrane and evaporated to dryness. 
Acetic acid was removed by flash drying with toluene.
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3.3 Mass Spectrometric analysis of CD59
3.3.1 GC-MS Composition analysis of llplds, protein and total sugar
All spectra were obtained with a Hewlett-Packard 5890-5970 GC-MS system. Mass spectra 
were recorded using electron Impact (70eV) Ionisation at a source temperature of 150°C 
and pressure of 2-4 x 10-5 Torr. The GC stage was equipped with an on-column Injector. 
The column head pressure was 5 psi giving a He carrier gas flow rate of about 0.5 ml/mln 
through a 30m x 0.25mm SP2380 bonded phase column (Supelco) or Econocap SE-54 
bonded phase column (Alltech). The GC to MS transfer line temperature was maintained at 
10°C above the maximum oven temperature. The transfer line was made from a 1m x 
0.25mm piece of deactivated fused silica (Supelco). The column to transfer line connections 
are made through glass quick seal connectors (Chromopack 4787).
3.3.2 Programme for Methanolysls/TMS sugars and llplds:
Column: SE-54; Initial temperature: 140°C; hold time: 2 mln; gradient: i6°C/mln; 
Intermediate temperature: 260°C (lOmln); gradient 2:15°C/mln; final temperature: 300°C 
(20mln); mass spec, acquisition: Linear scanning (m/z 40-800).
3.4 Composition analysis of total sugars associated witfi CD59
The reaction vessels were prepared from heat cleaned (3h at 500°C), glass capillary tubes 
9SMI size J, yellow band pipette capillaries, Sigma C6148) by flame sealing one end to form 
a microtube. scy//o-lnosltol (si) (0.1 mM, 4nmoles, 40pl) and water (50pl) were added to 
CD59 (50pg /10nl, 2nmoles) (Solution A). 80pl solution A were evaporated to dryness and 
then Incubated overnight at 85°C with 0.5M HCI/MeOH In a sealed capillary. 5ml of stock 
solutions containing 0.5nmoles of each component of two standards: 
Xyl/Fuc/Gal/Glc/sl/GlcNAc/SA and Man/Gal/GlcNAc/sl/SA and a blank were treated In the 
same way. After cooling, the tubes were opened, lOpI of pyridine were added to neutralise 
the HCI and the contents dried In the Speedvac; 50pl water were added to each. The 
samples were dried again to remove residual HCI followed by 20ml methanol to dehydrate 
the residues. 15pl TMS were added, the tubes sealed with Teflon tape and left for at least 30 
mlns. Ipl was Injected onto the GC. The monosaccharide components were obtained by 
Integration of the total Ion chromatogram peaks as follows:
(I) the peaks of the methanolysed sugar standards were Integrated to give a molar relative 
response factor (MRRF) for each monosaccharide versus the scy//o-inosltol Internal 
standard:
MRRF^onosacc = (area monosacc. peak)/(area scy//o-lnosltol peak)
(II) The amount of each monosaccharide (M) was calculated from the sample 
chromatograms as follows:
Amount of M = (area sample peak) x (amount Internal standard)/(area scy//o-lnosltol internal 
standard peak) x (MRRF i^onosacJnrnol
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3.5 Analysis of N- and O- linked glycans
3.5.1 Release and re-N-acetylatlon of glycans
0.6mg (31.6 nmoles) CD59 was dialysed Into 0.1%TFA and lyophlllsed. Glycans were 
released from CD59 by hydrazine at 95°C using the GlycoPrep 1000 (Oxford GlycoSystems 
Ltd) optimised for maximum recovery (approximately 85%) of both N- and O-linked sugars. 
The recovery Is assessed by de-slalylating and de-galactosylating blantennary complex 
sugars and then Incubating with galactosyl transferase. The free glycans associated with 
the anchor were not released under these conditions.
3.5.2 labelling of reducing terminus
50% (estimated approximately 13.4 nmoles) of the released and re-N-acetylated sugar 
library was reduced with NaB^H^
3.5.3 Fluorescent labelling of reducing terminus witfi 2-amlnobenzamlde (2AB)
10% (2.68nmoles) of the free glycans were evaporated to dryness using a Savant 
SpeedVac. 150pl of 2-amlnobenzamlde were added to DMSO (350pJ) and 200 pJ of this 
solution was added to a dye. 100ml of the mixture were added to the reductant and 
vortexed. 5pl of the final solution were added to each glycan sample, capped and Incubated 
at 65°C for 2 hours. After the Incubation the samples were centrifuged briefly and spotted 
onto 3MM paper In a single transfer. A chromatography tank was saturated with 
butanohethanohwater (4:1:1) and the excess reagents eluted from the labelled glycans by 
ascending paper chromatography. When the dye reached the top of the paper the strip was 
thoroughly dried and scanned using a fluorescent Instant Imager. The 2AB labelled glycans 
remaining at the origin were eluted with water.
40% (10.7 nmoles) of the unlabelled glycans was de-slalylated and purified through mixed 
bed resins for mass spectrometric analysis
3.5.4 Ion exchange separation of anionic sugars
A weak anion exchange column (Vydac 301VHP575) (7.5cmx50mm) was equilibrated In 
water. Labelled glycans were Injected In aqueous solution. Neutral structures were eluted In 
the void volume and charged glycans which bound to the column were successively eluted 
with an Increasing salt gradient of 0-500mM ammonium formate pH9. The classes of 
charged glycans were assigned by comparison with a standard fetuin glycan library.
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Gradient parameters:
Time Flow Curve %A %B
Start 1 ml/mln 6 0 100
12mln 1 ml/mln 6 5 95
25mln 1 ml/mln 6 21 79
SOmln 1 ml/mln 6 80 20
55mln 1 ml/mln 6 100 0
65mln 1 ml/mln 6 100 0
66mln 1 ml/mln 6 0 100
70mln 2ml/mln 6 0 100
89min 2ml/mln 6 0 100
90mln 1 ml/mln 6 0 100
3.5.5 Enzyme digestions
Glycans were evaporated to dryness on a SpeedVac. 20pJ of standardised enzyme solutions 
were added and incubated for 16fi at 37°C.
(a) Bacteriodes fragills endo-p-galactosidase (Oxford GlycoSystems): 0.5U/ml in 50mM 
sodium actetate buffer pH5.8; substrate concentration 40pM. Cleaves R-GlcNAcpi -3Gaipi - 
4GlcNAc/Glc.
(b) Bovine testes galactosldase (Oxford GlycoSystems): 1-2 U/ml In lOOmM 
citrate/phosphate buffer pH4; substrate concentration 40-100pg/ml. Cleaves Galp1-3,4>6 
GlcNAc/R.
(c) Artt)Fot>acter ureafaciens neuraminidase (Oxford GlycoSystems): 1-2U/ml In lOOmM 
sodium actetate buffer pH5; substrate concentration 5-30|xM. Cleaves NeuNAco2-6>3,8 R.
(d) Newcastle disease virus neuraminidase (Oxford GlycoSystems): 0.2U/ml In 50mM 
sodium actetate buffer pH5.5; substrate concentration >5pM. Cleaves NeuNAco2-3,8 R.
3.5.6 Purification of enzyme digests prior to P4 analysis
Samples were purified from protein and salts by passing through mixed bed resins of 
ChelexlOO (Na+)/Dowex AG50X12 (H+)/Ag3X4A (OH )/QAE Sephadex A-25, as described 
In 3.2.3.
3.6 Molecular modelling
CD59 co-ordinates were taken from the NMR solution structure (Kleffer et al 1994).
PNGose F co-ordinates were taken from the crystal structure (Norris et al 1994).
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Figure 3; Strategy for the analysis of the glycans associated with human erythrocyte
CD59
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4. Results
Figure 3 shows the overall scheme for the glycan analysis of the GPI anchored human 
erythrocyte cell surface antigen, CD59. Figure 4a-c shows the main chemical reactions 
Involved. The strategy Is In four parts: (a) analysis of the glycan part of the CD59 GPI anchor
(b) examination of the Asp18CysSer-sugar amide linkage with PNGaseF (c) 
characterisation of the N- and O- linked glycans associated with CD59 (d) the composition 
analysis of all glycans attached to CD59.
4. 1 Analysis of the glycans associated with the CD59 GPI. (Fig.3a)
4.1.1 Isolation of the free neutral anchor glycans (NG)
Intact CD59 (Fig. 4a) was dialysed Into water and freeze dried. The glycopeptlde was 
released from the Inositol phosphate - llpid fragment (Fig. 4b) by de-amlnatton and reduction 
with nitrous acid and sodium borohydride. Sugar phosphate bonds were cleaved with 
aqueous HF (Fig. 4b) to yield the free glycans (NG) (Fig. 4c) which were re-N-acetylated 
with acetic anhydride.
4.1.2 Separation of the free anchor glycans by High Perfomance Anion Exchange 
Chromatography (HPAEC)
The free glycans were separated on the basis of charge at high pH by Dionex anion 
exchange chromatography (Fig. 5). Three glycans were resolved at 2.51 (90%), 3.07 (9%) 
and 3.72 (1%) Dbnex units (Fig 5).The major species (90%) had a molecular volume on P4 
of 4.2 gu (Fig. 6a). The elutbn posltbns of this structure on P4 and Dbnex are consistent 
with those of MangAHM.
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Figure 5: HPAEC (Dionex) of neutral glycans from CD59. 90% of the glycans eluted at 
2.51 Dionex Units consistent with the presence of the Mang glycan In the anchor. 9% of the
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Figure 4a: Typical GPI anchor showing nitrous acid cleavage site 
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Figure 4c: Neutral glycans - products of dephosphorylation with HF
glycans eluted at 3.07 Dionex Units consistent with the presence of the Man3 glycan 
substitiAed with GalNAc. 1% of the glycans eluted at 3.72 Dionex Units. The composition of 
the glycans in the 2.51 and 3.07 DU peaks was confirmed by P4 GPC.
4.1.3 Characterisatbn of anchor glycans by P4 GPC and exoglycosldase sequencing 
The minor species (9%) had a molecular volume on P4 of 5.62 gu (Fig. 6d). The elution 
positions of this structure on P4 and Dionex are consistent with those of GalNAcMans 
anhydromannitol (AHM). The minor species (1 %) was not analysed.
The proposed structure of the major glycans (90% of total population) was confirmed by 
exoglycosidase sequencing and P-4 gel filtration. The 4.2gu structure was reduced with A. 
Saitoi a1-2 mannosidase to 3.2gu (Fig. 6b). This structure (Mana1,6AHM) was reduced to 
AHM (1.7gu) (Fig. 6c) after incubation with Jack Bean a-mannosidase which cleaves 
Mana1,6 linkages (in addition to Mana1.2 and Mana1,4).
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Figure 6a-c: Analysis of CD59 anchor glycans
(a) P4 gel permeation chromatogram of the major (90%) subset of the glycans in the CD59 
anchor eluting at 4.2gu. (b) Digestbn of glycans in 6a with a1,2 A. phoenbus mannosidase 
(also known as A. Saitoi) results in removal of one mannose residue and a corresponding 
decrease in size to 3.2gu. (c) Incubation of glycans from 6b with Jack bean a mannosidase
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(which cleaves h4ana1,2,4 and 6 linkages) removes 2 mannose residues and reduces the 
glycans to 1.5gu.
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Figure 6(d): P4 gel permeation chromatogram of the minor (9%) subset of the glycans in 
the CD59 anchor eluting at 5.62gu.
4.1.4 Conclusion
The populations of CD59 anchor glycans are:
Mana1-2Mana1-6Mana1-4GlcNH 91% 
Mana1-2Mana1-6Mana1-4[GalNAcpi,4]GlcNH 9%
Insufficient material was available to determine the linkage of GalNAc to glucosamine. The 
assignment of a pi .4 linkage is by analogy with other GPI anchor structures and from the 
Dbnex elutbn positbn.
4.2 The N-glycosidic linkage of CD59 is accessible to PNGase F: (Figure 3b)
Figure 7 shows a 12% SDS PAGE reducing gel of CD59 before (lane 2) and after (bne 3) 
digestbn with PNGase F. whbh cleaves N-linked sugars from proteins at the N-glycosidb 
linkage. In lane 2 the glycoprotein can be seen as a broad band with a molecular weight 
range of approximately 25-19kD, consistent with the presence of a number of glycoforms. 
There is no evbence of any unglycosylated protein which would suggest variable site 
occupancy. Lane 3 indicates that approximately 80% of the sugars have been cleaved non- 
selectively from the protein. The de-N-glycosylated protein migrates to 15kD and is visible as 
a narrow band indicating that all the glycoforms have been reduced to a single structure and 
that the asparaginel 8-sugar ambe linkage is accessible to PNGase F. This is consistent 
with the molecular modelling studies described in sectbn 4.5.
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Figure 7: SDS PAGE analysis of CD59. Tracks 1 and 4: Molecular weight standards. 
Tracks 2 and 3: CD59 -/+ PNGase F respectively.
4.3 Analysis of CD59 N- and 0-llnked glycans: (Figure 3c)
The N- and O- glycans were released by hydrazine at 95°C. 20% of the pool was labelled at 
the reducing terminus with 2AB and the remainder with NaB^H^.
4.3.1 Analysis by charge
The 2AB labelled glycans were analysed according to charge by weak anion exchange 
(WAX) chromatography (Fig. 8a). Peaks were assigned by comparison with standards of 
2AB labelled fetuin glycans (Fig.Bb.c). All glycans were reduced to neutral sugars following 
digestion with Arthrobacter ureafaciens neuraminidase (Fig.Bd) which removes terminal 
a2,3- and a2,6- linked NeuNAc. All the charge could therefore be ascribed to sialic acid. 
After extensive digestion with Newcastle disease virus neuraminidase (which removes only 
a2,3 linked NeuNAc) the proportions were 76.6%;19.4%:1.3B%;1.12%:1.11% (Fig.Be). 
100% of the A1 glycans remained intact while over 90% of the other structures were de- 
sialylated. This suggests that while the OA, NA2 and NA3 glycans contain a2,3 sialic acid 
the A1 sugars are terminated with «2,6 linked sialic acid.
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Figure 8: Analysis of CD59 glycans by massxharge. Weak anion exchange 
chromatography (Vydac 301VHP575) of glycan library.
a. Resolution of 2AB labelled CD59 glycans released by hydrazlnoiysis. N-linked glycans 
carrying 1, 2, 3 or 4 anionic charges are denoted by NA1, NA2, NAS, NA4 respectively: 
charged O-linked glycano by OA. b  Elution positionc of 2AB iabeiied standard fotuin N 
linked sugars used to assign peaks in 8a. c. Elution posltbns of fetuin N- and O-glycans 
confirming O-links elute between NA1 and NA2. d. Analysis of 2AB labelled CD59 glycans 
post digestbn with Arthrobacter Ureafaciens siaNdase. s. Analysis of 2AB iabeiied CD50 
glycans post digestbn with Newcastle Disease Virus sialidase.
Conclusion: Sialic acid content of CD59 N- and O-linked glycans is as follows: 
neutral : NA1 : OA : NA2 NAS
31.9% : 22.2% : 5.2% : 17.4% : 21.8%.
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Figure 11a: Typical cleavages in acid methanolysis
4.3.2 Analysis of neutral glycans by size
The neutral glycans resulting from the neuraminidase digestion were resolved by P4 gel 
permeation chromatography (Fig. 9a).
Analysis of N-linked glycans
Glycans eluting between 18 and 27 gu were digested with endo p-galactosidase. This 
enzyme, which cleaves p-linked galactose residues within the glycan chain but not terminal 
galactose, gave a range of products with molecular volumes consistent with the presence of 
multiantennary polylactosamine structures (Fig. 9b). The 11.5 digestion product (H3N5) 
indicates that there are blantennary complex sugars with lactosamine extensions. The 13.5 
structure (H3N6) indicates the presence of triantennary glycans with lactosamine extensions 
while the 18-25 gu peak suggests that the endogalactosidase digestion may not have 
reached completion. The 15gu fractions was identified as H5N4F using the reagent array 
sequencing method. The 13.8 and 11.2 structures remain to be analysed when more 
material is available.
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Figure 9: Analyels of neutral CD59 glycans by hydrodynamic volume using P4 gel 
permeation chromatography, a. Total glycan library released by hydrazlnoiysis and 
Iabeiied with tritium, b. Analysis of pool of 18-25 gu glycans. c. 18-25gu glycans from 9a/b 
after incut)ation with endo ^ -mannosidase.
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4.3.3 Analysis of CD59 O-linked glycans by sequential exoglycosklase digestion and P4 
The glycans eluting at 3.5gu were digested to 2.5gu with bovine testes p-galactosidase (Fig. 
10a) The reducing terminal glycan was shown to be ^HGalNAc by gas chromatography (GC) 
using a radioactive detector (Rg.lOb). These data are consistent with thé stmcture Gaip3,4, 
or 6-GalNAc. The presence of previously unreported O-linked sugars was confirmed by 
GCMS composition analysis (fig. 11b,c) in which the GalNAc residue, present only in O- 
linked glycans. was identified. The 2.5gu peak (fig. 10a) was also analysed by GC and did 
not contain cartsohydrate.
Conclusion: 50% of the CD59 N-linked glycans are of the multiantennary polylactosamine 
. . .  type. ° ' -  ;
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Figure 10a: Exoglycosldase analysis of the 3.6gu peak from figure 9a.
P4 gei permeation chromatogram of 3.6 gu peak following incubatbn with Bovine testes 
galactosidase shows reduction to 2.5gu consistent with the structure Gal.^ 1-3/4GalNAc. The 
2.5 gu peak in figure 9a. was analysed by radioGC and does not contadn cart>ohydrate.
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Figure 10b: Radio GC analysis of the reducing terminai glycan of the CD59 O-linked 
oligosaccharide.
Conclusion: CD59 contains the O-linked glycan: Gal pi - 3/4GalNAc
4.4 GCMS composition analysis of all CD59 sugars following methanolysis :
Figure 11a shows a typical cleavage pattern of a glycan anchor subjected to acid 
methanolysis. Figures 11b and c show the GCMS oligosaccharide composition analysis data 
following acid methanolysis of CD59. Figure 11b shows the full spectrum including the sialic 
acid peak, 11c is an expansion of the region containing fucose, mannose, galactose, N- 
acetyl galactosamine, and N-acetyl glucosamine. The peaks were assigned by analogy with 
known standards and the areas under each monosaccharide peak and the molar proportions 
of each of the species are shown in Table 1. The internal standard was scy//o-inositol which 
was present at 4nmoles.
Oligosaccharide Peak area nmoles/SOpg CD59
N-acetyl galactosamine 7.79E7 6.1 nmoles
N-acetyl glucosamine 3.44E8 34.6 nmoles
mannose 6.64E7 5.2 nmoles
galactose 2.38E8 31.6 nmoles
fucose 5.14E7 8.2 nmoles
sialic acid 4.39E7 10.0 nmoles
scy//o-inositol 5.69E7 4.0 nmoles
Table 1 : GCMS Composition analysis of the glycans associated with 50[ig CD59
The following conclusions can be drawn from the composition analysis of the CD59 glycans:
(i) The presence of GalNAc identified in the O-linked GalGalNAc glycan was confirmed.
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Figure 12: Molecular model of CD59 showing the glycoprotein modelled with (I) a 
polylactosamine N-glycan (yellow) at Asn 18, (11) a glycan anchor with a tri-mannosyl core (red) 
(Hi) an ethanolamine phosphate bridge at Man3 (mauve) and additional ethanolamine phosphate 
groups at Mani and Man2 in the anchor (also mauve) (indicated by preliminary analysis - data 
not shown) (iv) with two lipids (dark green) attached to inositol (brown) C2 via phosphate and a 
third attached directly to the inositol ring at C l (indicated by preliminary GCMS analysis and 
resistance to PIPLC) (v) the O-linked glycan (yellow) modelled alongside as the site of 
attachment to the protein is unknown. The protein structure (blue) is based on the 3D-NMR 
solution structure (Kiefferetal 1994).
(ii) The high proportion of N-acetyl glucosamine and galactose compared with mannose is 
consistent with a high percentage of multi-antennary and polylactosamine type 
oligosaccharides.
(iii) The high percentage of fucose suggests outer arm fucosylation as well as core 
fucosylation.
(iv) The presence of sialic acid residues was confirmed.
4.5 Molecular modelling
4.5.1 The N-linked oligosaccharides may orient the N-terminal active site of CD59 towards 
the binding site on the C5b-9.
Figure 12 shows CD59 modelled with (i) a polylactosamine N-glycan at Asn18, (ii) a glycan 
anchor with a tri-mannosyl core (iii) an ethanolamine bridge at Man3 and additional 
ethanolamine groups at Mani and Man2 in the anchor (indicated by preliminary analysis of 
the positions of the ethanolamine substituents - data not shown) (iv) with two lipids attached 
to inositol via phosphate and a third attached directly to the inositol ring (indicated by 
preliminary GCMS analysis and resistance to PIPLC). (v) the O-linked glycan modelled 
alongside as the site of attachment to the protein is unknown.
The N-linked oligosaccharides (size range 3-6nM) attached to CD59 (diameter 
approximately 12nM) at Asn18CysSer are close to the membrane surface. The glycans may 
orient the N-terminal active site of CD59 towards the binding site on the C5b-9 complex by 
restricting the conformational space available to the protein and limiting its interaction with 
the iipid bilayer.
4.5.2 The asparagine-sugar amide linkage of CD59 is not protected from the proposed 
active sites of PNGase F by the local protein conformation.
Figure 13 shows the crystal structures of CD59, RNase B and PNGase F. The structure of 
PNGase F is based on the crystal structure of Norris et al 1994. The protein is folded into 
two domains, each with an eight stranded antiparallel p-jelly roll configuration similar to the 
types of structures found in lectins. CD59 was modelled according to the crystal structure of 
Kieffer et al 1994. RNase B was modelled according to the crystal structure of Williams et al 
1987. All three molecules are modelled to the same scale. Two active sites have been 
proposed for PNGase F: (i) Thr42, Lys44, Asp99 and Thrl 01 on strands D and G of domain 
1 (ii) a site in a cleft at the opposite end of the molecule, flanked by five tryptophan residues 
and one phenylalanine residue. In contrast to the CD59 linkage the asparagine-sugar amide 
linkage in RNase was buried within the protein and not accessible to the active site of 
PNGase F. This is consistent with the experimental evidence in section 4.2 and in ch.4 
which demonstrates that the N-linked glycans can be cleaved from native CD59, but not 
from undenatured ribonuclease B.
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Figure 13: The crystal structures of CD59, RNase B and PNGase F
The structure of PNGase F is based on the crystal structure of Norris et al 1994. The protein is 
folded into two domains, each with an eight stranded antiparallel /Fjelly roll configuration similar 
to the types of structures found in lectins. CD59 was modelled according to the NMR solution 
structure of Kieffer et al 1994. RNase B was modelled according to the crystal structure of 
Williams et al 1987. All three molecules are modelled to the same scale. Two active sites have 
been proposed for PNGase F: (i) Thr42, Lys44, Asp99 and ThrlOl on strands D and G of 
domain 1 (ii) a site in a cleft at the opposite end of the molecule, flanked by five tryptophan 
residues and one phenylalanine residue. In contrast to the CD59 asparagine-sugar amide 
linkage, which is susceptible to the enzyme, the same linkage in RNase is protected by the 
protein and not accessible.
5. Discussion:
5.1 A comparison of CD59 and AChE suggests that structural features of the GPI anchors 
may be cell type specific (Fig. 14).
This study has enabled the first comparison of the glycosylation of two different GPI 
anchored proteins from the same cell. It raises the possibility that the glycosylation of GPI 
anchors may be cell type specific. 9% of erythrocyte CD59 is attached to the cell membrane 
by a GPI anchor in which the Mana1 -2Mana1 -6(GalNAcpi -4)Mana1 GlcNHg glycan links the 
protein to myo-inositol phosphate and the lipid. However 90% of the anchor glycans are of 
the Man a1-2Mana1-6 Mana1-4GlcNH2 type. This is identical to the glycan in the GPI 
anchor which attaches to AChE to human erythrocytes (Deeg et al 1992).
In addition, unusually, AChE and CD59 both contain an additional lipid attached to the 
inositol ring, and preliminary data suggest that, in common with AChE, CD59 contains two 
additional ethanolamine phosphate groups attached to Mani and Man2 in the glycan anchor. 
This may reflect the fact that, during biosynthesis, pre-assembled GPI anchors are attached 
to all proteins which contain the appropriate signal sequence. It may therefore be predicted 
that the GPI anchors attached to different proteins in the same cell will have common 
structural features. Subsequent processing of the tri-mannosyl glycan core is also controlled 
by the glycosylation machinery within the individual cell and may, in some cases, also be 
determined by the local conformation of the protein. More comparative studies are needed to 
explore the measure of control which the individual protein exerts over the glycosylation of 
its own anchor. The principle, however, has been well established for N-linked glycans 
where the further processing of the Glc^Mang structure attached to all N-glycosylation sites 
is species, cell and site specific.
5.2 Glycosylation analysis may be a useful means of identifying the source of secreted 
giycoproteins.
In general, glycosylation analysis may be a useful means of identifying the source of urinary, 
serum or other secreted glycoproteins.
Glycans associated with CD59 in the urine may originate from both soluble and membrane 
bound CD59; in addition the sugars may be degraded during the processes of excretion 
suggesting that the structures shown in Tables 2a and 2b are minimum structures. 
Interestingly, the major portion of soluble urine CD59 (U-CD59) has been shown to contain a 
GPI moiety terminating with inositol and not with inositol phosphate (Nakano et al 1994). 
This explains the absence of the inositol phosphate attached lipid tails and gives insight into 
the origin of the secreted form of CD59. Comparison of the glycosylation of the erythrocyte 
CD59 anchor with that of urine CD59 (U-CD59) indicates that most U-CD59 is unlikely to be 
derived from erythrocytes. This is consistent with the fact that erythrocytes are processed 
mainly in the spleen and that, in contrast to erythrocyte CD59, U-CD59 contains no lipid 
directly attached to inositol.
96
N-linked glycan
O-linked
Peptide
glycan
EtN
hECD59
hAChE
hECD59
9%
hECD59
hAChE
Ma1-2Ma1-6Ma1-4Glcl
mm ^
hAChE
hECD59
CHj
I
NH,
hAChE
hECD59
C18:0
Two studies have analysed the glycans attached to U-CD59. In the first (Table 2a) the 
heterogeneous set of glycans attached to Mana1-AHM of the dAR-uCD59 anchor Included 
only 27.2% of the Mans structure found In erythrocytes:
Mana1-2Mana1-6: 28.1% 
Mana1-2Mana1-2Mana1-6: 27.2%;
Manal -2Mana1 -6(GalNAcpi -4): 33.9%;
Manal -2Mana1 -2Mana1 -6(GalNAcpi -4):10.8%
Table 2a: The glycans
associated with the anchor 
from UCD59 (Nakano et al 
1994)
In the second, soluble U-CD59 anchor glycans were also more heterogeneous those of the 
erythrocyte cell surface protein. However a different set of structures were Identified which 
did not Include the Mang glycan. The glycans attached to ManGlcNHgmyo-lnosltol assigned 
by mass spectrometry (and without full linkage Information) are shown In Table 2b:
Mans: 14%;
MansGlcNAc: 13%;
MangGlcNAc + Man2GalGlcNAc:49%; 
MansGalGlcNAc:15%; 
Mans(NeuNAcGalGlcNAc): 5%; 
Manq(NeuNAcGalGlcNAc): 4%______
Table 2b: The glycans associated 
with the anchor from UCD59 (Sutton 
etal 1994).
The Inconsistencies between these two 
sets of data may be due to different 
Isolation procedures or to differences In the Individuals from whom the samples were 
obtained, however neither set Is fully compatible with the human erythrocyte CD59 analysis 
which contained 90% MangGlcNH. Thus, by an examination of the structures of the glycans. 
It Is possible to conclude that the major part of CD59 In urine does not originate from 
erythrocytes. These data also Imply that the glycosylation of GPI anchors Is cell type 
specific.
5.3 Human erythrocyte CD59 contains an additlonai lipid chain substituted at inositol C2 
Human erythrocyte CD59 Is PIPLC resistant. The PIPLC cleavage reaction depends on the 
formation of a cyclic phosphate between the phosphate group at Inositol Cl and the -OH 
group normally present at C2 (Fig.15); therefore It can be proposed that the third llpid 
identified In this study Is attached to the Inositol ring at C2. The presence of a third llpid 
chain provides an even more secure anchor Into membrane making It unlikely that CD59 
would be released either to allow It to re-enter the llpid bllayer at another point or to transfer 
to the membrane of another cell. This may be Important If such a mechanism prevents CD59 
solubilising In the membranes of non-host cells targeted for complement attack.
There Is a continuing debate regarding the origin of soluble CD59. The study of U-CD59 
suggests It Is processed without the llpid tails and therefore normally secreted from cells. It 
has been suggested that soluble CD59 may also result from a cleavage of GPI anchored
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Figure 15: PIPLC cleavage of the llplds attached through ethanolamine phosphate at 
Inositol 02 In GPI anchors This requires the formation of a cyclic phosphate involving 
positions C1 and C2. This is precluded by substitution of a third lipid at C1.
molecules by endogenous phospholipases. The data from this study suggest that soluble 
CD59 is unlikely to result from a cleavage reaction which requires the normally anchored 
CD59 molecule to be temporarily out of the membrane. Interestingly, both Decay 
Accelerating Factor (DAP) (Walter et al 1990) and human AChE (Roberts et al 1989, Deeg 
et al 1992) also contain the third lipid substituted in the inositol ring.
5.4 The N-glycosidic linkage of erythrocyte CD59 is accessibie to peptide N- giycanase F 
Recent studies (Suziki et al 1993) have revealed a series of species and tissue specific 
PNGases active in mammalian cells. Some glycoproteins, for example plasminogen, contain 
aspartic acid in place of asparagine at some unoccupied glycosylation sites. This suggests 
that variable site occupancy may in some situations be the result of the removal of an 
attached glycan chain. Protection of the N-glycosidic linkage from cleavage or, alternatively, 
making it accessible to specific types of PNGase may therefore be important processing 
mechanisms. The enzyme is also widely used to release N-linked sugars from proteins for 
structure-function studies where it is important to recover an undenatured protein. In several 
cases, for example in RNase B (ch4), this has not proved possible. The enzyme may be 
used as a probe to compare the accessibility of the N-glycosidic linkage in CD59. In contrast 
to RNase B, the N-linked glycans were readily removed from the undenatured CD59 protein, 
suggesting that, in this case, the local conformation of the protein does not shield the N- 
glycosidic linkage from the active site of the enzyme. The reaction was explored by 
molecular modelling (fig. 13) and the result is in contrast to ribonuclease B (ch.4) in which the 
asparagine-sugar amide linkage is protected from the proposed active sites of PNGase F by 
the local protein conformation.
5.5 68% of the giycans attached to CD59 are siaiyiated
Weak anion exchange chromatography and composition analysis using gas 
chromatography/mass spectrometry demonstrated that Hu erythrocyte CD59 is heavily 
siaiyiated. It contains 68% of 2,6- linked mono-, and a 2,3- linked di- and tri- siaiyiated 
glycans compared with 32% of neutral structures. This is consistent with the fact that most 
serum glycoproteins contain siaiyiated sugars. In contrast, human soluble CD59 expressed 
in CHO cells has no tri-sialylated glycans (ch.2A). UCD59 contains only 4% of 
monosialylated structures; 96% of the oligosaccharides are neutral. This may reflect the 
finding that it is asialo glycoproteins which are most rapidly removed from the circulation (for 
example by the asialo glycoprotein receptor in the liver) and excreted.
5.6 Human erythrocyte CD59 contains a high proportion of poiyiactosamine, muitiantennary 
N-iinked giycans
CD59 is glycosylated at Asn 18 with a range of smaller N-linked glycans including extended 
complex biantennary sugars (15.9gu, approximately 2,0000). However more than 40% are 
bi-, tri or tetra- antennary structures ranging from 20-30gu (approximately 2,500 - 4,000 D)
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containing poiyiactosamine extensions. The molecular model (Fig. 12) suggests that the N- 
linked sugars may play a role by preventing interactions of hydrophobic regions on the 
protein with the lipid bilayer. This may be important for CD59 to move rapidly to the site of 
insertion of the C5b-8 MAC complex. The sugar may also orient the protein, increasing the 
affinity of CD59 for a site on C5b-8 and allowing it to compete effectively with 09. This is 
consistent with the finding that 88% of the ability of CD59 to restrict homologous lysis is lost 
when the glycan is removed. The composition analysis (Tablel) confirms that CD59 contains 
a high proportion of N-acetyl glucosamine (34.6nmoles) and galactose (31.6nmoles) 
compared to man nose (5.2nmoles) indicative of poiyiactosamine extensions.
Once erythrocytes are released into the circulation they rapidly lose the ability to synthesise 
proteins, including glycosyl transferases and glycosidases. The glycosylation profile of CD59 
is therefore a combination of structures: those synthesised by the original glycosylation 
machinery of normoblasts, and those which are put on during the changes which follow the 
extrusion of the cell nuclei.
5.7 The presence of an anchor may allow further processing of CD59 giycans
In contrast to erythrocyte CD59 soluble human CD59 expressed in CHO cells (without the 
signal sequence and therefore the anchor) contains 41% bi-antennary core fucosylated 
complex glycans (14.7gu), 24% of a biantennary structure with one lactosamine extension 
(18gu) and only 15% of larger structures. It is unclear why the CHO cell line normally 
restricts the size of the glycans although it has the machinery to add polylactosamines. In 
this case, two possible reasons for the extended structures are (a) the anchor decreases the 
rate of transport of the protein through the Golgi and, (b) the glycosylating enzymes are all 
membrane anchored to the Golgi membrane allowing the anchored erythrocyte CD59 to 
interact with the enzymes more efficiently.
5.8 Human erythrocyte CD 59 contains at least one O-iinked glycan
No O-linked sugars have been reported previously on any CD59 molecule analysed to date. 
Asialo human erythrocyte CD59 failed to bind peanut agglutinin, a lectin which is specific for 
one of the core sequences for O-linked sugars Gaipi ,3GalNAc (Ninomiya et al 1992). This 
result may suggest either that the O-linked GalGalNAc glycans detected on CD59 are not 
linked (31-3 or that the sugar is not accessible to the lectin while attached to the protein. 
Although there is no peptide region with a high proportion of serine, threonine and proline 
residues which might constitute an O-linked domain, there are potential 0-glycosylation sites 
at Thrl 5, 29, 51, 52 and 60, and at Ser21. Proline residues close to Ser or Thr are known to 
favour O-glycosylation, perhaps because the proline ring causes a local change in the 
conformation of the peptide allowing neighbouring amino acids side chains to become more 
exposed (ch.8 3.5). A possible site for O-glycosylation may therefore be ThrlO which is 
preceded by a proline at residue 9 and is close to proline 7. The possibility also remains that 
the 0-link site may be in the C-terminal sequence absent in the recombinant protein.
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In contrast to erythrocyte CD59 no 0-links were detected in the glycans released from 
soluble human CD59 expressed in CHO cells following hydrazinolysis at 95°C (ch2). Neither 
the presence nor absence of 0-links was established for UCD59.
Interestingly, while the deduced amino acid sequence of CD59 predicts a protein core of 
approximately 10-11kD the molecular mass for de-N-glycosylated human erythrocyte CD59 
is 14kD by SDS PAGE. Currently it is not known if the residual mass can be accounted for 
entirely by the GPI anchor or whether there is also some unidentified O-glycosylation.
It is also worth noting that recombinant HuCD59 expressed in CHO cells has an apparent 
molecular mass of 24kD. After removal of the N-linked sugar, the protein migrates with 
native human CD59 to 14kD (Ninomiya et al 1992). The molecular weight differences 
between the two glycosylated proteins may be attributed to cell specific glycosylation and, in 
contrast to the findings in this thesis, the data suggest that either both or neither of the CD59 
molecules is O-glycosylated.
5.9 CD59 contains a 1,6-iinked siaiic acids
Although the A2 and A3 populations of CD59 were susceptible, NDV did not reduce the A1 
population to neutral. This suggests that the addition of a 1,6 sialic acid to one arm of the 
oligosaccharide prevents the addition of any more sialic acid residues to the developing 
glycan chain, resulting in an A1 subset of glycoforms. It also suggests that a2,6 sialic acid 
may not be added to a sugar which already has a sialic acid residue linked a2,3.
5.10 The presence of complex sugars at Asn 18 is essential for the function of CD59 
De-N-glycosylation of human erythrocyte CD59 with N-glycanase resulted in an 88% 
reduction of the C5b-9 complement inhibitory activity of the protein (Ninomiya et al 1992). 
There was no change in activity following digestion of CD59 with neuraminidase, suggesting 
that the presence of sialic acid is not required for the protective function of the sugar. 
Moreover, CHO cells transfected with Hu CD59 grown in the presence of 1-DMM showed a 
comparable reduction in the C5b-9 inhibitory activity. This suggests that the presence of N- 
linked MangGICg sugars at Asn18, which result from the inhibition of the normal processing 
pathways by DMM, an inhibitor of a-mannosidase, cannot substitute for the larger native
complex type.
The role of the sugars remains to be elucidated; it has been established that they do not 
contribute to the affinity of CD59 for the 08 and 09 components of the 05b-9 complex. This 
is controlled by epitopes on 08 and 09 which become exposed following a conformational 
change which occurs within the MAO complex (Ninomiya et al 1992).
5.11 Conclusions:
Some of the structural details of the glycosylation of the GPI anchored erythrocyte 
glycoprotein, OD59, have been elucidated. 91% of the anchor glycans were of the Mang 
type, identical to those on erythrocyte AOhE, consistent with the addition of a pre-assembled
100
anchor to both proteins in the ER. However, in contrast to AChE 9% of the core glycans 
attached to erythrocyte CD59 had been further processed by the addition of GalNAc. This 
suggests that the processing of the core glycans of GPI anchors may be cell type specific; 
this has been well established for N-linked glycans. In addition, an O-linked disaccharide 
was identified and >50% of the N-linked structures were of the siaiyiated, multi-antennary 
poiyiactosamine type. The glycans attached to erythrocte CD59 were different from the 
structures identified in two studies of urine CD59 indicating that UCD59 does not originate 
from erythrocytes. Molecular modelling suggests that the N-linked sugar, which is close to 
the membrane, may orient the active site of CD59 towards the C5b-8 receptor by restricting 
the conformational space available to the protein and preventing interactions with the lipid bi­
layer. Interestingly, another membrane anchored protein, CD2, also contains an N-linked 
glycan near the membrane (ch.2). This may also serve to orient the CD2 molecule for its role 
in mediating cell/cell interaction, thereby suggesting that glycosylation may indirectly 
maintain the spacing between opposing cell membranes.
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Abstract
Glycoproteins generally consist of a mixture of glycoforms, however the reasons for such 
diversity are not well understood. This study explores the possibility that the protein structure 
may control the accessibility of the N-linked oiigomannose sugars to processing enzymes and, 
conversely, that the presence of different oligosaccharides may modulate the recognition, 
stability and functional activity of some of the glycoforms of RNase B. Intact ribonuclease B 
was resolved by borate capillary electrophoresis into five populations (RNase Man 5-9) 
according to the particular oiigomannose structure associated with each glycoform. Alterations 
in the composition of the glycoform populations during digestion of ribonuclease B with A. 
Saitoi a1,2 mannosidase were then monitored. The terminal a1,2 linked mannose residue of 
the Man 6 glycoform was more resistant to the enzyme than the a1,2 linked mannose residues 
of the higher glycoforms, suggesting that the extent to which the protein can shield the sugar 
chain is variable and depends on the proximity of the protein to each oligosaccharide residue. 
Digestion of the free oligosaccharides under the same conditions, monitored by High 
Performance Anion Exchange Chromatography (HPAEC), revealed that the rate of cleavage of 
the free sugars was 100 times faster, suggesting a role for the protein in shielding the 
oligosaccharides from processing enzymes during biosynthesis. To determine whether the 
sugars confer stability on the protein, the Man 5,1 and 0 glycoforms were tested for resistance 
to pronase. All the glycans gave equal protection to RNase B compared with the unglycosylated 
protein. A polyclonal antibody raised against RNase A showed a reduced affinity both for the 
Man5 glycoform and for the native RNase B but not for RNaseManI demonstrating that some 
N-linked sugars can shield sites on the protein from antibody recognition. Pure individual 
glycoforms tested in a functional assay using double-stranded RNA substrate showed nearly a 
4-fold variation in activity; molecular modelling suggested that steric factors may play a role in 
modulating this interaction and that the sugars may variably disrupt one or more of the salt 
bridges between anionic residues in RNaseB and phosphate groups in the double stranded 
RNA substrate.
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Single Man 9 
conformer
Oligosaccharide
dynamics
Asn 34 side chain 
flexibility
Figurela: A. A single Man9 conformer of RNase based on the 2.5A X-ray crystal structure. B. 
A single Man9 conformer of RNase showing the dynamics of the oligosaccharide based on an 
overlay of 10 oligosaccharide conformations. C. The effect of Asn34 side chain flexibility on the 
orientation of the oligosaccharide in the Man9 glycoform of RNase B. (Taken from Woods et al 
1994 and Rudd et al 1995). The protein structure is based on the crystal structure (Williams et 
al 1987).
Amino acid sequence of RNase
KETAA AKFER QHMDS STSAA SSSNY CNQMM 1-30
KSRNL TKDRC KPVNT FVHES LADVQ AVCSQ 31-60
KNVAC KNGQT NCYQS YSTMS ITDCR ETGSS 61-90
KYPNC AYKTT QANKH 11 VAC EGNPY VPVHF 91-120
DASV 121-124
N-linked glycosylation site: Asn34LysThr 
• Active site residues include His12, Lys41, His119 
Disulphide bonds: 26-84, 40-95, 58-110, 65-72 
Molecular weight of unmodified chain: 13,690
Figure 1b
The Structure and Function of the Glycoform Populations of
Ribonuclease B
1. Background
1.1 Proteins may modulate the biosynthesis of N-iinked giycans
In chapter 2 it was suggested that the protein plays a role in modulating the biosynthesis of N- 
linked glycans. For example, site 65 on CD2 is glycosylated exclusively with oiigomannose 
structures, and examination of a molecular model of CD2 indicated that Asn65 may lie in a cleft 
in the protein. This suggests that, in some cases, the local protein conformation may restrict the 
structure of its own glycoforms to the oiigomannose class by shielding developing glycans from 
mannosidase and N-acetylglucosaminyl transferase processing enzymes. To explore such a 
possibility and, conversely, to probe the extent to which the particular oligosaccharide 
structures associated with single glycoform populations can specifically modify accessibility, 
stability and functional activity, a study was made of bovine pancreatic ribonuclease.
1.2 Structure of bovine pancreatic ribonuclease
This single domain, globular protein (Fig.1a,b) is a mixture of unglycosylated RNase A 
(13,690kd) and a collection of glycoforms (designated RNase B Man-5,-6,-7,-8 and -9) in which 
the oiigomannose series, Man-5 to -9 (Fig.2), is associated with the single N-glycosylation site 
at Asn34LeuSer. Although there have been many studies comparing the activity of 
glycoproteins with their deglycosylated counterparts, in general the significance of 
oligosaccharide diversity at one site is not known. For example, in this thesis functional studies 
of tissue plasminogen activator (t-PA) (ch.7) have shown that the rate of fibrin dependent 
plasminogen activation spans a range which depends on the glycosylation site occupancy of 
both t-PA and its substrate, plasminogen. At the extremes the fibrin dependent activity for 
Type II t-PA (two N-linked glycans) with Type 2 plasminogen (one O-linked glycan) is 2-3 times 
the value for Type I t-PA (three N-linked glycans) and Type 1 plasminogen (one N- and one O- 
linked glycan) (Wittwer et al 1989; Mori et al 1994). However, it is not known whether, within 
this framework, glycoform diversity at each individual site can provide a spectrum of activity, 
allowing the cell a means of achieving a finely regulated response to its environment. Such 
studies have not been possible previously because the technology required to separate 
individual glycoforms of a glycoprotein has not been available. However, the development of 
capillary electrophoresis to resolve the five glycoforms of bovine pancreatic RNase B (Rudd et 
al 1992) has allowed the preparation and analysis of individual pure glycoforms of a 
glycoprotein making it possible to address the fundamental question of the consequences of 
glycosylation changes at a single site.
Many physical parameters have been determined for bovine pancreatic RNase; in particular the 
crystal structures of both RNase A and B are available (Wlodawer et al 1988; Williams et al 
1987). The active site, centred around His12, His 119 and Lys41, has been well defined (Shall 
and Barnard 1969), as have the anionic binding sites involved in its interaction with RNA
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Figure 2a: The oiigomannose glycoforms of RNaseB. Most of these glycoforms exist as a 
number of isoforms which differ in branching and linkage. To illustrate this three alternative 
structures of the Man8 glycoform are shown. The relative proportions of the five populations 
were determined by capillary electrophoresis.
Schematic representation of MangGicNAc^OH showing numbering system
Figure 2b
(McPherson et al 1986). Importantly, X-ray crystallography (Williams et al 1987), circular 
dichroism and optical rotatory dispersion (Puett 1973) and ID- and 2D-1H-NMR (Joao et al 
1992) have demonstrated that the secondary and tertiary structure of RNase is unaffected by 
glycosylation and therefore the overall 3-D conformation of individual RNase glycoforms is the 
same.
1.3 The function of ribonuclease
Mammalian ribonucleases regulate many important biological functions by catalysing the 
degradation of single- and double- stranded ribonucleic acids (RNAs). RNase secreted from the 
pancreas catalytically degrades RNA in the gut, and is associated with pancreatic cancer 
(Reddi and Holland 1976). RNase is expressed in other normal and tumour cells (e.g. 
osteosarcoma, leiomyosarcoma; P. Fiten et al unpublished data). RNases are cytotoxic 
(D'Allessio et al 1991; Wool 1984), moreover RNases interfere with the double-stranded 
replicative intermediates of many viruses, with duplex-based latency of Herpes viruses 
(Stevens et al 1987), with viral capsid formation (Fisher and Johnson 1993) and with double­
stranded RNA-mediated induction of cytokines such as interferon (Van Damme et al 1985), IL-6 
(Van Damme et al 1987) and chemokines (Van Damme et al 1991). Ribonuclease-nucleic acid 
interactions have been extensively studied, but the contribution of the oligosaccharides has not 
been previously addressed.
2. Introduction
This study explores (a) the extent to which the protein structure protects the oiigomannose 
sugars associated with the different glycoforms of RNase B from modifications by A. Saitoi 
mannosidase enzyme (b) whether the oiigomannose sugars variably shield protease 
susceptible sites on the protein surface (c) whether the oiigomannose sugars on RNaseB 
variably shield antigenic sites on the protein from a polyclonal antibody raised against RNase A 
(d) the possibility that the oiigomannose sugars may variably modulate the activity of RNase 
towards double stranded RNA by steric hindrance.
3. Materials and Methods
3.1 Capillary Electrophoresis of RNase A and B
A 72cm fused silica capillary, ID 75pm, was used; voltage conditions were Ikv for Imin, 20kV 
for 9min, 30°C, wavelength for detection 200nm, injection time 1.5s, in 20mM sodium 
phosphate, 50 mM SDS, 5mM sodium tetraborate pH 7.2, on a Beckman P/ACE system with 
GoldTM Software. HPLC used a Waters System with a TSK 3000 gel filtration column 
equilibrated in potassium phosphate buffer (0.1 M pH 7.2).
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3.2 Purification of RNase A and B
Commercially available RNase A is frequently contaminated with RNaseB and vice-versa. 
Concanavalin A lectin binds proteins containing oiigomannose structures and can therefore be 
used to selectively bind the glycosylated variants of RNase. Where necessary, batches of 
RNase purchased from Sigma Chemical Company were typically further purified as follows: 
Purification of RNase A
Concanavalin A sepharose (Pharmacia) was pre-equilibrated with (i) 0.1 M HCI followed by (ii) 
NaOAc (5mM;pH5.2) containing CaClg (ImM) and MgClg (ImM) and 5mM a-methyl 
mannoside (iii) NaOAc (5mM;pH5.2) containing CaClg (ImM) and MgClg (ImM) (Buffer A).
1 mg of RNase A (Sigma) was applied to the column in the equilibration buffer. The unbound 
fraction (RNase A) was collected, dialysed into water and checked for purity by CE and SDS 
PAGE. 0.47mg was recovered (47% yield). No detectable amounts of Con A were leached from 
the affinity column.
Purification of RNase B
Concanavlin A was pre-equilibrated as above and RNase B (1 mg Sigma) was applied to the 
column as described for RNase A. The column was washed with buffer A containing 0.1 M NaCI 
to remove non-specifically bound molecules. RNase B (0.64mg) was eluted with 200mM a- 
methyl mannoside in the same buffer, dialysed into water and checked for purity by CE and 
SDS PAGE. Con A, which occasionally leached from the column in significant amounts, was 
removed by HPLC gel filtration using a TSK 3000 analytical HPLC gel permeation 
chromatography (GPC) column equilibrated in 0.1 M potassium phosphate pH7.2.
3. 3 Enzymatic modifications of RNase B glycoforms:
RNase A and B (Sigma Chemical Co.) were purified to electrophoretic homogeneity by 
Concanavalin A sepharose affinity chromatography and HPLC GPC.
Individual glycoforms were prepared by enzymatic modification of RNase B. All the digestions 
were monitored by capillary electrophoresis; in the case of RNase Man-1 the reaction was 
carried out in the CE carousel and samples were injected directly into the capillary from the 
reaction mixtures, eliminating the need to take aliquots and stop the reactions. All peaks were 
assigned by co-injection of the digestion mixtures with the standard RNase B ladder 
preparation. This was obtained by mixing digestion products taken at different time points 
during the Jack Bean a-mannosidase digestion to obtain a mixture of glycoforms from Man9- 
Manl. The glycoforms were purified from exoglycosidase enzymes by gel permeation HPLC 
before analysis. The final samples were eiectrophoreticaiiy pure by CE.
Enzyme digests (see fig. 4b):
(i) RNase B Man-5: RNase B was digested to a single population of RNase B Man-5 with A. 
Saitoi a 1,2 mannosidase at an enzyme:substrate ratio of 25mU :1mg in 1ml 50mM sodium 
acetate pH 5 in 96h at 37°C.
(ii) RNase B Man-1: RNase B was converted to a single population of RNase B Man-1 with 
Jack Bean a-mannosidase (5U:1 mg in 1 ml lOmM sodium citrate pH 4.5 / 0.2mM Zn acetate) in
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95 min at 30°C. A slower digestion was performed to reveal details of the early part of the 
reaction used 2U:1mg in 1ml 10mM sodium citrate pH 4.5 / 0.2mM Zn acetate).
(iii) RNase B Man-0: RNase B Man-1 was converted to a single population of RNase B Man-0 
with the p i-4 mannosidase Helix pomatia in 20h at 37°C in lOOmM sodium acetate pH4, with 
an enzyme:substrate ratio 10U : 50mg /ml.
(iv) RNase B GlcNAc: RNase B was converted to a single population of RNase BGIcNAc with 
EndoH at lU/mg RNase B in lOOmM sodium citrate buffer pH 5.5 for 16h at 37°C.
(v) Digestion with PNGase F (20U/mg) in 20 mM sodium phosphate pH 7.5 containing 50mM 
EDTA for 18h at 37°C.
3.4 Pronase digestion
In three separate experiments RNase A together with RNase Man-5, Man-1, or Man-0 were 
incubated with pronase in the CE carousel at 30°C +/- 3°C. The enzyme to substrate ratio was 
7.7U;10mg and the buffer was 50mMTris/HCI pH 7.5. Digestions were monitored continually by 
direct injection into the capillary and each incubation was repeated at least three times. The 
data were obtained by integration of the appropriate peaks. Similar digestions of the glycoforms 
in pairs were carried out under the same conditions.
3.5 Preparation of polyclonal a-RNase A
Purified RNase A was injected into a rabbit (20pg in complete Freund's adjuvant on day 1, 20 
pg in complete Freund's adjuvant after 2,4,6 and 8 weeks, and pure antigen after 10 weeks). 
Blood (10ml) was collected after 11 weeks. The serum (2ml) was removed from the clot and 
freeze dried (Rega Institute, Leuven). The serum was reconstituted in 2ml of PBS and applied 
to a protein A/Sephadex G25 column equilibrated in 0.14M potassium phosphate pH8. IgG was 
eluted with glycine pH 2.8 and checked for purity by HPLC. 8mg of IgG were recovered.
3mg of purified RNase A were bound to a sepharose CL4B affinity gel (0.25ml). The purified 
IgG (8mg) in PBS was recycled for 1 hour at room temperature through the affinity matrix in 
tandem with 1ml of Sephadex G25 (Pharmacia) to lower the pH immediately after elution. After 
extensive washing with PBS, bound material was eluted with glycine pH 2.8 and the pH 
immediately adjusted to 7. 0.4 mg of IgG was recovered in the bound fraction.
3.6 Preparation of RNase A affinity column
700pg of freeze dried CNBr activated Sepharose 4B were swollen for 15 minutes in ImM HCI 
and washed with 2 ml of the same solution (0.25ml gel). RNase A (3mg) was dissolved in the 
coupling buffer (NaHCOg [0.1 M, pH8.3] containing NaCI [0.5M]. The protein solution was mixed 
with the gel suspension for 4 hours at room temperature after which time approximately 95% of 
the protein had bound to the gel. Remaining active groups were blocked with 0.2M glycine pH 8 
and the excess protein washed away with coupling buffer followed by acetate buffer [0.1 M, 
pH4] containing NaCI [0.5M] followed by a further wash with coupling buffer. The blocking 
agent was removed by the coupling buffer. The ratio of RNase A to gel was 11.4mg/ml.
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3.7 ELISA assay
Microtitre plates were coated with the following mixtures of RNase A and RNase B glycoforms:
(1) RNase A 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100% and
RNase B (Man5-9) 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 0%
(2) RNase A 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100% and
RNase Man5 100, 90, 80, 70. 60. 50, 40, 30, 20, 10, 0%
(3) RNase A 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100% and
RNase Mani 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 0%
All solutions were 5pg/ml in PBS
Appropriate volumes of each solution were mixed in the microtitre plate wells (total volume 
200|il) and incubated overnight at room temperature to coat the wells with different mixtures of 
the RNase A and RNase B glycoforms as shown above. The plates were washed with 3x1% 
ovalbumin / 0.05% Tween in PBS and blocked with 1%BSA/PBS for 2 hours at room 
temperature. After washing with 3x1% ovalbumin / 0.05% Tween in PBS, rabbit IgGa-RNaseA 
(lOng/ml) was incubated in each well for 3 hours at 37°C (having previously established that 
this was a saturating level of antibody). The bound IgGa-RNaseA was detected with peroxidase 
labelled (goat) a-rabbit IgG by incubating 200pl of a 1:1000 dilution in each well for 2 hours at 
37°C. The antibody was visualised by incubating with orthophenylene diamine. The reaction 
was stopped with HgSO^ and the result read at 405nm. The results are the average of eight 
runs / sample.
4. Results
4.1 The protein structure may protect the RNase B glycans from A.Saitoi mannosidase 
The oiigomannose sugars linked to RNase B were released by hydrazine, reduced and 
radiolabelled with tritium and digested to a single Man5 structure with A.Saitoi a1,2 
mannosidase. The rate of digestion was monitored by High Performance Anion Exchange 
Chromatography (HPAEC) using a radioactive detector. The natural population of RNase B 
glycoforms (fig. 4a) was digested under identical conditions to a single population of the Man5 
glycoform (Fig. 4b). In this case the digestion was monitored by CE equipped with a UV 
detector reading at 200nM. The time taken to digest 33 nmoles of the released oiigomannose 
glycans at an enzyme:substrate ratio of 1:12.5mU was 34 minutes (Fig. 3a); the reaction was 
over 100 times faster than the digestion of the same sugars attached to 33 nmoles of RNase B 
which took more than 72 hours (Fig. 3b). The data in Fig. 3b also show that the Man 6 
glycoform is more resistant to the enzyme than the higher glycoforms, Man7-9. Reaction rates 
depend on several factors, some of which, such as temperature (37°C), pH (5.0), concentration
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(1 mmolar) buffer (50mM sodium acetate) and enzyme:substrate ratio (1: 12.5mU) were held 
constant. Two major variables, which could not be controlled since they were characteristic of 
the two species being compared, were (i) the different diffusion rates of the sugars and the 
glycoprotein and (ii) the steric effects of the protein on the accessibility of the sugars in intact 
RNase B.
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Figure 3: The rate of A.Saitoi mannosidase digestion of the (a) oiigomannose glycans 
released from RNase B compared with (b) the rate of digestion of the same sugars 
attached to RNase B (Rudd et al 1992)
(a) Anion exchange chromatogram (Dionex CarboPac PA1) of (I) the reduced and radiolabelled 
N-iinked oligosaccharides released by hydrazinolysis from ribonuclease B (ii) the same 
oligosaccharide library after digestion for 7 minutes with A. Saitoi a 1,2 mannosidase (iii) after 34 
minutes all oiigomannose structures have been reduced to ManS, detected by the label at 
the reducing terminus.
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Figure 4a: The natural glycoforms of RNase B (RNaseMan9-5) and the reaction products 
(RNaseMan 5, 1,0 and GlcNAc) from the digestion of the oiigomannose glycans on intact 
bovine pancreatic RNaseB. Most of these glycoforms exist as a number of isoforms. To 
illustrate this three alternative structures of the Man8 glycoform are shown.
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Figure 4b: Four enzymes were used to obtain the individual glycoforms (a) A. Saitoi a1,2 
mannosidase yielding RNaseManS from the natural mixture of glycoforms (b) Jack Bean 
a1,2,6>3 mannosidase yielding RNaseManI from the natural mixture of glycoforms or from 
ManS (c) Helix pomatia p i,4 mannosidase yielding RNaseManO from RNaseManI (d) EndoH 
yielding RNaseGlcNAc from the natural mixture of glycoforms.
(b) Capillary electrophoresis profiles of bovine pancreatic RNase B showing the time course for 
the digestion of the glycoprotein with A.Saitoi a1,2-mannosidase. Absorbance at 200nm is 
plotted against elution time for time points between 0 and 25h. This demonstrates that the five 
glycoforms (t\/lan5:48%, Man6:20%, Man7:11%, I^an8:17%, Man9:6%) initially present are 
reduced by the enzyme to a single structure, the one having the mannose 5 sugar. The Man6 
glycoform is more resistant to the enzyme than the other higher glycoforms.
4.2 Enzymatic modifications of RNase B to obtain eiectrophoreticaiiy pure glycoforms.
Recent advances in capillary electrophoresis have enabled each of the oiigomannose 
glycoforms of RNase B to be resolved at the protein level in their correct molar proportions. 
This has made it possible to analyse glycoform population changes directly and therefore to 
prepare a number of single, eiectrophoreticaiiy pure glycoforms for testing in the systems 
described in sections 5.3 - 5.6. RNase Man-5, Man-1 and Man-0 were prepared by modification 
of the naturally population of RNase B glycoforms (RNase ManS-9) with the exoglycosidase 
enzymes A. Saitoi a-(1,2) mannosidase, Jack Bean a-mannosidase. Helix pomatia p i-4 
mannosidase. RNaseGlcNAc was prepared using recombinant endoglycosidase H from 
Streptomyces plicatus. The digestion scheme is described in figure 4b and the results are 
shown in figure 5.
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Figure 5: Preparation and CE analysis of individual glycoforms of RNase.
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a. RNase B glycoform ladder (Man1-Man9) used to assign structures to the peaks obtained by 
CE analysis of the enzyme digests. To assign structures the standard mixture was co-injected 
with the samples.
b. Natural population of RNase Man-9,-8,-7,-6 and -5 glycoforms from bovine pancreatic 
RNase B which was the starting material for the biosynthesis of the Individual Man-5, Man-1 
and Man-0 glycoforms.
c. RNase-Man-5, prepared by reducing the whole natural glycoform population of RNase B to a 
single population with A. Saitoi a-(1,2) mannosidase which cleaves Man a(1-2) residues.
d. RNase Man-1, the product of the digestion of RNase B with Jack Bean a-mannosidase. This 
enzyme releases Man a(1-2), Man a(1-3) and Mana(1-6) residues from the natural mixture of 
RNase B glycoforms to yield the single Man-1 glycoform, .
e. RNase-Man 0, obtained by incubating the pure glycoform RNase-Man 1 (prepared as above) 
with Helix pomatia p 1-4 mannosidase.
f. RNase GlcNAc, the product of the digestion of RNase B with Endo H.
g. A co-injection of RNase A with RNase GlcNAc (from f)
h. Eiectrophoreticaiiy pure RNase A.
4.3 Glycosylation alters the global dynamic stability of RNase
The effects of variable glycosylation on the dynamics of RNase was explored by comparing NH 
proton exchange rates of RNase A and B and the RNase ManS and Mani glycoforms (Rudd et 
al 1994). The exchange of amide protons with solvent (DgO), which is a measure of dynamic 
stability or the solvent accessibility and unfolding of the protein, is decreased from 1.5-6 times 
by glycosylation of the RNase molecule; RNase B is therefore more stable than RNase A. 
Individual amino acid residues in RNase B affected by the presence of the sugars included 
His12, His119, Lys41 and Asp121 in the active site, and Arg 39, Arg 85 and LysSI which form 
salt bridges to phosphate groups on RNA. Comparisons of exchange rates in different 
glycoforms showed that protons at residue numbers 10,11,12,32,34 and 35 had relatively 
slower exchange rates which were dependent on the glycoform type. In the Man-6 to Man-9 
glycoforms these protons exchanged faster than in the Man-5 and Man-1 glycoforms. This 
suggests that the conformation of the Man6-9 oligosaccharides relative to the protein allows 
greater accessibility to the protein surface in these glycoforms compared with the Man5-Man1 
glycoforms.
4.4 Glycosylation protects all glycoforms equally against proteolysis.
In digestions of mixtures of RNase A and each of the Man-5, Man-1, Man-0 or RNaseGlcNAc 
glycoforms all of the glycosylated enzymes were approximately 20% +/- 3% less susceptible to 
the broad spectrum protease, Pronase, than RNase A (Rudd et al 1994). The overall rate of 
cleavage depends on the dynamic stability of the protein which includes the rate at which it 
unfolds and may also involve steric protection of susceptible sites on the protein by the sugars. 
The NH-ND exchange experiments demonstrated that the overall flexibility of all the
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glycosylated variants was less than for RNase A; this was consistent with the finding that all of 
the glycoforms tested showed increased resistance to the protease which cleaves ribonuclease 
at many sites, and with dynamic simulations (Woods et al 1994) which have shown that a large 
part of the surface of RNase B is shielded by the sugars.
4.5 Preliminary data suggests that RNase oligosaccharides may shield one or more antigenic 
sites from IgGaRNaseA
Figure 6 shows the results of ELISA assays testing the affinity of a polyclonal IgGaRNase A 
antibody for some of the glycoforms of RNase B. In figure 6a the wells of a microtitre plate 
have been coated with mixtures of RNase Mani and RNase A in proportions ranging from 0- 
100% of RNase A and 100-0% of RNase Mani. The polyclonal IgGaRNase A antibody binds 
equally in all the wells, regardless of the relative proportions of RNase A and Mani. This 
suggests that the antibody is equally able to recognise both molecules and that the Mani sugar 
does not shield antibody recognition sites on the protein. In contrast, Figure 6b shows that wells 
coated with 100% ManS bind less than 50% of the antibody bound by wells coated with 100% 
RNase A. Increasing the concentration of RNase A relative to ManS increases the amount of 
bound antibody until a plateau is reached when the proportion of RNase A:RNaseManS bound 
to the wells is approximately 40:60%. This indicates that the ManS glycoform has a lower 
affinity for the antibody than RNase A. It suggests, as expected, that the polyclonal antibody 
recognises more than one site on RNaseA and that the sugars attached to the Man 5 glycoform 
are able to shield one or more, but not all, of the antigenic sites from the antibody. However the 
interpretation of this data is complex and necessarily qualitative, since there are other factors 
which may contribute to this effect. These include (a) the relatively large size of the sugars 
compared with the protein; this may reduce the number of glycosylated molecules bound to the 
plate compared to RNase A and (b) the orientation of the molecules bound to the plate. While 
RNase A may be randomly oriented, the glycosylated protein may take up a restricted number 
of orientations determined by the fact that the sugar moiety cannot bind to the plate. Both these 
factors would result in a linear increase in binding across the whole range of mixtures of Man5 
and RNase A (from 0-100% RNase A), suggesting that they are not the dominant factors in this 
assay system. Interestingly, the data in 6a suggest that neither the orientation of the RNase 
Mani protein nor the number of molecules bound to the plate are significant factors in this 
case. In figure 6c RNase A has been tested against the mixture of RNase B glycoforms which 
contains 50% of the Man 5 structure. There is no significant difference between these data and 
those in Fig.6b, indicating that increasing the size of the oligosaccharides beyond Man 5 does 
not alter the affinity of the antibody. This is consistent with dynamics simulations of RNase B 
which indicate that while the Man9 sugars extend further from the protein surface than Man 5 
structure, this leads to only a 20% increase in the cross sectional area of the oligosaccharide 
chain (Woods et al 1994). This suggests that the area of the protein shielded by the Man6-9
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glycoforms may not be significantly more than in the Man 5 glycoform. 6d shows the result of a 
control assay in which RNase A was diluted with BSA from 0-100%. The data indicate that the 
binding of antibody to RNase A is linear with respect to the amount of RNase A bound to the 
plate.
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Figure 6: IgG anti RNaseA tested against the ManS and Mani glycoforms of RNaseB
Microtitre piate wells coated with RNase B (a) RNaseManI (b) RNaseManS (c) RNase B and 
(d) BSA diluted with from 0-100% RNaseA. After washing, polyclonal aIgGRNase A (lOng/mi) 
was incubated in each piate for 3 hours at 37°C and, after further washing, bound antibody was 
detected with peroxidase labelled anti-rabbit IgG. The results are the average of eight readings 
and the error is +/- 10%. The appropriate background (typically 0.08 absorbance units) was 
subtracted from each point.
4.6 RNase glycoforms show a range of enzymatic activity towards double-stranded RNA 
RNase is an endonuclease which cleaves RNA mainly on the 3'-side of pyrimidine nucleotides 
and many RNA molecules have sections of single stranded RNA interspersed with double 
stranded sections. The generation of a well defined, in vitro labelled double-stranded (ds) RNA 
substrate enabled the functional activities of RNase A, B, Man-5, Man-1, and Man-0 to be 
compared in an assay system which monitored the rate of cleavage of ds RNA by each 
glycoform. The activity of RNase A was more than three times greater than RNase B, and the 
individual glycoforms were intermediate in activity in the ratios 3.8:2.6:2.2;1.6:1, i.e.
RNase A > Man-0 = Man-1 > Man-5 = RNase B 
The naturally occurring mixture of RNase glycoforms showed no significant decrease in activity 
compared with Man-5 although it contained 50% of glycoforms larger than the Man-5 structure.
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Figure 7: Two views of the unglycosylated RNase molecule with the Man-9 and Man-5 
glycoforms drawn to scale
On the protein (white) the active site is cyan, the glycosylation site (Asn34, LeuSer) is green 
and the cluster of basic residues (Arg10, Lys31, Lys37, Arg33) in range of all the 
oligosaccharides is dark blue. These residues provide a strong local anion binding site where 
the 5' terminal phosphate of RNA interacts with the enzyme. Oxygen atoms are red, sulphur 
atoms yellow and nitrogen atoms blue. Two of the oligosaccharides associated with RNase B 
are shown on the left of the protein: GlcNAc2 Mang (upper) and GlcNAc2 f^an^ (lower)(Rudd et al 
1994). The protein structure is based on the crystal structure (Williams et al 1987).
Salt Bridges between RNA Ptiosptiate Groups 
and RNase Residues (Lys, Arg and His)
Glycosylation
site
Figure 8: The interaction of RNase B with RNA
A schematic diagram of the interaction of RNase B with RNA showing the anionic binding sites 
on RNase with which the 5' terminal phosphates of RNA form salt bridges (yellow zigzags). The 
sugar is shown alongside drawn to scale and Asn34, the site of attachment is marked. (Taken 
from l\/lcPherson et al 1986)
It appears that, while the activity can be increased by removing mannose residues from Man-5, 
extending the sugar chain beyond Man-5 does not decrease the functional activity of the 
enzyme further (Rudd et al 1994). These results demonstrate that the glycosylation of RNase is 
a factor which modulates the rate at which dsRNA is degraded.
4.7 Structure/function relationships probed by molecular modelling
The role of the oligosacccharides in the modulation of the activity of RNase was further 
explored by molecular modelling. Important amino acid residues for the interaction of RNase 
with (double-stranded) RNA are those within the active site of the enzyme and also a number 
which form salt bridges with phosphate groups in the backbone of RNA. There are 5 of these 
bridges, including one in the active site where cleavage of the phosphodiester bond takes 
place. In particular, a cluster of residues (Lys 31 Lys 37 Arg 10 and Arg 33) (Fig. 7) provides a 
strong local anion binding site where the 5' terminal phosphate of RNA interacts with the 
enzyme (McPherson et al 1986). The size of all the oligosaccharides associated with RNase is 
such that they can cover this cationic cluster (Fig.8, 9), thus hindering the formation of the salt 
bridge, and variably reducing the overall fit between the enzyme and substrate.
4.8 Undenatured RNase B Is resistant to recombinant PNGase F
Native RNase B was resistant to recombinant PNGase F, indicating that the asparagine-sugar 
amide linkage is protected by the protein from the active site of this enzyme (Fig.10). In 
contrast, EndoH is able to cleave the sugar chain to form RNaseGlcNAc (Fig. 5h), indicating 
that the linkage between the GlcNAc residues in the chitobiose core is accessible.
5. Discussion
5.1 The RNase protein variably protects the oligomannose structures at Asn34 from A.Saltoi 
a 1,2 mannosidase.
The rate of A.Saltoi mannosidase digestion of the released oligomannose glycans from RNase 
B is over 100 times faster than the digestion under identical conditions of the same sugars 
attached to the protein. Reaction rates depend on several factors; in this study the two major 
variables were (i) the different diffusion rates of the free sugars and the glycosylated protein 
and (ii) the steric effects of the protein on the accessibility of the sugars attached to RNase B. 
To assess whether the observed difference in rate could be accounted for by the difference in 
diffusion rates between the free and bound sugars, diffusion coefficients (DC) were compared. 
The DC for RNase A is 1.068x10'® (Van Holde 1971). This may be higher than for RNase B 
which contains the glycans attached to the protein, together with associated water molecules. 
The DC for the oligomannose sugars is not available, but would be predicted to be less than the 
value for the disaccharide sucrose, which is 4.5x10'® (Van Holde 1971) Clearly there is 
insufficient information to make an accurate quantitative assessment, however the observed 
difference in rate is more than 100 and it seems unlikely that this can be attributed entirely to 
differences in diffusion rates. Consistent with this is the observation that the Man6 glycoform is
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Figure 9: A molecular model of RNase B interacting with RNA.
The active site residues of RNase B are shown in blue, green and white spheres in CPK. The 
RNA helix is shown with the phosphate groups on a cross section of the spiral in dark blue and 
yellow spheres in CPK. The phosphate groups are shown interacting with the enzyme through 
one of the anionic binding sites, the active site. The Man 9 sugar is shown in red CPK with the 
GlcNAc residue linking the sugar to Asn 34 in yellow. The sugar has been added only to show 
relative sizes of the oligosaccharide, the enzyme and the section of RNA since the exact 
orientation o f the sugar with respect to the protein is not known. (Rudd, P.M and Saunders, 
M.R. - unpublished data.)
more resistant to the enzyme than the higher glycoforms. The DC of Man6 would be less than 
Man7,8 and 9 therefore, if the reaction were diffusion controlled, the rate for Man6 would be 
faster than that for the higher glycoforms, not slower as was observed. Since each glycoform is 
a different substrate for the enzyme, every digestion will have different kinetic characteristics. 
These data suggest that the slower rate of digestion of the a1,2 terminal mannose sugars on 
Man6 is a result of its lower affinity for the enzyme and that this may be due to its proximity to 
the protein matrix. This indicates that in RNase B the protein structure may play a role in 
protecting the sugars from A.Saitoi mannosidase. The biosynthetic processes involve the 
conversion of Man9-6 to the Man5 glycoform (see Ch.1). The natural mannosidase is bovine 
pancreatic mannosidase not A.Saitoi mannosidase; therefore it is not justified to extrapolate to 
the in vivo system, however these data do not preclude the possibility that the protein may give 
some protection to the oligomannose sugars in the native RNase B, reducing the efficiency of 
the enzyme so that only 50% of the natural mixture of glycoforms is converted to RNaseMan 5.
5.2 Oligomannose sugars shield part of the surface of RNase B and modulate the activity of the 
enzyme
The effect of variable glycosylation on the environment of important regions of the protein may 
be one of the factors by which the activity of RNase is modulated. The extent to which the 
oligosaccharides of RNase B can shield the protein surface has been examined in a computer 
simulation of the dynamic properties of the Man 9 sugars (Woods et al 1994, Fig.1). The 
simulation indicated that the core residues (Man(31-4GlcNAcpi,4GlcNAc) maintain a relatively 
stable conformation. For other glycoproteins, such as Erythrina corallodandron lectin (Shaanan 
et al 1991), where X-ray crystal structures clearly define the N-linked core residues, the 
oligosaccharides vary in sequence yet the core conformations are remarkably similar. This 
finding allowed the computer simulated model of the vibrating Man9 sugars to be linked to the 
X-ray structure of RNaseB. Variation of the side chain angles of the GlcNAc-Asn linkage over 
+/-30° showed that this motion had a major effect on the volume of space occupied by the 
oligosaccharide and consequently on the area of the protein surface shielded by the sugar. 
Interestingly, the modelling also suggests that Man5 may shield 80% of the area covered by 
Man9. This comparatively small difference is partly a result of the tight hydrophobic stacking of 
the terminal a1,2 linkages in Man9 (D1,D2,D3) against the penultimate mannose residues 
A,B,C (Fig. 2b). The result is that there is only a 20% increase in the cross sectional area of the 
Man9 oligosaccharide over the Man5 structure. This predicts that, if steric interactions between 
RNA and the oligosaccharides contribute to the decrease in enzyme activity, increasing the 
oligosaccharide size up to Man5 would lead to decreased activity while Man5 to Man9 
glycoforms would cause no further decrease in the reaction rate. In this thesis the naturally 
occurring mixture of RNase glycoforms showed no significant decrease in activity with RNA 
compared with Man-5 although it contained 50% of glycoforms larger than the Man-5 structure. 
It appears that, while the activity can be increased by removing mannose residues from Man-5,
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extending the sugar chain beyond Man-5 does not decrease the functional activity of the 
enzyme further. (RNase A (3.8) >ManO (2.6) = Man1 (2.2) >Man5 (1.4) =RNaseB (1 ))
Additional molecular modelling studies in this thesis suggest that different sized 
oligosaccharides may exercise variable steric effects both at the active site and at a cluster of 
residues involved in the formation of salt bridges to phosphate in RNA (Fig.7) decreasing the 
stability of the RNase/RNA complex (Fig. 8) and the rate of cleavage.
5.3 RNase glycoforms Interact variably with a-RNase A
Probing the surface of glycosylated RNase with an antibody raised against the unglycosylated 
molecule suggested that the Man5-9 sugars protect at least one antigenic epitope while the 
Man1 sugar does not. The approximate size of an antigenic epitope is between 5-7 amino acids 
(roughly 7x12x35A)
5.4 The dynamic stability of RNase B glycoforms is greater than RNase A
The dynamic stability of RNase B and the Man5 and Mani glycoforms was examined in NH-ND 
exchange experiments (Joao in Rudd et al 1994).The results indicated that the overall flexibility 
of all the glycosylated variants was less than for RNase A. This overall increase in rigidity may 
contribute to the increased resistance to Pronase and the decreased functional activity of the 
glycosylated variants compared with RNase A. Differences in the dynamic stability of the same 
amino acid residues in different glycoforms, including ones at the active site and an anionic 
binding site, may contribute to the > 3-fold variation in the functional activity of the glycoforms.
5.5 Glycosylation protects f\/ian 0,1 and 5 glycoforms equally against proteolysis
The dynamics simulations described in 5.2 above indicate that a substantial part of the protein 
surface is shielded by the Man5-9 oligomannoses structures. However shielding by Mani, 
ManO or a single GlcNAc residue is less significant suggesting that other factors may be 
important in the finding that all of the glycoforms showed increased resistance to Pronase. 
Pronase is a broad spectrum protease which cleaves ribonuclease at many sites. In digestions 
of mixtures of RNase A and each of the Man-5, Man-1, Man-0 or RNaseGlcNAc glycoforms the 
glycosylated enzymes were equally less susceptible (by 20%) to digestion by the protease than 
RNase A. One factor which controls the overall rate of cleavage is the dynamic stability of the 
protein which includes the rate at which it unfolds. The dynamic stability of RNase B was 
examined in NH-ND exchange experiments and the results indicated that the overall flexibility 
of all the glycosylated variants was less than for RNase A. This overall increase in rigidity may 
contribute to the increased protease resistance of the glycosylated variants compared with 
RNase A.
5.6 The protein structure of RNase B limits access to the glycans and may Influence processing 
The role of the RNase protein in protecting the sugar has been probed with A.Saitoi 
mannosidase and the data indicate that the a1,2 terminal mannose residue on the Man 6
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Figure 10: The crystal structures of RNase B, CD59 and PNGase F
The structure o f PNGase F is based on the crystal structure of Norris et al 1994. The protein is 
folded into two domains, each with an eight stranded antiparallel j3-jelly roll configuration similar 
to the types o f structures found in lectins. RNase B was modelled according to the crystal 
structure of Williams et al 1987. CD59 was modelled according to the NMR solution structure of 
Kieffer et al 1994. All three molecules are modelled to the same scale. Two active sites have 
been proposed for PNGase F: (i) Thr42, Lys44, Asp99 and ThrlOl on strands D and G of 
domain 1 (ii) a site in a cleft at the opposite end of the molecule, flanked by five tryptophan 
residues and one phenylalanine residue. In contrast to the CD59 asparagine-sugar amide 
linkage, which is susceptible to the enzyme, the same linkage in RNase is protected by the 
protein and not accessible.
glycoform is more resistant to cleavage than the terminal a1,2 oligosaccharides on the larger 
glycoforms. The protein limits access to the sugar and while endo H can cleave the 
oligomannose structures attached to the native glycoprotein within the chitobiose core, PNGase 
F is not able to cleave the asparagine - sugar amide linkage. The physical accessibility of 
oligosaccharides to the processing enzymes, as determined by the folding of the polypeptide 
chain, can influence the extent of oligosaccharide processing. Accessibility has been probed 
with enzymes such as endoglycosidase H, which cleave the oligosaccharide chain close to the 
site of attachment to the protein. Endo H has been used to examine the oligosaccharide chains 
attached to Sindbis glycoproteins. For Sindbis virus grown in CHO cells deficient in N- 
acetylglucosaminyl transferase Endo H (which cleaves between the GlcNAc residues in the 
chitobiose core) preferentially cleaved the unprocessed oligomannose glycans located at sites 
that normally contain complex sugars (Hsieh et al 1983). It has therefore been suggested that 
the inaccessibility of this linkage to Endo H is an indicator that structures will remain 
unprocessed. However, contrary to this, in this thesis endo H was shown to release the 
oligomannose glycans from native RNase B. In addition, RNase B from other organs, such as 
spleen, is glycosylated with complex as well as oligomannose sugars (Lawrence et al 1983 a,b, 
Yamashita et al 1986). Interestingly, it has been shown by Williams and Lennarz (1984) that 
RNase expressed in the presence of a reducing agent which prevents the formation of 
disulphide bonds, contains fully processed oligosaccharides. A similar experiment involving 
tissue plasminogen activator showed that prevention of protein folding resulted in 100% 
occupancy of Asn 184, a site which is naturally variably occupied (Allen et al 1995). These 
results indicate that the conformation of the protein may influence both the processing of 
glycans and the site occupancy.
In common with tissue plasminogen activator and plasminogen, RNase B has a variably 
occupied N-glycosylation site. The recent finding (Suzuki et al 1993) that several mouse and 
human cell lines [L-929 (mouse), BALB-3T3 (mouse fibroblast), BALB/c mouse plastocytoma 
and human skin fibroblast] possess natural PNGase activity suggests that the specific removal 
of N-linked glycans in vivo may be an important biosynthetic mechanism. For example, in 
plasminogen type II (ch.7) the unoccupied glycosylation site contains aspartic acid not 
asparagine, suggesting that this glycoform is the result of the removal of the N-linked sugar 
present in type I plasminogen (S. Innoue - personal communication). The protection of the 
asparagine-sugar linkage from inappropriate deglycosylation by PNGase may therefore be an 
important function of the local protein conformation. In the case of RNase B the protein 
structure protects the Asn - sugar amide linkage from one particular peptide-N-glycosidase F 
(F. meningosepticum) (Fig.10).
5.7 Conclusion
Pure individual glycoforms of bovine pancreatic RNase B have been prepared by enzymatic 
modifications of the native glycoprotein and analysed by CE. In a series of studies of native 
RNase B, the individual glycoforms and RNase A it was found (i) the protein variably protects
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the oligomannose sugars from exoglycosidase digestion (ii) the protein protects the sugar- 
amide linkage, but not the glycosidic linkage within the chitobiose core from PNGase F and 
EndoH respectively (iii) glycosylation increases the protease resistance of RNase B 
independent of glycoform type (iv) the individual glycoforms were used to demonstrate that the 
size of the attached oligosaccharide is a factor in protecting antigenic sites and in modulating 
the interaction between enzyme and substrate (v) the individual glycoforms were used to 
demonstrate that there are increases in dynamic stability throughout the whole molecule 
including active site residues and residues involved in the formation of salt bridges between 
RNase and RNA.
In principle such dynamic and steric effects of glycosylation may be expected to apply to all 
glycoproteins. The exact nature of the glycoform may also be an important feature of control 
for enzymes (such as tissue plasminogen activator discussed in ch.7) which are multidomain 
and whose interactions involve molecular rearrangements.
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Abstract
One of the characteristics of Carbohydrate Deficient Glycoprotein Syndrome (CDGS) is the 
presence in serum of abnormal glycoforms of transferrin. While the amino acid sequence and 
the glycans attached to CDGS transferrin are identical to those associated with the normal 
glycoprotein, the abnormal transferrin contains a higher proportion of unoccupied N-linked 
glycosylation sites. In transferrin from normal serum^over 95% of the two glycosylation sites are 
invariably occupied with either the bi- or tri-antennary non-fucosylated, fully sialylated complex 
glycans, SA2H5N4 and SA3H6N5. Both glycoform heterogeneity and variable site occupancy 
may lead to the generation of a range of glycoforms which contain from 6-0 sialic acid residues 
and therefore differ in the amount of negative charge they contain. Capillary electrophoresis 
(CE) has been used to resolve quantitatively the intact glycoform populations of both normal 
and CDGS transferrin at the protein level. The separation was based on the charge differences 
between the glycoform populations and involved using a buffer containing sodium glutamate. 
The individual glycoforms were identified using CE to monitor sequential exoglycosidase 
digestions of the sugars on the intact glycoprotein and the elution positions of the different 
glycoforms were determined. Abnormal levels of glycoforms containing one unoccupied 
glycosylation site and non-glycosylated transferrin, neither of which has been detected in 
normal transferrin, were identified in transferrin from CDGS patients. A rapid diagnostic test for 
the disease, which may also be an indicator of disease severity, has therefore been proposed 
which allows the glycoform populations of CDGS transferrin to be compared quantitatively with 
those in normal transferrin.
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Figure la : The basic CE instrument consists of a fused silica capillary with an optical window, 
a UV detector, a high voltage power supply, two electrode assemblies and two buffer 
reservoirs. Field strengths higher than 500 volts/cm can be applied to the narrow capillary 
allowing highly enhanced resolution compared with conventional gel electrophoresis.
Peptide is 
negatively 
charged
Peptide is 
positively 
charged
Electroosmotic Flow
  — ►
( 0 )  High pH
O- O- O- O- O- O- O- O- O-
Low pH
OH O- OH O- OH O- OH O- OH
+ + + +  + +  + +
Elution order
Cations
Neutrals
Anions
Figure 1b: Effect o f electroosmotic flow (EOF). In uncoated capillaries EOF is always 
towards the cathode. At high pH the capillary walls are strongly negatively charged and the 
EOF is greater than at low pH. At high pH most peptides are negatively charged and migrate 
towards the anode, however EOF is always stronger and anions are eventually swept to the 
cathode. At low pH most peptides are positively charged and move towards the cathode with 
the EOF. The elution order is the same in both cases: cations elute first, then neutrals and 
finally anions.
The Identification of Abnormai Glycoform Populations in Transferrin from Carbohydrate 
Deficient Glycoprotein Syndrome Serum by Capillary Electrophoresis may lead to a
rapid diagnostic test.
1. The structure of glycoforms
1.1 The assignment of glycoform structure by analysis of released oligosaccharides
Many current techniques for determining glycoform populations involve the analysis of 
oligosaccharide libraries obtained by releasing the sugars either from the intact glycoprotein or 
from glycopeptides. However, for a protein with more than one glycosylation site, the 
information relating to specific sets of glycoforms is lost, even if the glycosylation at each site 
can be fully defined. Glycoforms may be assigned from the analysis of the released sugars by 
assuming that the glycosylation sites on the intact glycoprotein can accommodate all the 
possible permutations and combinations of the sugars associated with the molecule, but there 
are many instances where this assumption is incorrect . For example, both CD2 (ch.2) and tPA 
(ch.7) contain one site which is almost entirely glycosylated with oligomannose structures. Even 
if a site analysis is carried out there may be constraints on the particular combinations of 
sugars which can be processed on any one molecule. For example, in Bowes Melanoma tPA 
the glycosylation analysis of the structures at Asn 448 shows that the site contains more neutral 
and fewer sulphated glycans in type I tPA when the site at Asn 184 is occupied compared with 
type II tPA when it is not (Dr. D. Wing - unpublished data. See ch.7 fig. 23). This demonstrates 
that glycosylation at one site can affect the processing at another and, moreover, it is not 
known whether specific glycans at site 184 are required to pair with either the sulphated or 
neutral structures at 448.
1.2 The resolution of glycoforms at the protein level by Capillary Zone Electrophoresis (CZE) 
Capillary electrophoresis (CE), which offers the possibility of separating intact glycoforms at the 
protein level, may therefore be a powerful addition to the existing carbohydrate technologies. At 
present other electrophoretic techniques such as SDS PAGE and isoelectric focusing (lEF) 
generate only a limited amount of analytical information relating to intact glycoforms. This is in 
part because the resolution which can be achieved in these techniques is restricted by the 
problems of heat dissipation which arise when high voltages are applied to conventional gel 
systems. In CE, the narrow capillary allows heat to be dissipated rapidly and field strengths 
higher than 500 volts/cm (up to 30kV) can be applied giving the potential for highly enhanced 
resolution. The basic CE instrument consists of a fused silica capillary with an optical window, a 
UV detector, a high voltage power supply, two electrode assemblies and two buffer reservoirs 
(Fig.1 a). In most assay systems the inner wall of the capillary column carries a negative charge 
because the silanol groups ionise above pH3. Positive ions in the electrolyte are attracted to 
the wall and, under high voltage, migrate towards the cathode creating a bulk flow of liquid 
called the electroosmotic flow (EOF) (Fig. 1b). If a sample is introduced into the capillary at the
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anode side all the components are carried by the EOF towards the cathode. Simultaneously the 
current flow will retard the negatively charged species so that the positive species elute first 
followed by the neutral and finally the negative. An inherent difficulty associated with analysing 
glycoforms by CE resides in the fact that the homogeneity of the polypeptide chain frequently 
masks the diversity of the glycans associated with it, so to achieve separation the structural 
differences between the glycans has to be amplified by complexing with an ionic species. The 
chemistry which has been used to achieve separations has, for the most part, exploited subtle 
differences in the conformation of the hydroxyl groups associated with the monosaccharide 
residues which make up the oligosaccharides. For example, the oligomannose glycoforms of 
bovine pancreatic RNase B have been separated into their individual glycoforms in their correct 
molar proportions by CE (Rudd et al 1992). This single domain, globular protein, which is the 
subject of chapter 4, is a mixture of unglycosylated RNase A (13,690 kd) and a collection of 
glycoforms (designated RNase B Man-5,-6,-7,-8 and -9) in which the oligomannose series, 
Man-5 to -9 is associated with the single N-glycosylation site at Asn34LeuSer. RNase Man-1 to 
-9 glycoforms, generated by enzymatic modifications of the natural population, were separated 
using borate buffer. Borate ions complex with cis diols and can therefore add a charge to 
neutral oligosaccharides. The number of charges depends on the number and accessibility of 
hydroxyl groups in the correct orientation and this may varies from one oligosaccharide to 
another, giving a basis for an electrophoretic separation. The glycoform ladder showing the 
resolution of RNase B is shown in figure 2b, and, for comparison, a conventional SDS PAGE 
analysis of the natural population of RNase B (Man9-5) is shown in figure 2a.
2 0 5 ------- ►
1 1 6 ------- 1
9 7 ------- '
45
29
Ribonuclease B
1
Figure 2: (a) SDS PAGE (15% reducing gel) separation of the natural population of 
RNase B glycoforms (RNase B ManS-9).
131
Man 5
0020
Mani
s
c
Man 2Man U
Man 3
Man 6
0-010
Man8 Man 7
Man 9
00
Elution time 4 8 m i
Figure 2 (b) Capillary electrophoresis separation of the set of glycoforms of RNase B 
containing from 1 to 9 oligomannose residues. The buffer was sodium phosphate,
50ml\/l SDS, 5mt\/l sodium tetra borate, pH 7.2.
To date there have been relatively few studies of glycoproteins or glycopeptides using CE, but 
those which have been described suggest that there are potentially many ways in which the 
structure and function of glycoproteins can be explored by this technology. There are currently 
very few methods available for separating glycoforms at the protein level and in this respect 
CE has proved to be a valuable addition to the existing technologies; however the methods are 
not generally applicable, and optimal buffer systems need to be developed for every 
glycoprotein individually. Once resolution conditions are established the way is open to monitor 
glycoform alterations in fine detail, and in the case of RNase B, this enabled single pure 
glycoforms of a glycoprotein to be prepared for the first time (Rudd et al 1992). Successful 
separations of other glycoproteins include the analysis of tPA glycopeptides (Taverna et al 
1992) and erythropoeitin (Tran et al 1991). Within the CE programme in the Glycobiology 
Institute glycoproteins containing oligomannose sugars (RNase B and prolyl hydroxylase) and 
neutral complex glycans (ovalbumin) have been resolved, and the work in this chapter 
describes a complementary project which involved an exploration of the possible application of 
CE to the analysis of transferrin, a glycoprotein which naturally contains almost exclusively 
sialylated complex glycans. The technology was developed within a collaborative project (with 
Dr. Brian Winchester), the aim of which was to develop a rapid method to screen transferrin 
quantitatively for unglycosylated and monoglycosylated glycoforms characteristic of
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Figure 3: The structures of the set of transferrin glycoforms associated with CDGS.
Transferrin from CDGS patient typically contains up to 37% of glycoforms in which only one 
glycosylation site is occupied, and 13% in which neither site has been glycosylated (Yamashita 
et al 1992), although the sugars at the sites are indistinguishable in type and charge from the 
normal glycans. CDGS transferrin may contain fully sialylated glycoforms with 2,3,4,5 and 6 
sialic acid residues (S1-S6) as well as a small population containing A1 and A3 sugars. In 
addition there is a population of non-glycosylated molecules, designated J. Normal transferrin 
also contains structures with S2-S6 sialic acid residues, but these are all derived from 
transferrin with both glycosylation sites occupied.
Carbohydrate Deficient Glycoprotein Syndrome (CDGS). CDGS is characterised biochemically 
by the absence of glycosylation at normally occupied sites on a wide range of proteins and the 
current diagnostic procedure is to examine a diagnostic marker, transferrin, for abnormal 
glycosylation by lEF. In general, a fuller understanding of the disease processes may lead to 
insights into the mechanisms that control site occupancy in normal proteins and to the functions 
of oligosaccharides.
1.3 Carbohydrate Deficient Glycoprotein Syndrome
The carbohydrate-deficient disorders are a group of multisystemic diseases characterised by a 
deficiency of the oligosaccharides attached to glycoproteins which may result from one or more 
defects in glycosylating enzymes. CDGS belongs to this group of diseases, and was first 
reported by Jaeken et al in 1984. It is characterised by severe disorders of the nervous system, 
which include growth retardation and psychomotor retardation, abnormal distribution of adipose 
tissue, 'peau d'orange', squints and abnormal ocular movements and infertility. A large number 
of serum glycoproteins have been reported to be abnormal and these include transport 
proteins, glycoprotein hormones, complement factors, enzymes, and enzyme inhibitors. 
Amongst these the transport protein, transferrin, is an important diagnostic indicator of the 
disease. Transferrin is an iron transport protein containing bi- and tri- antennary complex 
glycans attached to Asn413LysSer and Asn611ValThr, both of which sites are normally fully 
occupied. The glycosylation of transferrin has been analysed by paper electrophoresis and P4 
GPC and exoglycosidase sequencing of the released sugars (Yamashita et al 1989). It has also 
been analysed at the protein level by isoelectric focusing by Yamashita et al (1989) and within 
this present project by Dr. Brian Winchester. The lEF data indicate that normal human serum 
transferrin contains bi- and tri- antennary complex glycans +/- core fucose. However between 
96-98% of the sites contain bi-antennary glycans with no core fucosylation. No neutral 
structures were detected, 4% of the sugars contained one sialic acid residue, 95% contained 
two and 1% contained three, and all the glycosylation sites were occupied. This indicates that 
normal transferrin may contain glycoforms with 2,3,4,5 and 6 sialic acid residues (designated 
S2-S6). In contrast, transferrin from CDGS patient typically contained up to 37% of glycoforms 
in which only one glycosylation site was occupied, and 13% in which neither site had been 
glycosylated (Yamashita et al 1992), although the sugars at the sites were indistinguishable in 
type and charge from the normal glycans. Therefore CDGS transferrin may contain glycoforms 
with 1,2,3,4,5 and 6 sialic acid residues (SI-SB). The set of fully sialylated glycoforms (S2-S6) 
is shown in figure 3 together with non-glycosylated transferrin.
In this study the glycoforms of normal and CDGS transferrin were resolved by CZE on the 
basis of charge. The structure of the glycoform populations was assigned by monitoring the 
elution positions of enzymatically modified transferrin, and a peak characteristic of CDGS was 
identified.
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2. Materials and methods
2.1 High Performance Capillary Zone Electrophoresis (CZE) separations were carried out on a 
P/ACE System 2100 (Beckman Instruments) using a fused silica capillary (107cmx75pm ID). 
The detection was by UV at 200nm. Injections of 1-2mg/ml for 1.5-2 seconds were performed 
(5ng) under high pressure. The buffer was 50mM Tris, 50mM sodium glutamate 
(CHgCHgCOONa) (pH 8.54-8.64). The voltage was lOkV.
2.2 Enzyme digestions
(i) Arthrobacter ureafaciens neuraminidase (Oxford GlycoSystems):
The time course was performed over 260 minutes using an optimised dilution of the 
Arthrobacter ureafaciens neuraminidase at 4mU:2mg transferrin/200pl lOOmM sodium acetate 
pH5.0 at 37°C. Aliquots were removed from the reaction mixture during the digestion and the 
reaction stopped by freezing at -20°C. Arthrobacter ureafaciens neuraminidase cleaves 
NeuNAca2-6>3,8 R
(ii) Streptococcus pneumoniae p-galactosidase (Oxford Glycobiology Institute): digestion of 
asialo glycans: 2mg/ml of substrate were incubated with 300mU/ml of (3-galactosidase in 
50mM citrate/phosphate buffer pH6 for 18h at 37°C. The enzyme cleaves Gaipi-3,4>6 
GlcNAc/R
(iii) Streptococcus pneumoniae p-galactosidase + Streptococcus pneumoniae (5- 
hexoseaminidase (Oxford Glycobiology Institute); 2mg/ml of substrate were incubated with 
300mU/ml of p-galactosidase + 500mU/ml of p-hexoseaminidase in 50mM citrate/phosphate 
buffer pH6. Incubation was for 18h at 37°C. Streptococcus pneumoniae p-hexoseaminidase 
cleaves GlcNAc p i-2,4,6 Man or Glcpi-3,6Gal
(iv) Streptococcus pneumoniae p-galactosidase + Streptococcus pneumoniae p- 
hexoseaminidase + Streptococcus (diplococcus) pneumoniae Endoglycosidase D (Boehringer 
Co.); 2mg/ml of substrate was incubated with 300mU/ml of p-galactosidase + 500mU/ml of p- 
hexoseaminidase + 150mU of endoglycosidase D for 18h at 37°C in 50mM citrate/phosphate 
buffer pH6. Endoglycosidase D cleaves between the GlcNAc residues in the chitobiose core.
2.3 Substantially iron free normal human transferrrin (T-0519) was obtained from Sigma 
Chemical Company.
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3. Results
3.1 Resolution of normal serum transferrin glycoforms by CZE
Normal transferrin was separated into five glycoform populations (Fig.4) by CZE using Tris 
buffer and sodium glutamate (pH 8.54 - 8.64). Digestion of the normal population with 
Arthrobacter ureafaciens neuraminidase reduced all the glycoforms to one major and two minor 
asialo populations (Fig.5: 260 mins). Consistent with the findings of Yamashita et al (1990) 
these data confirm that normal serum transferrin contains no neutral glycoforms. The data 
indicate that transferrin consists of a population of glycoforms which have been resolved 
according to the number of sialic acid residues they contain. Approximately 95-98% of the 
glycoforms of normal human transferrin contain two di-sialylated bi-antennary complex sugars 
and a charge due to four sialic acid residues (S4) (Yamashita et al 1990). Analysis of 
commercial preparations, such as was used here in order to detect a range of glycoforms, have 
shown that the percentages of the glycoforms supplied are variable and depend on the 
manufacturing process, but the major glycoform is invariably S4 (Yamashita et al 1989; Van 
Pelt et al 1987; Spik et al 1975). On the basis of these previous analyses therefore. Peak 4 was 
assigned to S4, and the remaining peaks were assigned to transferrin carrying bi- or tri- 
antennary complex glycans with 2,3,5 or 6 sialic acid residues. The percentages of each peak 
(S2-S6) were 2%:12%:67%:13%:6% (Table I).
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Figure 4: Capillary electrophoresis separation of glycoforms of normal human 
transferrin. Peak 4 (S4) contains the major glycoform which is glycosylated with two di- 
sialylated biantennary complex glycans, the other peaks represent transferrin with 2,3,5 or 6 
sialic acid residues attached to bi- or tri- antennary complex glycans.
3.2 Time course showing the successive removal of sialic acid residues from normal human 
serum transferrin
The CE apparatus was arranged with the anode at the injection end of the capillary, therefore 
neutral glycoforms eluted first and the more negatively charged populations eluted later. These 
data show that all of the partial and final digestion products eluted earlier than any of the 
original glycoforms, indicating that all the populations have become less negatively charged 
due to the loss of sialic acid. The time course (Fig. 5) shows that digestion with Arthrobacter
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ureafaciens neuraminidase has successively removed sialic acid residues from the native 
population of S2-S6 glycoforms. The original five sialylated glycoforms have been modified to 
one population containing only neutral glycans.
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Figure 5: The neuraminidase digestion of the giycoform popuiations of normai human 
transferrin monitored by CE.
3.3 CZE analysis of sequential exoglycosidase digestions of the asialo glycoforms of human 
transferrin
The glycan structures attached to asialo transferrin were sequentially removed in a series of 
mixed exoglycosidase digestions shown schematically in figure 7. Following the neuraminidase 
digestion, incubation with p-galactosidase removed terminal galactose residues from the
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desialylated population, next p-hexoseaminidase removed terminal N-acetyl glucosamine, and 
finally endo D cleaved ttie remaining sugar within the chitobiose core leaving a single GlcNAc 
residue attached to the protein. The final sugar residue was not removed because cleaving the 
asparagine sugar linkage with PNGase F would convert the asparagine residue to aspartic acid 
and introduce a charge to the glycoform, altering the basis of this particular CE separation. The 
larger sugars elute earlier because they contain more hydroxyl groups and can therefore 
acquire more negative charge by complex formation with the glutamate ions in the buffer.
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Figure 6: The 0^ domain o f one of the glycoforms of transferrin (S5) showing the 
cleavage positions of the exoglycosidase enzymes used in the sequential digestion. The 
enzymes were (I) Arthrobacter ureafaciens neuraminidase (II) Jack Bean p-galactosidase (III) 
Jack Bean p-hexoseaminidase (IV) Endoglycosidase D. Transferrin consists of two domains, 
the Nf domain is not glycosylated.
This analysis (Fig. 7) was consistent with previous studies (Yamashita et al 1989, 1990) which 
show that the major population of transferrin glycoforms contains bi-antennary complex 
glycans. After each enzyme digestion the major glycoform eluted later, indicating that the 
glycans had been sequentially reduced in size by the specific enzyme in each of the digests. 
The analysis therefore defined the elution positions of the series of transferrin glycoforms (l-IV) 
modified by the glycosidase enzymes as shown schematically in Fig. 6. The data indicate that, 
within one charge band, this CZE method can resolve transferrin glycoforms on the basis of 
size. In addition, the oligosaccharides were able to be sequenced while attached to the protein 
and without denaturing (which would cause a loss of resolution). This indicates that the 
oligosaccharides attached to transferrin are accessible to the glycosidase enzymes. 
Importantly, this analysis established the elution position of a new transferrin glycoform 
containing only one GlcNAc residue at each site (IV).
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Figure 7: (a-d) The sequential digestion of the oligosaccharides attached to normal 
human transferrin showing the elution positions of the series of glycoforms generated 
by the digestions, (e) A sample of CDGS transferrin included for comparison (see 3.4)
3.4 CE analysis of transferrin isolated from two patients with CDGS.
Figure 8 shows the analysis of transferrin from two patients (b,c) compared with normal 
transferrin (a). A co-injection of the CDGS sample in (b) with normal transferrin analysed in (a) 
is shown in figure 5d. These data indicate that both the CDGS samples contain S4, S5 and S6 
in approximately the same proportion as transferrin from normal serum (see table 1). However 
they also contain increased levels of S2, and a population, J, which does not align with any of
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the populations previously identified in this study. The elution profile of this sample has also 
been aligned with the data in figure 7. This indicates that J elutes later, and is therefore 
smaller, than any glycoform in the exoglycosidase digestion series, including the population 
containing only a single N-acetyl glucosamine residue at each site. J also elutes earlier than 
any of the charged glycoforms (Fig. 5), indicating that it does not contain sialic acid. This 
suggests that J may contain non-glycosylated transferrin, the presence of which is a 
characteristic of CDGS transferrin.
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Figure 8a-d: The analysis of transferrin from two patients with CDGS (b,c) compared with 
normal transferrin (a). A co-injection of the CDGS sample in (b) with normal transferrin from (a) 
is shown in figure 8d.
139
Percent ratios of transferrin glycoforms
SO S2 S3 S4 S5 SB
NHT (Sigma) 0 2 12 67 13 6
CDHTI 11 34 4 41 8 2
CDHT 11 4 22 0 57 14 5
Table 1 : The ratio of transferrin glycoforms in normal and CDGS transferrin
3.5 CE analysis of desialylated CDGS
Figure 9 shows an overlay of the separations of the natural and asialo populations of CDGS 
transferrin. Peak E contains the fully sialylated bi-antennary complex glycoform (84). The data 
indicate that B contains transferrin with only one glycosylation site occupied and is the 
disialylated form, 82. E elutes later than B, consistent with the finding that glycoforms which 
contain more sialic acid elute later in the separation {3.2). E' is the asialo form of E and B' is 
the asialo form of B; E' is larger than B' and elutes earlier, consistent with the trend established 
earlier which demonstrated that the larger neutral glycoforms of transferrin elute earlier in the 
separation (3.4). These data support the assignment of B to a glycoform with only one occupied 
site containing a fully sialylated bi-antennary complex glycan (82). However it should be noted 
that the data do not exclude the possibility that B may contain some transferrin with two 
monosialylated biantennary complex sugars, on desialylation this glycoform would elute with E'.
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Figure 9: An overlay of CDGS transferrin and the same sample after de-slalylatlon with 
Arthrobacter ureafaciens neuraminidase.
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4. Discussion:
4.1 The glycoforms of transferrin have been resolved on the basis of charge by CZE
In this study, using Tris/glutamate buffer at pH 8.6, CZE has been used to the resolve the 
glycoforms of transferrin quantitatively at the protein level on the basis of charge. The charge 
was shown to be due to terminal sialic acid residues which were removed by digestion with 
Arthrobacter ureafaciens neuraminidase reducing the whole population to a single glycoform. 
Interestingly, the analysis of erythropoetin by CZE (Tran et al ) also showed that neuraminidase 
could reduce the multiple peak structure to a single peak. This suggests that CE resolution of 
glycoforms based on the differences in sialylation may be a useful approach to the analysis of 
other sialylated glycoproteins. In this study, in figure 4, the glycoform populations S2-S6 were 
assigned to molecules carrying from 2-6 sialic acid residues on the two glycans attached to 
each molecule of transferrin, by analogy with previous studies of transferrin isolated from 
human serum (Yamashita et al 1989). The relative proportions of the sialylated populations 
were S2:2%, 83:12%, 84:67%, 85:13%, 86:6%. The neuraminidase digestion was followed by 
CZE, and this allowed the variations in the relative proportions of the different glycoforms to be 
monitored throughout the digestion. In a similar study involving the digestion of the 
oligomannose glycans attached to RNase B, the Man6 glycoform population was found to be 
more resistant to the mannosidase enzyme than the others (Rudd et al 1992), suggesting that 
the protein gives some protection to this particular glycoform in which the terminal mannose 
residue is closer to the chitobiose core. In the case of transferrin, all of the sialic acid residues 
are terminal and equidistant from the chitobiose core. Although the residues were removed 
sequentially and all glycoform populations from 86 to 80 were observed during the course of 
the digestion, there was no indication that any particular sialylated glycoform was more 
resistant than the others, suggesting that all the sialic acid residues are equally accessible to 
Arthrobacter ureafaciens neuraminidase. Interestingly, although the assay system clearly 
established elution positions for variably sialylated glycoforms, it did not resolve the peaks 
further into glycoforms carrying the same charge but with a different mass. For example, 83 
which is derived from the loss of one 8A residue from transferrin with two bi-antennary complex 
glycans, is not distinguished from 83 which is derived from the loss of two 8A residues from a 
transferrin molecule carrying one tri- and one bi-antennary complex glycan.
4.2 Sequential exoglycosidase digestions of glycans attached to intact undenatured transferrin 
The results of sequential exoglycosidase digestions (Fig.7) of the intact, undenatured 
glycoprotein were consistent with previous studies (Yamashita et al 1989, 8pik et al 1975, and 
Van Pelt et al 1987) which indicated that the major population of sugars attached to normal 
human transferrin was the sialylated bi-antennary complex glycan, 8A2H5N4 (glycan 
composition formula of oligosaccharide containing 2xsialic acid, 5xhexose and 4xN-acetyl 
hexosamine glycans). 8equential digestions removed sialic acid, galactose and N-acetyl 
glucosamine in turn and the modified glycoforms took longer to elute as their size decreased.
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These data indicate that, within the neutral charge band, the system is capable of resolving 
glycoforms on the basis of size.
4.3 Glycosylation profile of CDGS transferrin
Separation of CDGS transferrin by CZE (Fig. 7e and 8) indicates that both patients have 
increased levels of 82 and also a population of glycoforms, J, not present in either in normal or 
desialylated normal transferrin. J elutes earlier than the 80 glycoforms and later than transferrin 
containing only two single GlcNAC residues attached to the protein. The elution position 
suggests that it may contain non-glycosylated transferrin. This would be consistent with 
previous studies of CDG8 transferrin, which has been shown to contain non-glycosylated and 
monoglycosylated molecules. The increase in 82 may be due to an increase in monosialylated 
transferrin, but this was not found by Yamashita, and suggests that the increase is more 
probably due to the presence of transferrin glycoforms in which only one glycosylation site has 
been filled with a fully sialylated bi-antennary complex sugar. This would also be consistent 
with previous studies of CDG8 transferrin. The data suggest that profiling transferrin under the 
conditions described in this chapter would reveal increased levels of 82 and 80, indicative of 
CDG8.
4.4 Variable sequon occupancy: factors which control protein glycosylation
Glycoforms which contain unglycosylated sites may arise for several reasons. For example in 
the previous chapter the possibility that ribonuclease A and B may arise from a competition 
between glycosylation and folding was discussed. In addition, natural sialidases have been 
identified in mammalian systems (Buzuchi et al 1993) which may modify the sugar side chains 
of glycoproteins by cleaving the asparagine-sugar linkage. In the case of CDG8 transferrin the 
data do not support the latter possibility. Following enzyme cleavage by PNGase, asparagine 
residues are converted to aspartic acid and the introduction of two additional charges to the 
transferrin molecule would alter the CE elution position, so that the glycoform would not be 
expected to elute with neutral structures. In addition, studies of one peptide N-glycosidase 
(PNGase F) in this thesis (ch.3,4) have suggested that it is specific and does not cleave N- 
linked glycans from all native glycoproteins. In CDG8 every glycoprotein which has been 
analysed so far has been deficient in glycosylation. It is therefore possible that the sites in 
CDG8 transferrin were not glycosylated in the endoplasmic reticulum (ER). 8ome general rules 
have emerged with respect to the factors which control the attachment of oligosaccharides to 
potential glycosylation sites in the ER. For example, to be glycosylated an asparagine residue 
must form part of the tripeptide sequon AsnX8er/Thr where X is any amino acid apart from 
proline, although the presence of this sequon is not in itself sufficient to ensure glycosylation. 
Although the same glycosylation machinery is available to all the proteins which are translated 
in a particular cell and use the secretory pathway, it has been estimated that between 10% and 
30% of potential glycosylation sites are not occupied (Gavel and von Heijne 1990). The three 
dimensional structure of the individual protein clearly has a role in determining the extent of its
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glycosylation (Goochee et al 1992). A number of mechanisms may be involved, including the 
position of the glycosylation site in the protein. However, in the case of CDGS none of these 
factors would seem to explain the widespead lack of glycosylation.
Another factor which controls the proportion of occupied sites is the availability of the dolichol 
pyrophosphate linked MangGlcNACgGICg precursor oligosaccharide. The lipid component of this 
precursor is dolichol, a long chain isoprenol of 14-20 isoprene units (Fig. 10) which anchors the 
growing oligosaccharide in the lipid bi-layer of the ER. Initially the sugar chain is elongated in 
the cytoplasm until a Man 5 glycan is attached at which point the molecule 'flips' so that the 
remaining processing of the Man 5 glycan to the MangGlcNACgGICg precursor takes place 
within the lumen of the ER (Fig.11). The precursor is transferred to the asparagine residue in 
the glycosylation sequon of the nascent glycoprotein by an oligosaccharyl transferase which is 
situated 30-40A above the membrane of the ER and oriented roughly parallel to the membrane 
surface (Nilsson et al 1993). There are many stages in this process which may lead to 
abnormal glycoprotein metabolism and result in the incomplete glycosylation of a wide range of 
glycoproteins (Jaeken et al 1993).
4.5 Alteration of glycosylation patterns with disease
Alteration of the glycosylation patterns of natural glycoproteins have been noted in some 
diseases. In this thesis, serum IgG isolated from a rheumatoid arthritis (RA) patient was found 
to contain increased levels of agalactosyl IgG (Chapter 6), consistent with the findings of others 
(Parekh et al 1985) which established that in RA the distribution of the glycoform populations in 
the Fc is altered, reflecting an increase in the proportion of N-linked glycans terminating in N- 
acetyl glucosamine. Interestingly, incomplete glycosylation has also been noted in serum 
transferrin as a result of alcohol abuse (Stibler et al 1986), in retinitis pigmentosa (Andreasson 
et al 1992) and in hepatocellular carcinoma (Yamashita et al 1989).
4.6 Applications of CE in glycobiology:
Once a method has been developed for fully or even partially resolving a glycoform mixture by 
capillary electrophoresis many investigations become possible. Some of these applications 
have been explored in this thesis in this chapter or in the study of RNase B (ch.4). These 
include: (I) resolving glycoforms, without destruction, at the protein level and enabling the 
preparation of individual glycoforms (ii) following details of enzymatic modifications to 
glycosylation directly during the course of the digestions (iii) probing alterations to glycosylation 
associated with disease (vi) following the enzymatic release of glycans from the protein (vii) 
exoglycosidase sequencing of oligosaccharides while attached to the protein (vii) comparing 
the stability of different glycoforms to protease activity (vii) examining the role of the protein in 
protecting the sugars from enzymatic digestion by comparing the susceptibility of the 
oligosaccharides bound to the protein to the same sugars in free solution. In addition the 
profiling of tPA (Taverna et al 1992) suggests that the technique may be useful for monitoring
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alterations to the glycoform populations during manufacturing processes and comparing the 
glycosylation of glycoproteins from different cell lines.
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Figure 1 : The antibody molecule consists of two heavy (H) and two light (L) chains, linked by 
disulphide bridges (solid lines) and divided into homologous regions of sequence (V^, Ci^1, 
C^2, Cf^, Vi and CJ each of which has an intrachain disulphide bridge. The folding of the 
chain within each domain is shown schematically, C^and fold in a very similar way to 
Arrows represent strands of p-sheet, and the solid bars are the intrachain disulphide bridges 
which link the two p-sheets of each domain. The homologous four stranded 'faces' of each 
domain are shown cross hatched. This face in C^2 is partially covered by the branched 
oligosaccharide chain, but it forms the domain pair interface in C ^ :C ^ .  In and
Vfthe stippled segments represent the hypervariable regions of sequence (H1, L1 etc) which, in 
the 3-dimensional structure, together form the antigen binding site (Dwek et al 1984).
Novel strategies to determine the glycosylation of IgG and to prepare pure agalactosyl
glycoforms of IgG, Fab and Fc.
Abstract
Immunoglobulin G (IgG) consists of two heavy (H) and two light (L) polypeptide chains. It can 
be cleaved by papain into two fragments of Fab (the antigen binding fragment) and one of Fc 
(the region which mediates many of the effector functions). IgG contains two conserved N- 
linked glycosylation sites at Asn 297 on each of the CH2 domains which are located in the Fc. 
In addition 20% of IgG molecules are also glycosylated in the hypervariable region of the Fab. 
In this chapter a novel strategy was developed to determine the glycosylation of IgG involving 
anion exchange chromatography with on-line fluorescent detection and simultaneous 
sequencing of multiple oligosaccharides analysed by matrix assisted laser desorption ionisation 
mass spectrometry. The sugars were released from human serum IgG by hydrazinolysis and 
desialylated with Arthrobacter ureafaciens sialidase. The pool of asialo oligosaccharides was 
analysed without separation of the individual components using a novel combination of 
exoglycosidase digestions, ion exchange chromatography and mass spectrometry. Consistent 
with previous analyses of human serum IgG a range of complex biantennary oligosaccharides 
were identified, confirming that IgG consists of a mixture of glycoforms. The distribution of 
charge on the released IgG glycans was determined using an optimised weak anion exchange 
chromatographic method. The same method was used to analyse the charged glycans released 
from serum IgG from a patient with rheumatoid arthritis (RA). The most notable difference in 
the charge profiles of the two IgG samples was that RA IgG contained two populations of 
monosialylated oligosaccharides (G1, G2) while normal IgG contained only one (G1). The 
released IgG glycans were digested with Arthrobacter ureafaciens sialidase, Choronia lampas 
fucosidase and Jack bean N-acetylhexosaminidase to reduce all the oligosaccharides to three 
populations differing only in the extent of their outer arm galactosylation. A comparison of the 
galactose content of normal and RA IgG, using cation exchange chromatography, indicated a 
decrease (13%) in G2 sugars and an increase (16%) in GO sugars in RA IgG compared with 
normal IgG, while the G1 population remained relatively stable (36% in RA compared with 39% 
in normal). These data are consistent with the trends established in previous studies of RA IgG 
in this laboratory. In addition to the increased levels of IgGO, another characteristic feature of 
RA is the presence in serum and synovial fluid of IgG rheumatoid factors (RFs) which self­
associate to form aggregates of IgG which may be either soluble or deposited in joints. RFs 
were shown to consist of IgG molecules which are glycosylated in the Fab region as well as in 
the Fc and contain mainly GO type sugars. IgGRF, containing approximately 85% of IgGO 
sugars, was used to test the possibility that the terminal N-acetyl glucosamine residues present 
on IgGO glycoforms may be exposed and available for binding. One candidate for binding is the 
calcium dependent serum lectin mannose binding protein which binds pathogens with a high
149
nf i  f t f
igGi lgG2
) (
I {
> c
riji
I (
lgG3 lgG4
S tru ^re  of human IgG subclasses showing heavy and light polypeptide 
chains and both Inter- and Intra- (yellow) chain disuiphide bridges.
N terminus
224 341 433
....T
Fab
Papain
Fc
Papain cleavage points of human IgOI. The major cleavage site 
IS between residues 224 and 225. Two minor cleavage sites are between 
residues 341/2 and 433/4
Figure 2a, b
concentration of terminal N-acetyl glucosamine residues on their surface. Preliminary studies 
explored the possibility that this lectin might also recognise terminal N-acetyl glucosamine 
residues on IgGO when multiply presented. IgGRF (GO approximately 85%) bound more 
strongly to the lectin than normal IgG (GO: 20%) when both were immobilised and concentrated 
on dot blots. To examine the preliminary finding more rigorously pure sets of IgGO, FabGO and 
FcGO glycoforms were prepared. Normal human serum IgG was cleaved by papain into Fab 
and Fc, and the natural mixtures of IgG, Fab and Fc glycoforms (containing G2, G1 and GO 
glycoforms) were modified to populations containing 100% GO type sugars by removing sialic 
acid and galactose residues with Arthrobacter ureafaciens and Streptococcus 6646K p- 
galactosidase. Subsequent analysis showed that IgGO and FcGO but not FabGO bound 
mannose binding protein when multiply presented on a microtitre plate.
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Novel strategies to determine the glycosylation of IgG and to prepare pure agalactosyl
glycoforms of IgG, Fab and Fc.
1. Background:
1.1 The structure of Immunoglobulin G
IgG (M.Wt. 150-160KD) consists of two heavy (H) and two light (L) chains linked together by 
disulphide bridges and divided into homologous regions of sequence (V^, Cy1, C^2, 0^3, V l 
and CJ (Fig. 1). and V l contain hypervariable regions of sequence which together form the 
antigen binding site. X-ray crystallography has shown that each region of homology in the IgG 
molecule corresponds to a compact, independently folded unit, and that these are linked 
together by short sections of extended polypeptide chain. Each immunoglobulin domain 
consists of two p-pleated sheets with antiparallel strands connected by loop regions. This 
general pattern is known as the immunoglobulin fold (Amzel and Poljak 1979) (ch.2). In 
humans there are four subclasses, distinguishable from each other by the arrangement of 
disulphide bridges in the hinge region of the molecule (Fig. 2a). The relative proportions of the 
different subclasses in polyclonal IgG are approximately IgGi: 70%, lgG2: 20%, IgGS: 7%, 
lgG4: 3%. IgG can be cleaved by papain into Fab (the antigen binding fragment) and Fc (the 
region responsible for the effector functions of the molecule) (Fig. 2b). The major cleavage site, 
on the C-terminal side of Lys 224, (Fig. 2b) is in the variable hinge region of the molecule and 
different subclasses of IgG show marked differences in susceptibility to the enzyme. lgG3 is the 
most susceptible followed by lgG1>lgG4>lgG2.
In IgG the two CH2 domains each contain a conserved glycosylation site at Asn297 to which 
complex biantennary oligosaccharides are covalently linked. On average 2.5+/-0.3 N-linked 
sugars are attached to each IgG molecule (Chang, S.C. 1993) of which two are located in the 
Fc. The additional oligosaccharides are found in the hypervariable regions in the Fab. IgG is 
associated with at least 30 different complex glycans (Fig. 3). The glycosylation pattern of IgG 
is species specific and may be influenced by physiological state (Rook et al 1991) or by cell 
culture conditions (Goochee et al 1992). Structural differences between the glycans arise 
primarily from sialylation, core substitutions and outer arm galactosylation.
(I) Sialylation
In normal human serum IgG typically 81% of the structures are neutral, 16% contain one sialic 
acid residue and 3% are disialylated (Rademacher et al 1985). All the sialic acid residues are 
linked a-2,6 to galactose and no other charged species have been detected. Most of the 
disialylated oligosaccharides are located in the Fab region (Rademacher et al 1985). Restricted 
access of the a2,6 sialyl transferase to the sugars within the CH2 domains may explain the low 
percentage of disialylated structures in the human Fc.
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Figure 5: The G2, G1 and GO classes of sugars released from IgG (sialic acid, core fucose 
and bisecting GlcNAc have been removed by enzymatic digestion)
Structural analysis of the glycans released by hydrazine from normal human serum IgG shows 
that all are of the complex bi-antennary type. They may be classified in several ways;
(i) according to the substitutions in the trimannosyl core. There are four different core structures 
(Fig. 3a) arising from the presence or absence of a1,6 fucose attached to the primary GlcNAc 
and pi,4-(bisecting) N-acetyl glucosamine attached to the second GlcNAc residue.
(ii) according to the number of terminal sialic acid residues. IgG sugars may be either neutral, 
mono- or di-sialylated (Fig. 4)
(iii) according to the number of galactose residue in the outer arm (Fig. 5)
(ii) Core substitution of fucose and N-acetylglucosamine
The addition of core fucose (F) and/or bisecting N-acetyl glucosamine (B) to the primary and 
secondary GlcNAc residues in the trimannosyl core allows four alternative core structures, 
+F+B, +F-B, -F+B, and -F-B (Fig. 4).
(iii) Outer arm N-acetyl glucosamine
Depending on the extent of galactosylation the complex glycans contain 0, 1 or 2 terminal N- 
acetyl glucosamine residues. Interestingly, polyclonal IgG has been found to contain a low 
percentage (3%) of structures with only one GlcNAc substitution on the trimannosyl core 
(Jefferis et al 1990). Invariably this was linked to the a1,3 arm, suggesting that the levels of 
GlcNAc transferase II (which adds GlcNAc a1,2 to the mannose on the a1,6 arm) may not 
always be sufficient to add GlcNAc to the 1,6 arm of every developing glycan.
(iv) Outer arm galactosylation
The outer arms of the biantennary sugars are classified into three types: those which contain a 
galactose residue on each arm (G2), those which contain one, either on the a1,3 or a1,6 arm 
(G1(a1,3) and G1(a1,6)) and those which contain no galactose (GO) (Fig. 5). NMR relaxation 
studies suggest that, for the glycans lacking galactose on the a1,6 arm, there is an increase in 
the solvent accessible surface of the protein. The decreased interactions of the oligosaccharide 
with the protein surface leads to an increase in the space available to the GO or G1 (a1,6) 
oligosaccharide, and exposure of the terminal GlcNAc residue. This suggests a model for G2 
and G1(a1,6) in which the sugars are bound to, or have restricted motion relative to, the peptide 
surface. For G1(a1,3) and GO glycans terminal pi-2GlcNAc residues become exposed and 
accessible to lectins such as the Psathyrella belutina lectin (Tsuchiya et al 1994). In contrast, 
examination of the X-ray data suggests that none of the oligosaccharide residues on sugars 
containing terminal galactose on the a1 ,6 arm are available for such interactions.
(a) IgG G2:
Approximately 40% of IgG glycans from normal serum IgG are of the G2 type. Based on the 
X-ray analysis of rabbit Fc, it has been proposed that the available space between the CH2 
domains is not sufficient to accommodate G2 sugars on both CH2 domains simultaneously. 
Interestingly, 24% of IgG in one sample of lgG4, which was glycosylated only in the Fc, 
contained oligosaccharides in which both the a1,3 and a1,6 arms of each sugar chain were 
galactosylated (Jefferis et al 1990). It is possible that a change in the conformation of the 
protein or the sugars may be required to allow the processing enzymes access to develop two 
fully galactosylated oligosaccharides and to accommodate two G2 glycans in the restricted 
interstitial space.
(b) IgG G1(a1,3) and G1(a1,6)
The relative proportions of these populations is related to IgG subclass. Analysis of IgG from 
sub-class specific paraproteins (Jefferis et al 1990) showed that, in all the lgG2 subclass 
samples analysed and in some of the lgG3 samples, G1(a1,3) predominated over G1(a1,6). In 
contrast, in polyclonal IgG and in subclasses IgGi and lgG4 paraproteins, the a1,6 arm was 
substituted up to four times more frequently than the a1,3 arm. In normal serum IgG glycans
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analysed by Parekh (D. Phil. Thesis 1988) the ratio of G1(a1,6):G1(a1,3) was 4:1. These data 
suggest that the relative affinity of the human Gal (3-1,4 transferase (of which only one has 
been identified to date) for each of the arm specific GlcNAcal ,4 residues may be influenced by 
differences in the structures of the IgG subclasses. In the ER, IgG is assembled completely 
with two heavy and two light chains prior to transfer to the Golgi apparatus where complex 
processing and galactosylation occurs (Bole et al 1986), and processing of the complex glycans 
takes place in the restricted space which the sugars occupy between the CH2 domains. 
Subclass differences in the 3-dimensional structure of the protein may variably affect the 
oligosaccharide-protein interactions which have been shown to be important for stabilising the 
a1,6 arm. Thus in IgGi and lgG4 the a1,6 arm terminal GlcNAc may be in a more favourable 
conformation for interaction with UDP-Gal and (3-galactosyl transferase than the a1,3 arm 
terminal GlcNAc. In contrast, in lgG2 and lgG3 the a1,3 arm displays a higher affinity for the 
enzyme, suggesting that in these subclasses the presentation of the terminal GlcNAc on the 
a1,3 arm is more favourable. Two sets of data support the suggestion that the polypeptide 
structure can influence the branch specificity of the transferase. In the first, Gal(31-4 tranferase 
from a number of sources was shown to preferentially transfer galactose to the a1,3 arm of 
symmetrically branched acetylated glycopeptide and oligosaccharide acceptors terminating in 
GlcNAc (Narashimhan et al 1985). This indicates that either cellular factors or the polypeptide 
structure influence the branch specificity of the reaction catalysed by the transferase in IgG. 
Secondly, in fusion constructs of murine myeloma cells, which secrete heterodimeric IgG 
composed of heavy chain derived from each parental cell, the heavy chains differ in the 
proportion of each monogalactosylated species. This also suggests that the polypeptide chain 
can influence in vivo the branch specificity of the transferase (Lee et al 1990).
(c) IgG GO
The incidence of IgG GO type oligosaccharides is an age related parameter (Parekh et al 
1998a). Overall, G1 does not vary with age, and G2 varies inversely to GO. In patients with 
rheumatoid arthritis (RA) both serum and synovial IgG contain an increased proportion of 
glycans which lack galactose and terminate in N-acetylglucosamine (Parekh et al 1984), the 
levels of which correlate with clinical score and with disease activity (Parekh et al 1988b). 13 
pairs of matched RA serum and synovial fluid samples were analysed using the Psathyrella 
velutina lectin (PVL) which interacts with terminal outer arm (31-2 linked N-acetylglucosamine 
(Tsuchiya et al 1993). In 11 patients PVL binding was significantly elevated (p=0.007) in the 
synovial fluid compared with the paired serum. Elevated levels of IgGO are associated with a 
restricted number of other diseases including juvenile RA, tuberculosis, Crohn's disease and 
systemic lupus erythematosus (Parekh et al 1989).
1.2 Rheumatoid factors
One of the characteristic immunological features of rheumatoid arthritis is the presence in 
serum and synovial fluid of rheumatoid factors (RFs); however their role in pathogenesis has 
not yet been established. RFs are defined as antibodies specific to antigenic determinants on
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IIgG aggregate formation may involve antigen-antibody recognition IgG aggregate formation may Involve oligosaccharides
Figure 6a,b: Taken from Nardella et al 1981 and Rademacher et al 1988 respectively
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Figure 7a: IgG Fc oligosaccharides
In the IgG molecule the branched oligosaccharide chains cover part of the four stranded faces 
of the CH2 domains and occupy the space between them. (Taken from Sutton and Phillips 
1983).
IgGFc. They exist in three main classes of immunoglobulins, and immune complexes form 
through the binding of IgM, IgA or IgG to the Fc region of IgG. IgGRFs consist of self 
associated IgG complexes containing a high proportion of IgGO glycoforms (85% S-C Chang D. 
Phil. Thesis). The monomers first form dimers which then self associate to tetramers, 
hexamers and larger oligomers. IgGRFs may be soluble or deposited on cell surfaces such as 
the synovium. In synovial fluid they constitute from 1-4% of the total IgG (Leader et al personal 
communication). The rheumatoid synovium synthesises 12-26% of the IgG in the synovial fluid 
of RA patients at the rate of 5-95mg/day compared with none in normal synovial fluid (Sliwinski 
and Zvaifler 1970). The classical model for the structure of IgG-IgG RF complexes is based on 
antibody-antigen recognition of the Fc of one IgG molecule by the Fab of another (Fig 6a) 
(Nardella and Mannik 1981). An alternative model for IgG RF complexes has been proposed 
(Parekh et al 1985) which involves protein-oligosaccharide interactions. This suggests that Fab 
sugars from one IgG molecule interact with a second through the 'lectin-like' protein surface in 
the Fc which becomes exposed in the GO type glycoforms (Fig.6b).
1.3 Protein-oligosaccharide interactions within the IgG molecule
The model of protein-oligosaccharide interactions in Fc has been determined by X-ray 
crystallography, (Sutton and Phillips, 1983) and the conformational analysis of the free IgG 
oligosaccharides by high resolution NMR (Rademacher et al 1983, Homans et al 1987). The 
free sugars contain regions of defined secondary structure and all but one of the glycosidic 
linkages exist in a single preferred conformation giving rigidity to the core structure. The a1,6 
linkage, which can adopt two conformations, gives a flexible arm to the oligosaccharide. In 
rabbit Fc, the a1 ,3 arm extends into the interstitial space where the relatively rigid a 1 ,3 arm of 
one of the oligosaccharides interacts with the core of the opposing sugar while the a 1 ,6 arm of 
each cartK)hydrate interacts with the domain surface (Fig. 7a). The crystal structure of human 
IgGFc predicts a total of 38 non-covalent interactions between the hexasaccharide unit 
(GlcNACgMan^GlcNAc) and the Fc face of the CHg domain and additional interactions for 
GlcNAc (13) and Gal (27) on the a1,6 arm and for the core fucose (7) attached to the primary 
GlcNAc (Padlan 1991). Some of these interactions are shown in figure 7b.
1.4 The role of IgG Fc oligosaccharides in C lq binding
Protein-oligosaccharide interactions play a role in maintaining the 3-dimensional structure of 
the two CH2 domains in the Fc. Both aglycosylated and degalactosylated IgG bind less 
efficiently to C lq and Fcy receptor (Nose and Wigzell 1983, Leatherbarrow et al 1985, 
Tsuchiya et al 1989 J. Rheum. 16 285-290). C lq binds to antigen-bound IgG thus activating the 
classical pathway of the complement system. Partial deglycosylation of IgG does not greatly 
affect C lq binding (Tsuchiya et al 1989), however complete deglycosylation of IgG does reduce 
the affinity of Clq, probably due to alterations in the alignment of the IgG CM2 domains 
(Leatherbarrow et al 1985).
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Figure 7b: The CH2 region of the antibody molecule taken from the crystallographic 
structure determined by Deisenhofer (1981). The crystal structure of IgG predicts 72 non- 
covalent interactions between the oligosaccharide and the amino acid residues of the CH2 
domain (Padlan 1991). These include interactions between Phe243, Pro245 and Thr260 which 
are in the proximity of Man5 and GlcNAcS; Gal7; GlcNAc6 and Gal7 respectively of the a1,6 
antenna.
2. Introduction to chapter 6
In general, the analysis of oligosaccharide structures attached to proteins is important both for 
the characterisation of glycoproteins and for examining the consequences of glycosylation in 
biological systems. The automation of techniques for releasing and analysing the structures of 
sugars have highlighted the need for new strategies to profile and sequence oligosaccharides 
so that the characterisation of glycoproteins can become routine. During the course of this work 
several new strategies were explored. Conventionally oligosaccharides, released from the 
protein by hydrazine or with the endoglycosidase PNGaseF, are reduced and radiolabelled at 
the reducing terminus with tritium. The glycan pool is resolved into its pure components and 
each is sequenced individually by means of a series of exoglycosidase digestions which 
sequentially remove the terminal sugars. The products of each incubation are analysed by gel 
filtration and the partially digested sugar is recovered and subjected to the next enzyme digest. 
This process has been rationalised by the introduction of the reagent array sequencing method 
(RAAM) in which the individual oligosaccharides are simultaneously digested with an enzyme 
array. However the difficulties involved in resolving the glycan pool into its individual 
components remain. This can be technically difficult when glycans are structurally very similar. 
Multiple separations are required to separate the glycans, traditionally using P4 GPC to exploit 
differences in hydrodynamic volume. In this chapter a strategy has been developed in which 
the need for both labelling and prior separation of glycans has been overcome. In conjunction 
with Dr. David Harvey, mass spectrometry has been used, first to determine the composition of 
the IgG glycan pool in a single analysis and subsequently to follow the sequential 
exoglycosidase digestions of each oligosaccharide simultaneously. HPLC techniques were 
developed to analyse fluorescent or radiolabelled glycans on the basis of charge, 
hydrophobicity and hydrodynamic volume. In this chapter WAX chromatography has replaced 
conventional high voltage electrophoresis (HVE) and cation exchange (CAT) chromatography 
proved a useful alternative to P4 gel permeation chromatography (GPC). The new technology 
explored in the course of this project was applied and extended during the work involving the 
leukocyte antigens in chapter 2.
In this chapter novel strategies were used to analyse the glycans released from normal human 
serum and RA serum IgG and the results were compared with previous studies by others. 
IgGRF was prepared to examine its glycosylation and to explore the role of glycosylation in the 
formation of self associating RF complexes. IgGRF (85% GO) was used in preliminary 
experiments to test whether the terminal GlcNAc residues on IgGO may be exposed and 
available for binding. The results suggested that, if multiply presented on a dot blot, the IgGO 
sugars were able to bind MBP. To examine the preliminary finding more rigorously pure sets of 
IgGO, FabGO and FcGO glycoforms were prepared. Normal human serum IgG was cleaved by 
papain into Fab and Fc, and the natural mixtures of IgG, Fab and Fc glycoforms (containing 
G2, G1 and GO glycoforms) were modified to populations containing 100% GO type sugars by 
removing sialic acid and galactose residues with Arthrobacter ureafaciens and Streptococcus 
6646K p-galactosidase.
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3. Methods
3.1 Preparation of normal and rheumatoid IgG by ammonium sulphate precipitation and DEAE 
ion exchange chromatography
Whole blood from a rheumatoid patient was incubated at 37°C for 1 hour and at 4°C for 4 
hours. The clot was removed and the remaining serum spun for 2 minutes at 2000 rpm to 
separate it from red blood cells. 1 ml of serum was transferred to a centrifuge tube and SOOpI of 
saturated ammonium sulphate pH7.2 were added dropwise to a final concentration of 33%. 
After incubating on ice for 2 hours the precipitate was recovered by centrifuging for 20 minutes 
at SOOOrpm in a JA21 rotor. The pellet was washed by re-suspending in 40% saturated 
ammonium sulphate pH7.2 and recovered by centrifugation as before. The pellet was dissolved 
in 1ml of 20mM potassium phosphate buffer pH7.2, dialysed into this buffer overnight and 
loaded onto a column of DEAE sephacel (4ml) equilibrated in the same buffer. The unbound 
fraction contained IgG. The yield was 6.8mg/ml. Normal human serum IgG was prepared by 
the same method on a large scale from 200ml of normal pooled serum obtained from the blood 
bank. The yield was 5.2 mg/ml of serum. The preparation was analysed by HPLC, SDS PAGE 
and western blotting.
3.2-3.5 refer to the methods used for oligosaccharide analysis
The methods used in this chapter and throughout this thesis for oligosaccharide analysis are 
collected together and discussed in Chapter 8, entitled 'Methods for oligosaccharide analysis'
3.2 Release and labelling of sugars for analysis
The sugars were released from adult and juvenile RA IgG, and from normal IgG, Fab, Fc and 
their GO counterparts by hydrazinolysis using the automated OGS GlycoPrep method. The 
released oligosaccharides were reduced and the reducing terminus radiolabelled or 
fluorescently labelled.
3.3 Analysis of charged sugars
Fluorescent or radiolabelled sugars were analysed by weak anion exchange (WAX) 
chromatography.
3.4 Analysis of asialo oligosaccharides
Unlabelled desialylated sugars were desalted by ion exchange chromatography on mixed bed 
resins prior to analysis by MALDI MS.
3.5 Analysis of the agalactosyl content of IgG
The released and labelled sugars were incubated with the standard 'GO mix' to remove fucose 
and N-acetylglucosamine residues. This reduced all glycans to one of three structures differing 
only in the extent of outer arm galactosylation. The digests were analysed by cation exchange 
(CAT) chromatography.
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3.6 Preparation of monomeric IgG sepharose affinity column
300 mg of globulins (human; Cohn fraction 11,111; Sigma) were applied to an HPLC column 
(TSK-55; 80x2.5cm) equilibrated in 0.05 M potassium phosphate/ 0.15M NaCI pH8. Fractions 
comprising the monomeric peak were pooled and concentrated (lOOmg). 90mg of normal 
monomeric IgG in 60 ml of 0.1 M NaHCOg / 0.5M NaCI pH 8.3 were coupled for 2 hours at 37°C 
to 11 ml of CNBr activated sepharose 4B previously washed in 11 mM HCI. After washing with 
coupling buffer vacant sites were blocked with ethanolamine (1M; pH8; 2h room temperature). 
The gel was subsequently washed in coupling buffer and in 0.1M sodium acetate/0.5M sodium 
chloride pH4. It was stored in 0.02M sodium borate/ 0.5M sodium chloride at a final 
concentration of 7mg of monomeric IgG/ml of gel.
3.7 Sucrose density gradient conditions
A series of sucrose solutions was prepared in which the concentration varied in 5% steps 
between 10% and 40% sucrose. For a 12ml gradient: 1.77ml of 40% sucrose was frozen at the 
bottom of a centrifuge tube. 1.77ml of each subsequent dilution (35%, 30%, 25%, 20%, 
15%,10%, 5%) was pre-coo led, added to the tube and frozen. Gradients prepared in this way 
were stored at -20°C until needed. 8-12 hours was allowed for thawing before use. A maximum 
of 500pl of sample was applied to the top of the gradient and the tube was spun for 22 hours at 
4°C and 40K rpm in a Beckman L8-70M using an SW40Ti rotor. Gradients were fractionated 
using an ISCO density gradient fractionator by pumping a chase solution of 40% sucrose into 
the bottom of the tube, forcing the gradient out of the top of the tube through a UV detector and 
into a fraction collector. Immunoglobulins G (7S), A(11 s) and M (19S) were well resolved under 
these conditions.
3.8 Preparation of IgG oligomer standards by chemical cross linking of IgG
Human IgG (800pl; 58nmoles; 11 mg/ml potassium phosphate buffer 0.1 M, pH7.2) was dialysed 
into sodium borate buffer (0.1 M, pH9). An equimolar quantity of dithiobis-succinimidyl 
proprionate (DTSP) (23.7pg/5.9pl DMF) was incubated in a reactivial for 7 days during which 
time 3 further aliquots of DTSP/DMF were added. The extent of cross linking was monitored by 
HPLC (TSK 3000) equilibrated in 0.1 M potassium phosphate buffer pH7.2, and the final 
equilibrium mixture fractionated by SDG 0-40%).
3.9 Preparation of IgGRF and RF depleted IgG
Serum (3ml) from a patient with hypen/iscosity syndrome and RA (GO 45%) was applied to a 
column of CNBr-activated sepharose 4B (13ml) to which 90mg of normal monomeric IgG had 
been coupled. The column was equilibrated and washed with 0.02M disodium tetraborate/0.5M 
sodium chloride pH 8.8. Bound material was eluted with 0.1 M sodium acetate/0.15M sodium 
chloride pH 3.5, pooled, concentrated to approximately 7mg/ml and fractionated by sucrose 
density gradient (12ml; 10-40%, pH3.5 SDG; centrifugation: 16h, 52k, 4°C). At pH 3.5 IgGRF is
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dissociated from IgG (7s), IgM (19s) and IgA (11s). The 7s pool containing IgGRF monomers 
was concentrated and dialysed into 0.1 M glycine/0.16M sodium chloride pH7. Sedimentation 
values were assigned by comparison with known standards obtained by chemically cross- 
linking IgG and from standard IgG and IgM. Unbound material from the monomeric IgG 
sepharose column, which contained IgG depleted of RF, was concentrated to the original serum 
volume (3ml) and IgG prepared as in 3.1.
3.10 Papain cleavage of IgG to investigate whether the % uncleaved IgG correlates with GO 
Human serum IgG was isolated from 20 juvenile RA patients by ammonium sulphate 
precipitation and subjected to papain cleavage. IgG (50p.g) in 20mM potassium phosphate pH7 
(5mg/ml) was incubated at 37°C for 4 hours with 0.1ml of sepharose CL4B derivatised with 
papain (Pharmacia) in 300^1 of buffer (20mM potassium phosphate pH7/Cys/HCI 20mM/EDTA 
4mM; enzyme substrate ratio 1:40). The percentage of papain resistant IgG was calculated by 
integration of the IgG, Fab and Fc peaks from analytical GPC (Zorbax GF250+450). The 
percentage of papain resistant IgG was plotted against the GO values for each IgG sample.
3.11 Papain cleavage of IgG to prepare Fab and Fc
IgG (500p,g in 500 |il 20mM potassium phosphate pH7) was incubated at 37°C with 1ml of 
sepharose CL4B derivatised with papain (Pharmacia) in 3ml of buffer (20mM potassium 
phosphate pH7/Cys/HCI 20mM/EDTA 4mM; enzyme substrate ratio 1:40). The reaction was 
followed by HPLC and reached equilibrium after 4 hours. After extensive dialysis into Tris/HCI 
pH7.5 (lOmM) Fab was separated from IgG and Fc by Protein G affinity chromatography.
3.12 Protein G sepharose affinity chromatography to separate IgG and IgG Fc from IgG Fab 
The sample was dialysed into Tris/HCI (lOmM; pH7.5) and applied to a protein G affinity 
column (5x5cm, selectisphere 10 Perstorp Biolytica). The flow rate was O.iml/min and 
absorbance was monitored by UV detection at 280nM. The column was washed extensively to 
remove unbound Fab. IgG and Fc were eluted with lOOmM glycine/HCI pH2.5. The pH of the 
fractions was immediately adjusted to 7 with 1M Tris to protect sialic acid residues. Both bound 
and unbound fractions were passed through the column a second time to remove any residual 
Fab from the IgG/Fc and vice-versa. Fc was separated from uncleaved IgG and any low 
molecular weight minor products which might have resulted from the papain cleavage by HPLC 
GPC. Fab, which does not contain additional papain cleavage sites, was concentrated in 
centricon filters (10k cut off membrane) and the buffer partially exchanged for sodium acetate 
pH5.5/10mM MnCl2  before finally dialysing into the same buffer. Following HPLC purification 
Fc fractions were concentrated and dialysed in the same way.
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3.13 De-galactosylation of IgG, Fab and Fc by Arthrobacter ureafaciens neuraminidase and 
Streptococcus 6646K Ç>-galactosidase
Normal serum IgG (800|ig), Fab (SOOfig) and Fc (200|ig) in 0.05M sodium acetate pH 5.5 
containing 10mM IVInClg at a concentration of 1 mg/ml were incubated with Arthrobacter 
ureafaciens neuraminidase (2U/ml) and Streptococcus 6646K (3-galactosidase (0.2U/ml) 
(Siekagaku Co. Ltd.) at 40°C for 16h. The method used was a modification of the conditions 
used in Kiyohara et al 1976. The reactions were terminated by incubating at 56°C for 10 
minutes. Control samples were treated in the same manner without the addition of enzymes. 
IgG, Fab and Fc sugars were analysed before and after (Kiyohara et al 1976) enzymatic 
removal of terminal GlcNAc and fucose. The glycans were released by hydrazine and labelled 
either with tritium or 2AB. Labelled glycans were analysed according to charge using WAX 
chromatography to confirm the digestion of sialic acid residues in the enzymatically modified 
samples. Following incubation of the glycans with the 'GO mix' (ch.8, section 1.4h) the %G0 of 
the modified IgG, Fab and Fc was determined by cation exchange chromatography (ch.8, 
section 2.3: Vydac 400 VHP575 column; gradient 0-80% MeCN containing 50mM formic acid) .
3.14 Detection of IgG binding to MBP in a preliminary study
A plate assay to detemine IgGO developed by Dr. Graham Rook (personal communication) was 
modified for use in a dot blot assay. 5pl of each IgG solution were spotted on to nitrocellulose 
blotting membrane impressed with a dot matrix by means of the Biodot apparatus (Biorad). The 
membrane was blocked with 5% BSA, 0.05% Tween in PBS for 16 hours at room temperature. 
After washing with 2x blocking solution and 1x PBS the protein was fixed with 0.5% 
glutaraldehyde / PBS for 30 minutes at 4°C. The membrane was washed with 0.1% lysine 
/PBS, incubated at 37°C for 90 minutes and for 16 hours at 4°C with MBP (10pg/ml/Ca^+/PBS). 
The membrane was washed as before and incubated with a polyclonal rabbit IgG a-human 
MBP. After a final wash the bound antibody to MBP was detected by incubating with rabbit IgG 
conjugated to alkaline phosphate for 90 minutes at room temperature. Visualisation was with 
NBT/BCIP.
4. Results:
4.1 Preparation and analysis of normal and rheumatoid IgG (Flow chart 1 )
Normal and RA IgG were prepared by ammonium sulphate precipitation and DEAE anion 
exchange chromatography. The yields were 5.2 mg/ml and 6.8 mg/ml of serum respectively. 
The purity of the IgG was assessed by HPLC (Fig. 8) and SDS PAGE (Fig. 9, tracks 1 and 2). 
IgG heavy chain was detected at approximately 50kD and IgG k  and X light chains at 
approximately 32Kd and 29 kD respectively. No p- (70kD) or a- (55kD)chain was detected and 
the absence of IgA and IgM was confirmed by Western blot analysis. Another possible 
contaminant is the 01 complex which may be bound to IgG and therefore co-isolate. No bands 
were visible on the gel at 22, 23, 24 or 83kD, the molecular weights of the components of the
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C1 complex after reduction. However such contaminants may be present at levels of less than
1% of the total protein.
RA
15 20 255 100
Figure 8: HPLC GPC analysis of (I) normal and (II) RA IgG (Hi) IgGRF (iv) standard proteins 
using a tandem column consisting of Zorbax G F 250 + 450 Zr-silica columns (2x9.4x250mm). 
The buffer was 0.1M potassium phosphate pH7.2.
Figure 9: SDS PAGE (10% reducing gel; Coomassie stained) of normal (track 1; lOjug) and 
rheumatoid (track 2: 5jug) IgG. The heavy chains have an apparent molecular weight of 
approximately 50kD and the light chains approximately 29 (k) and 33 (À) kO. Track 3 contains 
low molecular weight markers.
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4.2 Glycosylation analysis of normal and rheumatoid IgG
4.2.1 Release and labelling of IgG glycans
Sugars were released from 1mg of normal and 1mg rheumatoid IgG by hydrazinolysis using the 
Oxford GlycoSystems (OGS) GlycoPrep 1000 (85% yield (OGS specification; 16.6nmoles). 
80% of the sugars were labelled with tritium (13.3nmoles, approximately 1.7E8 counts), and 
20% retained unlabelled. 50% (6.6nmoles) of each labelled glycan pools was desialylated with 
Arthrobacter Ureafaciens sialidase.
4.2.2 Analysis by charge of radiolabelled glycans
A charge profile of both the normal and RA IgG radiolabelled glycan pools was obtained by 
weak anion exchange chromatography (WAX) (Fig. 10a,b). Aliquots containing 1E3 counts 
were injected and the profiles obtained by handcounting the radioactivity in the eluted fractions. 
In both cases more than 75% of the structures were neutral, and all structures became neutral 
after incubation with Arthrobacter ureafaciens neuraminidase (data not shown) indicating that 
all charge was due to sialic acid.
RA IgO sug a n  pWAX)NDimal IgO sugars (WAX)
1.3000
76% neutral; 14% A1; 10%A2 80% neutral; 15%A1; 5%A2
Figure 10a,b Charge analysis of tritium labelled normal and RA IgG sugars by WAX
After incubation with Arthrobacter ureafaciens neuraminidase all the structures become neutral, 
indicating that all charge is due to sialic acid. The profiles were obtained by hand counting the 
fractions eluted from the chromatography column. The flow rate was 1ml/min and 0.25ml 
fractions were collected. The gradient was applied at 12 minutes.
4.2.3 Analysis by charge of 2AB labelled glycans using on line fluorescent detection 
A charge profile of both the normal and RA IgG fluorescent labelled glycan pools was obtained 
by weak anion exchange chromatography (WAX) (Fig. 10c,d). The elution was monitored using 
an on line detector. The samples were applied to the column through an automatic injector 
which accounts for the broadening of the neutral peak. The gradient was applied at 12 minutes 
as in figure 10a,b.
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Figure 10e: Schematic illustration of the sets of charged glycoforms present in IgG. This 
refers to figure 10c,d. The core structure shown contains fucose, other core types (see figure 
5a) are also present (see Table 1). RA IgG contains both the G1 and G2 sets of monosialylated 
A1 type structures, while normal IgG contained only the G1 set.
The improved technology Indicates that the RF monosialylated (A1) population contains two 
structures. By comparison with standards the front of the peak was Identified as the pool of G1 
sugars In which the single terminal galactose Is slalylated while the late shoulder contained G2 
sugars In which only one of the terminal galactose residues has been slalylated. In contrast the 
data for normal IgG glycans Indicate that this glycan pool contain only monosialylated G1, and 
that the G2 glycans are either dislalylated (A2) or neutral (N).
Normal
A2
RA
Minutes
Fig. 10c,d Analysis of 2AB labelled normal and RA IgG sugars by WAX chromatography
with on line detection. The samples are identical to those in figures 8 and 9 except that the 
sugars have been labelled with 2AB instead of tntium.
4.2.4 Analysis of asialo IgG glycans by size using P4 GPC
De-slalylated tritium labelled IgG sugars from normal and rheumatoid IgG were profiled by P4 
GPC (Fig. 11 a,b). In each case fractions containing 1E5 cpm of radioactivity were applied to 
the column. The samples were co-lnjected with an Intemal standard containing a mixture of 
glucose oligomers prepared from a dextran hydrolysate. The elution of the glucose oligomers 
was monitored by refractive Index (Rl) while the samples were monitored by a radioactivity 
detector. The hydrodynamic volumes of the peak fractions which are marked were obtained by 
overlaying the Rl and radioactive traces.
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Figure 11 c,d: P4 GPC profiles of 2AB labelled asialo glycans from IgG from normal and 
RA serum. These samples are from the same glycan pool as those analysed in lla .b . The 
enhanced resolution is a result of the fluorescent labelling of the glycans which each elute 
within a shorter time period than the corresponding tritium labelled samples, allowing better 
resolution of the different species. The material eluting before and in the void (10ml) is an 
artefact of fluorescent labelling, the origin of which is currently unknown.
Normd IgG m ldo sugcrs P4 GPC
Figure 11 a,b: P4 GPC GlycoMap profiles of tritium labelled asialo glycans from normal 
and RA IgG
11c,d (opposite) show the P4 analysis of the same samples fluorescently labelled.
At this point the conventional sequencing strategy requires the individual species within these 
envelopes of peaks to be separated into individual components which are at least 80% pure. 
Reagent arrays could then be used to sequence each sugar in turn. The alternative approach 
developed in this chapter used the unlabelled glycan pool released by hydrazinolysis. This was 
desialylated with Arthrobacter ureafaciens sialidase, desalted on mixed bed ion exchange 
resins and analysed without further fractionation by MALDI MS.
4.2.5 Analysis of uniabelied asialo glycans from normal IgG by MALDI MS.
16 oligosaccharides were identified by MALDI MS (Fig. 12) beneath the incompletely resolved 
envelope of structures in fig. 11a. and these are shown in Table 1. In Table I the population of 
glycans identified in this MS analysis has been compared with the set of glycans released from 
polyclonal IgG (Cohn Fraction II) and resolved by HPLC (Jefferis et al 1990). This contained 15 
asialo glycans of different molecular weights. The composition of the glycans released from 
normal serum IgG and analysed by P4 GPC (Parekh D.Phil. Thesis 1987) is also shown for 
comparison. In this case 11 asialo glycans of different molecular weights were identified. The 
three sets of data, which relate to different samples of polyclonal IgG analysed by different 
analytical techniques, are in good agreement. The increased resolution obtained by HPLC 
reveals three of the four members a set of structures not previously reported in which the a 1 , 6  
arm of the biantennary glycan terminates with mannose. These structures were identified by 
MALDI MS and also the fourth (H3N3) which is the unfucosylated form of H3N3F reported by 
Jefferis. Although these data are consistent with those obtained by Jefferis et al it is possible 
that some of the minor components (those present at <2 %) of the mixture of glycans analysed 
in this chapter may be derived from contaminants in the IgG preparation or introduced from the 
environment. The purity of the IgG was assessed by SDS PAGE (Fig.9), and by Western blot 
analysis. There was no detectable p- or a- chain to suggest the presence of IgA or IgM 
contamination nor of the components of the Cl complex. Such contaminants, if present, would 
constitute < 1 % of the total protein. In the MS profile there are unidentified peaks with 
molecular weights which cannot be assigned to oligosaccharides, suggesting that there is some 
contamination of the sample. It is also possible that the structures A3, B3, C3 and D3, which 
contain a bisecting GlcNAc residue but not a core fucose residue, are derived from a
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hydrazinolysis artefact in which the reducing terminal is cleaved (Mr. Tom Naven -personal 
communication). In this analysis by MALDI MS the percentage of each structure was derived 
from measurements of peak height. This correlation should be treated with some caution. 
Although it is in general reliable, and these results are consistent with the findings of others, it 
should be noted that it has not been demonstrated that the efficiency of ionisation is identical 
for every oligosaccharide.
Pk M .W t Exp.M.W t. % % Jefferis % Parekh Formula Glycosylation
A1 1663.6 1662.6 5.5 4.7 8 . 2 H5N4 G2 - F-B
A2 1809.7 1808.6 32.5 24.6 22.3 H5N4F G2+F
A3 1886.7 1865.6 1.5 2.3 1 . 1 H5N5 G2+B
A4 2012.7 2 0 1 1 . 8 2 . 2 6 . 2 6.3 H5N5F G2 + B+F
B1 1501.5 1500.7 3.6 4.8 9.1 H4N4 G1- F-B
B2 1647.6 1646.7 20.9 24.8 24.5 H4N4F G1+F
B3 1704.6 1703.7 3.5 1 . 8 - H4N5 G1+B
B4 1850.7 1849.7 7.2 6.7 1 . 6 H4N5F G1 + B+F
Cl 1339.5 1338.9 0.9 2 . 6 2 . 8 H3N4 GO - F-B
0 2 1485.5 1484.9 8 . 8 13.9 18.7 H3N4F GO +F
03 1542.7 1525.7 2 . 2 1.3 1 . 0 H3N5 GO+B
04 1688.6 1687.9 4.4 3.2 1 . 2 H3N5F GO + B+F
D1 1136.4 1136.8 1 . 1 ND ND H3N3 GN1*
0 2 1282.5 1281.8 2 . 2 1.3 ND H3N3F GN1+F
03 1298.5 1297.8 0.9 0 . 6 ND H4N3 G1-GN
D4 1444.5 1443.8 2 . 6 1 . 2 ND H4N3F G1-GN+F
* Not previously reported ND - not detected
Table 1a: MALDI MS analysis of sugars released by hydrazine from normal IgG
The structural formulae correspond to the molecular weights and are without arm specificity. 
The glycans have been classified according to the extent of outer arm galactosylation. On this 
basis there are three types of asialo biantennary sugars: those which contain a galactose 
residue on each arm (G2), those which contain one, either on the a1,3 or a1,6 arm (G1(a1,3) 
and G1(a1,6)) and those which contain no galactose (GO) (Fig. 5). The percentage of each 
glycan structure was derived from measurements of the peak heights. The percentages 
obtained by Jefferis et al (1990) for the analysis of polyclonal human IgG sugars are given for 
comparison. The percentages of G2:G1:G0 were 41.7%:38.7%:19.6% compared with
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Glycan Exp. M.Wt BTgalact JB hexes CL fucosid
A1 1662.6 1338.8 933.5 933.2
A2 1808.6 1484.9 1079 933.2
A3 1865.6
A4 2 0 1 1 . 8 1688.8 933.5 933.2
B1 1500.7 1338.8 1079 933.2
B2 1646.7 1484.9 1079 933.2
B3 1703.7
B4 1849.7 1688.8 1079 933.2
Cl 1338.9 1338.8 933.5 933.2
C2 1484.9 1484.9 1079 933.2
C3 1541.8
C4 1687.9 1688.8 1079 933.2
D1 1136.8 1136.8 933.5 933.2
D2 1281.8 1281.8 1079 933.2
D3 1297.8 1135.7 933.5 933.2
D4 1443.8 1281.7 1079 933.2
Table 1b : Peaks Identified on Figure 12 (a-d)
The species A3, B3 and C3 were not detected after the digestion with p-gaiactosidase, and the 
D series were present in vanishingly small amounts. This may be due to sample loss and to the 
increased proportion of the other peaks by comparison.
41%:39%:20% obtained using the GO mix and cation exchange chromatography (Fig.15a) 
(Jefferis: 37.Q%:39.9%:22.3%). 80.6% of IgG sugars are fucosylated and 24.5% are bisected 
(Table 1a). (Jefferis: 81.9% fucosylated, 21.5% bisected.) It was noted that two other series 
appear in this profile, but in very low abundance. These are a series of oligomannose structures 
and a series of compounds with molecular weights compatible with a series of hybrid glycans. 
Such species have been detected previously in IgG (Harada et al 1987).
The experimental molecular weights shown are those determined in Figure 11 a and correspond 
to the structural formulae shown in table 1a. The theoretical molecular weights are the 
monoisotopic molecular weights calculated as discussed in the chapter 8  section 2.1). This 
discrepancy indicates that, in this instance, the instrument has not been accurately calibrated. 
Different oligosaccharides have characteristic molecular weights; however those which differ 
only in arm specificity cannot be distinguished by this technique, neither is any linkage 
information directly available in the spectrum. The structures predicted from the analysis of the 
glycan pool were confirmed by simultaneous exoglycosidase sequencing. This novel approach 
to sequencing was developed to avoid the problems associated with separating the pool of 
released IgG glycans into individual pure sugars. It was made possible by the recent 
developments in this laboratory in the application of mass spectrometry to the analysis of 
oligosaccharides.
(iv) Simultaneous exoglycosidase sequencing of the pool of asialo normal IgG sugars analysed 
by MALDI MS in conjunction with Dr. D. Harvey
The total pool of unlabelled asialo glycans was successively digested with Bovine testes p- 
galactosidase. Jack bean p-hexoseaminidase and Choronia lampas a-fucosidase. The scheme 
is shown in Fig. 13 and the data in Fig. 14 and table 1b. The glycans in the pool have been 
simultaneously exposed to each enzyme in turn. Analysis of the profiles allows the effect of a 
single enzyme on each of the major glycan populations to be assessed after each digestion.
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A: Bovine testes p-galactosidase B: Jack bean p-galactesidase 
C: Choronia lampas a-fucosidase
Figure 13: Schematic diagram showing the cleavage positions of the enzymes used to 
sequence simultaneously the IgG asialo glycans
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Human IgG oligosaccharides incubated with exoglycosidases
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Figure 14. MALDI mass spectra of the products of successive 
exoglycosidase digests of the A/-linked oligosaccharides released 
from human IgG by hydrazinolysis. The matrix in each case was 
2 ,5 -DHB. (a) Total oligosaccharide fraction; (b) incubation w ith 
bovine testis /?-galactosidase; (c) incubation w ith  jack beam (S- 
hexoseaminidase; (d) incubation w ith Charonia lampas fucosi- 
dase.
Digestion A: Incubation with Bovine testes p-gaiactosidase removed ail terminal galactose 
residues with a loss in molecular mass of 162D for each hexose residue digested. Digestion B: 
Incubation of the products from A with Jack bean p-hexoseaminidase removed terminal N- 
acetylglucosamine residues. Digestion C: Incubation of the products from B with Choronia 
lampas a-fucosidase removed the core fucose residues. After each digestion the products were 
desalted and analysed by MALDI MS (Fig. 14a-d).
The pool of IgG glycans was first analysed by MALDI MS (Fig. 14a) and then successively 
digested with Bovine testes (3-galactosidase (Fig. 14b), Jack bean (3-hexoseaminidase (fig. 14c) 
and Choronia lampas a-fucosidase (Fig. 14d). After each digestion the samples were desalted 
on mixed bed resins and analysed by MS, the analytical details are in table 1b. A comparison 
of figures 14a and 14b shows that the peak at 1808.6 mass units has been reduced to 1489.4 
mass units by Bovine testes (3-galactosidase which has removed two galactose residues. 
Simultaneously the peak at 1646.7 has been digested to 1484.9 mass units by the removal of 
one galactose residue. The minor peak at 1849 containing a bisecting N-acetylglucosamine 
residue has been digested to a mass of 1688.8 mass units by the loss of the single outer arm 
galactose. Other minor structures have all been reduced in size by amounts equivalent to the 
number of terminal galactose residues they contain. In the next digestion with Jack bean (3- 
hexoseaminidase (14c) all structures have been reduced by the number of terminal GlcNAc 
residues they contain; for example, the peak at 1484.9 in figure 14b is now detected at 1079 
mass units having lost two GlcNAc residues. In the final digestion (fig. 14d) core fucose was 
removed from the predominant structure in 14c. It can be seen that, as the digestions proceed, 
the multiple oligosaccharides present in the original pool are gradually reduced to a single 
common structure, the trimannosyl core. These enzyme digestions confirm the assignments in 
figure 14a which were based on molecular weight.
4.2.6 Analysis of the GO, 01 and G2 glycoform populations of normal and RA serum IgG.
The percentages of G2: G1: GO derived from the MS data were 41.7 : 38.7% : 19.6% 
respectively. The uncertainty about the validity of correlating peak height with the quantity of 
glycan in the sample indicated that these parameters should also be determined by converting 
the glycan pool to 3 populations distinguished only by their outer arm galactosylation. An 
enzyme mix and incubation conditions were optimised in conjunction with OGS for this 
purpose. The pool of IgG glycans released by hydrazine, radiolabelled and desialylated with 
Arthrobacter ureafaciens neuraminidase was incubated for 16 hours at 37°C with a standard GO 
mix containing Jack Bean (3-hexoseaminidase and Bovine epididymus a-fucosidase. D- 
galactonic acid y-lactone was added to inhibit the activity of (3 -galactosidase which may be 
present as an impurity in the Jack Bean (3-hexoseaminidase. (Ch. 8  section 1.4h). The enzymes 
remove outer arm and bisecting GlcNAc residues and core fucose thus reducing all the 
glycoforms of IgG to three populations which differ only in the extent of terminal 
galactosylation. After desalting the digest was analysed by cation exchange chromatography
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(Fig. 15 a) and the quantities of G2, G1 and GO obtained by integration of the appropriate 
peaks.
Normal IgG contained the following percentages of differently galactosylated sugars, G2: 41%, 
G1: 39%, GO: 20%. These are in good agreement with those obtained by MS: G2:41.7%, G1: 
38.7% and GO: 19.6%. RA IgG glycans were also analysed using the GO mix (Fig. 15b); the 
corresponding values were: G2: 28%, G1: 36% and GO: 36%.
GO: 36%, G1: 36%, G2: 28%(b)(a) GO: 20%, G1 : 39%, G2: 41%
Figure 15 a,b: Cation exchange chromatography of asialo IgG glycans digested with a 
mixture of fucosidase and hexosaminidase (GO mix). The profiles were obtained by hand 
counting the tritium labelled fractions from the column. The peaks were assigned by comparison 
with pure samples of G2, G1 and GO glycans. The percentages of GO, G1 and G2 were 
obtained by integration of the corresponding peaks.
The oligosaccharide analysis of a subset of IgG molecules
The total serum IgG from RA patients has been shown to contain increased levels of IgGO 
compared with normal controls. Another characteristic feature of RA is the presence in serum 
and synovial fluid of IgG rheumatoid factors (IgGRFs). IgGRFs are a subset of IgG molecules 
which bind IgA, IgM and also IgG and are expressed by particular clones of B-cells. The 
glycosylation of IgGRF has not been determined and it is not known whether, in addition to 
possessing common protein features in the variable region, IgGRFs also constitute a specific 
subset of IgG glycoforms. In the following section therefore, self associating IgGRFs were 
prepared from RA serum and the glycosylation was examined.
4.3 The preparation and glycosylation analysis of IgG RF
4.3.1 Preparation of a standard IgG oligomer preparation
This was prepared by chemically cross-linking IgG with DTSP to calibrate the sucrose density 
gradients which were used to separate IgGRF from IgA and IgM. In addition, the SDG 
fractionation was optimised using IgA, IgM and this mixture of IgG oligomers (Fig. 16,17).
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Preparation of RF IgG
RA serum
t
Pass through monomeric human IgG sepharose column
t
Wash column; elute RFs with sodum acetate pH3.5
t
Concentrate; apply to SDG pH3.5
t
Re-assoclate RF’s at pH7 (glyclne/HCI) ----- ► MBP/dot blot
t
Apply to SDG pH7
t
Analyse RF and RF complexes by SDS PAGE and RIA
Flow Chart 2
Monomers
I
<
Minutes
Monomers
Fraction
Figure 16: The fractionation of the chemically cross-linked oligomer preparation used to 
optimise and calibrate the SDG.
a. HPLC separation (TSK 3000) b. sucrose density gradient fractionation
4.3.2 Preparation of self associating IgG RFs (Flow Chart 2)
IgG RF in serum is complexed with IgG, IgA and IgM. IgGRFs either monomeric or self­
associated or bound to other immunoglobulins were isolated by passing RA serum through a 
monomeric IgG sepharose affinity column. The unbound fractions were retained and from this 
the residual IgG was isolated (RF depleted IgG). IgGRF complexes were eluted from the 
column at pH 3.5; at low pH IgGRF monomers (7S) dissociated from IgG, IgA and IgM and 
were resolved by SDG (Fig. 17b,c). Sedimentation coefficients of the peaks were assigned by 
comparison both with the oligomer standards (Fig. 16) and with IgG and IgM fractionated under 
the same gradient conditions (Fig. 17a). IgG rheumatoid factor activity was confirmed by ELISA 
and the positive 7S IgGRF fractions were pooled. The 7S pool was adjusted to pH 7 and the 
sample again fractionated by SDG. This indicated that the RF monomers had self-associated to 
a mixture of monomers to tetramers (Fig. 17d,e).
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Figure 17: Fractionation of RFs by sucrose density gradient
(a) Standard markers: IgG (7s) and IgM (19s)
(b) RF preparation resolved at pH3.5
(c) Magnification of 1c to show resolution of <19s material. The 73 fraction contained IgGRF 
used in the experiments below
(d) pH7 SDG of re-associated aggregates
(e) Radioimmune assay of the fractions in l i d  showing that the RFs have re-associated
4.3.3 Glycan analysis indicates that IgGRFs may both be glycosylated in the Fab region and 
contain increased levels of agalactosyl sugars
SDS PAGE of this preparation and others (Fig.9a) indicated that IgG RFs contained two heavy 
chains (Fig. 18) suggesting that up to 50% of IgG RFs are glycosylated in the Fab as well as 
the Fc, and that the proportion of extraglycosylated heavy chains increased with the size of the 
aggregates. This finding was confirmed and quantified by determining the number of sugar 
chains associated with Fab from RFs which was approximately 4 times as many as for normal 
IgG (Dr. S-C. Chang). Furthermore, glycan analysis of IgGRF showed that more than 85% of 
the sugars were of the GO type (Dr. S-C. Chang). Together these data suggest that IgG RF 
consists of a specific set of IgG glycoforms which carry Fab glycosylation and have increased 
levels of agalactosyl sugars.
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Figure 18: Analysis of RF aggregates
SDS PAGE of fractions from 11 d showing that the proportion of extraglycosylated heavy chain 
increases with the size of the RF aggregates.
These data indicate that total IgG and IgGRFs from RA serum contain increased levels of 
IgGO, and that RFs have an increased proportion of Fab glycosylation. A model has been 
proposed to explain the formation of IgGRF complexes (Parekh et al 1985) which involves the 
recognition of galactosylated Fab sugars on one IgG molecule by a 'lectin-like' site available on 
the Fc of a second IgG molecule of the IgGO type (See 1 2 and Fig.6 b). The data In this section 
are consistent with this model, and moreover further studies (Scragg et al unpublished data) 
have shown that the increased level of IgGO in RA IgG is mainly confined to the Fc region, and 
that the Fab region has a normal distribution of G2, G1 and GO type sugars. This suggests that 
in RFIgG Fab sugars may have a role in recognition.
In the section which follows the possibility that the GO oligosaccharides attached to IgGFc may 
be accessible for binding was probed with lectins, in the first instance as a means of isolating 
significant quantities of IgGO glycoforms. Intact IgG and reduced and alkylated heavy chains 
from an RA patient were passed through an affinity column of bovine conglutinin coupled to 
CNBr sepharose. 70% of H-chains (48%G0) and 91% of the intact IgG (48%G0) was recovered 
in the flow through None of the bound material could be recovered from the column by either
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200mM GlcNAc, 10mM sodium barbital pH 7.4 or 0.1 M sodium acetate. Conglutinin (which 
exists in bovines but not humans) binds terminal GlcNAc, mannose and fucose and has been 
shown to bind denatured IgG (Theil, S. personal communication), however data from these 
experiments suggested that although isolated heavy chains with GO sugars may bind the lectin 
to some extent, the sugars on native IgG (48% IgGO) were not available for recognition under 
these conditions. However, the affinity of one CRD on conglutin for one ligand is very low 
(mmolar) and high affinity binding requires multiply presented sugars. In these experiments the 
IgG monomers in the fluid phase were not multiply presented which suggested that under these 
conditions the affinity of the IgG for bovine conglutinin may have been too low to allow 
significant binding.
4.4 Terminal GlcNAc residues on IgGRF and IgGO may be exposed and available for 
binding
Another candidate for binding to exposed GlcNAc residues on IgG is a member of the collectin 
family, the serum mannose binding protein (MBP) which occurs in human serum. MBP is a 
Ca2+ dependent lectin with multiple CRDs each of which has a weak affinity for single terminal 
GlcNAc, mannose and glucose residues but which binds these sugars with high affinity if they 
are clustered together. In the next section human MBP was tested for binding to multiply 
presented IgGRFs containing >85% IgGO. Normal IgG, IgG RF and IgG prepared from serum 
depleted of IgGRF were immobilised to a blotting membrane to provide multiple presentation 
and tested for binding MBP. The physiological significance of this recognition event has not 
been investigated, however it may be noted that self associated IgGRF complexes are present 
in the synovial joints of RA patients, either as soluble aggregates or as deposits on the 
synovium (Leader et al - personal communication), and that MBP is present in RA synovial 
fluid (Malhotra et al 1995).
4.4.1 Preliminary experiments to investigate the affinity of normal IgG (GO 20%), IgG RF and 
IgG prepared from serum depleted of IgGRF (G0:45%) for serum f\4BP
5pl fractions of serial dilutions of normal IgG which contained from 10 to 0.001 |ig/5pl and of 
IgGRF and IgG from RF depleted serum containing from 3 to 0.001 pg/pl were multiply 
presented by spotting onto a nitrocellulose blotting membrane. The membrane was exposed to 
serum MBP and the bound lectin detected with an polyclonal aMBP antibody. Normal IgG 
bound significantly at lOpg, and weakly at Spg. IgGRF bound significantly at 3pg and at 1)ig 
and very weakly at 0.3pg. IgG from serum depleted of IgGRF bound weakly at 3|ig (Fig. 19). 
This suggests that IgGRF which contains self associating IgG and is therefore already multiply 
presented, binds MBP more efficiently than normal IgG which has been multiply presented only 
by concentration on the blotting membrane.
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On page 172 line 3 should read:
'IgG glycoforms containing 100% IgGO sugars were prepared by enzymatic 
modification of the natural....'
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Figure 19: Dot blot showing that RFIgG binds MBP at a 10-fold lower concentration than 
normal or RF depleted IgG. Top row contains a serial dilution of normal IgG; middle row 
contains IgGRF; bottom row contains the IgG remaining after the IgGRF had been removed. RF 
typically contains > 85% of GO type glycans (S-C. Chang).
As a result of these preliminary studies a more rigorous examination of the role of the sugars 
on IgGO glycoforms in binding MBP was carried out in conjunction with Dr. R. Malhotra. A set of 
IgG glycoforms containing 100% GO sugars by enzymatic modification of the natural 
population. 100% pure GO glycoforms of Fab and Fc were also prepared to localise the binding 
site on IgG. The affinity of these specific sets of glycoforms containing only sugars terminating 
in GlcNAc was compared with the corresponding natural populations.
4.5 The preparation of IgG Fab and Fc by papain cleavage of IgG
There are three possible cleavage sites for papain in human IgG (Fig. ab) one of which (224/5) 
is preferentially cleaved. The reaction conditions were optimised to reduce the cleavage at the 
more resistant sites to a minimum (none detected).
4.5.1 Papain cleavage of IgG
The optimised cleavage reaction, which separates IgG into Fab (M.Wt. 45-50kD) and Fc (M.Wt. 
54kD), did not reach completion. This was found to be generally the case regardless of the 
cleavage conditions, and during the optimisation procedures the extent of cleavage was noted 
to be sample dependent (Fig 20).
17?
RA serum
Fab
uncleaved IgQ
uncleaved 1gG
Normal serum 
(individual )
Fab
Fab
Pooled normal 
human serum uncleaved IgG
10 15
Minutes
20
Figure 20: Products of papain cleavage of IgG from (a) an RA patient (b) a single normal 
individual and (c) a pool of normal serum resolved by HPLC GPC (Tandem columns Zorbax 
GF 250 + 450; 2x9.4x250mm) showing the different susceptibilities of the three samples. In the 
normal IgG sample 18% of the total IgG population remains intact. In this particular RA IgG 
sample (GO 55%) 7.6% of the total IgG remained uncleaved.
Papain cleavage rates are known to be subclass dependent, however it is not known whether 
there are variations in susceptibility between different glycoforms of IgG within the same 
subclass. In particular it is not known whether low levels of galactosylated sugars (high GO) in 
the Fc make the hinge region more susceptible to papain. Therefore prior to the preparation of 
Fab and Fc, the following study examined the relationship between the percentage of IgGO 
sugars in 18 IgG samples and the percentage of uncleaved IgG.
4.5.2 IgG resistance to papain cleavage does not correlate with GO levels 
16 serum IgG samples were prepared from normal controls and patients with juvenile arthritis. 
The IgG samples, which contained a range of GO values, were subjected to papain cleavage 
under identical conditions. The digestion products were resolved by HPLC GPC, and the 
percentage of uncleaved IgG plotted against the percentage of IgGO. (Fig. 21). These data 
suggest that there is no direct correlation between the two parameters.
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Figure 21: The % uncleaved IgG remaining after papain cleavage does not correlate with 
the GO status of IgG. The IgG samples were prepared from serum obtained from 14 patients 
with Juvenile RA and 4 normal controls. There was no significant correlation between the 
percentage of GO sugars and the percentage of uncleaved IgG.
4.5.3 Preparation and analysis of Fab and Fc from normal serum IgG (Flow chart 1)
Fab and Fc were prepared by papain cleavage of normal human serum IgG (35mg). Uncleaved 
IgG and Fc were separated from Fab by Protein G affinity chromatography. IgG and Fc were 
separated by gel permeation HPLC when any peptides resulting from the minor products of 
papain cleavage would also have been removed. The HPLC analysis of IgG is shown in figure 
22a. There is some aggregated material in the sample which probably results from storage at - 
20°C (IgG is noted for the ability to form cryogenic precipitates). 25% of the IgG remained 
uncleaved. The HPLC analysis of the unbound fraction Fab (final yield 6 mg; 34%) is shown in 
figure 22b. The non-selective losses mainly occurred as a result of conservative pooling to 
maintain purity and during concentration steps. The analysis of the bound fraction (uncleaved 
IgG+Fc) is shown in figure 22c. Fc (final yield 1.5mg; 18%) was separated from uncleaved IgG 
by HPLC GPC. The analysis of the purified Fc fragment is shown in figure 22d. Peaks were 
assigned with reference to known standards.
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Figure 22: HPLC GPC (Zorbax GF250) analysis of (a) normal human serum IgG (b) 
purified Fab (c) uncleaved IgG and Fc eluted from a protein G affinity column (d) 
purified Fc. The variable region of the Fab has a range of molecular weights due both to 
variations in the polypeptide and the possibility that the region may be glycosylated. This 
results in a broad eiution band both for Fab and for intact IgG. In contrast, the Fc region is 
highly conserved and the elution profile correspondingly narrow.
4.5.4 Charge analysis of normal IgG, Fab and Fc sugars
The glycans were released from 200mg of normal IgG, Fab and Fc by hydrazine. The pool of 
glycans was labelled with 2AB and analysed by WAX (Fig. 23a-c) according to the procedures 
used earlier in this chapter. Comparable fluorescence for the Fab, Fc and IgG glycans was 
achieved by injecting a fraction of the Fab sugars corresponding to 5x as much protein as was 
required for IgG and Fc. This is consistent with the fact that only 20% of IgG molecules are 
glycosylated in the Fab region. Peaks were assigned by comparison with standard fetuin sugars 
resolved under the same conditions (Fig. 23d). The relative proportions of neutral:A1:A2 
glycans is shown in table 2. Fab contains a higher proportion of charged glycans, in addition 
most of the disiaylated glycans are associated with Fab.
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a Normal IgG
b Normal Fab
c Normal Fc
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Figure 23: a-d sugars released from normal IgG (a), Fab (b), Fc (c) and fetuin (d) were 
resolved by WAX chromatography. After treatment with Arthrobacter ureafaciens slalidase all 
structures became neutral indicating that all charge is due to sialic acid.
neutral %A1 %A2
Normal IgG 65.3% 28.3% 6.4%
Fab 40% 30% 30%
Fc 6 8 % 27.4% 4.6%
Table 2: The percentages of neutral, mono (A1) and di-sialylated (A2) glycans attached 
to normal IgG, Fab and Fc.
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Preparation of 100% GO IgG Fab and Fc glycoforms
Normal IgG, Fab, Fc
I
De-sialylate, de-gaiactosylate 
(A. ureafaciens slalidase. Streptococcus 6646K p-galactosldase)
Incubate at 56=0 for 10 minutes
I
(I) Analyse by weak anion exchange chromatography 
(check de-sialylatlon)
I
(ii) Analyse by cation exchange chromatography 
(check de-galactosylatlon)
I
(ill) Analyse by cation exchange chromatography post incubation 
with hexoseaminidase and fucosidase
(confirm 100% de-galactosylated IgG, Fab, Fc)
Flow Chart 3
4.6 Preparation and analysis of IgGO, FabGO and FcGO glycoforms (Flow Chart 3)
4.6.1 Preparation of IgGO, FabGO and FcGO
Normal serum IgG (lgG0:20%) (400fj.g) and purified Fab (SOOfig) and Fc (200p.g) were de- 
sialylated and de-galactosylated by incubating the proteins with Arthrobacter ureafaciens 
neuraminidase and Streptococcus 6646k. Concentrations were kept low (0.5mg/ml) to avoid 
aggregation of the GO glycoforms which was noted in other studies. Oligosaccharides were 
analysed for GO by cation exchange chromatography (Fig. 24) following hydrazine release, 
labelling and enzymatic removal of terminal GlcNAc and fucose. In each case the 
oligosaccharides associated with the molecules were 100% GO type. A number of controls were 
carried out to confirm the activity of the enzymes:
(i) Prior to the digestions the activity of Streptococcal 6646K (3-galactosidase was tested with 
free asialo G2 sugars. 100% were reduced to GO.
(ii) Sialidase activity was checked by analysing the sugars released from IgG, Fab and Fc 
treated with Arthrobacter ureafaciens sialidase and Streptococcal 6646K p-galactosidase by 
WAX chromatography. 100% of the structures were neutral.
(iii) The sugars released from IgG, Fab and Fc treated with Arthrobacter ureafaciens sialidase 
and Streptococcal 6646K p-galactosidase were analysed by cation exchange chromatography 
(Fig. 24) and MALDI MS to confirm galactosidase digestion was complete.
(iv) 100% de-galactosylation was confirmed by treating the released glycans with the GO 
standard mix to remove core fucose and bisecting GlcNAc residues. All populations eluted as a 
single peak on the cation exchange column.
4.6.2 Analysis of 2AB labelled GO glycoforms of (a) IgG (b) Fab (c) Fc by cation exchange 
chromatography
Figure 24 shows the analysis of the sugars released from IgG, Fab and Fc after treatment with 
Arthrobacter ureafaciens sialidase and Streptococcal 6646K p-galactosidase. 90% of IgG and 
Fc sugars elute as a single peak at the elution position of standard GO. Over 90% of the Fab 
sugars, which contained two major and two minor populations in figure 13c, eluted as a single 
peak (d) after treatment with the standard GO mix (ch. 8  section 1.4h) confirming that the sugars 
were all of the GO type. 80.6% of IgG sugars are fucosylated and 24.5% are bisected (Table 
1b). 70% of Fab structures are bisected, (Parekh) and Fab contains relatively few fucosylated 
structures. This suggests that the major peaks in 13c may represent the GO biantennary 
complex glycan +/- bisecting GlcNAc-fucose (+B-F; -B-F). The major peak in IgG and Fc is the 
core fucosylated GO biantennary complex glycan (-B+F). Of the total IgG oligosaccharides, on 
average Fab sugars account for only 20% of the total glycans, the remaining 80% are derived 
from the Fc. The relative proportion of Fab:Fc sugars were estimated from these data and were 
consistent with this finding. The sugars from each were released from equal amounts of 
protein. As in 5.3.4 it was necessary to inject sugars from 5x as much Fab protein as for Fc and 
IgG (125fil : 25^1 : 25|il) to obtain the same amount of absorbance, indicating that
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approximately 20% of the Fab chains in this sample were glycosylated. Subsequently the 
natural mixture of IgG, Fc and Fab glycoforms and the pure set of IgG, Fc and FabGO 
glycoforms together with RA IgG were tested for their affinity for MBP and to activate 
complement. The analysis examined the possiblity that the N-acetyl glucosamine residues 
which terminate all the oligosaccharides present in the set of IgGO glycoforms may have a role 
in recognition.
b Fob
L_.
100500
Minutes
4500 , 
4000 I 
3500 j  
3000 I 
2500 t
2000 I
1500
1000
500
Figure 24: Cation exchange chromatography of 2AB labelled sugars released from (a) 
IgGO (b) Fc GO (c) Fab GO and (d) tritium labelled Fab sugars post GO mix. The
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assignment of the peaks is discussed above; by comparison with known standards and the 
profile in figure 15a and the MS analysis of the IgG glycans in figure 12 all are assigned to the 
GO type. In (a) and (c) peak A is the complex biantennary glycan with a core structure (-B+F). In
(b) the earlier peak, B, contains the complex biantennary glycan with a core structure (-B-F) and 
the later peak, C, contains the complex biantennary glycan with a core structure (+B-F). (d) 
confirms that after incubation of (b) with the GO mix (containing fucosidase and 
hexosaminidase) the two glycans are reduced to a single structure eluting at the position of GO.
4.7 The interaction of MBP with IgG, IgGO and their fragments and IgG induced 
activation of the complement system
To investigate systematically the possibility that MBP might bind IgGO and thus activate the 
complement pathway, and to localise the binding site for MBP on IgG, the following compounds 
were tested both in MBP affinity and in C4b deposition assays: (i) Normal IgG (20% GO) (ii) RA 
IgG (36%G0) (iii) natural glycoforms of normal Fab and Fc (iv) the 100% GO subsets of 
glycoforms, IgGO, FabGO and FcGO. The assays were performed with IgG bound to microtitre 
plates and therefore examined the binding of multiply presented molecules. The man nose 
binding assay determined the relative amounts of MBP bound to microtitre plate coated with 
each of the arrays of glycoforms of IgG, Fab in (i-iv) above using a monoclonal antibody to 
MBP. In the C4b deposition assays microtitre plates were coated with IgG, IgGO or their 
fragments (i-iv) and vacant sites blocked with BSA. Mannose binding protein was incubated in 
the wells and the plates were then washed. MBP/Clq depleted serum was then incubated in the 
coated wells. The assay tested whether MBP bound to exposed N-acetyl glucosamine residues 
on IgG, Fab or Fc on the plates could activate the complement pathway (Fig. 27) by assaying 
for C4b deposits. Like Clq, MBP can activate the pro enzymes C ir and Cl s. It can also act 
via the mannose binding protein associated serum protease, MASP, which appears to 
substitute for C ir and CIs (Matsushita and Fujita 1992). CIs cleaves C4 to form C4a and C4b. 
C4b undergoes a conformational re-arrangement which exposes a thioester group (-S-C(=0)-C) 
which is highly susceptible to nucleophilic attack. The electron deficient C in the thioester bond 
is highly reactive and readily forms a covalent bond with electron donating groups, in particular 
OH or NHg. If C4 b is generated in the assay, much of it (approximately 90%) will be hydrolysed 
by water, but some will bind to hydroxyl or amino groups which are in close proximity (<400A) 
in the protein bound to the microtitre plates. The deposited C4b was then detected with a 
monoclonal antibody.
The data were obtained by Dr. R. Malhotra. The main conclusions were:
(i) The calcium dependent binding of MBP to IgGO or IgG was inhibited in a concentration 
dependent manner by mannose.
(ii) In the presence of Ca^+ MBP binds IgGO (G0=100%) > IgG from an RA patient (G0=36%)> 
normal IgG (G0=20%).
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Figure 25: Molecular model of FcGO and a single carbohydrate recognition domain 
(CRD) from MBP The model Is based on information from the MBP crystal structure (Weiss et 
al 1992) and NMR studies of the binding of free monosaccharides to the CRD (lobst et al 1994). 
The Fc structure is based on the crystal structure of Deisenhofer (1981) and the CRD is based 
on the crystal structure (Weiss et al 1992). The a i, 6 non-reducing terminal GlcNAc residue has 
been docked to the CRD saccharide binding site. The principle interaction involves the chelation 
of the two cis 3-4- hydroxyl groups of the GlcNAc residue from the Fc to the ion of the 
CRD. The CRD can also interact with the 3-arm non-reducing terminal GlcNAc residue by an 
altemative displacement of the Fc oligosaccharide chain. The C lq  binding site on the right hand 
side of the Fc domain (Burton et al 1980, Duncan and Winter 1988) is also shown. 
(Malhotra et al 1995)
(iii) GO glycoforms of normal IgG and Fc, but not Fab, show a higher Ca '^  ^dependent affinity for 
MBP than the unmodified normal populations of IgG and Fc and Fab.
(iv) IgGO induces 5x more deposition of C4b than IgG
(v) Increase in C4b deposition occurs when Fc is converted to FcGO. There is no change in C4b 
deposition occurs when Fab is converted to FabGO
(vi) Mannose significantly decreased the deposition of C4b suggesting that binding of MBP is 
through the oligosaccharide.
4.8 Molecular modelling of FcGO and a single carbohydrate recognition domain (CRD) 
from MBP (In conjunction with Dr. Mark Wormald)
The model (Fig. 25) indicates that, in IgGO glycoforms, terminal GlcNAc residues in the Fc are 
exposed and available to interact with the MBP lectin. This suggests a molecular basis for the 
experimental data which is based on NMR studies of the solvent accessible surface (Malhotra 
et al 1995). These indicate that in the GO glycoform the glycans are released from the protein 
surface, and therefore in the model the GO oligosaccharide has been moved freely relative to 
the protein around the Asn297 C-C bonds.
5. Discussion
5.1 Novel sequencing strategies
The development of automated methods for releasing and profiling oligosaccharides has 
highlighted a number of other areas in which conventional sequencing technology could be 
improved. During the work described in this chapter alternative methods for labelling, profiling 
and sequencing were explored and used, in conjunction with conventional sequencing, to 
analyse the glycans associated with IgG.
5.1.1 Fluorescent labelling of the reducing terminus of the glycans coupled with on line 
detection reduces artefacts, improves data analysis and reveals more information. 
Conventionally tritium is used to label the released glycans at the reducing terminus. Reduction 
of released glycan pools with ^H^B is non-selective, and the monitoring systems allow 
nanomoles of sugar to be detected. However, peptide fragments co-purifying with the 
oligosaccharides may inadvertently be labelled, giving rise to artefacts and causing problems 
with interpretation, particularly in charge analysis. The use of the fluorescent compound 2- 
aminobenzamide, which also labels oligosaccharides non-selectively (Hase et al 1976), has 
decreased the number of artefacts and extended the limits of detection by about 10-fold. In this 
laboratory, fluorescent labelling has allowed on line detectors to be coupled to HPLC columns 
eliminating the need for hand counting fractions. A comparison of the data in figure 10a,b 
(radiolabelling and hand counting) with 1 0 c,d (fluorescent labelling and on line detection) shows 
that the on-line detection system, in which the fluorescent eluate is monitored 2 0  times a 
second, records the full peak heights which have been missed in the hand counted 15 sec 
radiolabelled fractions. The improved data analysis has important implications. In this case it
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revealed that the A1 glycans associated with RA IgG consist of a mixture of G1 sugars in which 
the single terminal galactose is sialylated and G2 sugars in which only one of the terminal 
galactose residues has been sialylated. In contrast, the profile for normal IgG glycans indicates 
that the normal IgG A1 glycan pool contains only monosialylated G1 structures.
5.1.2 MS analysis eliminates the need to label and separate glycans.
The need for labelling has been eliminated altogether by the use of MALDI MS (Fig.12) which 
gives molecular weights to approximately +/-0.3 of a mass unit. The released glycans were 
desialylated, passed through mixed bed ion exchange resins and analysed directly by MALDI 
MS. Although the glycans may still contain peptide fragments as a result of the hydrazinolysis 
procedures, the relatively large and anomalous molecular masses of such artefacts make it 
improbable that they will be confused with sugars. The use of MS in this thesis is discussed in 
chapter 8  section 2 .1 .
5.1.3 WAX chromatography replaces HVE for charge analysis of the released glycans.
In conventional sequencing charge analysis involved separation of the glycans by high voltage 
electrophoresis (HVE). In this thesis, this technique has been replaced entirely by WAX HPLC 
which is preparative, fast, highly reproducible and gives improved resolution.
5.1.4 Cation exchange (CAT) chromatography has been used to analyse asialo glycans.
Figure 15a,b shows the quality of the resolution which has been achieved by HPLC (Vydac 
400VHP575) CAT chromatography. The technique is preparative, fast and highly reproducible 
over long periods of time and from column to column. Currently peaks are assigned by 
comparison with known standards; in addition to hydrodynamic volume other properties of the 
glycans, such as branching, influence the elution time. Although this makes it more difficult to 
predict elution times and to relate them to a fundamental property, CAT HPLC provides a 
useful alternative strategy to P4 gel filtration, which can at times give poor resolution (see Fig. 
11a,b). The soft P4 gel is technically difficult to handle. For example, it needs to be fined to 
select the narrow size range of particles which will resolve glucose oligomers of up to 24 
glucose units. In addition, the columns need to be maintained at constant temperature (50°C) 
and pressure and resolution is lost if the gel collapses, and this can happen even in newly 
poured columns.
5.1.5 Simultaneous exoglycosidase digestion of mixtures of glycans using MALDI MS to 
analyse the digests.
This novel approach to sequencing was developed to address the difficulties encountered in 
conventional exoglycosidase sequencing strategies which require the preliminary separation of 
the glycan pool into pure components using P4 GPC. This may be technically difficult because 
the individual components often elute in overlapping peaks. This necessitates selective pooling 
of central peak fractions and re-chromatography, with the result that much of the sample is lost.
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Once purified, sequencing individual glycans requires multiple manipulations, even with the 
advantages of the RAAM technology described in ch. 8  section 1.8. In this chapter (figure 12) 
MALDI MS has been used to determine the molecular weights, and therefore the composition, 
of the components of the glycan pool in a single analysis and subsequently to follow the 
sequential exoglycosidase digestions of each oligosaccharide simultaneously. Although arm 
specificity cannot be determined from this strategy, linkage information is obtained from the 
use of specific exoglycosidase enzymes. A combination of conventional and novel sequencing 
strategies was used to analyse the glycans associated with IgG.
5.2 Site specific glycosylation of IgG, Fab and Fc and IgGRF
5.2.1 The normal human asialo IgG glycan population is composed of a mixture of 16 complex 
biantennary glycans
16 glycans were identified in the mass spectrometry profile of the unlabelled asialo glycans 
released from normal IgG (Fig. 12, Table 1). One of these, H3N3 is the unfucosylated form of a 
structure previously noted by Jefferis (H3N3F), and has been previously reported (Harada et al 
1987). Other studies of the glycosylation of human IgG include those carried out by Mizouchi et 
al 1982, in which truncated, hybrid and mannose structures were detected at very low levels. In 
the analysis in this chapter some of these structures are present at low levels (<2%). Although 
they have also been reported by Jefferis, the possibility that, in this preparation, they are 
derived from low level contamination of the IgG cannot be ruled out. Some details of the 
analysis of polyclonal human IgG analysed by Jefferis (1990) and Parekh (1988) using HPLC 
and P4 GPC respectively are given in Table 1. Table 3 compares the relative proportions of the 
different classes of sugars identified in this chapter and in the two earlier studies. These tables 
suggest that the percentages of IgGO, G1 and G2 glycoforms remain relatively constant from 
sample to sample. However, it is not valid to draw such conclusions from an analysis of three 
samples. In a study of 400 normal controls carried out in this laboratory (Parekh et al 1988a) 
the percentage of IgGO was shown to be an age related parameter. The percentage of IgGO in 
normal IgG is lowest in the mid twenties (typically 20%) and rises with age to around 35-40%. 
lgG2 varies in inverse proportion to IgGO while IgGI remains relatively constant.
G2 G1 GO Fucosylated Bisected
(i) MALDI MS 41.7% 38.7% 19.6% 80.6% 24.5%
(ii) GO mix/CAT 41 39 2 0
(iii) HPLC (Jefferis) 37.8 39.9 22.3 81.9% 21.5%
(iv) P4 GPC (Parekh) 37.9 37.2 23.7
Table 3: The classes of sugars on normal IgG determined by (I) MALDI MS (ii) cation 
exchange chromatography after digestion of fucose and GlcNAc using the GO mix', (iii) 
HPLC (Jefferis et al 1990) (iv) P4 GPC and exoglycosidase sequencing (Parekh 1986)
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5.2.2 Site specific giycosyiation of IgG may partly be determined by the local protein structure 
The local 3-dimensional structure of the protein may be a factor which controls the levels of 
galactosylation and sialylation of Fab and Fc glycans. 76% of the glycans released from normal 
IgG were neutral, 12% were monosialylated and 10% were disialylated (Fig. 10 a,b). 95% of the 
disiaylated glycans were in the Fab fragment (Fig 23 a-c). This site specific glycosylation 
suggests that the protein structure has a role in directing its own glycosylation by restricting 
access to sialyl transferases to the developing glycan chain in the Fc. The increase in Fab 
sialylation over Fc reflects the higher percentage of galactose in Fab sugars, and this also 
suggests that there is restricted access of enzymes to the Fc glycans during processing. In the 
ER IgG is assembled completely with two heavy and two light chains prior to transfer to the 
Golgi apparatus where complex processing occurs (Bole et al 1986). Thus when the 
glycoprotein is exposed to galactosyl and sialyl transferases the Fc sugars are already confined 
within the interstitial region between the two CH2 domains where they interact with the protein 
surface. The terminal residues are therefore protected from glycosyl transferases by the 3- 
dimensional structure of the CH2 domains and their flexibility is restricted by oligosaccharide- 
protein interactions. The limited space does not significantly reduce the affinity of the N- 
acetylglucosaminyl transferases I and II, although a small percentage (2-3%) of normal IgG 
molecules have been detected without substitution of GlcNAc residues on the 1,3 arm of the 
trimannosyl core. However as the chain elongates the interstitial space decreases and the 
number of protein oligosaccharide interactions increases and the glycosylating enzymes 
become increasingly inefficient. As a result a significant proportion of normal Fc sugars are not 
fully galactosylated and the majority lack sialic acid. To some extent the sialylation of the Fab 
sugars is also restricted by the local three-dimensional protein structure; free light chains in 
BenceJones protein are heavily sialylated (>85%) indicating that in IgG the three-dimensional 
structure of the Fab region may influence the activity of the sialyl transferase. Serum 
glycoproteins are generally heavily sialylated, and terminal sialic acid is generally understood to 
prevent recognition and clearance by the asialo glycoprotein receptor. This implies that the 
local protein structure also has a role in reducing the affinity of the sugars on IgG for this 
receptor.
Another feature of site specific glycosylation in IgG involves the distribution of the types of core 
structures. In Fc the complex biantennary glycan which predominates has a single core type (- 
B+F) which is fucosylated (F) but does not contain a bisecting GlcNAc (B). In Fab two major 
core structures were detected: the data suggested that these are -B-F (approximately 40%) and 
+B-F (approximately 60%). The means by which the cell and the protein structure control the 
site specific glycosylation of the glycan cores are not known, neither are the consequences.
5.2.3 B-cell transferases control the levels of IgGO in normal and RA IgG
In addition to the constraints imposed by the structure of the individual protein, the cell plays a 
major role in defining glycosylation by controlling the levels and types of glycosylating 
enzymes. B-cells are a mixture of clones which have different sets and ratios of glycosyl
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Figure 26: A model of IgG subclassi showing Fab glycosylation
In addition to the conserved glycosylation site at Asn297 in the CH2 region of the heavy chain 
some IgG molecules contain glycosylation sites in the variable region of the Fab. This gives 
rise to heavy chians containing more than one oligosaccharide. Extraglycosylated heavy chains 
are associated with IgGRF complexes (Fig. 18) and it has been proposed that such glycoforms 
may be involved in complex formation (Parekh et al 1984).
transferases. The difference in levels of IgGO glycoforms of IgG in normal (20%) and RA (36%) 
noted in this chapter (Fig.15a,b) and elsewhere are not reflected in comparisons of other 
normal and RA serum glycoproteins such as transferrin (Endo and Kobata - unpublished data). 
The increased levels of GO in RA IgG are therefore more likely to result from low levels of 
galactosyl transferase (Gal-T) activity than from de-galactosylation of IgG in the circulation. 
This has been demonstrated by Furukawa et al (1989); the low activity levels are due to the 
fact that there is a specific GalT enzyme for IgG and that the apparent km of GTase in RA IgG 
B-cells for UDPGal is three times the level in B cells from normal serum. It has been suggested 
that a reason for this low activity may be that RFs in RA B-cell homogenates may bind to 
acceptor asialoagalacto IgG and inhibit transferase activity. However microsomal proteins 
(containing no RF) extracted from RA B-cells were also unable to galactosylate IgG as 
efficiently as the enzyme from normal B-cells. This result suggests that the cells producing IgG 
with high GO are a specific subset of B-cells and that IgGRFs, discussed below, are also the 
product of B-cell specific clones.
5.2.4 IgG RFs contain increased levels of Fab sugars and GO compared with normal IgG 
IgGRF contains two species of heavy chain (Fig.18). Both bands were reduced to a single band 
of approximately 47kD following digestion with PNGase F (data not shown) indicating that the 
heavier of the two chains is extraglycosylated in the Fab region. The relative proportion of this 
band increased to 50% of the heavy chain population in larger RF complexes, suggesting that 
Fab glycosylation (Fig. 26) may be involved in the formation of self associated IgGRF 
complexes. IgGRF monomers and complexes are present in the serum and synovial fluid of RA 
patients and a study by Chang (1993) indicated that Fab isolated from RA serum IgG contained 
more than four times as many sugar chains as normal Fab. IgGRF also contains increased 
levels of GO sugars (>85%; Chang 1993). Together these data suggest that RF complexes are 
composed of a subpopulation of IgG molecules which are glycosylated in the Fab region and 
have a high percentage of GO sugars in the Fc. A proposed model for IgG RF aggregates 
(Roitt et al 1988) (Fig 6 b) involves the interaction of galactosylated Fab sugars from one IgG 
molecule with the CH2 domain of a second. This requires a site to be exposed on the CH2 
domain which is able to participate in intermolecular oligosaccharide-protein interactions; such 
a site may be available in agalactosyl IgG. While an increased level of IgGO in serum 
constitutes a risk factor for the development of RA (Tomana et al 1994) and is an indicator of 
disease severity (Parekh et al 1988b) the possibility of a role for IgGO and IgG RF in the 
pathogenesis of the disease continues to be explored.
5.3 IgGO sugars can be recognised by mannose binding protein (MBP)
A route for activation of the classical complement pathway (Fig. 27) has been identified which 
involves the Ca^+ dependent lectin, MBP. MBP contains multiple polypeptides which are 
organised into subunits containing triple helical stalks in the collagen - like region of the 
molecule and globular heads in the C-terminal domain (Reviews; Weiss and Drickamer 1994,
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Figure 27: IgGO was bound to a microtitre plate and MBP incubated in the wells. Serum 
depleted of MBP and C1q was then incubated in the coated wells and the extent of complement 
activation assessed by assaying for C4b deposits (Malhotra et al 1995). The mauve colour 
indictes those molecules involved in the activation of complement by IgGO binding MBP.
Hoppe and Reid 1994). Each subunit carries two carbohydrate recognition domains, and one 
molecule of serum MBP contains up to 18 identical CRDs. The affinity of one CRD for a single 
terminal monosaccharide is relatively weak (kd:1mM) and to activate complement MBP 
requires multiple ligands to bind to the clustered CRDs. The large distance between the binding 
sites (5.3nM) (Weiss and Drickamer 1994) makes it impossible for a single mammalian high 
mannose oligosaccharide to interact with more than one CRD within the trimer. In serum the 
multiple binding of oligomannose cell surface oligosaccharides on various bacteria and fungi by 
MBP leads to their neutralisation by complement - mediated cell lysis or opsonisation. MBP 
binds terminal N-acetyl glucosamine, mannose, glucose and fucose residues. In this chapter 
IgGO, FcGO and FabGO glycoforms, which contained only oligosaccharides terminating in 
GlcNAc, were prepared. These pure glycoforms were used in binding studies which showed 
that multiply presented IgGO and FcGO bound MBP and fixed C4 more efficiently than multiply 
presented normal IgG, Fab, Fc or FabGO. This suggested that the GO oligosaccharides on Fc 
were involved in the recognition event. Molecular modelling studies (Fig.25) indicated that 
terminal GlcNAc residues on either the a1,3 or a1,6 arms of the Fc oligosaccharides are 
exposed and available for binding the MBP. In normal human IgG 80% of galactose in G1 type 
sugars is associated with the a1,6 arm. It is not known whether this ratio is altered in RA IgG. 
Interestingly, FabGO, which also contains exposed GlcNAc residues, did not interact 
significantly with MBP. The affinity of a single CRD for a single sugar residue is weak (1 
mmolar), therefore to achieve high affinity binding multiple CRDs on MBP must interact with 
multiply presented ligands. In the in vitro studies IgG, IgGO and the corresponding Fab and Fc 
fragments were multiply presented on the surface of the microtitre plate. Only 20% of Fab 
sugars are glycosylated therefore the density of terminal GlcNAc residues presented by FabGO 
was significantly less than for FcGO and IgGO in which every molecule contains two (or more in 
the case of IgG) GO sugars. This suggests that, if these data are to be relevant in vivo, multiple 
presentation of the GO sugars attached to many IgG molecules may be necessary. This may 
occur in deposits of monomeric IgGO on cell surfaces such as the synovium or in aggregated 
IgGRFs. 4% of IgG in RA synovial fluid is in the form of soluble aggregates, and more are 
deposited on the synovium (Leader et al - personal communication). MBP is also present in RA 
synovial fluid (Malhotra et al 1995) and it is possible that the activation of complement through 
the MBP binding IgGO may provide an additional route of complement activation within the 
rheumatoid joint.
5.4 Pure glycoforms of IgGO may allow further functions of GO sugars to be probed 
Aglycosylated and degalactosylated IgG bind less efficiently to C lq and Fcy receptor than 
normal IgG while protein A binding is not altered (Leatherbarrow et al 1985, Tsuchiya et al 
1989). In murine lgG2b (and predicted in human IgG - Duncan et al 1988) the C lq binding 
motif involves Glu318, Lys320 and Lys322 (Duncan and Winter 1981), the Fcy receptor binding 
site has been localised to Leu235 (Duncan et al 1988) and protein A requires an intact 
CH2/CH3 interface. These data suggest that, while the sugars do not affect the CH2/CH3
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interface, they may maintain the integrity of the CH2 domains and the hinge in a way that 
allows C1q and Fcy receptor to bind efficiently to IgG (For review: Brekke et al 1995). In 
another study (Leatherbarrow D.Phil) aglycosylated IgG was more susceptible to papain 
cleavage than normal IgG, but agalactosyl IgG has not been studied. In this chapter there was 
no correlation between the percentage of IgGO (figure 21), G1 or G2 (data not shown) and the 
susceptibility of IgG to papain cleavage at Lys224/225. These data may suggest that this 
cleavage is not affected by the nature of the sugar at Asn 297. However, there are problems 
associated with interpreting these data. No information is available regarding the combinations 
of sugars which can be accommodated in the Fc, and there is no direct correlation between the 
percentage of GO structures and the number of molecules of IgG containing IgGO. For IgG to 
be cleaved both heavy chains must be susceptible to the enzyme, and the rate of cleavage of 
IgG containing two different Fc sugars will depend on the rate of cleavage of the less 
susceptible chain. The preparation of IgGO involved Streptococcal 6646K p-galactosidase 
(Kiyohara et al 1976) which, in contrast to other known galactosidases, cleaves galactose 
residues from the protected sugars in the IgG Fc. The technology is now available to prepare 
IgGO to examine the papain cleavage and other properties of IgG. For example, in passive 
transfer experiments (Rademacher et al 1994), primed mice injected with 70% IgGO from mice 
with collagen type II arthritis developed arthritis, thereby implicating IgGO in the pathogenesis 
of the disease.
Pure glycoform populations have now been prepared for two glycoproteins, IgG and RNase B 
by enzymatic modifications of the natural populations, and a way may now be open to explore 
further the role of these and other glycoforms in modifying the properties of the proteins to 
which they are attached.
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Abstract:
Glycoproteins generally consist of populations of glycosylated variants of a single polypeptide 
(glycoforms). The potential oligosaccharide pathways available to a protein are dictated by the 
cell in which it is expressed, and the final composition of the N-linked glycoform population 
results from the cell specific processing of a common precursor, Glc l^VlangGlcNACg, by the 
biosynthetic glycosylation machinery within the individual cell. The consequences of cell 
specific glycosylation for the functional activity of an enzyme, tissue plasminogen activator 
(tPA) was explored by comparing the fibrin dependent and independent activity of tPA 
expressed in Bowes melanoma (BM) cells and a Human Colon Fibroblast (HCF) cell line. At a 
single time point the rate of fibrin stimulated production of plasmin from plasminogen by tPA 
from the BM cells was 1.36 times faster than the rate for the HCF derived tPA. The rate of 
production of plasmin from plasminogen in the absence of fibrin, which was linear with respect 
to time, was 1.7 times faster for the BM derived enzyme. Subsequently, variations in glycoform 
patterns and the consequences of variable site occupancy for lysine binding and functional 
activity were explored in tPA expressed in 8  different cell lines and fractionated at the protein 
level by lysine sepharose affinity chromatography. In BM cells type I tPA (3 occupied sites), 
type II tPA (2 occupied sites) and a minor fraction (D*), with high affinity for lysine and 
increased fibrin dependent and independent activity, were recovered. The minor fraction was 
found to contain a dimer of type II tPA which was designated type D tPA, and a molecular 
model was constructed suggesting a possible structure for the dimer. In an indirect amidolytic 
assay involving native human Glu-plasminogen and fibrin, type II tPA showed a 2-fold higher 
activity than type I. To explore the combinatorial effect of the variable glycosylation status of 
both tPA and plasminogen, kinetic constants for fibrin dependent plasminogen activation were 
determined for combinations of type I, II and D tPA with type 1 and 2 plasminogen. Within a 
four-fold range the fastest rate was achieved by the combination of type D* (type II + D) tPA 
and type 2 plasminogen. N-glycosylation of plasminogen increased the Km value for activation 
by all tPA variants, N-glycosylation of type I tPA at Asn-184 decreased the kcat (turnover) 
values for the fibrin dependent activation of plasminogen over type II tPA, while type D* tPA 
showed the highest turnover rate. In the presence of fibrinogen fragments, N-glycosylation of 
plasminogen at site 289 modulates the kinetics of association of enzyme and substrate, while 
N-glycosylation at site 184 on tPA modulates the turn-over rate of the enzyme.
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Figure 1: Fibrinolysis is regulated by a number of proteins which maintain a network of 
inhibitory and stimulatory reactions
Variable site occupancy controls the turn over rate of tissue plasminogen activator in 
the fibrin stimulated activation of plasminogen
1. Background
1.1 Plasminogen activators
Plasminogen activators (PA) are found in many tissues and fluids of the human body. They are 
proteolytic enzymes, whose only known substrate is the zymogen plasminogen. Plasminogen is 
cleaved by plasminogen activators to produce plasmin, a non-specific protease which is 
capable of degrading directly or indirectly most extracellular proteins (Vassalli et al 1991). Most 
of these enzymes are serine proteases which are modulated by several inhibitors, and are 
generated only in response to specific stimuli. Plasminogen activators include urokinase (uPA) 
and tissue-type plasminogen activator (t-PA), both of which are secreted by vascular 
endothelial cells. Plasmin has a broad spectrum of substrates and catalyses protein 
degradation in many biochemical systems including ovulation, neural development, 
embryogenesis, wound healing, tumour growth and metastasis, inflammation, extracellular 
matrix re-modelling and fibrinolysis (Dano et al 1985, Opdenakker et al 1992). Fibrinolysis and 
blood clotting are two dynamic processes which, under normal conditions, are in balance and 
disorders in either may lead to life threatening thrombotic or haemorrhagic events. In particular, 
fibrinolysis is regulated by a number of proteins which maintain a network of inhibitory and 
stimulatory reactions (Fig.1). The three main functional characteristics of tPA, which is present 
at 0.1 nM in serum, are binding to specific PA inhibitors (PAI), activation of plasminogen to 
plasmin, and specific binding to fibrin, leading to strongly enhanced plasminogen activation 
(Collen and Lijnen 1991).
1.2 Structure of tPA, plasminogen and fibrin
t-PA (70kD) was discovered by Astrup and Permin (1947) and was first purified from uterine 
tissue (Rijken et al 1979). However, tumor cell cultures have proved a more convenient source 
for studying the biochemical properties of tPA variants (Rijken et al 1981). It is present at only 
0.1 nM in serum. The molecule has been well characterised at the protein level. It consists of 
527 amino acids in five domains each of which show homology with domains of other proteins; 
these are the finger domain (homologous with a domain in fibronectin), growth factor domain 
(epidermal growth factor), kringle (K)1 and K2 domains (plasminogen and prothrombin), and a 
protease domain specific for serine proteases (Fig. 2). The inactivation of t-PA by its primary 
inhibitor, PAI typel, (PAI-1) is achieved through binding to the catalytic site, 
Asp371His322Ser478, (which is analogous to Asp194His40Ser32 in chymotrypsin and 
trypsinogen - Madison et al 1993) and to a secondary binding region, which includes the 
residues 296-304 while the finger domain and K2 are involved in fibrin binding (Horrevoets et al 
1994). Two chain t-PA is derived from the single chain molecule by plasmin catalysed cleavage 
at Arg 275 (A-chain 1-275; B-chain 276-527); the molecule undergoes a major conformational 
change, but remains held together by disulphide bonds. The catalytic efficiency of the single
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Figure 2: Two views of a model of tissue plasminogen activator showing a hypothetical 
spatial arrangement of domains: the fibronectin type 1 'finger' (F) domain (shown in red), the 
epidermal growth factor-type (EGF) domain (brown), kringles 1 and 2 (green and blue, 
respectively) and the catalytic serine protease domain (purple). The F, EGF and serine 
protease domains have been modelled from high resolution structures (Baron et al 1990, Cooke 
et al 1987, Walter et al 1982); kringle 2 is the known crystallographic structure (de Vos et al 
1992) from which the kringle 1 structure has been modelled. The figure illustrates the relative 
sizes of the sugars (shown in yellow) with respect to the protein for type I t-PA which is 
glycosylated at Asn 117, Asn184 and Asn 448. Type II t-PA lacks glycosylation at Asn 184. The 
complex bi-antennary oligosaccharide at Asn 184 appears to hinder the approach of 
macromolecules to the lysine-binding site (LBS) of kringle 2 (shown in white). The catalytic triad 
residues of the serine protease domain are also shown in white. (Opdenakker et al 1994)
Chain tPA zymogen is unusually high, approximately 15% of that of 2-chain tPA. (Boose et al 
1989). t-PA contains four potential N-linked glycosylation sites, one of which (site 184) is 
variably occupied. In type I the sites in K1 (Asn117SerSer), K2 (Asn184GlySer), and in the 
protease domain (Asn448ArgThr) are all glycosylated, while in type II only sites 117 and 448 
are occupied (Pohl et al 1984, Parekh et al 1989, Spellman et al 1989), the fourth sequon at 
Asn228ProSer, is not glycosylated. In addition, both type I and type II tPA contain an O-linked 
fucose residue at GlyGlyThr 61 (Harris et al 1991, Harris and Spellman 1993). In common with 
other glycoproteins, tPA shows species, cell and site specific patterns of glycosylation (Parekh 
et al 1989a; Wing, D.R. et al unpublished data). At Asn117 oligomannose sugars are highly 
conserved between species (Howard et al 1991), while the majority of the glycans at Asn 184 
and Asn448 are complex and hybrid structures. Occupancy of site 184 has been shown to 
affect the fine structure of the glycan population at site 448 demonstrating that glycosylation at 
one site can influence the processing at another. In Bowes melanoma type I tPA the major 
species at site 448 were neutral glycans of the complex or oligomannose type and only 13% of 
the glycans were sialylated or sulphated complex or hybrid structures. In type II, however 72% 
of the structures were sulphated complex glycans and there were relatively few neutral sugars 
(Parekh 1989a, Wing unpublished data). This suggests that in type I tPA the presence of a 
glycan at site 184 restricts the access of some of the glycosylation processing enzymes at site 
448, reducing their efficiency.
tPA interacts with plasminogen, which is the pro-enzyme form of plasmin. Plasminogen is a 
single chain glycopeptide (M.Wt. 92kD) containing 5 kringle regions and a serine protease 
domain (Fig 3) and, like tPA, is a mixture of two major glycoforms (Brockway and Castellino 
1972) which have the same amino acid sequence (Sottrup-Jensen et al 1978). Both glycoforms 
are O-glycosylated at Thr 345 and the sequence contains an N-glycosylation site at 
Asn289ArgThr which is occupied in type 1 (33%), but not in type 2 plasminogen (67%) (Hayes 
and Castellino 1979 a,b,c). The transition from plasminogen to active plasmin involves a 
cleavage of the Arg 561-Val 562 peptide bond in the serine protease domain after which a 
larger N-terminal A chain remains linked by two disulphide bonds to the smaller C-terminal B- 
chain which contains the protease active centre residues His 603, Asp 646, and Ser 741.
Fibrin, which forms a ternary complex with tPA and plasminogen, is derived from fibrinogen, 
which is a highly soluble plasma protein. Fibrinogen is converted into the insoluble monomer, 
fibrin, by the proteolytic action of thrombin which cleaves four Arg-Gly peptide bonds in 
fibrinogen, releasing fibrinopeptides and leaving fibrin monomers (Fig 4) which associate to 
form long insoluble fibres of fibrin.
1.3 Activation of plasminogen by t-PA within a ternary complex with fibrin. 
t-PA activates plasminogen in both a fibrin dependent and independent manner. Under normal 
physiological conditions activation of plasminogen by tPA occurs slowly. However, in the 
presence of fibrin, to which both plasminogen and tPA bind, ternary complexes are formed and 
activation is enhanced by 2-3 orders of magnitude. The initial slow production of plasmin during
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It-PA cleavage site(Arg 561)
Plasmin cleavage sife 
(Lys 78)
Figure 3: A schematic molecular model of plasminogen type 1 and type 2.
Plasminogen consists of five kringle regions and a serine protease domain. This model is 
constructed using the co-ordinates from the corresponding domains on tPA and is intended to 
convey the relative sizes of the oligosaccharides and the protein (Wormald, M. and Rudd, P. - 
unpublished data). Type 1 plasminogen (left) has two occupied glycosylation sites - at 
Asn289ArgThr in kringle 3 and at Thr345 in kringle 4. Type 2 lacks the N-linked sugar at Asn
289.
Fibrin monomer
Period = 230A
Proposed arrangement of fibrin monomers in a fibrin clot. 
This half-staggered array of fibrin monomers 
would yield the observed 230A period.
Figure 4: The arrangement of fibrin monomers in a fibrin clot
the "lag" phase observed in the fibrin dependent assay is almost entirely due to fibrin 
independent activation of plasminogen. As the reaction proceeds the rate of plasminogen 
activation increases for three reasons. First, as plasmin is produced the single chain t-PA is 
converted to the two chain form which degrades fibrin at 5 times the rate (van Zonneveld et al 
1986). Second, during the degradation process carboxy terminal lysine residues are generated 
on fibrin, and this leads to increased binding of tPA and plasminogen. Third, during activation 
of plasminogen to plasmin, as a result of proteolytic degradation by plasmin, the full length 
native molecule, Glu-plasminogen (92kD) is converted to Lys-plasminogen (84kD). Amino 
acids are cleaved from the N terminus leaving a terminal lysine residue available binding tPA. 
In addition Lys plasminogen binds more tightly to fibrin than the full length molecule. The 
combination of all these processes leads to the formation of more stable ternary complexes 
and an exponential increase in rate.
Fibrin binding to t-PA involves the finger domain (von Zonneveld et al 1986) and K2 (Bennett 
et ai 1991). High affinity binding of tPA to fibrin (Kd 3.2 +/- 0.6m.M) is the result of co-operative 
binding between the two low affinity binding sites (Horrevoets et al 1994). The binding of 
plasminogen to fibrin is mediated by three lysine binding sites located in K1 and K4 and 
particularly K5 in the region of the molecule known as mini plasminogen (Val 422-Asn 790). 
The N-linked carbohydrate chain at Asn 289 decreases the binding of purified plasminogen 
fragments containing the high affinity lysine-binding site to fibrin by 85% (Lijnen al 1981); 
however, for intact Lys plasminogen, which binds more strongly to fibrin than Glu plasminogen, 
the difference between the two glycosylated variants is only minor. This suggests that other 
interactions apart from those involving the high affinity lysine binding site might contribute to 
the binding of plasminogen to fibrin.
1.4 The role of glycosylation in the functional activity of tissue plasminogen activator 
The role of the carbohydrates in modulating the catalytic properties of tPA has been confirmed 
in many studies (Wittwer et al 1989, Parekh et al 1989, Berg et al 1993, Howard et al 1991). In 
these the fibrinolytic activity of type II tPA has consistently been found to exceed that of type I 
tPA (Einarrsson et al 1985), regardless of the cell line in which the tPA is produced. Variable 
occupancy of site 184 influences the rate at which plasmin is generated in two ways: the 
presence of an oligosaccharide at site 184 decreases the rate both by inhibiting the plasmin- 
mediated conversion of single to two chain tPA and by decreasing the affinity of tPA for lysine. 
In the first place, plasmin catalyses the cleavage of the Arg275-lle bond in native single-chain 
tPA to form a disulphide bond linked two-chain species. The second order rate constant 
(kcat/Km) for type II tPA is about twice that for type I tPA (Wittwer and Howard 1990) 
suggesting that glycosylation at site 184 hinders the conversion of single- to two-chain tPA. 
Single chain tPA has a lower enzyme activity than the two-chain form (Ranby et al, 1982b 
Wallen et al 1983). Secondly, fibrin clot assays have shown that type II tPA binds more 
efficiently to fibrin (Wittwer et al 1989), moreover the decreased affinity of type I tPA for lysine 
is well established and affinity chromatography is commonly used to separate type I tPA from
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Figure 4b: The sugars at Asn 184 may sterically hinder a lysine binding site (red) on tPA 
type I (above). This may inhibit the affinity of tPA for lysine and decrease the rate of fibrin 
stimulated activation of plasminogen compared with type II fPA (below).
type II. These data suggest that the presence of a glycan at site 184 interferes with the binding 
of tPA to exposed lysine on degraded fibrin (Fig. 4b).
1.5 The role oftPA glycosylation in recognition
The carbohydrates also function as recognition markers and are involved in the clearance of 
tPA through receptors in the liver:
(i) Human tPA has been shown to be partly cleared through the macrophage mannose receptor 
located on liver endothelial cells and Kupffer cells (Owensby et al 1988, Krause et al 1990, 
Rijken et al 1990) and in rat liver cells by Smedsrod et al (1988). Deletion of site 117 by site 
directed mutagenesis (Hotchkiss 1988) or enzymatic removal of the oligomannose sugars using 
Endo-H (Tanswell et al 1989) both decreased the clearance rate.
(ii) The asialoglycoprotein receptor was shown to be involved in the hepatic clearance of tPA in 
rabbits (Cole et al 1993), and clearance of tPA by the mannose and galactose receptors in the 
liver was demonstrated in rats by Smedsrod et al (1988). Increased branching and desialylation 
of the oligosaccharides at sites 184 and 448 has been shown to increase the affinity of tPA for 
this receptor (Lee et al 1983).
(iii) Studies of a mutant tPA, in which site 117 was deleted (Cole et al 1993), suggested that 
glycosylation at site 184 exerts some steric or conformational effect which attenuates clearance 
of tPA through the peptide mediated clearance through the liver parenchymal cells in rabbits.
(iv) The conserved O-linked fucose residue at Thr 61 (Harris et al 1991, Harris and Spellman 
1993) mediates tPA binding to Hep G2 cells in vitro through a calcium dependent mechanism 
after which tPA is rapidly intemalised and degraded (Hajar and Reynolds 1993).
2. Introduction to chapter 7
The structural and functional aspects of the molecules described earlier in this thesis have 
illustrated many of the well established characteristics of protein glycosylation. In tPA many of 
these properties operate together in this complex, multidomain enzyme. For example, as in the 
CHO cell derived leucocyte antigens (ch.2), the processing of the N-linked glycans on tPA 
depends on the glycosylation machinery and the culture conditions in the cells in which the 
enzyme is expressed. Studies of the leucocyte antigens and of IgG (ch.6 ) indicated that the 
protein plays a role in determining its own glycosylation; in tPA, specific glycosylation at 
individual sites has been well established, and this illustrates both the importance of the local 
protein structure and the effect which glycosylation at one site can have on the processing at 
another. In common with RNase (ch.4), tPA contains a glycosylation site which is variably 
occupied, and in both enzymes the glycans shield substantial areas of the protein surface since 
they are large in comparison with the protein domains to which they are attached (in tPA the 
glycans are approximately the same size as a kringle domain). In RNase, the occupancy of 
Asn34 modulates the functional activity of the enzyme; in tPA, variable occupancy of site 184 
modulates both the conversion of single to two chain tPA and the binding of tPA to fibrin and, 
as a consequence, the fibrin dependent activation of plasminogen to plasmin. The absence of a
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sugar at site 184 allows tPA to bind to fibrin through K2 and the finger region in a conformation 
which allows optimal stimulation of plasminogen; the N-linked glycan situated close to the 
membrane in human erythrocyte CD59 may orient the binding site on the protein for optimal 
interaction with the C5-9 complex (ch.3). In vitro the agalactosyl sugars on IgGFc bind the 
mannose binding protein and the Fab glycans may be involved in immune complex formation, 
while in tPA, in vivo, glycans have been shown to be recognition markers for the clearance of 
tPA by the asialo glycoprotein receptor (Asn 184 and Asn448), the macrophage mannose 
receptor (Asn 117) and the hepatic receptor for fucose (Thr61).
In chapter 2 a study was made of five different proteins (CD2, CD5d1, CD5+CD4d3,4, CD48, 
and sCD59) all expressed in the same Chinese Hamster Ovary (CHO) cell line. In contrast, in 
this chapter, a study has been made of a single protein, tPA, which has been expressed in a 
number of different cell lines (Human colon fibroblast (HCF), Bowes melanoma (BM), CHO, 
murine C127 (C l27) and MCF7). The role of glycosylation in modulating some of the functions 
and properties of t-PA has been explored from several angles. First, the effects of cell specific 
glycosylation on the overall rate of activation of plasminogen both in the absence and presence 
of fibrin has been explored in HCF and BM tPA. The influence of cell specific glycosylation and 
variable site occupancy on the affinity of each of the recombinant tPA glycoform subsets for 
lysine has been noted and exploited to prepare subsets of tPA glycoforms and their rates of 
plasminogen activation have been examined. As a result a subset of glycoforms with increased 
enzyme activity was identified and partially characterised. A study of the role of variable site 
occupancy in both tPA and plasminogen in modulating the formation and turnover rate of the 
ternary complex with fibrin raised the possibility that glycosylation may influence the rate of 
other enzymes in the fibrinolysis pathway. In preliminary work to explore this the glycosylation 
of neutrophil gelatinase type IV has been examined (ch.8 ). Throughout this study molecular 
modelling has been used to gain insight into the steric implications of the glycosylation of tPA 
for the structure and functional activity of the enzyme.
3. Materials and Methods
3.1 Expression and purification of tissue plasminogen activator.
The therapeutic potential, as well as its value as a model system for studying glycosylation, has 
led to the establishment of a number of cell lines for the production of t-PA. 2-chain t-PA 
prepared from the following cell lines was supplied through collaborations with Dr. J. Feder 
(Monsanto Company (M)) and Prof. G. Opdenakker (Dept, of Microbiology and Immunology, 
Rega Institute, University of Leuven, Belgium (R)): Bowes Melanoma (BM), Human Colon 
Fibroblast (HCF) from serum containing and serum free media, murine (C l27), Chinese 
Hamster Ovary (CHO), Phorbol Ester treated Melanoma cells, (3-estradiol treated MCF-7 cells, 
and unstimulated Bowes Melanoma (BM).
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3.2 Preparation of the glycosylated variants of t-PA from different cell lines by lysine - 
sepharose chromatography
800 ug of t-PA at 1 mg/ml in 1M ammonium bicarbonate were diluted with 1.2 ml of buffer, 
(lOmM sodium phosphate buffer pH 8.0 containing 0.15M KSCN 0.001% Tween 80, and 25 
KlU of aprotinin/ml), and applied to a lysine sepharose column (45 x 0.9 cm) equilibrated in the 
same buffer. The column was washed with 35 ml of equilibration buffer, at a flow rate of 
5 .5 ml/h and eluted with a linear gradient of 0 - 0.25M L-arginine in the same buffer (160ml); 
1.0ml fractions were collected. The column eluate was monitored by the direct amidolytic assay 
using the artificial substrate S2288 (Kabi Vitrum). Aliquots were assayed in 96-well microtitre 
plates using either a Molecular Devices kinetic microplate reader or a Titertek single time point 
plate reader. Fractions were pooled as required.
3.3 Preparation of fibrinogen fragments: Soluble fibrin fragments were produced by cleavage 
of human fibrinogen with cyanogen bromide, as described by Verheijen et al (1983). lOOmg 
fibrinogen (M.Wt. 340kd) + 0.13mg cyanogen bromide in 10 ml formic acid were incubated 
overnight at room temperature. The resulting fragments were dialysed against water and stored 
at -20°C. The concentration equivalents of fibrin fragments were estimated by assuming that 
one fibrin fragment is generated from each fibrinogen molecule i.e. that 1 mole fibrinogen is 
equivalent to 1 mole of fibrin fragments. On this basis the final solution was calculated to be 
29.4|imolar.
3.4 Assays of t-PA activity
a. Direct Amidolytic Assay measuring protease activity.
The direct amidolytic assay was performed at 37°C using the synthetic substrate S-2288 (Kabi 
Vitrum) in a reaction mixture consisting of 1 mM S-2288 in 0.1 M Tris buffer, pH 7.5 (at 25°C) 
containing 0.1% Tween 20 (v/v), and the absorbance monitored at 405nm. S-2288: (H-D- 
Isoleucyl-L-prolyl-L-arginine-p-nitroanilide-dihydrochloride; KabiVitrum) is a chromogenic 
substrate sensitive to a broad spectrum of serine proteases. S2288 binds to tPA at the catalytic 
triad in the active site in the protease domain where it is cleaved, releasing p-nitroaniline which 
absorbs at 405nm.
b. Stimulated Indirect Amidolytic Assay.
This was performed at 37°C in a reaction mixture consisting of 0.13pM Glu -type human 
plasminogen (Kabi Vitrum), 0.7mM plasmin substrate S-2251 (Kabi Vitrum), 0.6 pM soluble 
fragments of human fibrinogen or fibrin, and t-PA of defined protein concentration (determined 
by amino acid sequencing) or protease activity (determined by the direct amidolytic assay) in 
0.1 M Tris buffer, pH 7.5, containing 0.1 % Tween 20 and monitored at 405 nm on a Rye Unicam 
8620 spectrophotometer. The rate of conversion of plasminogen to plasmin was determined 
from plots of absorbance (A) at 405nm versus reaction time and also from derivative plots of
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dA /dt versus The unstimulated indirect assay was performed in the same way without the 
addition of fibrin. The reaction is shown schematically below;
Plasminogen + tPA + fibrin
Piasmin + 82251-pNA
pNA ( absorbs at 405nM)
82251 is H-D-Val-Leu-Lys-p nitroaniline
3.5 SDS PAGE and Immunoblotting. SDS polyacrylamide gel electrophoresis was performed 
according to the standard method. After electrophoresis, the separated samples in the gel were 
transferred to blotting membrane (Immobilon or nitrocellulose, Millipore) by electroblotting. The 
tPA bands were developed using rabbit anti-tPA polyclonal antibody and alkaline phosphatase 
or peroxidase conjugated to anti-rabbit IgG (Opdenakker et al 1988). Casein was used as the 
plasmin substrate in the direct zymographic analysis (Roche et al 1993).
4. Results
4.1 Determination of optimal conditions for the indirect stimulated assay
4.1.1 t-PA is not stimulated by fibrinogen
BM and HCF t-PA (0.142nmolar) were incubated with increasing amounts of intact fibrinogen 
(0 - 0.586 M) under the conditions for the stimulated indirect amidolytic assay. Following the 
method of Verheijen et al (1982) which uses the kinetics derived by Drapier et al (1979) plots of 
AGO vs f2 were made for each concentration of fibrinogen (data not shown). From these data 
the dependence of t-PA activity on fibrinogen (Fig 5a,b) concentration was plotted at a single 
time point (lOmin). The result demonstrates that t-PA is not stimulated by intact fibrinogen. The 
standard mixture of soluble fibrin fragments used in the following experiments was prepared by 
CNBr cleavage of fibrinogen, and this result establishes that residual uncleaved fibrinogen in 
the fibrin fragment preparation does not take part in the reactions.
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Figure 5a,b: Fibrinogen does not stimulate activity in either (a) Bowes melanoma (BM) 
or (b) Human Colon Fibroblast (HCF) tPA
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4.1.2 Stimulation of t-PA depends on the concentration of fibrin fragments 
Soluble fibrin fragments were prepared by CNBr cleavage of human fibrinogen. BM and HCF t- 
PA were incubated with increasing amounts of the fragments ( 0  - 0.586 M) under the 
conditions for the stimulated indirect amidolytic assay, keeping the concentration of 
plasminogen constant (0.13pM). Plots of AOD vs t^ were made for each concentration of fibrin 
(Fig. 6 a,b). From these data the dependence of t-PA activity on fibrin concentration at a single 
time point (lOmin) was plotted (Fig 6 c). At concentrations higher than 0.353pmolar (12pl of 
standard solution) problems developed with turbidity and solubility in some samples, therefore 
saturating levels of fibrin could not be used. The optimal concentration of fibrin was 
0.353|imolar, and this was used in subsequent assays. In this plot the y-axis represents the 
change in OD over the first 10 minutes of the reaction or the initial rate. Therefore Michaelis- 
Menton type analyses can be used for the interaction of constant concentrations of tPA and 
plasminogen in the presence of increasing concentrations of fibrin. At each fibrin concentration 
Bowes tPA was more active than HCF. The limiting factor for AOD after 10 minutes, "Vmax", 
was estimated to be 0.07 and 0.05 AOD/min respectively. The "Km" values for BM tPA were 
similar: 0.187pmolar and 0.192|imolar for HCF tPA. The amino acid sequences of BM and 
HCF tPA were identical and the differences between the two enzymes reside in the 
carbohydrate. Therefore these data suggest that differences in the glycosylation of tPA do not 
affect the formation of the ternary complex involving tPA, fibrin and plasminogen, but do 
influence the turnover rate of tPA.
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Figure 6a-b: AOD vs plots of activity of tPA (0.142nM) towards plasminogen (0.13pM), 
with increasing concentrations of fibrin (0-0.586IVI).
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Figure 6c: t-PA activity depends on the concentration of fibrin fragments.
4.1.3 t-PA activity depends on the concentration of plasminogen
BM and HCF t-PA were incubated with increasing amounts of plasminogen ranging from 0 - 
0.585)imolar using the previously determined concentration of fibrin (0.353^imolar) and 
I.Snmolar t-PA. The rate of plasmin formation was measured by the indirect amidolytic assay 
using S2251 (Fig 7). "Vmax" and "Km" were determined for both types of tPA. When 50% 
saturating fibrin levels were used, 50% saturating plasminogen levels were reached at 
approximately 0.13^imolar (0.352 units), and this concentration of plasminogen was used in the 
subsequent assays. Although the "Km" values were similar (0.13)imolar for BM and 
0.135p.molar for HCF), the "Vmax" for BM tPA (0.2 AOD/min) was more than twice as fast as 
that for HCF (0.095 AOD/min). This is consistent with the previous data (Fig.6 c) which suggests 
that differences in the glycosylation of tPA influence the turnover rate but not the formation of 
the ternary complex (Fig. 7).
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Figure 7: t-PA activity depends on plasminogen concentration.
In the next section the fibrin independent activities of BM and HCF tPA were compared using 
the optimised assay conditions.
4.2 Comparison of the activities of Bowes Melanoma and Human Colon Fibroblast tPA
4.2.1 The fibrin independent activity of BM tPA is greater than that of HCF t-PA.
The indirect assay was performed in the absence of fibrin to compare the unstimulated activity
of BM and HCF t-PA towards plasminogen. Excess t-PA (14.2nMolar) was used since, as
expected, the standard amount which had been optimised in the fibrin stimulated assay gave
low activity in this assay over the time scale. There was no lag phase in the fibrin independent
assay, and the rate of plasmin production was linear with respect to time^ (Fig 8 ). The slope for
2  a
BM t-PA was 0.034 AOD/min compared with 0.02 AOD/min for HCF. Fibrin independent activity
is an important parameter because high levels of fibrin independent activity can lead to internal
bleeding when recombinant tPA is used pharmacologically to disperse blood clots.
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Figure 8: The rate of fibrin independent activity of BM and HCF tPA is linear with respect 
to time^.
4.2.2 The combined fibrin independent and dependent activity of Bowes melanoma and Human 
Colon Fibroblast t-PA.
The total activity of tPA in the fibrin dependent activity includes a contribution that is derived 
from the fibrin independent activity. In this assay t-PA was added in increasing amounts (0-350 
ng) to the reaction mixture for the indirect amidolytic assay. The concentrations of the fibrin 
(0.352|imolar) and plasminogen (0.13pmolar) were the optimal concentrations established 
above. The constituents of the reaction mixture were all pre-incubated to 37°C before mixing. 
The rate of change of absorbance at 405nm was measured using a parallel kinetics 
spectrophotometer. Plots of AOD vs time^ (t^) were drawn (data not shown). At t = 7min (t^ = 
49min^) AOD was read from these plots and graphs of AOD at 7 min vs t-PA concentration 
were drawn (Fig 9). After 7 minutes the ratio of the rate of change of absorbance (i.e plasmin 
production) of BM vs HCF tPA when the tPA concentration was 2.48 nmolar was 1.36:1.
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Figure 9: A comparison of the combined fibrin stimulated and unstimulated activities of
BM and HCF tPA (Ratios BM:HCF 1.36:1)
4.2.3 Comparison of the fibrin dependent activity of Bowes and Human Colon Fibroblast t-PA. 
The fibrin dependent activity of tPA alone was obtained by reading the absorbances in the 
indirect stimulated assay against a blank which contained everything except fibrin. In this way 
the fibrin independent activity generated in the sample was accounted for in the blank.
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Figure 10: Fibrin dependent activity of BM and HCF tPA. The contribution of the fibrin 
independent activity has been subtracted.
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In the Indirect assay measuring both fibrin dependent and independent activity simultaneously, 
7min from the start of the reaction, at a concentration of 2.48nMolar, BM t-PA liberated 
approximately 33% more plasmin from plasminogen than HCF t-PA at the same concentration 
(Fig. 9). In an assay measuring fibrin dependent activity alone the lag phase for both samples 
was about 4 minutes (Fig.10); however the initial rate of fibrin dependent cleavage of 
plasminogen by BM t-PA was 2.4 times as fast as the HCF t-PA. In this experiment no activity 
was observed in the lag phase since this was counteracted by reading the absorbances against 
a fibrin negative blank. These data indicated that overall the activity of BM tPA, which contains 
a higher proportion of less processed oligomannose structures, was greater than that of HCF 
tPA, and suggest that the differences in glycosylation which result from the expression of tPA in 
different cell lines are involved in modulating the activity of tPA. In the next section the effects 
of cell specific glycosylation on the glycoform pattern, the binding to lysine and the fibrin 
stimulated activity of subsets of tPA from a number of cell lines were investigated.
4.3 Cell specific glycosylation of t-PA.
t-PA was expressed in the following cell lines in two laboratories: (a) (from Professor G. 
Opdenakker): unstimulated BM, HCF from serum containing and serum free media, Phorbol 
Ester treated BM, (^-estradiol treated MCF-7 (b) (from Monsanto Ltd.): Cl27, CHO, HCF and 
BM.
4.3.1 Profiling the glycoform populations of recombinant tPA from a range of cell lines: 
t-PA was fractionated on the basis of the differences in the affinity of the glycosylated variants 
for lysine sepharose. Each sample of tPA (50|ig) was applied to a lysine sepharose affinity 
column and eluted with an arginine gradient (0-0.5M). The fractions were assayed for protease 
activity in the direct assay using S2288, and characteristic profiles of the glycoform populations 
were obtained for each cell line (Fig. Ila-i). These reflect differences in the glycosylation of t- 
PA which result both from the different arrays of processing enzymes in each of the cell types 
and from variations in cell culture conditions. This profiling technique allows the composition of 
different populations of t-PA glycoforms to be compared at the protein level, and for rapid 
screening purposes this eliminates the need to release and analyse the carbohydrates. It also 
represents the distribution of glycoforms; this information is lost in oligosaccharide profiling 
using released sugars. The fractions eluted from the column were pooled as shown in figure 11. 
The pools contain sets of tPA glycoforms which have been separated on the basis of their 
different affinities for lysine. Those with lower affinity for lysine, and by implication for terminal 
lysine residues on degraded fibrin (Type I tPA), elute early in the concentration gradient, while 
the glycoforms with higher affinity (Type I tPA) elute later. Up to 5 sets of fractions from each 
tPA sample were collected (Fig.11,12 table 1). In each case the first pool contained a subset of 
glycoforms (type la) eluting in the conductivity range of 20.95-22.35ms/cm (within a band 
covering 1.4ms/cm), the second pool (type I tPA) and eluted between 21.63 and 23.68ms/cm (a 
band of 2.05) ms/cm, the third (which was apparent only in BM (R)) contained type III and type
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Figure 11a-i: tPA from a number of cell lines was fractionated by lysine-sepharose 
chromatography. Activity in each fraction (monitored by the direct amidolytic assay) was 
plotted against the fraction number. The conductivity of each fraction was also measured and 
the profiles are in line with respect to conductivity. The conductivity trace is shown in 11a and b 
and the conductivity values of the peak fractions are recorded in Tablel.
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IV tPA and eluted at 23.71 ms/cm, Type I eluted in a conductivity band between 23.29 and
26.01 ms/cm (band of 2.72) ms/cm and type D eluted between 25.28 and 26.04ms/cm (band of 
0.76ms/cm). It is apparent that these conductivity bands overlap to some extent, suggesting 
that the lower affinity of type I and type I for lysine is not compensated for by alterations in the 
glycosylation. Some cell lines express type la tPA which elutes within the conductivity range of 
type I and some type I glycoforms elute in the type D range. However, interestingly, there is no 
overlap between type I and type II. The width of each conductivity band may be related to the 
heterogeneity of the glycoforms in the range of samples - type I is the broadest and most 
heterogeneous followed by type l>type la>type D. This suggest that type la and type D may be 
specific subsets of type I and type I tPA respectively.
In particular it was noted in this analysis that all the types of BM tPA, which was shown in the 
previous section to be more active in both fibrin dependent and independent assays than HCF 
tPA, eluted later in the gradient than the corresponding HCF glycoforms and contained a higher 
proportion of type la glycoforms.
tPA type la type 1 type l+ll type I type D
(a) HCFM 22.0 22.32 23.29 25.6
(b) BMM 22.12 23.68 26.01
(c) BM(u:R) 22.08 22.94 23.71 25.29 26.04
(d) HCFR 20.95 21.63 23.87
(e) C127 21.19 22.79 24.78 25.28
(f) CHO 22.47 23.57 25.17
(g) PMABM 21.43 22.93 25.03 25.66
(h) MCF7 21.62 23.57 25.55
(i) uBM(R) 22.35 23.52 25.4
Table 1: Conductivity at peak fraction for pools of glycoforms from a range of tPA 
samples eluted from a lysine sepharose affinity column. The units are ms/cm; error +/-1%.
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Figure 12: Conductivity of types la, I, II and D from a range of cell lines. The data was 
taken from table 1.
1: HCF (M) 2:BM (M) 3. uBf\/i (R) batch 1 4. HCF (R) (serum in medium)
5. C127 6. CHO 7. PM A BM (R) 8. MCF7 (R) 9. uBM (R) batch 2
u = unstimuiated
The glycoform subsets from figure Ila-i were analysed further by a combination of SDS PAGE, 
Western blotting and assays of fibrin stimulated activity. Some representative results are 
shown in the following section.
Unstimuiated Bowes melanoma t-PA (Fig. 11c):
Immunoblot analyses of the glycoforms of BM t-PA from an unstimuiated cell line, fractionated 
on lysine-sepharose, are shown in figure 13a. In contrast to the phorbol ester stimulated BM 
tPA, pool C contained two novel forms of t-PA migrating as a doublet with an apparent 
molecular weight of about 60kD. These have been noted in earlier studies of BM tPA 
(Opdenakker et al 1988) and have been designated Type II and Type IV tPA. They have not 
been investigated further, but the data indicate that t-PA from mammalian cell lines is more 
heterogeneous than was previously believed. Possible explanations for the existence of these 
structural variants include glycosylation changes, however the possibility of N-terminal, 0- 
terminal or internal clipping or other post-translational modifications cannot be discounted. In 
addition, lane E, which contains material from the pool with the greatest affinity for lysine, pool 
lib, contains Type I t-PA as expected, and also a component at 115 -125kD which reacts with 
the a-tPA antibody. This was designated type D tPA. Zymography of the same set of 
glycoforms (Fig.13b), using casein as the indicator substrate, resolved the BM t-PA sub-types 
from pools la. I, l+ll, I and lib, as well as type D tPA in pool lib. The gel indicates that type D 
tPA, migrating at approximately 120kD, also has activity towards casein. The data also 
demonstrate that the proteins, which are re-natured in the gel before caseinolysis, have 
retained proteolytic activity.
2 1 0
The figure legends opposite should read:
Figure 13a: Zymography of tPA from pools la, I, l+ll, II and lib (Fig.11c), using 
casein as the Indicator substrate. Lanes A,B,C,D,and E are from blots of material from 
pools la, I, l+ll, II, lib (as in the immunoblot in figure 13a) respectively. The gel indicates 
that type D tPA, migrating at approximately 120kD, also has activity towards casein.
Figure 13b: Analysis of glycoform populations of BM tPA by SDS PAGE, and 
Immunoblotting. Lanes A,B,C,D,and E are blots of material from pools la, I, l+ll, II, lib 
respectively. Track F contains a sample of standard Bowes melanoma tPA for 
comparison.
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Figure 13a: Analysis of glycoform populations of BM tPA by SDS PAGE, and 
Immunoblotting. Lanes A,B,C,D,and E are blots of material from pools la, I, l+ll, II, lib 
respectively.
B D E
complex
t-PA type
Figure 13b: Zymography of tPA from pools la, I, l+ll, II and lib (FIg.llc), using casein as 
the Indicator substrate. Lanes A,B,C,D,and E are from blots of material from poo/s la, I, l+ll, 
II, lib (as in the immunoblot in figure 13a) respectively. The gel indicates that type D tPA, 
migrating at approximately 120kD, also has activity towards casein.
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Human colon fibroblast t-PA (Fig. 11 d):
Immunoblot analyses of t-PA from the pools designated unbound, I, I and II (lanes A-D 
respectively) which were eluted from lysine-sepharose are shown in figure 14. Standard 
melanoma preparations, which contain t-PA Types l-IV, (lanes E and F) are included as 
controls. Mainly Type I and Type I tPA were detected in this gel. This may suggest that the 
levels of other tPA variants in this sample are too low to be detected or that the resolution of 
the gel does not allow a further separation of tPA variants.
c o l o n  f i b r o b l a s t  m e l a n o m a
B C D E F
Figure 14. Inrimunoblots of pools B-D (fig.1 Id) from the lysine-sepharose fractionation 
of HCF tPA. Track A contains ttie unfractionated HCF sample, Track E  is ttie immunoblot of 
unfractionated Bowes melanoma tPA; F is unfractionated Bowes melanoma tPA from a phorbol 
ester stimulated cell line.
Phorbol ester stimulated Bowes melanoma cell line (Fig. 11h)
An immunoblot of unfractionated phorbol ester stimulated Bowes melanoma tPA is shown in
figure 14 (track E). In contrast to the unstimuiated Bowes tPA (track F), PMA stimulated cells
do not produce type IV tPA. The released sugars from each of the four sets of glycoforms
(pools 1-4 Fig.11h) were profiled by P4 gel permeation chromatography (data not shown). Each
contained a different range of oligosaccharides, suggesting that the sets of glycoforms of t-PA
bind to lysine-sepharose with different affinities which are associated differences in their 
glycosylation
t-PA from /i-estradiol treated MCF7 cells (Fig. 11i)
The apparent absence of material in these samples (Fig.11i) was investigated by measuring the 
activity of unfractionated material Interestingly, this was also very low indicating that tPA from 
this cell line has very low protease activity as assessed by its activity towards S2288.
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Murine t-PA from C127 cell lines (Fig. 11 e):
After fractionation on lysine-sepharose samples from pools 1-3 (Fig. lie) were analysed by 
SDS PAGE (Fig. 15). Type D tPA is present in pools 2 and 3.
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Figure 15: SDS PAGE (10% non-reducing, Coomassie stained) of Murine t-PA from C l27 
cells. Tracks 1 and 6: High and low M. Wt. markers Tracks 2-4 Pools 1-3 from lysine-sepharose 
fractionation Track 5: unfractionated murine C l27 cells tPA.
Chinese Hamster Ovary tPA (Fig. 11g)
Fractions from the lysine-sepharose pools 2 and 3 (Fig. 11g) were analysed by SDS PAGE 
(Fig. 16). The overloaded gel of the unfractionated material indicates the presence of type D 
tPA at approximately 20kD. Lanes 2, 3 and 4 contain additional minor bands. Such bands have 
been noted by others (Ghislain Opdenakker, personal communication) and the amount varies in 
different cell lines. They appear to be the result of processing rather than glycosylation or other 
post translational modifications or clipping.
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Figure 16: SDS PAGE (8-25% gradient, non-reducing, Coomassie blue stained gel) of 
CHO t-PA. Tracks 1 and 5: High and low M. Wt. markers; Tracks 3 and 2 contain Type II and 
type I tPA respectively from the lysine sepharose column; Track 4: unfractionated CHO tPA. 
HCF t-PA from Monsanto cell lines (Fig. 1 la):
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The glycoform fractionation of this material on lysine-sepharose (Fig. 11a) can be compared 
with a similar fractionation of HCF tPA expressed in the same cell line, but in a different 
laboratory (Fig.lid). The data are consistent with the well established finding that cell culture 
conditions affect glycosylation.
BM tPA (Monsanto) and BM (Rega Institute)
The glycoform profiles of the samples fractionated on lysine-sepharose (Fig. 11 b,c) show that 
the samples from the Rega Institute contain additional sets of glycoforms eluting between types 
1 and 2 and also a larger amount of material eluting before type I.
4.4 Separation of subsets of tPA on lysine sepharose
t-PA expressed in BM, HCF, CHO and C127cell lines was fractionated by lysine-sepharose 
chromatography (Fig. 11c,d,g,f). Sets of glycoforms were pooled as shown and assayed for 
protease activity in the 82288 assay.
4.5 Kinetic studies of the sets of glycoforms isolated from t-PA expressed in a range of 
cell lines:
Samples with matched protease activity were withdrawn from each pool and their fibrin 
dependent activity compared in the indirect assay using S2251 (Fig.17a-d). The relative 
activities of the subsets of t-PA correlated with their elution positions on the lysine sepharose 
column; those fractions which bound most tightly to lysine, and therefore eluted later in the 
gradient, were also those with the greatest activity. In every sample of tPA tested there was an 
increase (4-5 times other fractions) in activity for the final pool which was eluted with 
approximately 0.5M arginine. SDS PAGE and/or zymography showed that this fraction 
contained a high molecular weight fraction (120kD) with tPA activity (e.g. Fig. 13). Table 2 
gives the initial rates from the data in figure 17a-d respectively, which show the effect of adding 
increasing amounts of each subset of tPA glycoforms to the indirect stimulated assay (using 
S2251 to determine the rate of generation of plasmin).
The histograms which follow (fig. 18) are for C127 tPA. They show the initial rate for each type 
of tPA (unfractionated, la, I, I and D over the range of concentrations from 100-500 ng and are 
taken from table 1). For type I, I and D tPA there is an excess of fibrin stimulated tPA activity, 
the reaction is pseudo-first order and the initial rates are proportional to the concentration of 
tPA. Under these conditions saturation has not been reached. In the unfractionated sample and 
in type la the fibrin dependent activity is insufficient to give first order kinetics until a 
concentration of 300ng has been reached. The reactions at 100 and 200 ng therefore include a 
factor which represents the fibrin independent activation of plasminogen. The composition of 
fraction la is not known, but it is of interest because it appears to contain a subset of tPA 
glycoforms which have a high level of fibrin independent activity and a low affinity for fibrin.
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Figure 17 a-d (opposite): Fibrin dependent activities of glycoform pools of tPA from 
BM(a), HCF(b), CHO(c) and Cl 27(d) cell lines.
The tPA was ^actionated by lysine sepharose chromatography. tPA activity in each fraction 
was monitored by the direct amidolytic assay using the chromogenic substrate S2288. The 
fractions were pooled as indicated in figure 11c,d,g and f. The activity of each pool was 
measured by S2288 activity and an equivalent activity of each pool was then assayed in the 
indirect fibrin stimulated amidolytic assay using the chromogenic substrate S2251. The lowest 
concentration of each pool (1) contains approximately 100ng of tPA. The activities of increasing 
levels (2x and 3x are also shown).
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T ime(min)
tPA ng uf la 1 l+ll I D
BM 100 199 26 26 66 66 252
200 293* 39 39 80 80 279
300 293* 39 53 106 106 279
HCF 100 5 1.3 5 80
200 8 5.3 16 213
300 19 8 21 213
0127 100 0.5 0.05 2.7 5 13
200 1.3 0.13 3.2 11 31
300 2.7 0.27 4.3 15 37
400 5.3 0.8 5.8 19 48
500 8 1.3 6.9 23 56
CHO 100 2.7 0.003 1.4 5
200 8 0.003 2.7 8
300 12 0.005 4.1 13
400 16 0.008 5.4 23
500 37 0.01 5.9 25
Table 2: initial rates for the activation of plasminogen by BM, HCF, 0127 and CHO tPA
The units are AmOD/min. These data were obtained by taking the initial slopes from the dA/dt 
plots in figure 17a-d respectively. The plots show the addition of increasing amounts (from 100- 
300 or SOOng) of each subset of tPA glycoforms to the indirect stimulated assay using S2251 to 
determine the rate of generation of plasmin. The scale on the y-axes is 1cm: IS.SAmOD units.
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Figure 18: Histograms of initial slopes (AdA/dt (mOD)/ min) for peaks 1-5 from the 
separation of Cl 27 tPA on lysine-sepharose plotted vs tPA concentration (0-500ng).
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In Table 3 (below) the initial slopes for plasminogen activation by murine C127 and also CHO, 
BM and HCF recombinant tPA have been compared at a single concentration of tPA (300ng).
C127 CHO BM HCF
Unfr. 2.7 12 293 19
Type la 2.7 0.005 39 -
Type 1 4.3 4.1 53 8
Type l+ll - - 106 -
Type I 15 13 106 21
Type D* 37 - 279 213
Table 3: Initial slopes (dA/dt (mOD)/min) for plasminogen activation by SOOng of
different glycoform populations of murine 0127, CHO, BM and HCF recombinant tPA.
Error + /-10%
Several conclusions can be drawn from the data in table 3.
(i) The activity of pool D* is cell line dependent and this may relate to the particular 
glycosylation of the subset of glycoforms it contains. BM D* and HCF D*tPA are the most 
active. The activity of type D* in BM is approximately 5x greater than type I and 2.5x greater 
than type II. In a similar assay using BM tPA (R) the activity of type D* in BM was found to be 
3.9x greater than type I and 2.4x greater than type I (Table 3). CHO cells did not contain a 
fraction eluting beyond type I, but the activity of CHO type I is proportionately high compared 
with the relative activity of the other glycoform subsets. This suggests that in CHO cells type D 
tPA may have eluted with the type I fraction.
There was no lag phase in any assay involving Type D* tpA, in keeping with its high activity. 
Type D tPA was not recovered as a pure sample and pool D* contained on average about 50% 
of type I tPA. The activity of D is greater than might be suggested by the analysis of type D*.
(ii) BM tPA is more active in every subset compared with tPA from other cell lines. This is 
consistent with the earlier results comparing BM with HCF tPA (see Fig.8) and may reflect the 
smaller and less charged oligosaccharides associated with BM tPA. Glycans with a lower 
molecular volume and lower levels of sialic acid may allow more efficient fibrin binding and 
also provide less steric hindrance to the formation of type D tPA.
(iii) The pre-peak in BM, CHO and in C127 tPA has not yet been defined and may contain 
another interesting set of tPA glycoforms. HCF also contains a shoulder eluting before type I 
tPA, but this was not recovered independently. In common with peak D*, on a molar basis this 
peak represents a small proportion of the total protein.
(iv) Analysis of the unfractionated samples shows that the activity of BM>HCF>CHO>C127 
The oligosaccharides have been profiled from each of these samples and the results show that 
overall BM contains the smallest, least processed sugars, followed by CHO, C127 and HCF tPA 
(Parekh et al 1989)
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(v) The rate for unfractionated BM Is anomalous, it is higher than the most active fraction. This 
may be experimental error or it may suggest that some further fraction of tPA with a higher 
activity than type D* tPA was not eluted from the column.
(vi) The reactions for pools la and I suggest that there is a lag phase in these fractions at low 
concentrations which is not present in other pools.
To examine the high activity in pool D* further and to identify the high molecular weight fraction 
(designated type D tPA) SOOfig of BM tPA (R) was fractionated on lysine sepharose (Fig. 19). 
Type I, type I and fractions 85-120 (containing a mixture of type D tPA and type I tPA and 
designated D*) were examined further in section 3.3-3.5 in collaboration with Mr. Kazuya Mori 
who obtained the data. This work has been published (Mori et al 1995).
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Figure 19 A,B: Separation of tPA by Lysine-sepharose chromatography and the enzyme 
activities of the fractions.
Bowes melanoma derived t-PA was applied to a lysine-sepharose affinity column and eluted 
with an L-arginine gradient (0-0.25M), followed by a wash of 0.25M L-arginine and a final step 
of 0.5M L-arginine. Every 5th fraction was dialysed against buffer, and both the reactivity to 
anti-tPA antibody and the enzyme activity were measured. A, cross: conductivity of arginine in 
the gradient (ms/cm^); open circle: t-PA activity in the direct assay (mOD/min) using 
chromogenic substrate (S-2288); closed circle: antigen level of t-PA measured by polyclonal 
antibody based ELISA (pg/ml). B, open circle: t-PA activity in direct assay (same data as A); 
open squares: t-PA activity in the indirect amidolytic assay without PCS (mOD/(min^/^jg/ml)); 
closed squares: t-PA activity in indirect amidolytic assay with PCS (mOD/(min^/pg/ml)x10). The 
fractions 52-63, 70-83 and 110-123 were pooled as types I, II and D* respectively.
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Figure 19C: Western blot analysis of the fractions eluted from lysine- sepharose
Each fraction was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE, 9%), 
then transferred to a blotting membrane. t-PA was detected using polyclonal rabbit anti-t-PA 
IgG and alkaline phosphatase conjugated polyclonal anti-rabbit IgG. I and II, indicates position 
of type I or II tPA. The high molecular weight form oftPA (type D) is present in fractions 85-120.
4.6 Kinetic studies of Bowes Melanoma types 1,11 and D tPA
The activities of pooled fractions from type I tPA, type I tPA peak and type D* tPA from figure 
19 were compared in three assays. The results are shown in Table 4a. In the direct amidolytic 
assay using S-2288, these 3 types of tPA had similar specific protease activity. In the 
unstimulated (without fibrin) indirect amidolytic assay, using 82251, type D* tPA showed a 5.8 
times and 4.2 times higher activity than type I or type I tPA, respectively. In the presence of 
fibrin, type D* tPA had 3.9 times and 2.4 times higher activity than type I and type I tPA, 
respectively. Interestingly, the activity of type D* tPA was significantly less stimulated by fibrin 
than were type I and type I tPA (1:1.6:1.7 respectively).
4.7 Characterisation of type D tPA
The molecular weight (120kd) of type D tPA suggests that it may be a dimer of tPA or a 
complex of tPA with some other molecule of a similar molecular weight. For example, tPA can 
be isolated as a complex with plasminogen activator inhibitor, PAI-1. The molecular weight of 
this complex (approx. llOkd) is close to that of a tPA dimer. The data in figure 19B eliminates 
the possibility that type D tPA may be such a complex of tPA and PAI-1. In figure 20a, track 1 
shows the immunoblotting by anti-tPA antibody of unfractionated tPA pre-incubated with PAI-1 
and run under non reducing condition. Track 2 contains type D tPA alone run under non 
reducing conditions. Tracks 3 and 4 contain the same samples run under reducing conditions. 
Under non-reducing conditions type D tPA has a molecular weight consistent with a tPA dimer 
and does not migrate to the same position as either monomeric tPA (64-69kd) or tPA-PAI-1 
complex. Under reducing conditions the tPA-PAI-1 complex is not cleaved and continues to 
run at llOkd (Track 3). Type D tPA, on the other hand, is reduced and migrates to the same 
position as type I tPA (Track 4). Figure 20b shows that reduction of the dimer with p- 
mercaptoethanol reduces the dimer to a single band migrating to the same position as type I 
tPA. This suggests that type D tPA is composed of type I tPA. Type D tPA was not a result of 
an equilibrium between monomeric and dimeric tPA since no more dimers formed in the type I 
fraction eluted from the lysine sepharose column even after concentration. This suggests that 
type D tPA may consist of a specific subset of type I glycoforms.
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Figure 20a: Western Diot analysts comparing t-PA-PAI-1 complex with type D t-PA
before and after reduction.
Tracks 1 and 3; t-PA-PAI-1 complex. Tracks 2 and 4; type D t-PA. The samples were separated 
by SDS-PAGE (9%) and transferred to the blotting membrane. t-PA was detected by rabbit anti- 
t-PA IgG and alkaline phosphatase conjugated polyclonal anti-rabbit IgG.
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Figure 20b: Western blot analysis of types I, II and D t-PA eluted from lysine-sepharose 
after reduction.
All samples were reduced with 2% 2-mercaploethanol before applying to the SOS-gel (9%). The 
immunodetection was carried out using rabbit anti-tPA polyclonal antibody and alkaline 
phosphatase conjugated anti-rabbit IgG Track 1: mixture of type I. II and D tPA: 2: 
unfractionated tPA: 3 type I tPA: 4 type II tPA. 5. type D tPA.
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4.8 Effect of variable glycosylation of both Glu-plasminogen and tPA on kinetic parameters of 
plasminogen activation.
The rate of plasminogen activation has been shown to increase when site 184 is not 
glycosylated. It is also enhanced by dimérisation of the tPA. The following investigation 
explored whether the different glycoforms of plasminogen (typel and type2) were equally 
susceptible to fibrin stimulated cleavage by type I and type I and type D tPA.
The kinetic constants for the fibrin stimulated activation of plasminogen 1 and 2 by tPA I, I and 
the pool containing type D tPA (D*) were determined and are in table 4b.
a. The Km values were similar for the activation of type 1 plasminogen by all the tPA variants. 
Likewise the Km values for the activation of type 2 plasminogen by each of the tPA variants 
were similar. However the Km values for interactions involving type 2 plasminogen were always 
lower than for type 1. This suggests that N-glycosylation at Kringle 3 in type 1 plasminogen 
may interfere in some way with the association of tPA and Glu-plasminogen.
b. The kcat values were always larger for type I tPA compared with type I tPA acting on the 
same plasminogen variant. This suggests that the tumover rate (kcat) is faster for the less 
glycosylated type I tPA variant. The Km values for the interaction of type D* tPA with 
plasminogen are of the same order as those obtained from the interactions of type I and type I 
tPA, suggesting that the association of tPA and plasminogen in the presence of fibrin is 
independent of the type of tPA. These data show that the Km of type I tPA with type 2 
plasminogen is lower than for type I tPA with type 1 plasminogen. The other combinations of 
the types of tPA and plasminogen fall in between these extremes. The overall combined effect 
of variations in the glycosylation of tPA and of plasminogen is a 2.3-fold activity span in which 
the two fully glycosylated molecules have a fibrin dependent kcat/Km value which is 43% of the 
kcat/Km values resulting from the interaction of the two least glycosylated variants (Table 4b). 
A representative experiment is shown (figure 21).
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Figure 21 : The kinetics of the activation of type 1 and 2 plasminogen by tPA variants I, II 
and D in the presence of fibrinogen fragment.
The concentrations of tPA and plasminogen in the assay were adjusted to 10ng/ml and 0 .1pM 
respectively. Generation of plasmin was monitored by measuring the absorbance at 405-490
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nm at 3 minute intervals. Open circle: type I tPA and type 1 plasminogen. Closed circle: type I 
tPA and type 2 plasminogen. Open square: type II tPA and type 1 plasminogen. Closed square: 
type II tPA and type 2 plasminogen. Open triangle: type D tpA and type 1 plasminogen. Closed 
triangle: type D tPA and type 2 plasminogen.
Activity of three types of tPA on three different assays
assay(n=4)
direct 
amidolytic
unstimulated stimulated
mOD/ [min * (pg/ml)] mOD/ [min *^ (pg/ml)] lU/pg
tPA mean SD mean SD mean SD
1 9.8 1.2 3.33 0.50 429.7 33.8
II 8.5 1.0 4.60 0.55 710.8 100.4
9.0 0.8 19.29 1.75 1684.8 121.0
Table 4a:
Kinetic constants of activation of different glycoforms of 
plasminogen by tPA variants with fibrinogen fragment using S2251
tPA Plasminogen Km kcat kcat/Km
(nM) (sec^) (uM'‘'*sec ')
1 1 81.77 ±4.72 0.118 ±0.008 1.45
2 47.51 ±2.88 0.106 ± 0.014 2.22
II 1 85.63 ±6.96 0.187 ±0.020 2.02
2 51.14 ±2.27 0.170 ±0.026 3.34
d ' 1 101.23 ± 7.85 0.422 ±0.037 4.20
2 62.70 ± 16.25 0.388 ±0.073 6.37
:n=4)
Table 4b:
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Figure 22A,B: Two views of a schematic model of a dimer of type II t-PA.
Each tPA monomer (one shown in blue, the other in magenta) is composed of five domains, a 
fibronecfm type I finger module, an EGF-like module, two kringles and a serine protease 
domain. This model was constructed using the co-ordinates of the finger and growth factor pair 
(Smith et al in preparation) and kringle 2 (de Vos et al 1992) from human t-PA. Kringle 1 and 
the serine protease domains were modelled by homology. In Fig.22A the oligomannose 
carbohydrate at site 117 and fucose at site 61 are yellow or green. The disulphide cross-link at 
Cys 83 is shown in red. The complex structures at site 448 (also yellow or green) are shown in 
figure 226 where the molecule has been rotated through 18(P relative to the orientation shown 
in figure 22A. (Mor/ et al 1995).
4.9 Molecular modelling studies (in collaboration with Dr. K. A. Downing) to examine a possible 
structure for a tPA dimer
The data suggest that type D tPA may be composed of a particular subset of type I tPA 
glycoforms. It is not the result of an equilibrium involving monomers since, after the initial 
separation on lysine sepharose, it does not reappear in the major fraction of type I tPA even 
after concentration. In proposing a possible site for linking two tPA type I monomers to form 
the more active type D tPA there are a number of considerations to be taken into account. 
Firstly, type D tPA has a higher activity than other types of tPA both in the presence and 
absence of fibrin. This suggests that dimérisation does not interfere with the access of 
plasminogen to the active site (the catalytic triad. His Ser Asp) in the serine protease domain. 
Secondly, the dimer is dissociated into monomers by reducing agents and this suggests that a 
disulphide bond is involved in its formation. The primary amino acid sequence of tPA includes 
a number of cysteine residues which are believed to be cross linked. In addition there is a free 
cysteine residue at site 83 and the possibility exists that, within a subpopulation of type I tPA, 
this may interact with the equivalent cysteine on a second tPA molecule to form an 
intermolecular disulphide bond producing a homodimer.
Thirdly, the increased fibrin dependent activity of type D tPA suggests that fibrin binding sites in 
the finger domain, and in Kringle 2 where the lysine binding site binds degraded fibrin, 
(Zamarron et al 1984) remain accessible.
Fourthly, type D tPA has a similar activity to type I and type I tPA in the direct assay using the 
artificial plasminogen substrate, S2288 (which is a short conjugated peptide), to measure 
protease activity. This is consistent with the previous data which suggests that type D has a 
similar structure to type I and I at the active site in the serine protease domain which is the 
primary binding site for plasminogen. However, since type D has a 9-fold increase in activity 
over types I and I tPA in the unstimulated indirect assay using S2251, it is possible that 
dimérisation may cause a conformational change which affects a secondary binding site to 
plasminogen. Such a secondary site has been identified by Geppert and Binder (1992) and is in 
the A-chain (residues 1-275).
In collaboration with Dr. A.K. Downing a molecular model has been constructed (Fig. 22a,b) 
which takes these constraints into account.
5. Discussion
5.1 Pattems of glycoform distribution in tPA expressed in a range of cell lines 
The type of cell has a major role in determining the extent and type of glycosylation, which is 
both species and tissue specific (Parekh et al 1989a). Many different enzyme reactions 
(typically 8 for a complex oligosaccharide such as those on tPA) are involved in the processing 
pathways. The profiles of the enzyme arrays, which includes their type, concentration, kinetic 
characteristics and compartmentalisation, reflect the phenotype of the cell in which the protein
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is glycosylated. The glycosylation of recombinant glycoproteins can be exquisitely sensitive to 
changes in manufacturing conditions, such as the glucose concentration of the culture medium 
(Goochee and Monica 1990). The glycosylation pattern basically reflects the type of cell used in 
the expression system and the use of different cell lines can result in significant glycosylation 
differences. For example, there are differences in the branching structure in the complex type 
oligosaccharides in human colon fibroblast (hcf) tPA when compared with those of tPA derived 
from Bowes melanoma cell line. These suggest that Bowes melanoma cells express GlcNAc 
transferase (GnT) III and VII, but not GnT IV, while human colon fibroblast cells express GnT 
IV, but not GnT III and VII. In this chapter the glycoform populations of tPA expressed in a 
range of cell lines have been compared by eluting the glycoprotein from a lysine-sepharose 
affinity column with an arginine gradient to partially resolve the subsets of glycoforms. The 
profiles were obtained by analysing the eluted fractions specifically for protease activity using 
an artificial substrate S2288. This is a relatively rapid screening method which does not require 
the tPA sample to be highly purified and may therefore be useful for following glycosylation 
changes during cell culture. This approach also has an advantage in that the glycosylation is 
profiled directly at the protein level allowing comparisons to be made of the glycoform pattems 
in different samples. In contrast, the more commonly used method for profiling glycosylation 
variations of tPA in cell culture systems involves prior purification of the tPA followed by gel 
filtration of the released and radiolabelled glycans. This method has the intrinsic disadvantage 
which is that, for a protein with more than one glycosylation site, the analysis of the released 
glycan pool cannot provide information about the particular combinations of glycans which are 
attached to the protein nor can it portray the complexity and distribution of the glycoform 
populations.
The individual profiles obtained in this study (Fig. 11) were characteristic of the cell line and 
culture conditions in which the tPA was expressed, and, predictably, there were many 
differences in the glycosylation pattems. tPA from unstimulated BMP (BM tPA prepared in the 
Rega Institute(R)), HCF from serum positive and serum free media (R), Phorbol Ester treated 
BM(R), p-estradiol treated MCF-7(R), C127(Monsanto (M)), CHO(M), HCF(M) and BM(M), and 
in, a separate experiment, BM (Rega) were all applied to a lysine sepharose column. Sets of 
glycoform populations were successively eluted from the column with an arginine gradient (0- 
0.25M).
A comparison of the glycoform profiles of two HCF preparations obtained from serum 
containing media (Fig. 11a and d) shows that there are variations between the batches. This is 
consistent with the well established fact that differences in culture conditions affect the 
glycosylation process (Goochee et al). A direct correlation between protease activity in the 
direct unstimulated assay using S2288 and protein concentration, as judged by a-tPA antibody, 
has been established for BM tPA (Mori et al 1995). Therefore it is of interest to note that the 
profile of tPA from p-estradiol treated MCF7 cells (Fig.llh), obtained by measuring the S2288 
protease activity of each sample, suggests that there is no active tPA in the fractions. In fact 
the activity of the unfractionated sample towards the peptide substrate, S2288, which contains
224
only three amino acid residues and binds in the active site was also very low. The reason for 
the low protease activity of this particular sample of tPA towards this peptide is not known, 
however it seems unlikely to be related to glycosylation. Examination of the molecular model 
(Fig. 22) indicates that even the largest tetra-antennary glycan so far identified on tPA would be 
unlikely to hinder sterically such a small peptide from entering the active site.
On lysine-sepharose columns glycoforms with the least affinity for lysine eluted first. All of the 
tPA samples contained two major peaks containing type I tPA, with three occupied 
glycosylation sites, eluting first and type I tPA, with two occupied sites, eluting later. However, 
the relative proportions of these glycoforms varied from 60% of type I in HCF(Monsanto) to 
30% in C127 tPA. In addition to the two major components all of the samples contained tPA 
eluting at positions before, between or following the two main peaks. This indicates that both 
type I and type I tPA consist of a wide range of glycoforms with different affinities for lysine 
and, by implication, for fibrin. Together with the gel of BMP in figure 13b, which shows the 
presence of type III and IV tPA, the lysine sepharose profiles and activity studies suggest that 
most tPA preparations are more heterogeneous than has been suggested previously. In further 
support of this evidence for heterogeneity, a previously unreported dimer of tPA type I (type D) 
with strong affinity for lysine was identified and characterised in this chapter. It is possible, but 
not so far demonstrated, that the additional peaks may also contain glycoforms of tPA which 
are unglycosylated or display variable site occupancy at sites other than Asn 184. Interestingly, 
Cl27 Type I tPA, expressed in the presence of dimethylmannoside (dMM) with oligomannose 
structures at 184, bound lysine with an affinity between type I and type I (Howard et al 1991). 
This suggests Type III and IV tPA identified in the BM cell line, which contains an increased 
proportion of oligomannose structures, may consist of Type I tPA with oligomannose structures 
at 184. Howard et al 1991 found that tPA from type I with either charged or neutral complex 
sugars had the lowest affinity for lysine. This suggests that the subset of glycoforms, type la, 
eluting before type I may contain sugars of this type.
5.2 Some factors which influence fibrinolytic activity
5.2.1 Affinity of tPA glycoforms for lysine
In every sample of tPA the fibrin stimulated activity of the glycoforms increased with the affinity 
of the subsets for lysine sepharose (Fig. 17, table 1). In figure 11, which shows the lysine 
sepharose elution profiles of the tPA samples, minor variations in the gradient mixing may have 
occurred in the different preparations. This has been accounted for by measuring the 
conductivity of every fraction eluted from the column. In figure 11 the profiles are therefore 
aligned according to the arginine gradient. It can be seen that, in general, the peaks in the BM 
samples (11b,c,h,j) elute at a higher concentration of arginine than HCF tPA (a,d). This 
indicates that overall the glycoforms of BM have a stronger affinity for lysine than HCF tPA, 
and suggests that BM tPA will be more active in the fibrin stimulated assay. This is consistent 
with the kinetic analyses of unfractionated samples which showed that the activity of BM (M) is
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2-3 times greater than HCF (M) tPA (Fig.7 and Table 1). Kinetic analysis of a number of 
unfractionated tPA samples from the Rega Institute disclosed a range of fibrin stimulated 
activities in which BM>HCF>CHO>C127. Some of the possible reasons for these differences in 
activity are discussed below:
5.2.2 Relative proportions of type la, I, II and D
In the first instance activity differences between samples are related to the relative proportions 
of type la, type I, type I and type D tPA, which bind to lysine with increasing affinity. In this 
respect the proportion of type D tPA is particularly significant.
In the C127, BMP and HCF cell lines a proportion of tPA (approximately 1-4%) was expressed 
as a glycoform with a molecular weight of approximately 120kD. Although this fraction 
represented a small proportion of the total protein it had a dramatically increased activity. The 
material was characterised as a dimer of type I tPA (type D tPA), and may be a product of cell 
culture preparations and therefore not physiologically relevant. However in view of the 
widespread therapeutic use of recombinant tPA it may be important to recognise this species, 
which has greatly increased activity both in the fibrin independent (Table 4a (BM)) and fibrin 
stimulated reactions (Table 4a (BM)). The tightly bound fraction, designated D*, which in each 
case contained type D diluted with type I tPA, had from 2-1 Ox the activity of type I tPA in the 
fibrin dependent assay depending on the cell line (Table 2 (CHO, 0127, HCF and BMP) and 
Table 4a,b (BM)). The activity of pure type D tPA is therefore in excess of these values. The 
effect of dimérisation on clearance has not been studied, however inspection of the proposed 
molecular model (Fig. 22) suggests that access to the O-linked fucose residues at Thr61, which 
has been reported to bind to a hepatic receptor (Hajar et al 1993), would not be significantly 
hindered. This suggests that type D tPA is composed of type I tPA. Type D tPA was not the 
result of an equilibrium between monomeric and dimeric tPA since no more dimers formed in 
the type I fraction eluted from the lysine sepharose column even after concentration. This 
suggests that type D tPA may consist of a specific subset of type I glycoforms. The data in 
figure 12 also suggest that type D tPA, which throughout all the cell lines elutes in a relatively 
narrow conductivity band (0.76ms/cm), may consist of a specific subset of type I glycoforms. 
The amount of type D tPA in each sample was qualitatively assessed by gels to be 
C127>BM>HCF»>CHO over an estimated range of 1-4% of the total protein. To assess the 
influence of increasing the percentage of type D (using the data in table 4a), the increase in 
overall activity of BM tPA containing 4% type D compared with 1% type D is 11%. However, in 
itself this contribution to the overall activity, although significant, is not sufficient to explain fully 
the observed differences in rate. For example. Cl 27 tPA contains a higher proportion of type D 
than any of the other tPA samples, but its activity is lower. 0127 also contains a relatively lower 
proportion of type llitype I tPA compared with other samples. This may suggest that a 
significant proportion of type I tPA from 0127 consists of a subset of glycoforms which is able 
to form dimers through intermolecular disulphide bonds. In figure 190 (track 2), which is an 
immunoblot of a non-reducing gel of pool D*, there is evidence of a band with a molecular
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weight of approximately 240KD. This suggests that type I tPA may form tetramers or possibly 
even larger aggregates.
5.2.3 Fibrin independent activity
Another interesting feature which emerges from the kinetics data in Table 2 and figure 17 is 
that the subset of glycoforms type la have a high level of fibrin independent activity, a low 
affinity for fibrin, and a low fibrin dependent activity. The amount varies in each cell line and 
culture, the PMA stimulated BM cell line contains about 18%, while the HCF (M) contains less 
than 5%. The glycosylation of fraction la is not known, but the discussion which follows (section 
5.2.4) suggests that it may contain type I tPA with large complex glycans at site 184. In figure 
12 the conductivity range of type I tPA from different samples of tPA was narrow (1.4ms/cm) 
suggesting that it might consist of a specific subset of type I glycoforms. This possibility is 
consistent with data from Howard et al (1991) which found that tPA from type I with either 
charged or neutral complex sugars had the lowest affinity for lysine. The contribution of this set 
of glycoforms and of unstimulated activation of plasminogen to the overall activity is not known. 
Increased levels of glycoforms which activate plasminogen in the absence of fibrin may 
increase the fibrin stimulated activity of tPA by degrading fibrin to produce terminal lysine 
residues. The ratio of fibrin independent activity of type I + la:ll:D in BM was 1:1.4:5.8 (Table 
4a). The corresponding ratios for fibrin stimulated activity are 1:1.6:3.9. The extent to which the 
fibrin dependent activity of different types of tPA depends on fibrin independent activation, 
perhaps by particular subsets of glycoforms, is not known.
5.2.4 The detailed glycosylation at site 184
The affinity of type I tPA for fibrin and thus the fibrin dependent activity of type I tPA and the 
overall activity of a sample, may also be influenced by the specific set of sugars at site 184. 
These are in a position to obstruct sterically the lysine binding site in K2 and examination of the 
molecular model (Fig.22) indicates that longer, more highly branched sugars would be more 
effective in fulfilling this role. Site analysis of HCF and BM (Parekh et al 1989) shows that the 
major populations of asialo glycans at 184 are smaller in BM (22.5% complex (C):16gu; 11% 
(C):15gu and 10.1% oligomannose:14gu) compared with HCF (39.3% (C):15gu; 12.4% (C):16 
gu and 11.1% (C):18gu), although the remaining populations of glycoforms (56.4% BM; 
37.2%HCF) are in the range of 9-14 gu in BM compared with 14-22gu in HCF. Overall Bowes 
has a higher percentage (35.2% (M8-M4) compared with 13.8% (M7-M4) in HCF) of 
oligomannose glycans at site 184. A study of the mannose 9 (M9) glycan (Woods et al 1994) 
indicated that there is tight hydrophobic stacking of each of the three terminal residues with the 
adjacent penultimate residue in the chain. This suggests that the M7-M8 oligomannose 
structures in tPA may not cover significantly more of the protein surface than a M6 glycan. 
These data suggest that a contribution to the increased rate observed for BM compared with
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Figure 23: Glycosylation at site 184 affects the glycan composition at site 448
The classes of glycan structures present at Asn 448 on tPA depend on the site occupancy of 
Asn 184 while those at site 117 do not. In type I tPA the major species are neutral and of the 
complex or oligomannose type, and only 72% of the glycans are sialylated or sulphated 
complex or hybrid sugars (Wing et al - unpublished data). In type II 13% of the glycans are 
complex or sulphated structures. The sugars at site 117 are almost invariably oligomannose in 
both type I and type II tPA regardless of the cell line in which the tPA is expressed.
HCF may come from specific differences in the glycosylation of site 184. This is consistent with 
the finding by Howard et al (1991) that oligomannose structures at site 184 in Cl27 tPA 
increased the activity of tPA 2-3 times, however removal of sialic acid from tPA had no effect. 
Binding to lysine and fibrin is mediated by the K2 domain, and while the finger region also binds 
to fibrin, it does not interact through lysine (van Zonneveld et al 1986). Alteration of the 
glycosylation at site 448 to oligomannose structures did not affect lysine binding (Howard et al
1991).
5.2.5 Overall glycosylation and charge profiles
Oligosaccharide profiling of the total asialo glycan pool (Parekh et al 1989) indicated that 
overall BM contained the smallest, least processed sugars, followed by CHO and Cl27 with 
HCF tPA containing the largest, most processed glycans. There was, therefore, no direct 
correlation between the overall glycosylation pattem and activity. All of the tPA samples were 
shown to have identical amino acid sequences, therefore these data suggest that the rate 
differences may be related to specific variations in the glycosylation pattem at particular sites. 
The charge profiles of the four samples indicate that BM tPA contains the highest proportion of 
neutral glycans, followed by HCF, CHO and Cl27 and interestingly, this order correlates with 
the relative activities of the samples. Site 117 is glycosylated almost entirely with neutral 
oligomannose structures therefore charge differences relate to sites 184 and 448 in type I tPA 
and only to site 448 in type II. It is therefore interesting to note that in BM type I tPA there are 
no sialylated structures at site 448, and all the charge is due to sulphate (Wing et al 
unpublished data). In type I the charge distribution at 448 Includes a smaller proportion of 
charged sugars than in type I but most of them are sialylated (Fig. 23). This suggests that 
increased sialylation at site 448 in type I tPA or at either site 448 and/or site 184 in type I tPA 
may reduce the activity of tPA. In support of this, Howard et al (1991) also found that 
desialylation or the presence of oligomannose structures at 184 or 448 increased activity. 
However, neuraminidase treatment did not increase lysine binding (Howard et al 1991), 
suggesting that the lower activity of tPA containing increased levels of sialylated structures 
noted in this chapter is not related to the affinity of this set of glycoforms for lysine, but may 
modulate some other aspect of plasminogen activation. The data from this chapter also 
suggest that the substitution of sulphate for sialic acid may increase the enzyme activity since, 
in contrast to BM tPA, the less active HCF, CHO, and Cl27 derived enzyme contained charge 
due only to sialic acid (Parekh et al 1989). BM cells are derived from a neural cell line, and 
interestingly studies of other neural glycoproteins have noted the presence of high levels of 
sulphated compared to sialylated glycans. The function of tPA in the brain is not associated 
with fibrinolysis, but is related to subtle modulations of cell/cell and cell/ECM interactions which 
are required for neuronal and synaptic plasticity (Sappino et al 1993).
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The factors which combine to give increased fibrinolytic activity to tPA may therefore include; 
(i) an increase in the proportion of type II tPA (monomers and dimers) which reflects a 
decrease in the efficiency with which site 184 is modified by the GlcNACgMang oligosaccharide 
precursor (ii) an increase in the proportion of type II glycoforms which dimerise through 
intermolecular disulphide bonds (iii) a decrease in sialylated structures and an increase in either 
neutral or sulphated glycans at site 448 (iv) a decrease in sialylated and fully processed 
glycans at site 184 in type I. (v) The level of fibrin independent activation is also a significant 
parameter. Interestingly, high affinity binding to fibrin may not invariably be the dominant 
factor, for example, single chain tPA has greater affinity for fibrin but it is 20-50 times less 
active than the 2-chain form (Wittwer and Howard 1990; Tate et al 1986).
It is interesting to speculate how significant variations in the levels of type I and type II tPA 
might arise. The proportions of type litype II are approximately 50% of each in the human cell 
lines studied in this chapter and in others (personal communication Dr. M. Spellman). However 
different proportions have been noted in some cell lines, such as murine tPA in this chapter 
where the percentage of type 1:11 is about 70:30 and in utorino tPA where there is an increased 
level of type I tPA and a ten-fold decrease in activity compared with tPA from porcine heart 
muscle (Rijken et al 1979). This suggests that under some circumstances, the percentage of 
occupied sites might vary in human tPA. Such a situation might develop in endothelial cells 
close to the site of an intravascular fibrin clot. If unusually high levels of tPA are being 
expressed the addition of the MangGlcNACg precursor to Asn 184 may become less efficient 
and this would result in a reduction in the number of glycosylation sites being filled. The 
consequence of this may be an increase in type II tPA and the release of a form with more 
fibrin dependent activity at the site of the clot. Moreover, increased levels of tPA expression at 
such sites may in itself lead to inefficient processing of other glycans and to lower levels of 
sialylation, if the proportion of glycoproteins to be processed rises to levels at which the 
concentrations of the glycosylating enzymes are insufficient to process every glycan fully. This 
may also lead to the release of a more active form of tPA. Interestingly, tPA expressed in CHO 
cells cultured in medium containing dithiothreitol, which prevents disulphide bond formation, 
were fully glycosylated at site 184. The tPA was normally folded and secreted when the 
reducing agent was removed and only type I tPA was identified (Allen et al 1995). This 
suggests that the rate of folding and disulphide bond formation of tPA determines the extent of 
occupancy of site 184.
5.3 tPA glycosylation affects the tumover rate of the enzyme while the glycosylatbn of 
plasminogen affects the association of the temary complex.
Both the fibrin dependent and independent activity of BM t-PA was significantly higher than that 
of HCF t-PA (Fig.8, 9). In fibrin stimulated plasminogen activation the Km values for both types 
of t-PA were similar, however the Vmax value for BM (0.2 AOD/min) was over twice the Vmax 
for HCF (0.095 AOD/min). This indicates that the glycosylation of tPA does not affect the 
formation of the temary complexes, but that it does modulate the turn over rate. Some insight
229
tPA glycosylation 
at Asn 184 decreased 
affinity for fibrin
tPA
Plasminogen glycosylation at Asn228 
decreases 
rate of 
formation of 
temary 
complex
/ Plasminogen glycosylation 
at Asn 288 
hinders 
interaction 
with tPA
tPA glycosylation 
at Asn 184 decreases 
tumover rate
Figure 24: The effect of variable site occupancy on the Km and kcat values for the fibrin 
dependent activation of plasminogen by tPA
This schematic drawing is intended to convey the main conclusion from this chapter which is 
that variable glycosylation of tPA at Asn 184 is a critical factor in the mechanism which controls 
the fibrinolytic activity of tPA, affecting the turn over rate (kcat) but not the formation of the 
ternary complex (Km). The factors which combine to give increased fibrinolytic activity to tPA 
are; (i) an increase in the proportion of type I tPA (ii) an increase in the proportion of type I 
glycoforms which dimerise through intermolecular disulphide bonds (iii) a lower proportion of 
sialylated structures and an increase in either neutral or sulphated glycans at site 448 in either 
type I and /or type I (iv) a lower proportion of sialylated structures at site 184 in type I. kcat and 
Km values are shown in table 4.
reducing agent was removed and only type I tPA was Identified (Allen et al 1995). This 
suggests that the rate of folding and disulphide bond formation of tPA determines the extent of 
occupancy of site 184.
5.3 tPA glycosylatbn affects ttie turnover rate of the enzyme while the glycosylation of 
plasminogen affects the association of the ternary complex.
Both the fibrin dependent and independent activity of BM t-PA was significantly higher than that 
of HCF t-PA (Fig.S, 9). In fibrin stimulated plasminogen activation the Km values for both types 
of t-PA were similar, however the Vmax value for BM (0.2 AOD/min) was over twice the Vmax 
for HCF (0.095 AOD/min). This indicates that the glycosylation of tPA does not affect the 
formation of the ternary complexes, but that it does modulate the turnover rate. Some insight 
into the molecular details of this finding come from a study by Horrevoets et al (1993) who 
demonstrated that deletion of either the finger domain or K2 on tPA results in an increase in Kd 
for the binding of tPA to fibrin. This suggests that binding of tPA to fibrin, mediated 
simultaneously by both the finger and the K2 domains. Is essential for a correct orientation of 
the enzyme on the fibrin polymer to give the optimal stimulation by fibrin on plasminogen 
activation. The data from this chapter suggest that the interaction between tPA and fibrin is 
critical, not for the formation of the ternary complex, but for the turnover rate which involves 
the rie-arrangement of the complex, the cleavage of plasminogen and the release of tPA from 
the cleavage product, plasmin. This is consistent with a study by Paoni et al (1993) in which 
mutations of tPA which increased Its specificity for fibrin caused a reduction in kcat, but not in 
Km. Examination of the molecular model (Fig. 4b) shows that glycosylation at Asn 184 shields 
a binding site for lysine In kringle 2, suggesting that variable sequon occupancy confers on the 
protein a means to modulate fibrin binding and as a result the tumover rate of tPA, which is a 
critical event in the fibrinolysis pathway. Consistent with this, data from this chapter (Table 2), 
which was discussed earlier, suggested that the differences in activity between the different 
types of tPA may be a result of glycosylation differences at one particular site, rather than an 
overall change in glycosylation.
To confirm the finding that tPA glycosylation influences the tumover rate and to explore the 
factors which might govern the formation of the ternary complex, type 1 and type 2 
plasminogen were interacted with type I and type II BM tPA in the fibrin stimulated assay. Fig. 
21 and Table 4b show that type 1 and type 2 plasminogen exhibit different kinetics when 
interacting with type I or type II tPA in the ternary complex with fibrin. The variable 
glycosylation of both molecules affects the overall rates of the reactions (kcat/Km) which range 
from 1.5pM'^sec 1 for interaction of the two fully glycosylated enzymes to 3.3pM isec'i for the 
least glycosylated ones (Table 4b). The variable glycosylation of tPA affects kcat, the absence 
of glycosylation at Asn289 on plasminogen type 2 is associated with a decrease in Km for 
activation by both types of tPA. These data indicate that the glycosylation status of tPA affects 
only the tumover rate and not the formation of the ternary complex and are consistent with the
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N-glycosylation of intact Glu-plasminogen had no effect on fibrin binding. However the 
glycosylation decreases lysine binding affinity, suggesting that, after cleavage of fibrin by 
plasmin, which exposes new plasminogen binding sites (Suenson et al 1984), the N-linked 
glycan may decrease the binding to terminal lysine. Interestingly, glycosylation at Asn289 does 
not significantly affect the binding constants of ligands for the two allosteric sites (K4 and K5), 
nor the forward rate of a -  to p- conformational change. It does, however, reduce the rate of the 
reverse p- to a- conformational change which is from an open conformation to a compact form, 
and this may be important in the formation and rearrangement of the temary complex with 
fibrin and tPA (van Zonneveld et al 1986)
5.4.2 0-glycosylatk)n at Thr 345 (figure 3)
Type 2 plasminogen, which contains only O-linked glycans, exists in six glycoforms which are 
distinguished from each other by the amount of sialic acid (from 1.3-13.65 mol/mol of protein) 
they contain. All forms were converted to plasmin by tPA, however the rate of the fibrin 
dependent conversion of plasminogen to plasmin increased as the proportion of sialic acid 
decreased (3.77x1 (T* - 1.65x10® M"V^) (Pirie-Shepperd et al 1995). This suggests that, in 
addition to site occupancy, microheterogeneity also plays a role in the regulation of fibrinolysis. 
Differently sialylated plasminogen may represent systemic pools of this proenzyme that can be 
activated at different rates on the fibrin clot, ensuring persistence of fibrinolytic activity.
5.5 The irtteracÿon of Type D tPA with plasminogen and fit>rin
In a direct amidolytic assay, using the chromogenic substrate 8-2288 to probe the interaction of 
a small peptide with the active site in the tPA serine protease domain, all three types of tPA 
showed a similar specific activity (activity/monomer) (Table 4a). This suggests that the 
proteolytic cleavage site is unaffected by either glycosylation or dimérisation. In contrast, in the 
indirect unstimulated amidolytic assay, which probed the interaction of tPA variants with native 
unfractionated human Glu-plasminogen substrate, activities were in the ratio 4:1:1.2 for type D* 
tPA : type I : type II tPA. This suggests that dimérisation of tPA results in an increased rate of 
plasminogen activation in the absence of fibrin. The interactions of type 1 and type 2 
plasminogen with types I, II and O* (type II + type D) tPA have kcat/Km values which range 
from 1.5 to 6.4. The data in Fig. 21 shows that the rate of production of plasmin is greatest 
when the least glycosylated variants of both tPA and plasminogen are involved and the tPA 
type II is in the dimeric fomri (type D). The Km values for the interaction of type D* tPA with 
plasminogen were of the same order as those for the interactions of type I and type II tPA, 
consistent with previous data which suggested that the association of tPA and plasminogen in 
the presence of fibrin is independent of the type of tPA, and showing that the type II dimer 
reacts in a kinetically similar manner to the monomer in this step. However, the kcat values for 
type D* tPA with type 1 and type 2 plasminogen are significantly greater than for either type I or 
type II tPA. This suggests that the pure dimers of type II tPA (type D) have an increased 
tumover rate. Since the rate constants are for type D diluted with type II; the absolute value for
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D will be even higher. The kcat/ Km value for the interaction of type D* tPA with type 2 
plasminogen is 4 times as large as the value for type I tPA and type 1 plasminogen. The fibrin 
dependent catalytic activity of tPA therefore spans a 4 fold range and is dependent on both the 
glycosylation of tPA and plasminogen and the dimers of type II tPA. The Km values, on the 
other hand, are modulated only by glycosylation at site 289 on kringle 3 of plasminogen.
Type II and type D tPA bind more tightly to fibrin than type I and are therefore more likely to 
remain attached to the fibrin matrix following the cleavage event. In addition, the re­
arrangement of the temary complex and the release of plasmin are faster in the absence of 
glycosylation at 184 and in dimérisation. These three factors together increase the tumover rate 
of tPA.
6. Conclusion
This chapter has confirmed previous findings that tPA expressed in different cell lines has 
different activities and glycosylation pattems. The glycoform profiles of tPA expressed in 
different cell lines have been defined at the glycoprotein level without the need to release the 
oligosaccharides and, in addition, lysine-sepharose affinity chromatography has been used to 
separate different sut)sets of glycoforms. Kinetic analysis of these sut>sets indicated that 
increasing fibrin stimulated activity correlated with increased affinity for lysine. A fast acting 
tPA which bound tightly to lysine sepharose was designated type D tPA and partial 
characterisation suggested that this was a dimer composed of a specific sut)set of tPA type II 
glycoforms. Molecular modelling illustrated that such a dimer might form through an inter- 
molecular disulphide bond at Cys83. The kinetics of the interaction t>etween types I, II and D 
tPA and types 1 and 2 plasminogen showed a four fold range of activity and the combination of 
the least glycosylated forms of each molecule had the highest rate of fibrin stimulated activity, 
and the dimer was the most active form of all. At)sence of glycosylation of site 184 in tPA was 
shown to increase the tumover rate (kcat), which involves increasing the affinity of tPA for fibrin 
and increasing the rate at which the cleavage event and the release of plasmin occurs. 
Occupancy of site 289 in plasminogen decreased the rate of the formation of the temary 
complex (Km), probably by sterically hindering the binding of plasminogen to tPA. Variable site 
occupancy of site 184 in tPA has. been shown by others to modulate the conversion of single 
chain to the more active 2-chain form and to modulate the binding of tPA to fibrin, and our 
results indicate that, in addition, absence of glycosylation at this site may be a pre-requisite for 
dimérisation. It has t>een shown that variat)le site occupancy of site 184 is a means of 
controlling the tum over rate, confirming the critical role of this glycosylation site in the function 
of the enzyme. In addition some evidence has been put forward for the existence of a sut)set of 
glycoforms which have increased levels of fibrin independent and fibrin dependent activity, and 
for a role for the neutral and sulphated sugars at site 448 in allowing increased fibrin dependent 
activity compared with sialylated glycans.
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The future
The glycosylation of tPA does not affect the rate of formation of the temary complex which 
therefore does not depend on tPA binding to lysine. The observed differences in activity 
between different sources of tPA and different subsets of glycoforms are related to the turnover 
rate: One factor which influences this may be the affinity of tPA for fibrin. Binding to fibrin 
through lysine in K2 is increased in the absence of glycosylation at site 184, and by the 
presence of oligomannose rather than complex sugars at this site. The glycosylation at other 
sites does not affect this binding. The effect of glycosylation on fibrin binding through the finger 
domain, which does not involve lysine, is not known. In addition, another important factor in the 
turn over rate is the efficiency with which tPA cleaves plasminogen immobilised on fibrin. The 
role that tPA glycosylation plays in this event has not been well studied. The mechanism of 
fibrin independent activity is also not well studied; in particular it is not known whether all or 
some glycoforms of tPA can engage in tx)th fibrin dependent and independent activity or 
whether there are specific subsets for each. In this respect, analysis of the glycosylation of the 
minor subset of glycoforms, type la, which has low levels of fibrin dependent activity, may give 
some insight into the role of glycosylation in the fibrin independent activity of tPA. The exact 
nature of the glycosylation of multidomain proteins may be an important feature of control, 
particularly for enzymes which are involved in both inter- and intra- molecular rearrangements. 
In addition to its role in fibrinolysis, tPA can initiate the protease cascade which is associated 
with remodelling of the extracellular matrix (Stack et al 1990), and in which other glycosylated 
molecules such as collagenase, stromelysin and gelatinase are involved (Opdenakker and van 
Damme 1992). Since there is a 2-fold increase in fibrin dependent activity between type II 
tPA/type 2 plasminogen over type I tPA/typel plasminogen it is interesting to speculate that 
further amplification of the range of activity might result from the interaction of specific sets of 
glycosylated variants of all of the enzymes. If it proves to be so then differential glycosylation 
would allow the protein a means to modulate the rate of such a cascade. The localised 
generation of tPA in the ECM is under the control of several ECM-associated proteins which 
stimulate plasminogen in the absence of fibrin. These include type IV collagen, which is a more 
efficient stimulator of tPA than fibrin (Stack et al 1990). In this respect, human gelatinase B, 
which degrades type IV collagen, has been isolated from neutrophils and tumor cells (Professor 
G. Opdenakker, The Rega Institute). The glycosylation of neutrophil gelatinase B has been 
defined (ch.8) as a preliminary step towards investigating the possibility that its enzymatic 
activity may be modulated by glycosylation thus identifying other steps in the cascade process 
where glycosylation can result in subtle control.
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Abstract
In this thesis standard procedures have been used to release and ^ u e n c e  oligosaccharides 
and these methods are collected together in this chapter. In addition, technology which has 
been developed recently in the Glycobiology Institute has been used to explore some novel 
approaches to sequencing. These approaches include the development of a method to 
sequence mixtures of glycans simultaneously using MALDi MS, a method which eliminates 
the need to purify individual glycans before using exogiycosidase enzymes. Another 
application of MALDI MS involved the analysis of the products of the Reagent Array Analysis 
Method (RAAM) enzyme digests. This method eliminates the need to quantify the products 
of the enzyme digests, a step which is required in the conventional RAAM procedure. Also in 
this chapter, recently developed HPLC methods, using both ion exchange and normal phase, 
have been applied to the analysis of fluorescent and radiolabelled anionic and neutral 
sugars. There was a significant improvement in the quality of the resolution which could be 
achieved, both of oligosaccharides carrying different numbers of charged grolips and of 
glycans with the same charge but with different molecular volumes. The composition of the 
pool of oligosaccharides released from a glycoprotein is commonly used to infer the 
composition of the original glycoform populations. This indirect method is used partly 
because relatively few techniques are available for separating and analysing glycoforms 
directly at the protein level. In this chapter capillary electrophoresis has been used to resolve 
both the neutral glycoform populations of RNase B and the charged glycoform populations of 
transferrin in molar proportions. Finally, current technology available for analysing Olinked 
sugars has been used in a stiidy of the glycosylation of neutrophil gelatinase B. While the N- 
linked sugars were identified as complex biantennary glycans, the analysis revealed that 
85% of .the sugars associated with this protein are O-linked and these include a series of 
linear O-llnked glycans with a type 1 core. The largest of these, Galp1-(4,3,6)HexNAcp1- 
(2,3,4,6)Gaipi-(4,3,6)HexNAcpi-(2,4,3,6)Gaipi-(3)(4,6)GalNAc, is an unusual O-linked 
sugar, O-glycans of this size more often contain branches. The O-glycans may be clustered 
in a region of amino acids (452-503) which is rich in proline, serine and threonine and is 
homologous with a region in o2(V) collagen. The analysis highlighted the need to develop 
further the technology currently available for analysing O-linked glycans.
Methods for oligosaccharide analysis used in this thesis
In this chapter standard methods for oligosaccharide sequencing used throughout this thesis 
have been collected together. In addition some new applications of Matrix Assisted Laser 
Desorption Ionisation Mass Spectrometric (MALDI MS), Capillary Electrophoresis (CE), 
HPLC and Fluorophore Assisted Caitohydrate Electrophoresis (FACE) to oligosaccharide 
analysis are described. In addition the current technology available for sequencing Olinked 
glycans has been used in the analysis of the sugars attached to gelatinase B.
1. Standard methods for oligosaccharide sequencing
For a comprehensive review see Annual Reviews in Biochemistry (Dwek et al 1993).
1.1 Release and re-N-acetylation of glycans
Intact glycoproteins (40pg-2mg) were dialysed into 0.1%TFA and lyophilised. Glycans were 
released by hydrazine (Fig.1) using the GlycoPrep 1000 (Oxford GlycoSystems Ltd) at a 
temperature of 95°C for maximum recovery of both N- and O-linked sugars or 65°C for the 
optimal release of O-linked glycans (Patel et al 1993). Hydrazinolysis releases N- and O- 
linked oligosaccharides non-selectively in their correct molar proportions and, under 
optimised conditions, in >85% yield. The GlycoPrep 1000 automatically re-N-acetylates the 
released sugars to reinstate any N-acetyl groups removed from the original glycans by the 
hydrazinolysis procedure. The acetohydrazone group is then cleaved yielding the intact 
glycan in the closed ring form and in its original conformation. The glycans are purified from 
buffers and excess reagents on ion exchange resins and delivered in aqueous solution (2ml).
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Figurel: Hydrazinolysis reaction followed by re-N-acetyiation and acetohydrazone
cleavage
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1.2 H^ lat)elling of reducing terminus
Released and re-N-acetylated oligosaccharides were incubated at 30°C with 2mCi pH] 
lactitol and a five-fold excess of NaB^H^ (6mM) in 0.05M NaOH adjusted to pH 11 with boric 
acid. After 4 hours an equal volume of 1M NaB^H^ in buffered 0.05M NaOH was added and 
the incubation continued for 2 hours (Fig.2). The reaction was terminated by the addition of 
1M acetic acid and the mixture passed through Dowex AG-50 X12 (H+) and concentrated to 
dryness. The residue was freed from boric acid by repeated evaporation (5x) with methanol, 
dissolved in water and subjected to paper chromatography. After 60 hours, when pH] lactitol 
was well resolved from the reduced oligosaccharides the paper was scanned for radioactivity 
and each radioactive region eluted with water and concentrated (Ashford et al 1987).
CHgOH
OH
NHOH
NH
CFO
CFO CH
CH;
NaBH./NaOH
pH 11.5
OH
NH
0=0
CH,
Figure 2: The reactions involved in labelling glycans by reduction with sodium
borohydrlde
1.3 Fluorescent labelling of reducing terminus with 2-aminobenzamide (2AB)
Salt free glycans (25 pmoles - 50 nmoles) were evaporated to dryness using a Savant 
SpeedVac. 150pl of 2-aminobenzamide were added to DMSO (350pl) and 200 pJ of this 
solution was added to bromophenol blue dye. lOOpI of the mixture of 2-aminobenzamide. 
DMSO and bromophenol blue were added to the reductant (sodium cyanotorohydride) and 
vortexed. 5pl of the final solution were added to each glycan sample, the tube was capped 
and the mixture incubated at 65°C for 2 hours (Fig. 3). After the incubation the samples 
wore centrifuged briefly and spotted onto Whatman 3MM paper in a single transfer. A 
chromatography tank was saturated with butanohethanol:water (4:1:1) and the excess 
reagents were eluted from the labelled glycans by ascending paper chromatography. When 
the dye reached the top of the paper the strip was removed, thoroughly dried and scanned 
using a fluorescent instant imager. The 2AB labelled glycans remaining at the origin were 
eluted with water.
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OHOH NHNH
2AB
CKCK
NH
OHOH
NHNH Reductant
0=0
CH.CK
Figure 3: Reductive amination with the fluorescent compound 2AB
(Excitation waveiength: 340nm, emission waveiength 420nm)
1.4 Giycosidase digestions
Glycans were evaporated to dryness on a SpeedVac. 20pl of a standardised solution of the 
required enzyme were added to the glycans and the mixture incubated for 16h at 37°C. The 
conditions used for each enzyme are summarised below;
(a) Bacteriodes fragilis endo-^alactosidase (Oxford GlycoSystems); 0.5U/ml in 50mM 
sodium actetate buffer pH5.8; substrate concentration 40pM. Cleaves R-GlcNAcp1-3Galp1- 
4GlcNAc/Glc
(b) Arttirot)acter ureafadens neuraminidase (Oxford GlycoSystems): 1-2U/ml in tOOmM 
sodium actetate buffer pH5; substrate concentration 5-30pM. The enzyme cleaves 
NeuNAco2-6>3,8 R
(a) Newcastie disease virus neuraminidase (Oxford GlycoSystems): 0.2U/ml in 50mM 
sodium actetate buffer pH5.5; substrate concentration >5pM. The enzyme cleaves 
NeuNAco2-3,8 R
(d) Bovine testes gaiactosidase (Oxford GlycoSystems): 1-2 U/ml in lOOmM 
citrate/phosphate buffer pH4; substrate concentration 40-100pg/ml. The enzyme cleaves 
Gaipi-3,4>6 GlcNAc/R.
(e) Streptococcus pneumoniae N-acetyi ^ -hexoseaminidase: Substrate concentration: 20mM 
with 300U/ml of enzyme in lOOmM sodium citrate phosphate pH6. Incubation: 18h, 37°C. 
The enzyme cleaves GlcNAc p i-2,4,6 Man or GlcNAcpi-3,6Gal.
(f) Jack bean N-acetyi ^ -hexoseaminkiase:
Substrate concentration: 20pM sugar/1 OU/ml enzyme in lOOmM sodium citrate buffer pH5 
37°C for 16-24 hours. The enzyme cleaves GlcNAc pi-2,4,6R or GalNAcp1-2,3,4,6R.
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(g) Bovine epididymus a-fucosidase (Oxford GlycoSystems) 0.2U/ml In lOOmM sodium 
citrate pH6. Substrate concentration was 40pM. The enzyme cleaves fucose a- 
1,6>2,>3,>4R.
(h) IgG GO mix (SOpl) contained (i) 15U p-hexoseaminidase (Jade Bean) (300U/ml) (il) 75mU 
a-fucosidase (Bovine kidney) (1 5U/ml) in lOOmM sodium citrate / phosphate buffer, pH 4.5 
containing 0.15M NaCI, lOmM zinc acetate, 0.02% sodium azide, 5mM D-galactonic add y- 
ladone The last reagent was added to inhibit the activity of gaiactosidase which may be 
present as an impurity. lOpI were used for each enzyme digest of approximately 250pmol 
(0,5mg glycan substrate. The digestion of asialo IgG glycans was carried out overnight at 
37®C. After desalting the digestion products were analysed by P4 GPC or by cation 
exchange Chromatography.
1.5 Exogiycosidase sequencing of anctwxr glycans
In ch.3 the oligosaccharide moiety of the GPI anchor attached to CD59 was analysed using 
the following enzyme digestion conditions:
(a) Asper^lius phoenicus al-2mannosidase (APAM) (also known as ASaitoi a i -2 
mannosidase.)
This enzyme is spedfic for a-D-Man1-2D-Man glycosidic bonds. Digestions were performed 
in iOpI 0.1 M sodium acetate pH 5.0 containing 0.01 mU (0.04mg) of APAM (Oxford 
GlycoSystems Ltd. X-5009) for 16-24 hours at 37*0 under a toluene atmosphere at a 
substrate concentration of between 15mM and 2mM. The products were de-salted by 
passing through 0.2ml AG50X12 (H*) and eluted with 1ml water. The samples were 
evaporated to dryness and residual acetic add removed by flash drying.
(b) Jack bean a-~mannosida$e (JBAM)
This enzyme has a broad spedficity for any terminal, non-substituted, a-D-Man residue. 
Digestions were performed using 30pl enzyme (25U/ml) in 0.1M sodium acetate pH5. 
Substrate concentration was between lOmM and 5mM, and the mixture of enzyme and 
substrate was incubated for 2-4 hours at room temperature followed by 16-24 hours at 37°C. 
The products were desalted with AG50X12(H*) (0.2ml), filtered through a 0.2pm membrane 
and evaporated to dryness. Acetic add was removed by flash drying with toluene.
1 6  Purification of enzyme digests prior to P4 analysis and Mass Spectrometry 
Samples were purified from protein and salts by passing through mixed bed resins of 
ChelexlOO (Na*)/Dowex AG50X12 (H*)/Ag3X4A (OH‘)/QAE Sephadex A-25, eluting with 5- 
10 t>ed volumes of water and evaporating to dryness.
1.7 Biogel P-4 gel filtration
This technique allows neutral glycans to be separated on the basis of hydrodynamic volume, 
and gives a dired measurement of size. It can be used preparatively, without intemal 
standards, or analytically by co-chromatographing a set of glucose oligomer intemal
Exogiycosidase
p-N-acetyihexosaminidase 
(S. pneumonia)
«3/4 fucosidase (Almond meal) 
a-fucosidase (Bovine kidney)
p-galactosidase (Bovine testes)
P-N-acetylhexosaminidase 
(Jack bean)
Array
1 2 3 4 5 6  7 8 9
ooo ooo ooo 
ooooooooo 
ooo ooo ooo 
ooo ooo ooo 
ooooooooo
Specificity
^2,3 linked 
GlcNAc/GalNAc
a-3,4 linked fucose 
All «-linked fucose
p-3,4 linked Gal
P-2,34,6 linked 
GlcNAc/GalNAc
H5N4F
Ratios 3:
Key
3  N-Acetyl glucosamine (GlcNAc) Fucose (Fuc)
® Mannose (Man)________ A  fiaiaçtose (Gal)
The Reagent Array Analysis Method
RAAM signature
15 10 5 GU
mV 14.4 8.15
7.22
21201510
Retention volume (ml)
Construct glycan
Experimental signature
14 12 10 8 6 4
Glucose units
Theoretical signature
1-------1------ T
14 12 10 a 6 4
Glucose units
I
Match quality calculated
and structure / sequence assigned
standards with radiolabelled neutral glycans. The simultaneous detection of the oligomer 
standards by refractive index (Rl) and the neutral glycans by an on-line radioactive or 
fluorescence monitor allows accurate determination of the size of the glycans in terms of 
effective 'glucose units' (gu). A combination of specific exogiycosidase digestions and re- 
chromatography of the digests enables the glycan structures to be analysed. The analyses 
described in this thesis were performed using the Oxford GlycoSystems Glycomap 
Instrument which is based on the P4 chromatography system.
1.8 Reagent Array Analysis Method (RAAM) for Automated Oligosaccharide Sequencing 
The RAAM method for the primary sequence analysis of N-linked oligosaccharides (at 
the picomole level) uses exoglycosidases in multiple defined mixtures (Edge et al 1992, 
Prime and Deamley 1993). The analysis is performed in a single chromatographic step. 
The method, schematically summarised in figure 4a, involves dividing an aqueous 
oligosaccharide solution, in this case of the complex biantennary glycan H5N4F, into 
equal aliquots. Each aliquot is incubated with a precisely defined mixture of 
exoglycosidases, the products of each incubation are combined, and a single analysis is 
performed on the pool of products. The set of mixtures of exoglycosidases is referred to 
as the ‘reagent array'. Each reagent array is used to generate a fragment of the 
oligosaccharide, and by omitting one or more different exoglycosidase(s) from each 
mixture, different stop-point' fragments of the oligosaccharide are generated. In each 
enzyme mix, digestion will continue until a linkage is reached that is resistant to all the 
exoglycosidases present in that mix. Full use is therefore made of both positive data 
(the exoglycosidases hydrolyse linkages up to the stop' point) and negative data (the 
exoglycosidases do not hydrolyse linkages beyond the stop' point). The original 
oligosaccharide is = labelled 'at the single ri^ucing terminus, - therefore only p^&ducts 
retaining the original reducing terminus are seen by the detection system. P4- 
chromatographic separation of the combined products generates a pattern of fragments 
that is a signature' of that: oligosaccharide generated by the specific array used (Figure 
4b). This signature is characterised by the elution position and relative signal intensity 
of each fragment! ;The software^ algorithm performs a re-construction of carbohydrate 
structure from the observed signature (Fig. 4c).
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2. Novel applications of technology to oligosaccharide and glycoform analysis
2.1 Matrix Assisted Laser Desorption Mass Spectrometric (MALDi MS)
(i) MALDI MS is a relatively simple mass spectrometric technique (Dwek et al 1993, Harvey 
et al 1994, Beavis et al 1990, Karas and Hillenkamp 1988, Hillenkamp and Karas 1990) 
which gives molecular weights without the need to derivatise the oligosaccharides and which 
does not produce extensive fragmentation. The sample is presented to the ion source co­
crystallised with a UV absorbing matrix. The composition of the matrix affects the efficiency 
of the desorption process; this may be t)ecause the energy which the matrix at)sorbs from 
the ion source is transmitted to the sample. A number of compounds have been tested as 
matrices in UV desorpton mass spectrometry of oligosaccharides, in particular cinnamic acid 
derivatives (Beavis and Chaitt 1990) such as a-cyano-4-hydroxycinnamic acid (Beavis et al
1992) are frequently used. In this thesis the matrix was dihydroxyt)enzoic acid (DHB) (Stahl 
et al 1991). The structures of these two compounds are shown below.
CH=C(CN)COOH COOH
OH
OH
a-cyanohydroxycinnamic acid dihydroxybenzoic acid
Neutral glycans and DHB were first co-crystallised from acetonitrile : water (70:30) and then 
re-crystallised from ethanol. The dried target was placed In the MS and Irradiated with pulses 
of laser light. The magnetic sector instrument used in this thesis was a Fisons Instruments 
(VG Analytical) AutoSpec-FPDQ spectrometer consisting of a standard Autospec instrument 
fitted with an array detector and a LSI nitrogen laser (frequency of 337 nm; pulse width 
3nsec). The highest mass which can be measured without significant loss of resolution is 
5kD and the accuracy is approximately +/- 0.3 of a mass unit. While proteins and 
glycopeptides generally give abundant [M+H]* ions together with low amounts of dimer and 
doubly charged peaks, oligosaccharides give only single peaks which arise from the [M+H]* 
or, more commonly [M+Na}*. The technique requires only fmol-pmol amounts of material 
and is tolerant of small amounts of buffer salts, although in this thesis all samples were 
purified by ion exchange chromatography to prevent unnecessary suppression Of the signal. 
The detection limit of the signal was taken to be approximately 3 times the noise level. 
Oligosaccharide analyses were performed either on unlat>elled neutral glycans or on 2AB 
labelled glycans. Released glycans were desialylated with Arttuobacter Ureafaciens 
neuraminidase which cleaves both a-2,3- and a-2,6- linked sialic acid. Analysis of 
radiolabelled glycans betore and after neuraminidase treatment confirmed that all charge 
was due to sialic add and had been removed. The neutral glycans were purified from
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neuraminidase and from buffer salts by passing through a mixed bed resin consisting of 
200pJ each of Chelex 100 (Na+) over Dowex AG50X12(H+) over AG3X4 (OH ) over QAE 
Sephadex A-25 and eluting with 3ml water. The sugars were evaporated to dryness by rotary 
evaporation and dissolved in 10pl water. Approximately 50-100 pmol of sugars in 1-5pl water 
were twice recrystallised on the target with 0.5pl dihydroxybenzoic acid. 5-20 shots were 
taken at each exposure and 20-30 spectra were averaged. The molecular weights of the 
components of the mixtures were determined after calibrating each spectrum with standards. 
The molecular weight of an oligosaccharide is the sum of Its monosaccharide components 
plus water. The glycans are normally present as sodium adducts and this accounts for a 
further 23D. Two molecular weights were used (Table 1) depending on the resolution used to 
obtain the spectra. In high resolution spectra, in which more shots are fired, more sample is 
required and individual isotopes are identified, the monoisotopic masses of the most 
abundant isotopes were used; for low resolution spectra in which isotopes are not resolved, 
the chemical mass was used.
Monosaccharide Monoisotopic mass Chemical mass
residue
Hexose 162.053 162.14
Deoxyhexose 146.058 146.14
N-acetyl hexosamine 203.079 203.19
Pentose 132.042 132.12
Sialic acid 291.095 291.26
Water 18.011 18.02
Sodium 22.990 23.00
Potassium 39.10 38.964
Table 1: Monoisotopic and chemical masses of the common components of 
oligosaccharide ions
Applications
(i) MALDI MS analysis of glycans by simultaneous digestions of oligosacctiarides in glycan 
pools. In this thesis a method was developed to overcome the need to purify individual 
oligosaccharides before sequencing and to eliminate the need for labelling (Harvey et al 
1994). Released glycans were desialylated and desalted as described above and the 
components analysed by MALDI MS. The glycan pool was then incubated with a single 
exogiycosidase enzyme and after purification the products of the digest were analysed by 
MALDI MS. An examination of the profiles showed which sugars had been digested by the 
enzyme and how many residues had been removed. The sugars were subjected to a series 
of enzyme digestions in tum and the analysis of the products of each allowed the 
composition of the original pool to be determined. In chapter 2 this technology was used to
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sequence the N-linked glycans released from the leucocyte antigens CD2, CDSdl, 
CD5/CD4d3/4 and sCD59 and on IgG sugars in chapter 6 (section 4.2.5). Smaller O-linked 
glycans could not be unambiguously identified by this matrix assisted laser desorption 
method using DHB because the components of the matrix, which also ionise, have molecular 
weights in the same range as O-linked glycans (approximately 350-800 daltons). This 
method therefore requires modification before it can be applied to O-linked glycans.
A major advantage of the magnetic sector instrument is that the individual peak heights are 
directly proportional to the ion concentration of each component. In contrast, for 
spectrometers using time of flight separations, this relationship l>ecomes non-linear at lower 
molecular weights (<1000 daltons) (Mr. T. Naven, unpublished data). It has also been 
demonstrated that oligosaccharides are non-selectively ionised (Dr. D. Harvey - unput)lished 
data). However, to obtain quantitative data it is necessary to take many scans (typically 20- 
30) over a wide area of the sample spot, and there may still be some doubt in the 
quantitation since this depends on an even distribution of the individual sugars across the 
target area. In the following section a method was developed to analyse RAAM data by mass 
spectrometry which did not rely on accurate quantitation.
(ii) MALDI MS analysis of RAAM sequencing data of complex N-linked sugars 
A method was developed to modify the RAAM sequencing technique (section 1.8) for use 
with unlabelled glycans using MALDI MS to analyse the data instead of P4 GPC. The 
standard RAAM analysis using the N-linked glycan array (shown in Fig. 4a) was applied to 2 
separate aliquots of unlat)elled desialylated glycans from CDS. At the end of the incubation 
time one set of samples was pooled and purified on mixed t)ed resins as in the normal 
protocol. The second set was not pooled, but each reaction product was individually purified 
on mixed bed resins. The components of both the pooled sample and the nine individual 
purified reaction products were analysed by MALDI MS. The stop point fragments are shown 
schematically in figure 5.
H8N4F(1810mu)
(product o f d l0MtB Sihfi)
☆
H3IM(1340imi) 
(product o f digest d) ,  ^
H3N2P(1080mu)
(product o f d%#sts c .s a n d f)
H3N2 (933mu) (product o f digests ■ and b)
A  galactose ®  mannose
^  N-aeetylglucosanilne ^  flicese
Figure 5: The stop point fragments generated by the nine individual RAAM digests
Predicted ratios of H5N4F:H3N4:H3N2F:H3N2 are 3:1:3:2
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Figure 6P: The MALDI MS analysis of the combined stop point fragments generated 
from the individual RAAM digests of H5N4F. 6 a-d: The MALDI MS analysis of the 
individual stop point fragments generated from the individual RAAM digests of H5N4F 
(continued overleaf). Data analysis is in tabies 2a,b.
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Figure 6 en: The MALDI MS ahalysis of the stop point fragments generated from the 
individual RAAM digests of HStUF. (Data analysis is in Table 2a,b.)
In the standard RAAM protocol the software algorithm performs a re-construction of the 
original carbohydrate structure from the observed P4 GPC signature, and this is derived 
from the quantitation of the relative amounts of stop point fragments in the final pool of 
glycans.The results of the conventional RAAM analysis of this sample, H5N4F, are 
shown in figure 4b,c, and the analogous MS analysis of the pooled fractions is shown in 
figure 6P. It can be seen from Table 2a that the quantitative MS analysis of the RAAM stop 
point mixture does not correlate well with the predicted ratios (Figure 4a). The peak height 
for the 1810 mass units fragment (H5N4F) is low, maybe as a result of losses or because of 
variations in the distribution of this species on the target. To overcome the need to depend 
on peak height measurements the second set of digests were not pooled but analysed 
individually. In this case each MS profile (figure 6 a-i) is of a single stop point fragment. The 
ratios of the products obtained from the MS analysis of these individual incubations are 
given in Table 2b, together with the theoretical ratios of the stop point fragments. The ratios 
of the stop point fragments, from which the original carbohydrate can be reconstructed, is 
obtained by adding up the numt>er of each of the different stop point fragments from the 9 
digests (6a-i).
Fig. 6P: MS of pooled digests 933 1081 1340 1810
Ratio of peaks from MS peak height 1.9 2.6 0.8 1
Theoretical ratio of stop point
fragments from H5N4F: 2 3 1 3
Table 2a: MS analysis of pooled stop point fragments after RAAM digests compared witti
ttieoretlcal ratio.
6a. RAAM 1 933
6b. RAAM 2 933
6c. RAAM 3 1081
6d. RAAM 4 1341
6e. RAAM 5 1081
6f. RAAM 6 1081
6g. RAAM 7 1810
6h. RAAM 8 1811
6i. RAAM 9 1812
Ratio of peaks by addition of
results of individual digests: 2 3 1 3
Table 2b: The ratios of the stop point products derived from the MS analysis of the individual
incubations
Table 2: RAAM analysis of the aslalo N-linked CDSdl glycan analysed by MALDI MS
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2.2 Ion exchange separation of anionic sugars
In anion-exchange chromatography charged glycans (almost invariably acidic) are eluted 
sequentially from a suitable column by an increasing concentration of a counter anion. This 
separation is based on net charge, although in some cases additional interactions between 
the uncharged body of the glycans and the resin are involved. Two ion exchange systems 
commonly used for resolving sugars are high performance anion exchange chromatography 
(HPAEC) using PAD or radioactive detection (Dionex) and mono-Q sepharose anion 
exchange chromatography. In this thesis weak anion exchange (WAX) chromatography, 
developed by Mr. Geoffrey Guile (Guile et al 1994) was used to provide a high resolution, 
preparative method to separate charged glycans without degradation. The technology was 
applied to the charge analysis of the glycans released from the leucocyte antigens (ch.2) and 
to the glycans from normal and RA IgG. The improved resolution, which resulted from the 
use of the fluorescent label, 2AB, and on-line fluorescence detection, revealed that the RA 
IgG sugars contained two populations of monosialylated glycans compared with one in 
normal IgG (ch.6 section 4.2.3 figures 10a,b and 10cd). The WAX column (Vydac 
301VHP575) (7.5cmx50mm) was equilibrated in water (buffer B) and 2AB or radiolabelled 
glycans were injected in aqueous solution. Neutral structures were eluted in the void volume 
and charged glycans which bound to the column were successively eluted with an increasing 
salt gradient of 0-500mM ammonium formate pH9 (bufferA). The classes of charged glycans 
were assigned by comparison with a standard fetuin glycan library.
The gradient applied to the column is shown in table 3.
Time Flow Curve %A %B
Start 1 ml/min 0 100
12min 1 ml/min 6 5 95
25min 1 ml/min 6 21 79
50min 1 ml/min 6 80 20
55min 1 ml/min 6 100 0
65min 1 ml/min 6 100 0
66min 1 ml/min 6 0 100
70min 2ml/min 6 0 100
89min 2ml/min 6 0 100
90min 1 ml/min 6 0 100
117min OmI/min 6 0 100
Table 3: Gradient parameters for WAX chromatography (Vydac 301 VHP575)
Typical profiles are shown in figure 7a,b.
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2.3
This technology was developed to provide a high resolution separation system as a 
complement to the existing P4 technology. Fluorescently labelled glycans were applied to 
two tandem Vydac 400 VHP cation exchange columns (2x7.5cmx50mm) equilibrated In 
water. The oligosaccharides were eluted with a linear gradient In which the starting solution 
was water containing SOmM formic add and the final solution was 80% acetonltrile also 
containing SOmM formic acid. The technology was used to determine the relative proportions 
of G2;G1 ;G0 sugars assodated with normal and RA IgG (ch.6 sedlon 4.2.6 fig. 15a.b).
NA2
g
1 0*1 0A2
10 12S2 60
Mbwltf
Minute:
Figure 7: (a) Analysis of the hydrazine released pool of 2AB labelled glycans from 
CD5d1 by WAX chromatography.
Assignment was by comparison with standard fetuin sugeffs 
(b) Analysis of 2AB labelled glycans after digestion with Newcastle Disease 
virus neuraminidase.
All structiffes became neutral, indicating that all charge is due to 2,3^inked sialic acid.
2.4 FluorOf^ wre Assisted CarbohyKbate Electropttoresis (FACE) using GlycO/Millipore 
eleGtrof^ iorasis and imagii%i system and labelling kits.
This technique was explored as a means of using a gel electrophoresis system to profile the 
glycosylatlon of picomole quantities of glycans. It Is based on the prindple that sugars
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labelled at the reducing terminus by reductive amination with the charged fluorescent group, 
8-amlnonapthalene-1,3,6-trlsulphonlc acid (ANTS), will be resolved on 60% acrylamlde gels 
approximately according to their mass : charge ratios (Jackson 1994). The three sulphonic 
acid groups donate a net negative charge to the labelled glycans allowing both acidic and 
neutral sugars to be resolved. The fluorescent label enables the derivatives to be detected 
with high sensitivity (In the picomole range). A wheat starch digest consisting of a mixture of 
malto-ollgosaccharldes from 1 to approximately 30 glucose units Is provided as a standard 
marker against which sample mobility can be measured. This technique has proved to be a 
useful means of making a rapid qualitative assessment of the charge states of 
oligosaccharides, and of the complexity of the components of glycan libraries released from 
glycoproteins. Absolute assignment of structure may be attempted through repeated 
analyses following the use of exoglycosldase enzymes.
NH2 so.
so.
ANTS
8-aminonaphthalene-1,3,6-triau Iphonate
Method
Hydrazine released oligosaccharides (SOOpmoles) In water were dried to a pellet In a 
centrifugal vacuum evaporator and re-dlssolved In 5pJ of ANTS/acetIc acld/water 
(0.15M/3/17v/v). 5pl of sodium cyanoborohydrkJe dissolved In dimethyl sulphoxlde (1M) 
were added to the mixture which was then vortexed and spun In a microcentrifuge. The 
samples were Incubated at 37°C overnight, or at 45°C for 3 hours, and then evaporated to a 
viscous gel In a centrifugal vacuum evaporator. The fluorophore labelled sample was 
resuspended by adding 10-20pJ of distilled water. 2pJ of the sample (SOpmoles) were mixed 
with 2pJ of glycerol/water (1:4 v/v) thorini dye and loaded onto the gel. The standard wheat 
starch digest glycan mixture (1 25pmoles) was suspended In 50pl of distilled water. 50 pi of 
glycerol /water (1/4 v/v) with thorini dye were added and 4pl (50pmole) were applied to the 
gel. The samples were analysed by SDS PAGE using pre-poured 60% acrylamlde gels and 
0.1 M Tris/Trlclne running buffer, pH 8.3. The gels were run at lOW/gel for between 1.5-2 
hours and scanned with a fluorescent Instant Imager.
Application
FACE was used to assess the distribution of charge on the bl-antennary complex glycan, 
H5N4F, attached to CD5 domain 1 (CD5d1) and to compare the results with the charge 
analysis by WAX chromatography (Fig. 7a,b). The results of the FACE analysis of the 2AB 
labelled CD5 glycans are In figure 8a,b. The three bands visible In Track 2 are consistent
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Line 2 on page 255: 
2AB should read ANTS
V.
with the presence of three populations of N-linked glycans (N, NA1 and NA2), tracks 1 and 3 
contain 2AB labelled glucose oligomer standards. In figure 8b (Track 2) the three 
populations have been reduced to a single band by Arthrobacter ureafaciens neuraminidase, 
consistent with chromatography data (ch.28 section 3.2) which indicates that the charge 
associated with the CD5d1 glycans is due to sialic acid. Band intensity was determined 
using instant imaging fluorescent densitometry; the results are summarised in table 4.
The analytical principle of a massxharge separation is the same for both the WAX and the 
FACE systems and neither technique can unambiguously assign structures without second 
dimension analysis. Peak assignment of charged glycans on the WAX HPLC system is 
normally made by comparing the profile of the sample with that of a standard set of fetuin 
N- and 0-glycans. While a similar approach can be applied to the electrophoresis system, 
the resolution required for accurate assignment of the elution position of the differently 
charged species is poor compared with WAX HPLC (figure 7); in addition the interpretation 
of the data is complicated by the presence of a number of artefactual bands (not assigned) 
which commonly occur on the FACE gels. Moreover the 0-linked sugars are not visible on 
the FACE gels because the technique, although very sensitive (low p mole range, compared 
with WAX high p mole range), does not have the range of sensitivity needed to detect the 
smaller populations of charged O-links (12% and 15% figure 8) at the same time as the 
more abundant N-linked populations (32% and 36% figure 8). The possibility also exists that 
highly charged low mass species will elute from the end of the gel during the 
electrophoresis. To address these problems it would be necessary to compile the data from 
a range of different sample loadings, run times and gel exposures. Quantitative analysis of 
individual glycan pools by FACE is generally in line with the data obtained by WAX 
chromatography (Table 4), but standardisation is needed to make an accurate assessment 
of the potential for this technique.
Figure 8: The separation of ANTS labelled CDSdl glycans by gel electrophoresis 
(FACE system), (a) Tracks 1 and 3: ANTS labelled standard mixture of glucose oligomers. 
Track 2 shows the analysis of hydrazine released glycans from CD5d1, labelled with ANTS.
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Figure 9a: The basic CE instrument consists of a fused silica capillary with an optical 
window, a UV detector, a high voltage power supply, two electrode assemblies and two 
buffer reservoirs. Field strengths higher than 500 volts/cm can be applied to the narrow 
capillary allowing highly enhanced resolution compared with conventional gel 
electrophoresis.
Peptide Is 
negatively 
charged
Peptide is 
positively 
charged
Electroosmotfc Flow
: ' 7. ^
0 ” 0 “ O” 0 “ 0 “ O- 0 “ 0 “ 0 “
++ t  ++ +++ ++++^++ +++++++
Low  pH - ......... -
OH O- OH O- OH O- OH O- OH
4" 4 ’ +  ■4* +
f t
Elution order
Cations
Neutrals
Anions
Figure 9b: Effect of electroosmotic flow (EOF). In un coated capillaries EOF is always 
towards the cathode. At high pH the capillary walls are strongly negatively charged and the 
EOF Is greater than at low pH. At high pH most peptides are negatively charged and migrate 
towards the anode, however EOF is always stronger and anions are eventually swept to the 
cathode. At low pH most peptides are positively charged and move towards the cathode with 
the EOF. The elution order is the same in both cases: cations elute first, then neutrals and 
finally anions.
(b) Analysis of the same glycan pool before (track 3) and after (track 2) desialyfation with 
neuraminidase. Tracks 1 and 4: ANTS labelled standard mixture of glucose oligomers.
In 8a the bands which have electrophoresed to positions equivalent to 8,7 and 6 glucose 
oligomers are the neutral, mono- and di-sialylated CD5d1 glycans respectively. Only the 
major bands were assigned and the O-linked glycans, identified on the WAX 
chromatography analysis (Fig.7), which have a relatively low abundance and high 
mass:charge ratio were not identified. The gel has been exposed to the scanner for longer 
than the gel in 8b to decrease the errors in the densitometry readings for the neutral t)and. 
Figure 8b shows the analysis of the same glycan pool before (track 3) and after (track 2) 
desialylation with neuraminidase. In track 2 the monosialyated glycan has been reduced to 
the size and charge of the neutral glycan by the loss of one sialic add residue, while the di- 
sialylated glycan has been reduced to the size and charge of the neutral glycan by the loss 
of two sialic add residues. All three strudures visible in figure 8a are therefore located at 
the same position as the neutral glycan in figure 8b. The t)ands were assigned from the 
analysis of the glycans by P4 GPC and WAX chromatography and from the standard elution 
position of the core fucosylated blantennary complex sugar (H5N4F) on the FACE system.
N-N-finks N-O-links MAI NA2 OA1 OA2
(i) WAX (7a) 15%.------  32% 36% 12% 5%
Gi)WAX(7a/b) 17% 38% 45%
Gii) FACE (8a) 10% 40% 50%
Total N-links Total O-links
Gv)WAX(7b) 85% 15%
(V )  P4 66% 33%
Table 4: A comparison of the charge profiles of CDS obtained by different methods.
(i) The percentages of the charged (NA1, NA2, OA1, OA2) and neutral populations 
calculated from figure 7a. The percentage of neutral N- and O- links cannot be separated. 
GO The percentages of the N-linked population only, calculated from the charged and asialo 
WAX profiles (fig. 7a,b) QiO The N-linked populations analysed by FACE (Fig. 8a) (tv) The 
ratio of total N : O-links analysed by WAX from figure 7b. Percentages were obtained by 
integration of the WAX data by fluorescent densitometry of the FACE data, (v) The ratio of 
N:0-links from the P4 data in ch.2B section 3.3 figure 3.
2.5 The resolution ofglycoforms by Capillary Electrophoresis
Capillary electrophoresis (CE) (Jorgensen and Lukacs 1983), which offers the possibility of 
separating intact glycoforms at the protein level, may be a powerful addition to the existing 
carbohydrate technologies G^ udd et al 1995). At present other electrophoretic techniques 
such as SDS PAGE and isoelectric focusing (lEF) generate a limited amount of analytical 
information relating to intact glycoforms. However the resolution which can be achieved is
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restricted because the high voltages which are required to give improved separations give 
rise to problems of heat dissipation in conventional gel systems. In CE field strengths higher 
than 500 volts/cm (up to 30kV) can be applied to a narrow capillary giving the potential for 
highly enhanced resolution. The basic CE instrument consists of a fused silica capillary with 
an optical window, a UV detector, a high voltage power supply, two electrode assemblies and 
two buffer reservoirs (Fig.Oa). In most assay systems the inner wall of the capillary column 
carries a negative charge because the silanol groups ionise above pH3. Positive ions in the 
electrolyte are attracted to the wall and, under high voltage, migrate towards the cathode 
creating a bulk flow of liquid called the electroosmotic flow (EOF) (Fig. 9b). If a sample is 
introduced into the capillary at the anode side all the components are carried by the EOF 
towards the cathode. Simultaneously the current flow will retard the negatively charged 
species so that the positive species elute first followed by the neutral and finally the 
negative. An inherent difficulty associated with analysing glycoforms by CE resides in the 
fact that the homogeneity of the polypeptide chain frequently masks the diversity of the 
glycans associated with it. Separations are achieved by amplifying structural differences 
t^tween the oligosaccharides, for example, by compiexing with an ionic species. The 
chemistry which has been used to achieve separations has, for the most part, exploited 
subtle differences in the conformation of the hydroxyl groups associated with the 
monosaccharide residues which make up the oligosaccharides. For example, the 
oligomannose glycoforms of bovine pancreatic RNase B have been separated into their 
individual glycoforms in their correct molar proportions by CE (Fig. 10a) (Rudd et al 1992 
and ch4) by compiexing ds diols with borate ions. The glycoforms of transferrin, also 
resolved by CE (Fig. 10b) are the subject of ch.5 in this thesis.
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Figure 10: (a) The Man5-9 glycoforms of bovine pancreatic RNase B resolved in their 
correct molar proportions by CE. A 72cm fused silica capillary, ID 75um, was used; 
voltage conditions were 1kv for Imin, 20kV tor 9mln, 30QC, wevelengtti for detection 200nm, 
injection time 1.5 s, in 20mM sodium ptwsptwte, 50 mAf SDS, 5mM sodium tetratxHste pH 
7.2, on a Beckman P/ACE system.
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Figure 10: (b) The glycoforms of normal and carbohydrate deficient human transferrin 
resolved by CE. The structures A-J are shown diagramatlcally twiow In figure iOc,
Capillary Zone Bectrophoresis (CZE) separations of transferrin were carried out on a P/ACE 
System 2100 (Beckman Instruments) using a fused sirica capillary (107cmx75pm ID). The 
detection was by UV at 200nm. Injections of 1-2mg/mi for 1.5-2 seconds were performed 
(5ng) under h i^  pressure. The buffer was 50mM Tris, 50mM sodium glutamate 
(CH^Ch2COONa) (pH 8.54-8.64). The applied voltage was lOkV.
Di-sialo
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Hexa-sialo transferrin Non-glycosylated transferrin
Figure 10c: Transferrin glycoforms present In CE analysis (Fig. 10b)
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3. The glycosylatlon of neutrophil gelatlnase B: a study using the technology which is 
currently available for the analysis of O-linked sugars.
3.1 Background:
Tissue plasminogen activator (tPA) contains three giycosyiation sites, one of which (Asn 
184) is variably occupied. The enzyme occurs naturally in two forms: type i in which ail three 
sites are occupied, and type II which contains only two N-iinked oiigosacccharides. Type II 
tPA is more active than type i towards its natural substrate, plasminogen (Parekh et ai 1989). 
Plasminogen contains a variably occupied N-giycosyiation site (Asn 297), and also occurs in 
two glycosylated forms: type 1 which contains one N and one O-linked glycan and type 2 
which contains only the 0-iinked structure, in ch.7 it was established that the type of 
plasminogen modulates the kinetics of association of enzyme and substrate within the 
ternary complex of tPA, plasminogen and fibrin while the giycosyiation of tPA modulates the 
turnover rate. The combinatorial interaction of these variably glycosylated species allows a 
range of activities in which glycoforms of tPA and plasminogen which contain unoccupied 
glycosylatlon sites react faster than their fully glycosylated counterparts. This finding lead to 
the concept that glycosylatlon may be a means of control in the protease cascade reaction in 
which several glycosylated enzymes, including tPA, plasminogen and gelatlnase and others, 
are involved. Matrix metalloproteinases, including coiiagenases, stromeiysins and 
gelatinases, are key mediators in the physiological degradation of extracellular matrix 
molecules in tissue remodelling. They are also implicated in many pathologies including 
acute and chronic inflammation associated with diseases such as Rheumatoid Arthritis and 
Multiple Sclerosis (Opdenakker and van Damme 1994). Plasminogen activation is one of the 
activation processes of the matrix metalloproteinases, while activation of gelatlnase A by 
stromeiysin is another one. Ail these enzymes are interconnected in a cascade and 
gelatlnase B is the most complex and terminal one. Three molecular types of gelatlnase 
have been identified: (I) neutrophils stimulated with IL-8 secrete a 91 kd gelatlnase 
(calculated M.Wt. from amino acid sequence is 75kd) which is also found in high 
concentrations in the synovial fluid of arthritic joints (Opdenakker et ai 1991, Masure et ai 
1991) (il) normal human peripheral blood monocytes stimulated with IL-1 secrete an 85kd 
gelatlnase (Opdenakker et ai 1991) and (ill) the 92 kd and 85 kd forms have been 
characterised as truncated forms of the 96kd gelatlnase from human tumor ceils (Wilhelm et 
ai 1991, Van Ranst et ai 1991). Gelatlnase B is the largest member of a family of structurally 
related matrix metalloproteinases. It contains seven protein domains, three potential N- 
giycosyiation sites and a number of serine and threonine residues which may be O- 
giycosyiated, although none has been reported. The experimental molecular weight of 
human neutrophil gelatlnase B is 92 kD. Treatment with N-giycanase reduced this from 
92kDa to 87kD (fig. lOd). There are no enzymes which cleave all O-linked glycans from 
proteins, therefore in this project hydrazinolysis and oligosaccharide analysis has been used 
to determine whether any of the additional 12kD of molecular weight can be attributed to O- 
giycosyiation. in addition, the identification and analysis of the 0-glycans has been
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Figure 10d: Zymography of SDS PAGE of human neutrophil gelatlnase B Incubated 
with PNGase F
The native material migrates at 90-95kD, a homodimer migrates at approximately 200kD and 
a heterodimer with neutrophil gelatlnase B associated lipocalin migrates at 130kD.
-. without enzyme; 0: with enzyme before incubation;
2, 4, 6: with enzyme and 2, 4 and 6 hours incubation respectively.
In tracks 1-5 the enzyme was used as recommended in the Oxford GlycoSystems Kit; 
tracks 6-10 used a 1:100 dilution of the enzyme supplied in the kit.
undertaken as a preliminary step to assess the possible role of O-glycosylation in the 
interaction of gelatinases with their natural substrates.
The project has also explored some of the limitations of the technology conventionally used 
to sequence O-glycans.
3.2 Methods
3.2.1 Preparation of gelatinase B
Gelatlnase B was purified as described by Masure et al (1991). The 91 kD form was analysed 
by amino terminal sequence analysis and was shown by zymography to be catalytically 
active.
3.2.2 Enzymatk: de^ycosylation of gelatinase B with N-glycanase
The purified enzyme was treated with PNGase F (N-glycanase) from different commercial 
sources (Oxford GlycoSystems -native form, and Boehringer-recombinant form) and 
analysed by zymography. This treatment reduced the molecular mass by approximately 
5kDa to 87kDa.
3.2.3 Release and analysis of glycans
Glycans were released using the GlycoPrep 1000 optimised at 95°C for the release of N- 
and O-linked glycans. Reduction, radiolabelling and P4 GPC were carried out according to 
standard procedures described earlier in this chapter. Charge analysis used WAX 
chromatography and N-glycan analysis used the RAAM also described earlier. The analysis 
of O-linked glycans was by sequential exoglycosldase digestion.
3.3 Results: Analysis of charged glycans released from neutrophil gelatinase B 
Gelatinase B was subjected to PNGase F to release N-linked glycans. Figure lOd shows the 
position of the native and deglycosylated material on an SDS gel. visualised by zymography. 
The native material migrates at 90-95kD (fig. lOd, tracks 1 and 6 labelled - ). In addition a 
homodimer was identified at 200kD and a heterodimer with neutrophil gelatinase B- 
associated lipocalin (NGAL) also noted by i^elsen et al (1993) was located at 120kD. The 
gradual disappearance of these additional bands after the removal of the N-linked sugars 
(fig. lOd: tracks 3-5 and 8-10; 2, 4, and 6 hours) may suggest a role for glycosylatlon in the 
formation of oligomers.
The sugars were also released from 40pg (lOnmoles) of neutrophil gelatinase B (from 
Professor Ghislain Opdenakker. The Rega Institute, Leuven) using the OGS GlycoPrep 
1000. (Yield specified by the manufacturer is >85%). The glycans were reduced and 
radiolabelled with tritium (total counts 1E8 cpm). 10% of the sample was subjected to charge 
analysis by WAX chromatography (Fig.lla). 30% of the structures were neutral. The 
remainder consisted of a mixture of sialylated N and O-links which were assigned by 
comparison with the analysis of fetuin sugars on the same system. After incubation with
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neuraminidase and hydrolysis with acetic acid (1M 95°C 1h) 90% of the sugars became 
neutral (Fig.11b). The remainder may be artefacts associated with radiolabelling but the 
possibility that they are sulphated or phosphated glycans has not been ruled out.
NA1. 0A1
NA2
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Figure 11: (a) Charge analysis of glycans released from neutrophil gelatinase B 
analysed by WAX chromatography (10E3 cpm was injeeted and the tractions were hand 
counted), (b) Charge analysis of glycans released from neutrophil gelatinase B after 
incubation with Arthrobact&’neuraminidase analysed by WAX chromatography.
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3.4 Analysis of the asialo glycans associated with neutrophii gelatinase 
The released de-siaiylated glycans were analysed by P4 GPC (Fig.12).
cr
Figure 12: P4 GPC analysis of asialo glycans from neufrophll gelatlnase.
Over 85% of the glycans eluted with molecular volumes typical of O-linked giycans (t>etween
3.5 and 10.5gu), and 15% were larger structures (between 10.5 and 15.5gu).
Peaks B (15gu) and 0  (14.2 gu) (fig. 12) were rechromatographed and analysed by RAAM 
and identified as the N-linked glycans H5N4F2 and H5N4F respectively. Peaks E (9.7gu), G 
(G.Sgu) and I (3.5 gu) were identified as O-linked glycans and analysed by sequential 
exoglycosldase digestions according to the scheme in figure 13. Peaks F (5.5 gu) and H (8.5
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gu) were resistant to Jack Bean hexosaminidase and Jack Bean a-mannosidase and 
remain to be assigned. It is possible that they may contain a-linked glycans or fucose at the 
terminal non reducing positions. The void (A) contained a small amount of non-cartx)hydrate 
material, and peak D contained too little material to be analysed. J and K at 2.5 and 1.5 gu 
respectively were not analysed, they contain material of very low molecular volume and, 
although the possibility that they are derived from gelatinase cannot be ruled out, these 
elution positions are generally associated with environmental contaminants.
3.5 Sequential exoglycosidase analysis of O-linked glycans
BT p-Gal JB p-Hex BT p-Gal JB p-Hex BT p-Gal
Gaipl HexNAcpi 
4 4
6
3 Gaipi- -  HexNAcpi -3 Gaipi
4
6
GalNAcpi-^H
Figure 13: Scheme for sequential exoglycosidase sequencing of O-linked glycans
BT fi-gal: Bovine testes galactosidase;
JB fiJiex: Jack bean fi-hexosaminidase
Peak G (6.5gu) was re-chromatographed (Fig. 14a) and the central peak fractions pooled to 
obtain a relatively pure sample of the major glycan in the pool. The aqueous solution of 
sugars was evaporate to dryness and incubated with Bovine testes p-galactosidase. The 
digest was purified on mixed bed ion exchange resins and chromatographed on P4 where it 
eluted at 5.65gu (Fig. 14b). This indicated that the glycan had been reduced by one glucose 
unit and that the terminal sugar which had been removed was 1-3,4 or 6 linked galactose. 
The oligosaccharide eluted from the P4 column was pooled, dried, and incubated with Jack 
Bean p-hexosaminidase. On re-chromatographing the glycan eluted at 3.67gu (14c) 
indicating that 1-2,3,4 or 6 linked N-acetylglucosamine or N-acetylgalactosamine had been 
removed from the non-reducing terminus. The glycan was again digested with bovine testes 
p-galactosidase to a glycan eluting at 2.69gu (14d) indicating that the terminal residue was 1-
3,4 or 6 linked galactose. Finally the 2.69gu peak was analysed by gas chromatography 
which showed that the reducing terminal radiolabelled monosaccharide was N- 
acetylgalactosamine (14e).
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Figure 14a-d: Exoglycosidase sequencing of peak G
Peaks E and I were sequenced in an analogous manner and it was finally established that in 
figure12 peaks E.G and I were members of a series of O-linked glycans:
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Pk E:
Gaipi -(4,3,6)HexNAcpi -(2,3,4,6)Gaipi -(4,3,6)HexNAcpi -(2,4,3,6)Gaipi -(3)(4,6) GaINAc
Gaipi -(4,3,6)HexNAcpi -(2,4,3.6)Gaipi -(3)(4,6) GaIN Ac
Gaipi-(3)(4.6) GaIN Ac
PkG:
Pkl:
Table 3: The series of O-linked glycans associated with gelatlnase B. The relative 
proportions of the glycans in these peaks (E:G:I) was 1:2.6:1.5
ops
Rib
Ara
Man
Gat
Inos
G lcN A t
GalNAc
Figure 14e: RadioGC analysis of terminal monosaccharide from peak G. The standard 
monosaooharides Ara, Rib, Man, Gal, Inos and GlcNac were co-injected with the sample 
which was Identified as GalNAc.
3:5 DIscussbn 
Sequencing O-linked glycans
This project highlights the need to develop new technology to automate the sequencing of O- 
linked glycans. The existing RAAM technology is unsuitable for^analysing repeating subunits, 
and currently such structures are determined by repetitive digestions.
In addition, more enzymes are required to determine the structure of the glycosidic linkages. 
For example, Jack Bean p hexosaminidase is relatively non-specific and digests either 
GlcNAc or GalNAc linked p i-2,3,4 or 6. The only alternative enzymes currently available are 
highly specific and therefore cannot be used when there are limited amounts of material. For 
example chicken liver p-hexosaminidase will digest only GlcNAc pi-3,4. Such specific 
enzymes are essential for this type of sequencing, but when supplies of material are limited, 
as is the case with gelatinase B, enzymes of intermediate selectivity may also be required. 
O-linked sugars are not normally suitable for MS analysis because they have molecular 
weights in the same range as the matrix components, although labelling with 2AB (120d) can 
in some cases overcome this problem.
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Figure 15: Diagram of domains in the proenzymes human gelatinase A and B 
(hGEL-A and hGEL-B) and murine gelatinase B (mGEL-B)
The scale at the top shows the number of amino acids in the protein relative to the 
domains in hGEL-A and -B and mGEL-B. The enzymes are built from 6 or 7 domains 
some of which are homologous with previously characterised domains in other 
proteins: e.g. FN: fibronectin; Zn: Zinc binding domain; VC: collagen type V domain 
and hemopexin.
N-linked giycosyiation sites are denoted by the symbol Y, serine and threonine 
residues which are potential sites for O-glycosylation are denoted by the symbol I. 
Murine and human gelatinase B contain a section of primary sequence rich in proline, 
serine and threonine, which is not conserved in human gleatinase A.
The glyœsylation of gelatinase B from human neutrophils
The analysis indicates that gelatinase B contains a series of glycans with a type 1 core 
structure (Gaipi,3GalNAcR). These have not been reported previously, and contribute to the 
observed additional molecular weight of the enzyme which is not accounted for by the amino 
acid composition and the N-glycans. The proportion of N-linked glycans is relatively low in 
proportion to the O-links, and may be even less than these data suggest since, as discussed 
earlier, the conditions used to release and recover the glycans allow a higher proportion of 
the total N-llnks to be recovered compared with the O-links. Two N-linked structures were 
identified, H5N4F2 and H5N4F. Core type I 0-glycans are synthesised by stepwise addition 
of monosaccharide residues to the GalNAc core, beginning with pi-3 GalNAc. Elongation 
can proceed along a number of pathways, the most common is the addition of Gaipi- 
4GlcNAc, and the results of this analysis are consistent with this. A common feature of core I 
type O-links is the presence of a-linked terminal residues, such as o2-3 or 6 linked sialic acid 
and fucose, at the reducing terminus. Consistent with this WAX chromatography (Fig. 11) 
indicated that gelatinase contains mono-sialylated 2,3 or 2,6 linked sugars which can be 
removed by incubation with Arthrottacter ureafaciens neuraminidase.
Structure and function of O-linked oligosaccharides attached to gelatinase 
The amino acid sequence of human and mouse gelatinase B as deduced from molecular 
cloning experiments (Wilhelm et al 1989, Masure et al 1993) indicates that the molecule 
contains many serine and threonine residues a number of which are in the vicinity of proline 
residues. In particular, in both murine and human 92kD gelatinase B there is a section of the 
primary sequence between residues (in human residues 452 to 503) which is rich in Pro, Ser 
and Thr residues (fig. 15). Such a region of amino acids is characteristic of a peptide region 
which may contain a cluster of O-linked glycans. Interestingly this region, which is 
homologous with a portion of the helical region of o2(V) collagen (Weil et al 1987), is not 
present in other members of the secreted metalloprotease gene family. Most O-linked 
glycans are attached to the hydroxyl groups in the side chains of either threonine or, less 
often, to serine residues through GalNAc, although glycans such as GlcNAc (Hart et al 1988) 
or fucose (Harris et al 1991) may also be O-linked to the peptide backbone. There is no 
consensus sequence In the peptide for GalNAc O-linked to Thr or Ser, however It Is common 
to find proline in close proximity. This may be because the nitrogen in the backbone is part 
of the proline side chain and limiting the conformations available to the protein (Branden and 
Tooze 1991). This prevents the N atom from hydrogen bonding and also provides some 
hindrance to the a-helical conformation. Although it fits well into the first turn of an a-helix, in 
other positions proline normally forms a bend in the peptide chain which exposes the 
residues which are close to proline in the primary amino acid sequence.
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Molecules which contain a significant proportion of O-linked glycans, such as mucins and 
CDS (ch2), frequently contain stretches of peptide sequence with repeating serine, threonine 
and proline residues. The clustered O-iinked glycans repel each other, particularly when 
sialylated. and their structural role may be to extend the polypeptide chain. Sections of the 
peptide which contain many proline residues in the chain assume a helical structure. When 
sugars are attached to serine or threonine within these helices the protein and sugars 
together may assume a 'bottle brush-like' structure. O-linked sugars may also inhibit 
proteolytic digestion of peptides and contribute to protein stability. The activity of human 
granulocyte colony stimulating factor Is largely eliminated on removal of the O-linked sugars 
and it has been proposed that the sugars maintain the protein conformation and prevent 
polymerisation (Oh-eda et al 1990). O-linked sugars may also be involved in binding events, 
for example on the zona pellicuda of mouse eggs O-linked sugars are implicated in the 
binding of the glycoprotein ZP3 to the sperm receptor (Florman and Wassarman 1985) and 
O-linked glycans on IgA bind to a T-celi receptor which is upregulated in rheumatoid arthritis 
(Rudd et al 1994). O-linked glycans. including blood group antigens, often show significant 
alterations in diseases such as cancer and in inflammation. Neutrophil gelatinase B is found 
in high concentrations in the synovial fluid of rheumatoid patients. However, the implications 
of the O-glycosylation of gelatinase for the structure and function of the enzyme have not yet 
been assessed; this is a preliminary step in the investigation of the role of glycosylatlon in an 
enzyme which, in common with tPA, and plasminogen is involved in the re-modelling of the 
extra-cellular matrix.
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